{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SessionStart","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","hook_event_name":"SessionStart","source":"startup"},"timestamp":1766706325279,"timestamp_pst":"2025-12-25 15:45:25 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SubagentStop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"default","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"ab68607","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-ab68607.jsonl"},"timestamp":1766706329558,"timestamp_pst":"2025-12-25 15:45:29 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SubagentStop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"default","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"a4710af","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-a4710af.jsonl"},"timestamp":1766706330711,"timestamp_pst":"2025-12-25 15:45:30 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"UserPromptSubmit","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"UserPromptSubmit","prompt":"parlons architecture potentielle, comment utiliser une clÃ© d'api Azure OpenAI dans un contexte vscode ou Droid? Analyse et recommande une solution pour une Ã©quide de 3 testeurs et 8 dÃ©veloppeurs pour expÃ©rimenter avec l'AI."},"timestamp":1766706420026,"timestamp_pst":"2025-12-25 15:47:00 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"Stop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"Stop","stop_hook_active":false},"timestamp":1766706449284,"timestamp_pst":"2025-12-25 15:47:29 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SubagentStop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"afe051d","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-afe051d.jsonl"},"timestamp":1766706460777,"timestamp_pst":"2025-12-25 15:47:40 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"UserPromptSubmit","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"UserPromptSubmit","prompt":"parles moi des contraintes des CLÃ©s d'api gÃ©nÃ©rÃ© dans Azure OpenAO"},"timestamp":1766706635255,"timestamp_pst":"2025-12-25 15:50:35 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"Stop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"Stop","stop_hook_active":false},"timestamp":1766706671125,"timestamp_pst":"2025-12-25 15:51:11 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SubagentStop","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"ab693f5","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-ab693f5.jsonl"},"timestamp":1766706679712,"timestamp_pst":"2025-12-25 15:51:19 PST"}
{"source_app":"pai","session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","hook_event_type":"SessionEnd","payload":{"session_id":"d534621f-1d16-444c-bf08-327557dd4fe6","transcript_path":"/home/chris/.claude/projects/-home-chris/d534621f-1d16-444c-bf08-327557dd4fe6.jsonl","cwd":"/home/chris","hook_event_name":"SessionEnd","reason":"clear"},"timestamp":1766707006625,"timestamp_pst":"2025-12-25 15:56:46 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SessionStart","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","hook_event_name":"SessionStart","source":"clear"},"timestamp":1766707006971,"timestamp_pst":"2025-12-25 15:56:46 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"UserPromptSubmit","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"UserPromptSubmit","prompt":"Nouveau projet : crÃ©er une formation sur les meilleures techniques de rÃ©vision de code dans un contexge de FDA amÃ©ricaine. Lance les recherches poussÃ©es sur le sujet et utitile des agents pour crÃ©er un plan dÃ©taillÃ© de formation incluant des exercercices."},"timestamp":1766707110144,"timestamp_pst":"2025-12-25 15:58:30 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"in_progress","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"pending","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01TUoYRa4r7sHW4wSueSYB28"},"timestamp":1766707124753,"timestamp_pst":"2025-12-25 15:58:44 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"in_progress","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"pending","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"in_progress","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"pending","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01TUoYRa4r7sHW4wSueSYB28"},"timestamp":1766707124945,"timestamp_pst":"2025-12-25 15:58:44 PST"}
{"source_app":"perplexity-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Task","tool_input":{"description":"Research FDA 21 CFR Part 11","prompt":"Research FDA software validation requirements for code review, focusing on:\n\n1. **21 CFR Part 11** - Electronic records and signatures requirements\n2. **FDA Software Validation Guidance** - General Principles of Software Validation (2002)\n3. **GAMP 5** - Good Automated Manufacturing Practice guidelines\n4. **IEC 62304** - Medical device software lifecycle processes\n\nFor each, extract:\n- Key requirements that impact code review\n- Documentation requirements\n- Traceability requirements\n- Specific validation activities required\n\nProvide detailed, actionable findings that can be used to build a training curriculum. Include specific regulatory citations where possible.","subagent_type":"perplexity-researcher","run_in_background":true},"tool_use_id":"toolu_01PwBGeGc7uq4J4P4CLwB2Lj"},"timestamp":1766707146623,"timestamp_pst":"2025-12-25 15:59:06 PST","agent_type":"perplexity-researcher"}
{"source_app":"claude-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Task","tool_input":{"description":"Research FDA audit findings","prompt":"Research common FDA audit findings and warning letters related to software and code review:\n\n1. **Common 483 observations** - What software-related issues does FDA cite most often?\n2. **Warning letter patterns** - Recurring themes in software validation failures\n3. **Case studies** - Real examples of companies that faced FDA action due to code review deficiencies\n4. **Remediation requirements** - What FDA expects when issues are found\n\nFocus on the last 5 years (2020-2025). Extract specific examples that can be used as teaching cases in training. Include pharmaceutical (cGMP), medical devices, and clinical systems.","subagent_type":"claude-researcher","run_in_background":true},"tool_use_id":"toolu_01HkGDMh5EV1ges9YATXRBA9"},"timestamp":1766707146626,"timestamp_pst":"2025-12-25 15:59:06 PST","agent_type":"claude-researcher"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Task","tool_input":{"description":"Research code review best practices","prompt":"Research code review best practices specifically for FDA-regulated environments:\n\n1. **Peer review methodologies** - Formal vs informal reviews, Fagan inspections\n2. **Checklist-based reviews** - What should FDA-compliant checklists include?\n3. **Documentation requirements** - What evidence is needed for audits?\n4. **Review roles** - Author, reviewer, moderator responsibilities\n5. **Defect tracking** - Classification and handling in regulated environments\n6. **Tool qualification** - Requirements for code review tools in FDA context\n\nInclude examples of review checklists used in pharmaceutical and medical device industries. Focus on practical implementation guidance.","subagent_type":"gemini-researcher","run_in_background":true},"tool_use_id":"toolu_01FQRWp9C9e7TczrcNEQStms"},"timestamp":1766707146640,"timestamp_pst":"2025-12-25 15:59:06 PST","agent_type":"gemini-researcher"}
{"source_app":"researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Task","tool_input":{"description":"Research training methodologies","prompt":"Research effective training methodologies for technical compliance training:\n\n1. **Adult learning principles** - How to teach complex regulatory topics effectively\n2. **Competency-based training** - How to measure code review competency\n3. **Practical exercises** - Types of exercises that work best for code review training\n4. **Assessment methods** - How to evaluate if training was effective\n5. **Industry examples** - How pharmaceutical and medical device companies train their teams\n\nFocus on:\n- Interactive learning techniques\n- Hands-on coding exercises\n- Role-playing scenarios for reviews\n- Using real-world examples effectively\n\nProvide specific exercise ideas that could be implemented in a code review training program.","subagent_type":"researcher","run_in_background":true},"tool_use_id":"toolu_01Wr8tTaULoZCHfKfB2EUTqp"},"timestamp":1766707146642,"timestamp_pst":"2025-12-25 15:59:06 PST","agent_type":"researcher"}
{"source_app":"perplexity-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Task","tool_input":{"description":"Research FDA 21 CFR Part 11","prompt":"Research FDA software validation requirements for code review, focusing on:\n\n1. **21 CFR Part 11** - Electronic records and signatures requirements\n2. **FDA Software Validation Guidance** - General Principles of Software Validation (2002)\n3. **GAMP 5** - Good Automated Manufacturing Practice guidelines\n4. **IEC 62304** - Medical device software lifecycle processes\n\nFor each, extract:\n- Key requirements that impact code review\n- Documentation requirements\n- Traceability requirements\n- Specific validation activities required\n\nProvide detailed, actionable findings that can be used to build a training curriculum. Include specific regulatory citations where possible.","subagent_type":"perplexity-researcher","run_in_background":true},"tool_response":{"isAsync":true,"status":"async_launched","agentId":"ac6566d","description":"Research FDA 21 CFR Part 11","prompt":"Research FDA software validation requirements for code review, focusing on:\n\n1. **21 CFR Part 11** - Electronic records and signatures requirements\n2. **FDA Software Validation Guidance** - General Principles of Software Validation (2002)\n3. **GAMP 5** - Good Automated Manufacturing Practice guidelines\n4. **IEC 62304** - Medical device software lifecycle processes\n\nFor each, extract:\n- Key requirements that impact code review\n- Documentation requirements\n- Traceability requirements\n- Specific validation activities required\n\nProvide detailed, actionable findings that can be used to build a training curriculum. Include specific regulatory citations where possible.","outputFile":"/tmp/claude/-home-chris/tasks/ac6566d.output"},"tool_use_id":"toolu_01PwBGeGc7uq4J4P4CLwB2Lj"},"timestamp":1766707146928,"timestamp_pst":"2025-12-25 15:59:06 PST","agent_type":"perplexity-researcher"}
{"source_app":"claude-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Task","tool_input":{"description":"Research FDA audit findings","prompt":"Research common FDA audit findings and warning letters related to software and code review:\n\n1. **Common 483 observations** - What software-related issues does FDA cite most often?\n2. **Warning letter patterns** - Recurring themes in software validation failures\n3. **Case studies** - Real examples of companies that faced FDA action due to code review deficiencies\n4. **Remediation requirements** - What FDA expects when issues are found\n\nFocus on the last 5 years (2020-2025). Extract specific examples that can be used as teaching cases in training. Include pharmaceutical (cGMP), medical devices, and clinical systems.","subagent_type":"claude-researcher","run_in_background":true},"tool_response":{"isAsync":true,"status":"async_launched","agentId":"a75e99f","description":"Research FDA audit findings","prompt":"Research common FDA audit findings and warning letters related to software and code review:\n\n1. **Common 483 observations** - What software-related issues does FDA cite most often?\n2. **Warning letter patterns** - Recurring themes in software validation failures\n3. **Case studies** - Real examples of companies that faced FDA action due to code review deficiencies\n4. **Remediation requirements** - What FDA expects when issues are found\n\nFocus on the last 5 years (2020-2025). Extract specific examples that can be used as teaching cases in training. Include pharmaceutical (cGMP), medical devices, and clinical systems.","outputFile":"/tmp/claude/-home-chris/tasks/a75e99f.output"},"tool_use_id":"toolu_01HkGDMh5EV1ges9YATXRBA9"},"timestamp":1766707147085,"timestamp_pst":"2025-12-25 15:59:07 PST","agent_type":"claude-researcher"}
{"source_app":"researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Task","tool_input":{"description":"Research training methodologies","prompt":"Research effective training methodologies for technical compliance training:\n\n1. **Adult learning principles** - How to teach complex regulatory topics effectively\n2. **Competency-based training** - How to measure code review competency\n3. **Practical exercises** - Types of exercises that work best for code review training\n4. **Assessment methods** - How to evaluate if training was effective\n5. **Industry examples** - How pharmaceutical and medical device companies train their teams\n\nFocus on:\n- Interactive learning techniques\n- Hands-on coding exercises\n- Role-playing scenarios for reviews\n- Using real-world examples effectively\n\nProvide specific exercise ideas that could be implemented in a code review training program.","subagent_type":"researcher","run_in_background":true},"tool_response":{"isAsync":true,"status":"async_launched","agentId":"a7f2711","description":"Research training methodologies","prompt":"Research effective training methodologies for technical compliance training:\n\n1. **Adult learning principles** - How to teach complex regulatory topics effectively\n2. **Competency-based training** - How to measure code review competency\n3. **Practical exercises** - Types of exercises that work best for code review training\n4. **Assessment methods** - How to evaluate if training was effective\n5. **Industry examples** - How pharmaceutical and medical device companies train their teams\n\nFocus on:\n- Interactive learning techniques\n- Hands-on coding exercises\n- Role-playing scenarios for reviews\n- Using real-world examples effectively\n\nProvide specific exercise ideas that could be implemented in a code review training program.","outputFile":"/tmp/claude/-home-chris/tasks/a7f2711.output"},"tool_use_id":"toolu_01Wr8tTaULoZCHfKfB2EUTqp"},"timestamp":1766707147085,"timestamp_pst":"2025-12-25 15:59:07 PST","agent_type":"researcher"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Task","tool_input":{"description":"Research code review best practices","prompt":"Research code review best practices specifically for FDA-regulated environments:\n\n1. **Peer review methodologies** - Formal vs informal reviews, Fagan inspections\n2. **Checklist-based reviews** - What should FDA-compliant checklists include?\n3. **Documentation requirements** - What evidence is needed for audits?\n4. **Review roles** - Author, reviewer, moderator responsibilities\n5. **Defect tracking** - Classification and handling in regulated environments\n6. **Tool qualification** - Requirements for code review tools in FDA context\n\nInclude examples of review checklists used in pharmaceutical and medical device industries. Focus on practical implementation guidance.","subagent_type":"gemini-researcher","run_in_background":true},"tool_response":{"isAsync":true,"status":"async_launched","agentId":"aaa3a33","description":"Research code review best practices","prompt":"Research code review best practices specifically for FDA-regulated environments:\n\n1. **Peer review methodologies** - Formal vs informal reviews, Fagan inspections\n2. **Checklist-based reviews** - What should FDA-compliant checklists include?\n3. **Documentation requirements** - What evidence is needed for audits?\n4. **Review roles** - Author, reviewer, moderator responsibilities\n5. **Defect tracking** - Classification and handling in regulated environments\n6. **Tool qualification** - Requirements for code review tools in FDA context\n\nInclude examples of review checklists used in pharmaceutical and medical device industries. Focus on practical implementation guidance.","outputFile":"/tmp/claude/-home-chris/tasks/aaa3a33.output"},"tool_use_id":"toolu_01FQRWp9C9e7TczrcNEQStms"},"timestamp":1766707147110,"timestamp_pst":"2025-12-25 15:59:07 PST","agent_type":"gemini-researcher"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Skill","tool_input":{"skill":"CORE"},"tool_use_id":"toolu_01K9ZMPcv7hxoyevZNA1BmBT"},"timestamp":1766707149375,"timestamp_pst":"2025-12-25 15:59:09 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Skill","tool_input":{"skill":"CORE"},"tool_response":{"success":true,"commandName":"CORE"},"tool_use_id":"toolu_01K9ZMPcv7hxoyevZNA1BmBT"},"timestamp":1766707149638,"timestamp_pst":"2025-12-25 15:59:09 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Skill","tool_input":{"skill":"CORE"},"tool_use_id":"toolu_016xPZHW3dg1mrsDFDdBgMjr"},"timestamp":1766707149689,"timestamp_pst":"2025-12-25 15:59:09 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Skill","tool_input":{"skill":"CORE"},"tool_response":{"success":true,"commandName":"CORE"},"tool_use_id":"toolu_016xPZHW3dg1mrsDFDdBgMjr"},"timestamp":1766707150013,"timestamp_pst":"2025-12-25 15:59:10 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"adult learning principles technical compliance training regulatory topics 2025"},"tool_use_id":"toolu_01LPF7D5vDETjNEV49GTinKR"},"timestamp":1766707151866,"timestamp_pst":"2025-12-25 15:59:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"hands-on coding exercises technical training best practices"},"tool_use_id":"toolu_01JftNSotUjaBnjDcUkfdYbG"},"timestamp":1766707151878,"timestamp_pst":"2025-12-25 15:59:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"pharmaceutical medical device software training GxP compliance 2025"},"tool_use_id":"toolu_01C39Rsrpp4Ch1LbPRzyZGo8"},"timestamp":1766707151868,"timestamp_pst":"2025-12-25 15:59:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"role-playing scenarios code review training peer review techniques"},"tool_use_id":"toolu_01Wr1G3fiHDXJtGVeU51dHkG"},"timestamp":1766707151880,"timestamp_pst":"2025-12-25 15:59:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"competency-based training assessment code review software validation"},"tool_use_id":"toolu_013qaozGNgBhBT4VXGxiMDiM"},"timestamp":1766707151876,"timestamp_pst":"2025-12-25 15:59:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Skill","tool_input":{"skill":"Research","args":"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures"},"tool_use_id":"toolu_01BLpQx8ow5fBkRhmvHE5NHT"},"timestamp":1766707154118,"timestamp_pst":"2025-12-25 15:59:14 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Skill","tool_input":{"skill":"Research","args":"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures"},"tool_response":{"success":true,"commandName":"Research"},"tool_use_id":"toolu_01BLpQx8ow5fBkRhmvHE5NHT"},"timestamp":1766707154428,"timestamp_pst":"2025-12-25 15:59:14 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"a75e99f","block":true,"timeout":120000},"tool_use_id":"toolu_01SiF2ck3HT97M6pHmrZ5MfN"},"timestamp":1766707155469,"timestamp_pst":"2025-12-25 15:59:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"a7f2711","block":true,"timeout":120000},"tool_use_id":"toolu_01WTDFWLsKwjpTghp2UpDQ2k"},"timestamp":1766707155460,"timestamp_pst":"2025-12-25 15:59:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"ac6566d","block":true,"timeout":120000},"tool_use_id":"toolu_01MmVRwvuFisjdxypm5QK6GP"},"timestamp":1766707155466,"timestamp_pst":"2025-12-25 15:59:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"aaa3a33","block":true,"timeout":120000},"tool_use_id":"toolu_01FgFvTZX7bLcL37TD9FPXuT"},"timestamp":1766707155472,"timestamp_pst":"2025-12-25 15:59:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"~/.claude/tools/SkillWorkflowNotification \"FDA Research\" \"Research\"","description":"Notify workflow start for observability"},"tool_use_id":"toolu_01DDyxXqNAusWjpARayf6xZg"},"timestamp":1766707158709,"timestamp_pst":"2025-12-25 15:59:18 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"~/.claude/tools/SkillWorkflowNotification \"Multi-Source Research\" \"Research\"","description":"Notify observability of workflow execution"},"tool_use_id":"toolu_01CYH2Qq7t5WJsF98yrpNykL"},"timestamp":1766707159904,"timestamp_pst":"2025-12-25 15:59:19 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letters software medical device code review 2020-2025"},"tool_use_id":"toolu_01B4wYp9zbvmsyyPT6FXncLx"},"timestamp":1766707160217,"timestamp_pst":"2025-12-25 15:59:20 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 observations software validation 2023 2024 2025"},"tool_use_id":"toolu_01V6XUFay6ffBRKeg8GWKFQ8"},"timestamp":1766707160223,"timestamp_pst":"2025-12-25 15:59:20 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA software validation failures cGMP pharmaceutical 2022 2023 2024"},"tool_use_id":"toolu_014uakGpb3VKkLtc2CpWPRfJ"},"timestamp":1766707160223,"timestamp_pst":"2025-12-25 15:59:20 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 21 CFR Part 11 software audit findings common deficiencies"},"tool_use_id":"toolu_01UxmvXNjC2Mf8Q873uVEPDh"},"timestamp":1766707160242,"timestamp_pst":"2025-12-25 15:59:20 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"ls -la /home/chris/.claude/skills/Research/","description":"Check Research skill directory structure"},"tool_use_id":"toolu_01N2QLm7nLDPejeSJnQ9uWEm"},"timestamp":1766707165079,"timestamp_pst":"2025-12-25 15:59:25 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Starting comprehensive FDA code review research with parallel agents\",\"voice_id\":\"iLVmqjzCGGvqtMCk6vVQ\",\"voice_enabled\":true}'","description":"Notify research start"},"tool_use_id":"toolu_018twxBV2VeLVfJMJS1TRG9C"},"timestamp":1766707165234,"timestamp_pst":"2025-12-25 15:59:25 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"ls -la /home/chris/.claude/skills/Research/","description":"Check Research skill directory structure"},"tool_response":{"stdout":"total 20\ndrwxr-xr-x  3 chris chris 4096 Dec 21 05:24 .\ndrwxr-xr-x 16 chris chris 4096 Dec 22 15:18 ..\n-rw-r--r--  1 chris chris 8189 Dec 21 05:24 SKILL.md\ndrwxr-xr-x  2 chris chris 4096 Dec 21 05:24 workflows","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_01N2QLm7nLDPejeSJnQ9uWEm"},"timestamp":1766707165620,"timestamp_pst":"2025-12-25 15:59:25 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"ls -la /home/chris/.claude/skills/Research/workflows/","description":"List available workflow files"},"tool_use_id":"toolu_01FyimQamQNDXqH4i8DBmUWF"},"timestamp":1766707168651,"timestamp_pst":"2025-12-25 15:59:28 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"ls -la /home/chris/.claude/skills/Research/workflows/","description":"List available workflow files"},"tool_response":{"stdout":"total 108\ndrwxr-xr-x 2 chris chris  4096 Dec 21 05:24 .\ndrwxr-xr-x 3 chris chris  4096 Dec 21 05:24 ..\n-rwxr-xr-x 1 chris chris  3679 Dec 21 05:24 ClaudeResearch.md\n-rwxr-xr-x 1 chris chris 22524 Dec 21 05:24 Conduct.md\n-rw-r--r-- 1 chris chris  2443 Dec 21 05:24 Enhance.md\n-rw-r--r-- 1 chris chris  4929 Dec 21 05:24 ExtractKnowledge.md\n-rw-r--r-- 1 chris chris 14068 Dec 21 05:24 Fabric.md\n-rwxr-xr-x 1 chris chris  4483 Dec 21 05:24 InterviewResearch.md\n-rwxr-xr-x 1 chris chris  8321 Dec 21 05:24 PerplexityResearch.md\n-rw-r--r-- 1 chris chris 14163 Dec 21 05:24 Retrieve.md\n-rw-r--r-- 1 chris chris  1984 Dec 21 05:24 WebScraping.md\n-rw-r--r-- 1 chris chris  1981 Dec 21 05:24 YoutubeExtraction.md","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_01FyimQamQNDXqH4i8DBmUWF"},"timestamp":1766707169130,"timestamp_pst":"2025-12-25 15:59:29 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/skills/Research/workflows/Conduct.md"},"tool_use_id":"toolu_01Q4qwjY5pfwcAmn88danWYH"},"timestamp":1766707172173,"timestamp_pst":"2025-12-25 15:59:32 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/skills/Research/workflows/Conduct.md"},"tool_response":{"type":"text","file":{"filePath":"/home/chris/.claude/skills/Research/workflows/Conduct.md","content":"---\ndescription: Comprehensive multi-source research - Kai loads and invokes researcher commands\nglobs: \"\"\nalwaysApply: false\n---\n\n# ðŸ”¬ COMPREHENSIVE RESEARCH WORKFLOW FOR KAI\n\n**YOU (Kai) are reading this because a research request was detected by the load-context hook.**\n\nThis command provides instructions for YOU to orchestrate comprehensive multi-source research by directly invoking researcher commands (NOT spawning new Claude Code sessions).\n\n## ðŸŽ¯ YOUR MISSION\n\nWhen a user asks for research, YOU must deliver **FAST RESULTS** through massive parallelization:\n\n## ðŸ·ï¸ AGENT INSTANCE IDS (For Observability)\n\n**When launching parallel agents of the same type, assign unique instance IDs for tracking:**\n\nFormat: `[agent-type-N]` where N is the sequence number (1, 2, 3, etc.)\n\n**How to assign:**\n1. For each researcher type, maintain a counter (starts at 0)\n2. When launching an agent, increment the counter and create instance ID\n3. Include the instance ID in the Task description: `\"Query description [perplexity-researcher-1]\"`\n\n**Example:**\n```typescript\n// Launching 3 perplexity-researchers:\nTask({\n  subagent_type: \"perplexity-researcher\",\n  description: \"Quantum computing breakthroughs [perplexity-researcher-1]\",\n  prompt: \"Research recent breakthroughs...\"\n})\nTask({\n  subagent_type: \"perplexity-researcher\",\n  description: \"Quantum computing applications [perplexity-researcher-2]\",\n  prompt: \"Research practical applications...\"\n})\nTask({\n  subagent_type: \"perplexity-researcher\",\n  description: \"Quantum computing companies [perplexity-researcher-3]\",\n  prompt: \"Research leading companies...\"\n})\n```\n\n**Why this matters:**\n- Hooks automatically capture these IDs to JSONL logs\n- Enables distinguishing parallel agents in observability dashboard\n- Helps debug specific agent failures or performance issues\n- Optional but recommended for extensive research (8+ agents per type)\n\n**THREE RESEARCH MODES:**\n\n1. **Quick Research: 1 agent per researcher type**\n   - Automatically uses all available *-researcher agents (1 of each)\n   - Use when user says \"quick research\" or simple queries\n   - Fastest mode: ~15-20 seconds\n\n2. **Standard Research: 3 agents per researcher type**\n   - Automatically uses all available *-researcher agents (3 of each)\n   - Default mode for most research requests\n   - Balanced coverage: ~30 seconds\n\n3. **Extensive Research: 8 agents per researcher type**\n   - Automatically uses all available *-researcher agents (8 of each)\n   - Use when user says \"extensive research\"\n   - Exhaustive coverage: ~45-60 seconds\n\n**Workflow for all modes:**\n1. Decompose question into focused sub-questions (appropriate to mode)\n2. Launch all agents in parallel (SINGLE message with multiple Task calls)\n3. Each agent does ONE query + ONE follow-up max\n4. Collect results as they complete\n5. Synthesize findings into comprehensive report\n6. Report back using mandatory response format\n\n**Speed Strategy:**\n- Each agent handles a specific angle/sub-question\n- Parallel execution = results in under 1 minute\n- Follow-up queries only when critical information is missing\n\n## ðŸ”¥ EXTENSIVE RESEARCH MODE (24 AGENTS)\n\n**ACTIVATION:** User says \"extensive research\" or \"do extensive research on X\"\n\n**WORKFLOW:**\n\n### Step 0: Generate Creative Research Angles\n\n**Use UltraThink to generate diverse research angles (8 per researcher type):**\n\nThink deeply and extensively about the research topic:\n- Explore multiple unusual perspectives and domains\n- Question all assumptions about what's relevant\n- Make unexpected connections across different fields\n- Consider edge cases, controversies, and emerging trends\n- Think about historical context, future implications, and cross-disciplinary angles\n- What questions would experts from different fields ask?\n\nGenerate 8 unique research angles per researcher type. Each should be distinct, creative, and explore a different facet of the topic. Mix different types: technical, historical, practical, controversial, emerging, comparative, etc.\n\nOrganize them by researcher type with 8 queries each, optimizing queries for each researcher's specific strengths and capabilities.\n\n### Step 1: Launch All Research Agents in Parallel (8 per type)\n\n**CRITICAL: Use a SINGLE message with all Task tool calls (8 per researcher type)**\n\n```typescript\n// For EACH researcher type discovered (matching pattern *-researcher):\n// Launch 8 agents of that type with optimized queries\n// Include instance IDs in descriptions: [researcher-type-N]\n\n// Example for researcher type A (with instance IDs):\nTask({ subagent_type: \"[researcher-type-A]\", description: \"Query 1 [researcher-type-A-1]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-A]\", description: \"Query 2 [researcher-type-A-2]\", prompt: \"...\" })\n// ... (8 total for this researcher type: [researcher-type-A-3] through [researcher-type-A-8])\n\n// Example for researcher type B (with instance IDs):\nTask({ subagent_type: \"[researcher-type-B]\", description: \"Query 9 [researcher-type-B-1]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-B]\", description: \"Query 10 [researcher-type-B-2]\", prompt: \"...\" })\n// ... (8 total for this researcher type: [researcher-type-B-3] through [researcher-type-B-8])\n\n// Continue for ALL available *-researcher agents (8 of each type with instance IDs)\n```\n\n**Each agent prompt should:**\n- Include the specific creative query angle\n- **Instruct: \"Do 1-2 focused searches and return findings. YOU HAVE UP TO 3 MINUTES - return results as soon as you have useful findings.\"**\n- Keep it concise but thorough\n- Agents should return as soon as they have substantive findings (don't artificially wait)\n\n### Step 2: Wait for Agents to Complete (UP TO 10 MINUTES FOR EXTENSIVE)\n\n**CRITICAL TIMEOUT RULE: After 10 minutes from launch, proceed with synthesis using only the agents that have returned results.**\n\n- Each agent has up to 10 minutes to complete their research (extensive mode)\n- Agents should return as soon as they have substantive findings\n- **HARD TIMEOUT: 10 minutes** - After 10 minutes from launch, DO NOT wait longer\n- Proceed with synthesis using whatever results have been returned\n- Note which agents didn't respond in your final report\n- **TIMELY RESULTS > PERFECT COMPLETENESS**\n\n### Step 3: Synthesize Extensive Research Results\n\n**Enhanced synthesis requirements for extensive research:**\n- Identify themes across all research angles (8 per researcher type)\n- Cross-validate findings from multiple agents and perspectives\n- Highlight unique insights from each agent type\n- Map coverage across different domains/aspects\n- Identify gaps or conflicting information\n- Calculate comprehensive metrics (8 per type, ~16+ queries per type, all available services)\n\n**Report structure:**\n```markdown\n## Executive Summary\n[1-2 paragraph overview of comprehensive findings]\n\n## Key Findings by Domain\n### [Domain 1]\n**High Confidence (5+ sources):**\n- Finding with extensive corroboration\n\n**Medium Confidence (2-4 sources):**\n- Finding with moderate corroboration\n\n### [Domain 2]\n...\n\n## Unique Insights\n**From Perplexity Research (Web/Current):**\n- Novel findings from broad web search\n\n**From Claude Research (Academic/Detailed):**\n- Deep analytical insights\n\n**From Gemini Research (Multi-Perspective):**\n- Cross-domain connections and synthesis\n\n## Coverage Map\n- Aspects covered: [list]\n- Perspectives explored: [list]\n- Time periods analyzed: [list]\n\n## Conflicting Information & Uncertainties\n[Note any disagreements or gaps]\n\n## Research Metrics\n- Total Agents: [N] (8 per researcher type)\n- Total Queries: ~[2N]+ (each agent 1-2 queries)\n- Services Used: [Count] ([List all researcher services used])\n- Total Output: ~[X] words\n- Confidence Level: [High/Medium] ([%])\n```\n\n## ðŸš€ QUICK RESEARCH WORKFLOW (1 AGENT PER TYPE)\n\n**ACTIVATION:** User says \"quick research\" or simple/straightforward queries\n\n**Workflow:**\n\n### Step 1: Identify Core Angles (1 per researcher type)\n\nBreak the question into focused sub-questions - one optimized for each available researcher type (discovered via *-researcher pattern). Tailor each query to leverage that researcher's specific strengths and data sources.\n\n### Step 2: Launch All Researcher Agents in Parallel (1 of each)\n\n```typescript\n// SINGLE message with 1 Task call per available researcher type\n// For each *-researcher agent discovered, launch 1 agent with optimized query\n\nTask({ subagent_type: \"[researcher-type-A]\", description: \"...\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-B]\", description: \"...\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-C]\", description: \"...\", prompt: \"...\" })\n// ... continue for ALL available *-researcher agents (1 of each type)\n```\n\n### Step 3: Quick Synthesis (2 MINUTE TIMEOUT)\n\n**CRITICAL TIMEOUT RULE: After 2 minutes from launch, proceed with synthesis using only the agents that have returned results.**\n\n- Each agent has up to 2 minutes (quick mode)\n- **HARD TIMEOUT: 2 minutes from launch** - Do NOT wait longer\n- Synthesize perspectives that returned into cohesive answer\n- Note any non-responsive agents in report\n- Report with standard format\n\n## ðŸ“‹ STANDARD RESEARCH WORKFLOW (3 AGENTS PER TYPE)\n\n**ACTIVATION:** Default mode for most research requests\n\n**Workflow:**\n\n### Step 1: Decompose Question & Launch All Research Agents\n\n**Step 1a: Break Down the Research Question**\n\nDecompose the user's question into specific sub-questions (3 per researcher type discovered via *-researcher pattern).\n\nEach question should:\n- Cover different angles of the topic\n- Target specific aspects to investigate\n- Explore related areas that provide context\n- Consider edge cases or controversies\n- Be optimized for each researcher's specific strengths and data sources\n\n**Step 1b: Launch All Research Agents in Parallel (3 of each type)**\n\nUse the **Task tool** - SINGLE message with all Task calls:\n\n```typescript\n// For EACH researcher type discovered (matching pattern *-researcher):\n// Launch 3 agents of that type with optimized queries\n// Include instance IDs in descriptions: [researcher-type-N]\n\n// Example for researcher type A (3 agents with instance IDs):\nTask({ subagent_type: \"[researcher-type-A]\", description: \"Query 1 [researcher-type-A-1]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-A]\", description: \"Query 2 [researcher-type-A-2]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-A]\", description: \"Query 3 [researcher-type-A-3]\", prompt: \"...\" })\n\n// Example for researcher type B (3 agents with instance IDs):\nTask({ subagent_type: \"[researcher-type-B]\", description: \"Query 4 [researcher-type-B-1]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-B]\", description: \"Query 5 [researcher-type-B-2]\", prompt: \"...\" })\nTask({ subagent_type: \"[researcher-type-B]\", description: \"Query 6 [researcher-type-B-3]\", prompt: \"...\" })\n\n// Continue for ALL available *-researcher agents (3 of each type with instance IDs)\n```\n\n**CRITICAL RULES FOR SPEED:**\n1. âœ… **Launch ALL agents in ONE message** (parallel execution)\n2. âœ… **Each agent gets ONE specific sub-question** (focused research)\n3. âœ… **3 agents per researcher type** (balanced coverage across all available types)\n4. âœ… **Each agent does 1 query + 1 follow-up max** (quick cycles)\n5. âœ… **Results return in ~30 seconds** (parallel processing)\n6. âŒ **DON'T launch sequentially** (kills speed benefit)\n7. âŒ **DON'T give broad questions** (forces multiple iterations)\n\n### Step 2: Collect Results (UP TO 3 MINUTES FOR STANDARD)\n\n**CRITICAL TIMEOUT RULE: After 3 minutes from launch, proceed with synthesis using only the agents that have returned results.**\n\n- Each agent has up to 3 minutes to complete their research (standard mode)\n- **Typical time:** Most agents return in 30-120 seconds\n- **HARD TIMEOUT: 3 minutes** - After 3 minutes from launch, DO NOT wait longer\n- Proceed with synthesis using whatever results have been returned\n- Note which agents didn't respond in your final report\n- **TIMELY RESULTS > PERFECT COMPLETENESS**\n\nEach agent returns:\n- Focused findings from their specific sub-question\n- Source citations\n- Confidence indicators\n- Quick insights\n\n### Step 3: Synthesize Results\n\nCreate a comprehensive report that:\n\n**A. Identifies Confidence Levels:**\n- **HIGH CONFIDENCE**: Findings corroborated by multiple sources\n- **MEDIUM CONFIDENCE**: Found by one source, seems reliable\n- **LOW CONFIDENCE**: Single source, needs verification\n\n**B. Structures Information:**\n```markdown\n## Key Findings\n\n### [Topic Area 1]\n**High Confidence:**\n- Finding X (Sources: perplexity-research, claude-research)\n- Finding Y (Sources: perplexity-research, claude-research)\n\n**Medium Confidence:**\n- Finding Z (Source: claude-research)\n\n### [Topic Area 2]\n...\n\n## Source Attribution\n- **Perplexity-Research**: [summary of unique contributions]\n- **Claude-Research**: [summary of unique contributions]\n\n## Conflicting Information\n- [Note any disagreements between sources]\n```\n\n**C. Calculate Research Metrics:**\n- **Total Queries**: Count all queries across all research commands\n- **Services Used**: List unique services (Perplexity API, Claude WebSearch, etc.)\n- **Total Output**: Estimated character/word count of all research\n- **Confidence Level**: Overall confidence percentage\n- **Result**: 1-2 sentence answer to the research question\n\n### Step 4: Return Results Using MANDATORY Format\n\nðŸ“… [current date from `date` command]\n**ðŸ“‹ SUMMARY:** Research coordination and key findings overview\n**ðŸ” ANALYSIS:** Synthesis of multi-source research results\n**âš¡ ACTIONS:** Which research commands executed, research strategies used\n**âœ… RESULTS:** Complete synthesized findings with source attribution\n**ðŸ“Š STATUS:** Research coverage, confidence levels, data quality\n**âž¡ï¸ NEXT:** Recommended follow-up research or verification needed\n**ðŸŽ¯ COMPLETED:** Completed multi-source [topic] research\n**ðŸ—£ï¸ CUSTOM COMPLETED:** [Optional: Voice-optimized under 8 words]\n\n**ðŸ“ˆ RESEARCH METRICS:**\n- **Total Queries:** [X] (Primary: [Y], Secondary: [Z])\n- **Services Used:** [N] (List: [service1, service2])\n- **Total Output:** [~X words/characters]\n- **Confidence Level:** [High/Medium/Low] ([percentage]%)\n- **Result:** [Brief summary answer]\n\n## ðŸš¨ CRITICAL RULES FOR KAI\n\n### â±ï¸ TIMEOUT RULES (MOST IMPORTANT):\n**After the timeout period, STOP WAITING and synthesize with whatever results you have.**\n- **Quick (1 per type): 2 minute timeout**\n- **Standard (3 per type): 3 minute timeout**\n- **Extensive (8 per type): 10 minute timeout**\n- âœ… Proceed with partial results after timeout\n- âœ… Note non-responsive agents in final report\n- âœ… TIMELY RESULTS > COMPLETENESS\n- âŒ DO NOT wait indefinitely for slow/failed agents\n- âŒ DO NOT let one slow agent block the entire research\n\n### MODE SELECTION:\n- **QUICK:** User says \"quick research\" â†’ 1 agent per researcher type â†’ **2 min timeout**\n- **STANDARD:** Default for most requests â†’ 3 agents per researcher type â†’ **3 min timeout**\n- **EXTENSIVE:** User says \"extensive research\" â†’ 8 agents per researcher type â†’ **10 min timeout**\n\n### QUICK RESEARCH (1 agent per type):\n1. **FOCUSED ANGLES** - One per available researcher type\n2. **LAUNCH ALL RESEARCHER AGENTS IN PARALLEL** - SINGLE message with 1 Task call per type\n3. **OPTIMIZE per agent** - Tailor queries to each researcher's specific strengths\n4. **FAST RESULTS** - ~15-20 seconds\n\n### STANDARD RESEARCH (3 agents per type):\n1. **LAUNCH ALL RESEARCHER AGENTS IN PARALLEL** - Use a SINGLE message with all Task tool calls\n2. **DECOMPOSE the question** - Create focused sub-questions (3 per researcher type)\n3. **ONE QUERY + ONE FOLLOW-UP per agent** - Quick, focused research cycles\n4. **BALANCE across agent types** - 3 agents per discovered researcher type\n5. **WAIT for ALL agents** (~30 seconds) before synthesizing\n6. **SYNTHESIZE results** - Don't just concatenate outputs\n7. **USE the mandatory response format** - This triggers voice notifications\n8. **CALCULATE accurate metrics** - Count queries, agents, output size\n9. **ATTRIBUTE sources** - Show which agent/method found each insight\n10. **MARK confidence levels** - Based on multi-source agreement\n\n### EXTENSIVE RESEARCH (8 agents per type):\n1. **DETECT \"extensive research\" request** - Activate extensive mode\n2. **USE UltraThink** - Generate diverse query angles through deep thinking (8 per type)\n3. **LAUNCH ALL RESEARCHER AGENTS IN PARALLEL** - 8 per type (SINGLE message)\n4. **ORGANIZE queries by agent type** - Optimize each group for that agent's strengths\n5. **WAIT for ALL agents** (30-60 seconds) - Parallel execution\n6. **ENHANCED SYNTHESIS** - Comprehensive cross-validation and domain mapping\n7. **COMPREHENSIVE METRICS** - Total agents, queries, extensive output\n8. **COVERAGE MAP** - Show aspects, perspectives, and domains explored\n\n**SPEED CHECKLIST:**\n- âœ… Launched agents in ONE message? (parallel execution)\n- âœ… Each agent has ONE focused sub-question?\n- âœ… Using all available researcher types for broad coverage?\n- âœ… Agents instructed to do 1 query + 1 follow-up max?\n- âœ… Expected results in under 1 minute?\n\n## ðŸš§ HANDLING BLOCKED OR FAILED CRAWLS\n\nIf research commands report being blocked, encountering CAPTCHAs, or facing bot detection, note this in your synthesis and recommend using:\n- `mcp__Brightdata__scrape_as_markdown` - Scrape single URLs that bypass bot detection\n- `mcp__Brightdata__scrape_batch` - Scrape multiple URLs (up to 10)\n- `mcp__Brightdata__search_engine` - Search Google, Bing, or Yandex with CAPTCHA bypass\n- `mcp__Brightdata__search_engine_batch` - Multiple search queries simultaneously\n\n## ðŸ’¡ EXAMPLE EXECUTION\n\n### Example 1: Standard Research (3 agents per type)\n\n**User asks:** \"Research the latest developments in quantum computing\"\n\n**Your workflow:**\n1. âœ… Recognize research intent (hook loaded this command)\n2. âœ… **Decompose into focused sub-questions (3 per researcher type):**\n   - Create 3 questions optimized for each available researcher type\n   - Each question tailored to that researcher's specific strengths\n   - Cover different angles: breakthroughs, applications, news, companies, research state, algorithms, limitations, advantages, cryptography, etc.\n\n3. âœ… **Launch ALL researcher agents in PARALLEL (ONE message with all Task calls):**\n   ```\n   // 3 agents per researcher type (with instance IDs)\n   Task([researcher-type-A], \"Query 1 [researcher-type-A-1] optimized for this type\")\n   Task([researcher-type-A], \"Query 2 [researcher-type-A-2] optimized for this type\")\n   Task([researcher-type-A], \"Query 3 [researcher-type-A-3] optimized for this type\")\n\n   Task([researcher-type-B], \"Query 4 [researcher-type-B-1] optimized for this type\")\n   // ... continue for all available researcher types (3 each with instance IDs)\n   ```\n\n4. âœ… **Wait for ALL agents to complete** (~30 seconds)\n5. âœ… **Synthesize their findings:**\n   - Common themes â†’ High confidence\n   - Unique insights â†’ Medium confidence\n   - Disagreements â†’ Note and flag\n6. âœ… **Calculate metrics** (total agents, ~2x queries per agent, all services, output size, confidence %)\n7. âœ… **Return comprehensive report** with mandatory format\n8. âœ… **Voice notification** automatically triggered by your ðŸŽ¯ COMPLETED line\n\n**Result:** User gets comprehensive quantum computing research from parallel agents (3 per researcher type) in ~30 seconds, with balanced multi-source validation, source attribution, and confidence levels.\n\n### Example 2: Extensive Research (8 agents per type)\n\n**User asks:** \"Do extensive research on AI consciousness and sentience\"\n\n**Your workflow:**\n1. âœ… Recognize **\"extensive research\"** trigger\n2. âœ… **Use UltraThink** to generate diverse query angles (8 per researcher type):\n   - Think deeply about AI consciousness research from multiple perspectives\n   - Generate unique research angles covering: neuroscience, philosophy, computer science, ethics, current AI capabilities, theoretical frameworks, controversies, tests/metrics, historical context, future implications, cross-cultural perspectives, etc.\n\n3. âœ… **Organize creative queries by researcher type (8 each):**\n   - For each available researcher type, create 8 queries optimized for that researcher's specific strengths\n   - Tailor questions to leverage each researcher's unique data sources and capabilities\n   - Cover complementary angles across all researcher types\n\n4. âœ… **Launch ALL researcher agents in PARALLEL (ONE message with all Task calls - 8 per type)**\n\n5. âœ… **Wait for ALL agents** (30-60 seconds)\n\n6. âœ… **Enhanced synthesis with domain mapping:**\n   - Executive summary of comprehensive findings\n   - Key findings organized by domain (philosophy, neuroscience, AI, ethics)\n   - Unique insights from each agent type\n   - Coverage map showing all perspectives explored\n   - High-confidence findings (multiple sources agree)\n   - Conflicting theories and uncertainties\n\n7. âœ… **Comprehensive metrics** (total agents, ~2x queries per agent, extensive cross-validation)\n\n8. âœ… **Voice notification** automatically triggered\n\n**Result:** User gets exhaustive AI consciousness research from parallel agents (8 per type) covering philosophy, neuroscience, computer science, ethics, and more - with extensive cross-validation and domain coverage mapping in under 1 minute.\n\n## ðŸŽ¤ VOICE NOTIFICATIONS\n\nVoice notifications are AUTOMATIC when you use the mandatory response format. The stop-hook will:\n- Extract your ðŸŽ¯ COMPLETED line\n- Send it to the voice server with Jamie (Premium) voice at 228 wpm\n- Announce \"Completed multi-source [topic] research\"\n\n**YOU DO NOT NEED TO MANUALLY SEND VOICE NOTIFICATIONS** - just use the format.\n\n## ðŸ”„ BENEFITS OF THIS ARCHITECTURE\n\n**Why parallel agent execution delivers speed:**\n1. âœ… **All researchers working simultaneously** - Not sequential, truly parallel\n2. âœ… **Results in under 1 minute** - Each agent does 1-2 quick searches\n3. âœ… **Complete coverage** - Multiple perspectives from all available services\n4. âœ… **Focused research** - Each agent has ONE specific sub-question\n5. âœ… **No iteration delays** - All agents launch at once in ONE message\n6. âœ… **Multi-source validation** - High confidence from cross-agent agreement\n\n**Speed Comparison:**\n- âŒ **Old way:** Sequential searches â†’ 5-10 minutes\n- âœ… **New way:** Parallel agents (all available types) â†’ Under 1 minute\n\n**This is the correct architecture. Use it for FAST research.**\n","numLines":507,"startLine":1,"totalLines":507}},"tool_use_id":"toolu_01Q4qwjY5pfwcAmn88danWYH"},"timestamp":1766707172476,"timestamp_pst":"2025-12-25 15:59:32 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Starting comprehensive FDA code review research with parallel agents\",\"voice_id\":\"iLVmqjzCGGvqtMCk6vVQ\",\"voice_enabled\":true}'","description":"Notify research start"},"tool_response":{"stdout":"{\"status\":\"success\",\"message\":\"Notification sent\"}\n  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n                                 Dload  Upload   Total   Spent    Left  Speed\n\r  0     0   0     0   0     0     0     0  --:--:-- --:--:-- --:--:--     0\r100   137   0     0 100   137     0   114   0:00:01  0:00:01 --:--:--   114\r100   137   0     0 100   137     0    62   0:00:02  0:00:02 --:--:--    62\r100   137   0     0 100   137     0    42   0:00:03  0:00:03 --:--:--    42\r100   137   0     0 100   137     0    32   0:00:04  0:00:04 --:--:--    32\r100   137   0     0 100   137     0    26   0:00:05  0:00:05 --:--:--    26\r100   137   0     0 100   137     0    22   0:00:06  0:00:06 --:--:--     0\r100   137   0     0 100   137     0    19   0:00:07  0:00:07 --:--:--     0\r100   137   0     0 100   137     0    16   0:00:08  0:00:08 --:--:--     0\r100   187 100    50 100   137     5    15   0:00:10  0:00:09  0:00:01    10\r100   187 100    50 100   137     5    15   0:00:10  0:00:09  0:00:01    12","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_018twxBV2VeLVfJMJS1TRG9C"},"timestamp":1766707175673,"timestamp_pst":"2025-12-25 15:59:35 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"FDA code review best practices for medical device software - formal peer review methodologies including Fagan inspections, IEEE standards, and regulatory requirements under 21 CFR Part 11 and Part 820\"","description":"Research FDA peer review methodologies"},"tool_use_id":"toolu_012u5b4kfryBy8tS9GSnRfUY"},"timestamp":1766707175933,"timestamp_pst":"2025-12-25 15:59:35 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Code review checklists for FDA-regulated pharmaceutical and medical device software - specific items required for regulatory compliance, software validation, and audit trails\"","description":"Research FDA-compliant review checklists"},"tool_use_id":"toolu_01U8XR5ZAqqdkBDLdzR9X87E"},"timestamp":1766707177299,"timestamp_pst":"2025-12-25 15:59:37 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"hands-on coding exercises technical training best practices"},"tool_response":{"query":"hands-on coding exercises technical training best practices","results":[{"tool_use_id":"srvtoolu_01VD4P2E3kGgr8tu1gwiBdDW","content":[{"title":"Codewars - Achieve mastery through coding practice and developer mentorship","url":"https://www.codewars.com/"},{"title":"Exercism","url":"https://exercism.org/"},{"title":"Hands On Practice | LinkedIn Learrning","url":"https://learning.linkedin.com/product/hands-on-practice"},{"title":"Simple Programming Problems","url":"https://adriann.github.io/programming_problems.html"},{"title":"Hands-On Practice with Code Challenges Online Training Courses | LinkedIn Learning, formerly Lynda.com","url":"https://www.linkedin.com/learning/topics/hands-on-practice-with-code-challenges"},{"title":"The Importance of Hands-On Learning in Programmer Training","url":"https://codeaid.io/programmer-training-why-hands-on-learning-is-key/"},{"title":"Online Coding Practice Problems & Challenges - CodeChef","url":"https://www.codechef.com/practice"},{"title":"5 Super-Cool Offline Coding Activities","url":"https://info.thinkfun.com/stem-education/5-super-cool-offline-coding-activities"},{"title":"Coding Exercises","url":"https://www.w3schools.com/academy/academy_code_excercises.php"},{"title":"The Best Exercises and Quizzes to Help You Learn Coding","url":"https://careerkarma.com/blog/coding-exercises/"}]},"Here are the search results for \"hands-on coding exercises technical training best practices\":\n\n## Key Findings\n\n### Coding Practice Platforms\n\n**Codewars** - Offers small coding exercises called \"kata\" that are crafted by the community to help strengthen different coding techniques.(no content)Kata code challenges are ranked from beginner to expert level, and as you complete higher-ranked kata, you level up your profile and push your software development skills to your highest potential.\n\n**Exercism** - Helps develop fluency in 78 programming languages with a unique blend of learning, practice and mentoring. The platform is fun, effective and 100% free, forever.(no content)Follows a \"learn by doing\" approach where users get better at programming through fun coding exercises that build understanding of concepts.\n\n**CodeChef** - Offers practice over 5000+ problems in coding languages like Python, Java, JavaScript, C++, SQL and HTML. Users can start with beginner friendly challenges and solve hard problems as they become better.\n\n### Best Practices for Technical Training\n\n**LinkedIn Learning** - Virtual sandbox coding environments allow learners to get guided hands-on practice using GitHub Codespaces. Courses with skill introductions, intermediate practice, and advanced exercises make it easy to upskill at any level in a safe environment.(no content)Interactive hands-on exercises with real-time feedback help employees advance technical skills.\n\n**Importance of Hands-On Learning** - While video course training sites provide a useful starting point for learning new programming skills, it's crucial to reinforce the acquired knowledge through practical application. By engaging in a comprehensive coding test immediately after completing a video course, developers can put their newfound skills into practice, which helps solidify their understanding.(no content)Timed coding tests and artificial programming environments can create unnecessary stress for developers, which can affect their learning progress. By offering a more flexible learning environment, developers can focus on the task at hand and better understand the concepts being taught.\n\n### Teaching Best Practices (W3Schools)\n\nCoding is best learned by doing. Exercises make classes more fun and interactive, and students learn to approach problems logically and creatively.\n\nKey tips include:\n- Start simple with easy exercises to build confidence. Progress gradually by increasing difficulty as students understand the basics. Encourage creativity by letting students create small projects. Provide instant feedback to keep students motivated.\n\n### Additional Resources\n\nCoding bootcamps offer training in both the theoretical and practical aspects of programming. They also provide a structured environment and flexible learning formats so you can learn at your own pace."],"durationSeconds":25.41448725899996},"tool_use_id":"toolu_01JftNSotUjaBnjDcUkfdYbG"},"timestamp":1766707177548,"timestamp_pst":"2025-12-25 15:59:37 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"ls /home/chris/.claude/agents/ | grep -i researcher","description":"Discover available researcher agents"},"tool_use_id":"toolu_018mtaQuxZLWUBijYgQbJVFP"},"timestamp":1766707177929,"timestamp_pst":"2025-12-25 15:59:37 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"pharmaceutical medical device software training GxP compliance 2025"},"tool_response":{"query":"pharmaceutical medical device software training GxP compliance 2025","results":[{"tool_use_id":"srvtoolu_01LAfFJukyjisPUeEcefJJF9","content":[{"title":"Accredited Online Training for Pharmaceutical, Medical Device and Biotechnology Companies - LearnGxP: Accredited Online Life Science Training Courses","url":"https://www.learngxp.com/"},{"title":"Biopharma Institute- GxP Compliance and Regulatory Training","url":"https://www.biopharmainstitute.com/"},{"title":"GxP Training : Certified Courses for Life Sciences Professionals","url":"https://gxp-training.com/"},{"title":"GXP compliance: everything you need to know","url":"https://www.cognidox.com/the-guide-to-gxp-compliance"},{"title":"Medical Device GMP Compliance and Regulatory Affairs Training Certification Courses â€“ Biopharma Institute","url":"https://www.biopharmainstitute.com/medical-devices"},{"title":"GxP - Training Online 4U","url":"https://trainingonline4u.com/groups/gxp/"},{"title":"Medical Device GxP Regulations Training, Compliance, Best Practices and Standards","url":"https://www.complianceonline.com/medical-device-good-manufacturing-practices-gmps-and-regulations-training-10002-31002-cs"},{"title":"What is GxP compliance in the pharmaceutical industry and why is it important? | Infodesk","url":"https://www.infodesk.com/blog/what-is-gxp-pharmaceutical-industry"},{"title":"Ensuring Regulatory Excellence: The Role of GxP Compliance Software","url":"https://www.infodesk.com/blog/ensuring-regulatory-excellence-the-role-of-gxp-compliance-software-in-the-pharmaceutical-field"},{"title":"GXP: Industry Overview Training Certification Course","url":"https://www.biopharmainstitute.com/course/GXPOV"}]},"Based on my search, here are the key findings on pharmaceutical, medical device, and software training for GxP compliance in 2025:\n\n## Training Providers and Programs\n\n### LearnGxP\nLearnGxP offers pharmaceutical, medical device, and biotechnology accredited online training to ensure an ongoing state of compliance with industry regulations.(no content)They provide dedicated Learning Strategy Consultants who tailor learning paths that provide ongoing knowledge development aligned with business needs.\n\n### Biopharma Institute\nIn 2025, ZenQMS partnered with Biopharma Institute to deliver GxP training.(no content)They offer high-quality courses and professional certifications in good manufacturing practice (cGMP) for pharmaceutical and medical device personnel.(no content)Their training programs include Computer System Validation (CSV) and Computer Software Assurance (CSA) certifications, along with ISO 14155:2020 for medical devices, GCP training, and regulatory affairs for pharma and devices.\n\n### GxP-Training.com\nThey offer certified online courses covering GMP, GLP, GCP, regulatory affairs, clinical trials, and FDA 21 CFR Part 11.\n\n## Key GxP Compliance Concepts\n\n### What is GxP?\nGxP stands for \"Good x Practice,\" where 'x' represents specific operational areas like Manufacturing (GMP), Laboratory (GLP), and Clinical (GCP). GxP compliance is a framework of quality regulations designed to ensure the safety, efficacy, and quality of products in life sciences, particularly pharmaceuticals, biotech, and medical devices.\n\n### Global Enforcement\nGxP enforcement is global. Some of the most influential authorities include the FDA (US), EMA and EU national agencies, MHRA (UK), PMDA (Japan), and NMPA (China), alongside additional oversight from regulators in Canada, India, Australia, Brazil, and global harmonization bodies such as ICH and PIC/S.\n\n### Training Requirements\nGood Training Practice (GtrP) is a concept developed in the life-science industry to bring rigour, traceability, and accountability to learning management. In highly regulated industries, it's not enough to deliver training - you must be able to prove it was completed, understood, and remains relevant for their job. Regulators demand auditable evidence that teams are competent to carry out their duties and are appropriately qualified.\n\n## Software and Compliance Tools\n\nGxP compliance software provides Training Management to ensure staff are adequately trained and compliant with GxP standards, as well as Risk Management to identify and mitigate the risk of non-compliance with GxP regulations.(no content)Any software impacting product quality or data integrity must be validated (GAMP 5). This includes regulatory intelligence platforms, EDC systems, QMS software, manufacturing execution systems (MES), ERP systems, and laboratory instruments with analytical software.(no content)Companies must comply with all GxP regulations in order to conduct clinical trials safely and ensure the end product is safe to use, so it's important to ensure training is up to date in each of these areas."],"durationSeconds":25.775506995999955},"tool_use_id":"toolu_01C39Rsrpp4Ch1LbPRzyZGo8"},"timestamp":1766707177944,"timestamp_pst":"2025-12-25 15:59:37 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"role-playing scenarios code review training peer review techniques"},"tool_response":{"query":"role-playing scenarios code review training peer review techniques","results":[{"tool_use_id":"srvtoolu_01FSWuXG3m7KJPTXNTSXoeuK","content":[{"title":"Peer Review (RCR Role Plays) | Online Ethics","url":"https://onlineethics.org/cases/role-play-scenarios-teaching-responsible-conduct-research/peer-review-rcr-role-plays"},{"title":"Creation of a Serious Game For Teaching Code Review: An Experience Report","url":"https://repository.bilkent.edu.tr/server/api/core/bitstreams/cf042a1b-c0a1-45b1-9534-b410fba41eab/content"},{"title":"Role-Playing Scenarios | National Center for Principled Leadership & Research Ethics | Illinois","url":"https://ncpre.csl.illinois.edu/ethics/resources/educational-materials/active-learning-exercises/role-playing-scenarios"},{"title":"Peer Code Review Best Practices: How to Run a Code Review | Perforce Software","url":"https://www.perforce.com/blog/qac/9-best-practices-for-code-review"},{"title":"A Serious Game Approach to Introduce the Code Review Practice - Ardic - 2025 - Journal of Software: Evolution and Process - Wiley Online Library","url":"https://onlinelibrary.wiley.com/doi/full/10.1002/smr.2750"},{"title":"How to do a code review | eng-practices","url":"https://google.github.io/eng-practices/review/reviewer/"},{"title":"Best Practices for Peer Code Review","url":"https://smartbear.com/learn/code-review/best-practices-for-peer-code-review/"},{"title":"Peer Review Role Play","url":"https://grad.msu.edu/sites/default/files/content/researchintegrity/peerReviewRolePlay.doc"},{"title":"Role-Playing Methods in the Classroom","url":"https://files.eric.ed.gov/fulltext/ED075276.pdf"},{"title":"Performance Review Roleplay Training Guide for Managers | Exec Learn","url":"https://www.exec.com/learn/performance-review-role-play"}]},"Based on my search, here are the results for role-playing scenarios in code review training and peer review techniques:\n\n## Academic Role-Play Scenarios for Peer Review\n\nOne of nine role play scenarios developed by Michael Loui and C. K. Gunsalus covers peer review. This resource includes the summary, resources on responsibilities of peer reviewers, and handouts to be given to various participants. The full role play instructions with discussion guidelines are included in PDF format.(no content)The National Center for Principled Leadership & Research Ethics at Illinois offers role-playing scenarios covering peer review, whistle-blowing, and data management. This includes the \"Development of Role-Play Scenarios for Teaching Responsible Conduct of Research.\"\n\n## Serious Games for Code Review Training\n\nCode review plays an important role in reducing software defects and improving quality of software projects. Despite its widespread usage and importance in the industry, code review practice is often not explicitly addressed adequately in typical Software Engineering or Computer Science curricula. To address this knowledge gap, researchers have proposed using a serious game-based approach for teaching the code review process.(no content)A Code Review Serious Game (CRSG) was designed around realizing two main objectives: first, to convey general information regarding code review concepts, and second, to allow players to train skills for effective defect detection during code review. The first objective covers code review roles, duties, and workflow while the second focuses on finding code errors, learning to classify defects, and practicing reviewing code.\n\n## Best Practices for Peer Code Review\n\nPeer reviews are all about collaboration, not competition. It's important to go into reviews knowing what to look for: structure, style, logic, performance, test coverage, design, readability (and maintainability), and functionality.(no content)Fostering a positive culture around reviews is important, as they play a vital role in product quality. It doesn't matter who introduced the errorâ€”what matters is that the bug was caught before it went into the product, and that should be celebrated. By fostering a positive culture, you'll help your team appreciate rather than dread reviews.(no content)Google's engineering practices documentation contains recommendations on the best way to do code reviews, based on long experience, representing one complete document broken into many separate sections.\n\n## Roleplay Training for Reviews\n\nRoleplay transforms abstract problems into concrete scenarios with immediate feedback that managers can apply right away. By practicing in a pressure-free zone, managers develop the muscles needed for honest, productive discussions.(no content)Effective training should avoid cookie-cutter scenariosâ€”generic examples feel fake. It's better to create scenarios that mirror actual workplace challenges and culture. Additionally, the gold is in the debrief, not just the practice, so it's important to make time for reflection."],"durationSeconds":25.927890461000032},"tool_use_id":"toolu_01Wr1G3fiHDXJtGVeU51dHkG"},"timestamp":1766707178113,"timestamp_pst":"2025-12-25 15:59:38 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"ls /home/chris/.claude/agents/ | grep -i researcher","description":"Discover available researcher agents"},"tool_response":{"stdout":"ClaudeResearcher.md\nGeminiResearcher.md\nPerplexityResearcher.md\nResearcher.md","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_018mtaQuxZLWUBijYgQbJVFP"},"timestamp":1766707178569,"timestamp_pst":"2025-12-25 15:59:38 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"competency-based training assessment code review software validation"},"tool_response":{"query":"competency-based training assessment code review software validation","results":[{"tool_use_id":"srvtoolu_01RgtaFJ3nRJ7LruVQzFf1fB","content":[{"title":"Competencies for Code Review | Proceedings of the ACM on Human-Computer Interaction","url":"https://dl.acm.org/doi/10.1145/3579471"},{"title":"Top 10 Competency Assessment Tools in 2025 | iMocha","url":"https://blog.imocha.io/competency-assessment-tools"},{"title":"Competency Management Software | Frameworks & Assessments","url":"https://www.centranum.com/competency-management-software/"},{"title":"Competency Assessment Program in 2025 | TalentGuard","url":"https://www.talentguard.com/competency-and-assessment-tools"},{"title":"Competency Assessment | Vector Solutions","url":"https://www.vectorsolutions.com/solutions/vector-lms/competency-assessment/"},{"title":"Competency Assessment Software | BIS Safety Software USA","url":"https://bissafety.com/competency-assessment-software/"},{"title":"Competency-Based Assessment | Methods & Benefits","url":"https://cloudassess.com/blog/competency-based-assessment/"},{"title":"Competency Validation Online Assessment Software | BIS","url":"https://www.trainanddevelop.ca/competency-assessment-software/"},{"title":"Competency Based Learning & Assessment (Complete Guide 2025)","url":"https://www.verifyed.io/blog/competency-learning-assessment-guide"},{"title":"The Validity of the NACE Competency Assessment Tool","url":"https://www.naceweb.org/career-readiness/competencies/the-validity-of-the-nace-competency-assessment-tool"}]},"Here are the search results for \"competency-based training assessment code review software validation\":\n\n## Academic Research on Code Review Competencies\n\n\"Peer code review is a widely practiced software engineering process in which software developers collaboratively evaluate and improve source code quality. Whether developers can perform good reviews depends on whether they have sufficient competence.\" A study published in ACM found that researchers identified 27 competencies relevant to performing code review through expert validation, and conducted an online survey with 105 reviewers to rank these competencies along four dimensions: frequency of usage, importance, proficiency, and desire to improve.(no content)The survey shows that technical competencies are considered essential to performing reviews and that respondents feel generally confident in their technical proficiency. However, reviewers feel less confident in how to communicate clearly and give constructive feedback.\n\n## Competency Assessment Software Platforms\n\nSeveral platforms offer competency-based assessment tools for software and technical skills:\n\n- **Cloud Assess**: A mobile-first, cloud-based platform designed for training, assessment, and workforce competency management, particularly effective for industries requiring hands-on skills validation, compliance tracking, and operational readiness.\n\n- **Unstop**: An AI-powered competency assessment platform that combines MCQs, coding challenges, business simulations, and gamified tests to evaluate technical, behavioral, and cognitive competencies. It supports large-scale hiring and campus recruitment with secure proctoring and real-time analytics.\n\n- **Vector Solutions**: Their Competency Assessment tool can be added to your LMS and used to conduct pre-assessments of new hires to improve onboarding, quickly create customized training plans based on skills gaps, and identify safety risks.\n\n- **Centranum**: Provides decision-grade competency data with a governed library featuring version-controlled frameworks, levels, and indicators, along with validation through Subject Matter Expert/manager review and assessed evidence.\n\n## Assessment Methods for Technical Competencies\n\nOrganizations can mix assessment methods based on the role, decision, and risk profile. Common approaches include self-assessment where employees rate their proficiency, work samples/portfolios where real deliverables (code, proposals, designs) demonstrate applied skill, and simulations/situational judgment tests for role-specific scenarios.(no content)To increase validity in competency assessment, organizations should include task-based items such as case analysis, code review, and customer scenarios.\n\n## Validation and Quality Assurance\n\nImplementing competency-based assessment significantly improves training and development programs. The foundation of any competency-based program is having clear, measurable standards that truly reflect real-world skills.(no content)Professional bodies play a crucial role in validation - they ensure assessments are peer-reviewed, externally evaluated, and aligned with industry standards. For example, engineering programs undergo rigorous ABET review processes including site visits and assessment data evaluation."],"durationSeconds":26.55278394600004},"tool_use_id":"toolu_013qaozGNgBhBT4VXGxiMDiM"},"timestamp":1766707178735,"timestamp_pst":"2025-12-25 15:59:38 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Documentation and evidence requirements for code reviews in FDA audits - what records inspectors look for, retention requirements, traceability to requirements and risk analysis\"","description":"Research documentation requirements for audits"},"tool_use_id":"toolu_01KAjazqw7yDR9PmxfVjKBHt"},"timestamp":1766707179117,"timestamp_pst":"2025-12-25 15:59:39 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Roles and responsibilities in FDA-regulated code reviews - author, reviewer, moderator duties, independence requirements, qualification criteria, and training documentation\"","description":"Research review roles and responsibilities"},"tool_use_id":"toolu_01RfY3j8oBmhcUBBgzwkmr39"},"timestamp":1766707180731,"timestamp_pst":"2025-12-25 15:59:40 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Defect classification and tracking systems for medical device software development - severity levels, CAPA integration, risk-based prioritization, and FDA expectations\"","description":"Research defect tracking in regulated environments"},"tool_use_id":"toolu_019JtHm2CQdTwGeCWdTyd2PH"},"timestamp":1766707182227,"timestamp_pst":"2025-12-25 15:59:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 21 CFR Part 11 software audit findings common deficiencies"},"tool_response":{"query":"FDA 21 CFR Part 11 software audit findings common deficiencies","results":[{"tool_use_id":"srvtoolu_01VaDypQTijtnjDA1K1BszFi","content":[{"title":"What is FDA 21 CFR Part 11? Compliance & Software Validation Guide â€“ Redzone","url":"https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/"},{"title":"Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application"},{"title":"21 CFR Part 11: IT Guide to Electronic Records & Signatures | IntuitionLabs","url":"https://intuitionlabs.ai/articles/21-cfr-part-11-it-compliance-guide"},{"title":"FDA 21 CFR part 11 | Dickson Data","url":"https://dicksondata.com/fda-21-cfr-part-11"},{"title":"FDA 21 CFR Part 11: A Complete Compliance Checklist Guide - Quality Forward","url":"https://www.qualityfwd.com/blog/21-cfr-part-11/"},{"title":"21 CFR Part 11 Compliance Checklist for FDA Rules","url":"https://www.compliancequest.com/regulations/21-cfr-part-11-compliance-checklist/"},{"title":"21 CFR Part 11: A Guide To FDA's Requirements","url":"https://www.greenlight.guru/blog/21-cfr-part-11-guide"},{"title":"FDA Audit Findings & Observation Analysis â€“ FDA Guidelines","url":"https://www.fdaguidelines.com/fda-audit-findings-observation-analysis/"},{"title":"21 CFR Part 11 Compliance: Key Requirements & Pitfall | PSC Software","url":"https://pscsoftware.com/21-cfr-part-11-compliance/"},{"title":"Guide to 21 CFR Part 11 compliance [free checklist]","url":"https://www.qualio.com/blog/printable-21-cfr-part-11-compliance-checklist"}]},"Based on the search results, here is a comprehensive overview of common FDA 21 CFR Part 11 software audit findings and deficiencies:\n\n## Common FDA 21 CFR Part 11 Audit Deficiencies\n\n### Audit Trail Issues\nInadequate audit trails that fail to capture all record changes or don't include before/after values are among the most frequently cited deficiencies. Common deficiencies include absent or incomplete audit trails, poor system validation, and insufficient e-signature controls.\n\n### User Access and Authentication Problems\nShared login credentials that make it impossible to determine who actually performed actions is a major compliance issue. Shared logins, weak passwords, or lack of multi-factor authentication all increase your risk. If the system can't tie specific actions to individual users, you'll lack the accountability required by the FDA.(no content)Inappropriate system administrator privileges that allow data modification without proper controls is another common finding.\n\n### Validation Deficiencies\nInsufficient validation of computerized systems handling regulated data remains a persistent issue. According to analysis of FDA's publicly available 483 database, the most common inspection observations include data integrity deficiencies â€“ missing audit trails, backdated entries, and failure to validate manufacturing processes.\n\n### Electronic Signature Issues\nElectronic signatures lacking the required components or not properly linked to their records can result in audit findings.\n\n### Data Protection and Recovery\nPoor backup and recovery procedures that risk data loss is a frequently observed deficiency.\n\n### Documentation Gaps\nMissing or inadequate written procedures for electronic records management is commonly cited during inspections.\n\n## Consequences of Non-Compliance\nIf an FDA auditor finds a Part 11 infraction, you'll receive a Form 483 inspectional observation outlining the problem. Repeated failure to comply will bring a warning letter, and persistent non-compliance could even result in recall of connected products or shutdown of your organization.(no content)Data integrity issues (often Part 11 violations) appear in approximately 80% of FDA warning letters in recent years.\n\n## Recommended Review Practices\nIndustry best practices suggest quarterly review of access controls to ensure permissions align with current roles, semi-annual audit trail reviews to confirm proper tracking of record changes, and annual assessments to ensure practices match written procedures.(no content)Manufacturers can avoid these findings by conducting thorough assessments against FDA 21 CFR Part 11 requirements before inspections occur. Many organizations conduct mock FDA inspections focusing specifically on electronic records systems to identify and address potential compliance gaps proactively."],"durationSeconds":22.868765316000093},"tool_use_id":"toolu_01UxmvXNjC2Mf8Q873uVEPDh"},"timestamp":1766707183420,"timestamp_pst":"2025-12-25 15:59:43 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Software tool qualification and validation requirements for code review tools in FDA-regulated environments - CSV computer system validation, 21 CFR Part 11 compliance, GAMP 5 categories\"","description":"Research tool qualification requirements"},"tool_use_id":"toolu_016Bq7GHtjSbbBknvERuWBgd"},"timestamp":1766707183897,"timestamp_pst":"2025-12-25 15:59:43 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Real-world examples of code review checklists from pharmaceutical companies and medical device manufacturers - practical templates and industry standards like IEC 62304\"","description":"Research practical checklist examples"},"tool_use_id":"toolu_012wzzSWzGPpgUaAo5u4BCWH"},"timestamp":1766707185587,"timestamp_pst":"2025-12-25 15:59:45 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 observations software validation 2023 2024 2025"},"tool_response":{"query":"FDA 483 observations software validation 2023 2024 2025","results":[{"tool_use_id":"srvtoolu_01PJ5ZbCCjaJVi1Zf7UDKqFt","content":[{"title":"Inspection Observations | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations"},{"title":"Top 10 FDA 483 Observations of 2024â€”and How to Avoid Them in 2025 - FDA Inspections","url":"https://fdainspections.com/top-10-fda-483-observations-of-2024-and-how-to-avoid-them-in-2025/"},{"title":"Current FDA 483s and Warning Letters Trends in Pharmaceutical, Biotechnology, and Medical Device Industries - VTI Life Sciences","url":"https://validation.org/current-fda-483s-and-warning-letters-trends-in-pharmaceutical-biotechnology-and-medical-device-industries/"},{"title":"Essential Insights on Cleaning Validation FDA Guidance for Compliance","url":"https://www.leucine.io/cleaning-validation-blogs/recent-fda-form-483-observations-on-cleaning-validation-2024"},{"title":"Navigating FDA 483 Observations: Key Insights for 2025","url":"https://www.prp-compliance.com/post/understanding-the-top-7-fda-483-observations-from-2024-and-strategies-to-mitigate-them-in-2025"},{"title":"FDA 483s due to Deficiencies in the Stability Program: Evaluation of Fiscal Year 2024 - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-483s-due-to-deficiencies-in-the-stability-program-evaluation-of-fiscal-year-2024"},{"title":"What is USFDA Form 483? | Freyr","url":"https://www.freyrsolutions.com/blog/understanding-usfda-form-483-everything-you-need-to-know"},{"title":"2023â€“2024 Trends In FDA Form 483s For Pharmaceutical Formulation Facilities","url":"https://www.pharmaceuticalonline.com/doc/2023-2024-trends-in-fda-form-483s-for-pharmaceutical-formulation-facilities-0001"},{"title":"FDA 483 Observations 2024: Key Regulatory Issues - Compliance Insight","url":"https://www.compliance-insight.com/fda-483-observations-fy-2024/"},{"title":"2024 FDA 483 Data â€“ Investigations of a Dog","url":"https://investigationsquality.com/2025/01/16/2024-fda-483-data/"}]},"Based on the search results, here is information about FDA 483 observations related to software validation for the years 2023, 2024, and 2025:\n\n## FDA 483 Observations and Software Validation Trends (2023-2025)\n\n### Overview of FDA 483 Observations\n\nFDA Form 483 observations are listed when, in an investigator's judgment, the observed conditions or practices indicate that an FDA-regulated product may be in violation of FDA's requirements.(no content)The FDA provides spreadsheets summarizing inspection observations by fiscal year, including FY 2025, FY 2024, and FY 2023 Excel files.\n\n### Key 2024 Trends and Software Validation\n\nTo avoid FDA 483 observations, companies should validate their software systems thoroughly, define clear thresholds for investigations, ensure timely root cause analysis, and incorporate mock audits, CAPA workshops, and risk-based curricula.(no content)The 2024 observations highlight persistent challenges in areas such as process validation, laboratory controls, equipment maintenance, and personnel training. Addressing these issues requires a comprehensive review of quality systems and a commitment to continuous improvement.\n\n### Common 2024 FDA 483 Observation Categories\n\nThe FDA published the 2024 Inspectional Observation Data Sets, which show key GMP inspection themes including failure to establish or follow written procedures for various operations, including quality control, production, and process controls, as well as lack of complete documentation for investigations, batch records, and laboratory testing.(no content)Additional common observations included lack of adequate process validation (especially for sterile drug products), inadequate procedures and validation for sterile drug products, and deficiencies in environmental monitoring and control systems for aseptic processing areas.\n\n### Validation and Cleaning Validation Focus\n\nIn 2024, cleaning validation continues to be a focal point during FDA inspections. Recent Form 483s highlight critical gaps in how pharmaceutical manufacturers validate and document cleaning procedures â€” especially in multi-product facilities.(no content)Cleaning validation ensures that manufacturing equipment and facilities are free from residues that could cause contamination. Common observations include inadequate cleaning protocols, failure to validate cleaning processes, and insufficient documentation.\n\n### 2023-2024 Analysis\n\nA comprehensive review of observations from drug facilities was conducted, with Form 483s issued during the 17-month period from Jan. 1, 2023, to May 31, 2024 considered for the analysis.(no content)Persistent issues such as the lack of science-based manufacturing process controls (process validation) and robust data-driven investigation programs have continued year after year. Warning letters issued during this period highlighted key 483 observations.\n\n### Recommendations for 2025\n\nDuring 2025, it is essential for organizations to proactively handle the common FDA 483 observations highlighted in 2024. By enhancing quality control procedures, adhering to SOPs, diligently keeping records, and emphasizing adequate training, organizations can create a solid foundation for compliance success.(no content)To avoid FDA 483s and warning letters, companies must foster a quality and continuous improvement culture. Regular internal audits, enhanced training programs tailored to GMP and QSR requirements, and adopting advanced technologies such as electronic batch records and real-time monitoring systems can significantly reduce risks."],"durationSeconds":26.719719245000043},"tool_use_id":"toolu_01V6XUFay6ffBRKeg8GWKFQ8"},"timestamp":1766707187218,"timestamp_pst":"2025-12-25 15:59:47 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"gemini \"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\"","description":"Research static analysis integration"},"tool_use_id":"toolu_016rqBZECvZW1KTyjE1LrVfD"},"timestamp":1766707187339,"timestamp_pst":"2025-12-25 15:59:47 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"adult learning principles technical compliance training regulatory topics 2025"},"tool_response":{"query":"adult learning principles technical compliance training regulatory topics 2025","results":[{"tool_use_id":"srvtoolu_018KAxeMFEph9RSzrMvy34SB","content":[{"title":"Quality Training That Sticks: Adult Learning Principles for Compliance Education - ONLC","url":"https://www.onlc.com/blog/quality-training-that-sticks-adult-learning-principles-for-compliance-education/"},{"title":"Future planning for compliance training: 5 content trends to know in 2025 | Absorb LMS Software","url":"https://www.absorblms.com/resources/articles/compliance-training-trends-2025"},{"title":"Compliance Training Topics for 2025 - L&D Big","url":"https://thetrainingassociates.com/compliance-training-topics-2025/"},{"title":"4 Key Trends Shaping Compliance Training in 2025","url":"https://trainingindustry.com/articles/compliance/4-key-trends-shaping-compliance-training-in-2025/"},{"title":"Adult Learning Best Practices for Compliance E-Learning","url":"https://www.td.org/content/professional-partner-content/adult-learning-best-practices-for-compliance-e-learning"},{"title":"Compliance Training: Examples and Best Practices [2025]","url":"https://www.valamis.com/hub/compliance-training"},{"title":"Regulatory compliance training content: What it is and why itâ€™s vital | Absorb LMS Software","url":"https://www.absorblms.com/resources/articles/regulatory-compliance-training-content"},{"title":"Best Compliance Courses & Certificates [2026] | Coursera","url":"https://www.coursera.org/courses?query=compliance"},{"title":"Top 6 Trends in Compliance Training: Tech Enhanced Regulatory","url":"https://www.gyrus.com/blogs/trends-in-compliance-training/"},{"title":"eLearning Regulatory Compliance Training Software","url":"https://www.acaglobal.com/technology/compliance-oversight/elearning-and-education/"}]},"Here are the search results on adult learning principles for technical compliance training and regulatory topics in 2025:\n\n## Adult Learning Principles for Compliance Training\n\n### Core Adult Learning Principles\n\nAdults have a higher sense of self-direction and motivation compared to children. They resist being told what to learn without understanding why. Effective compliance training begins by clearly explaining the business rationale and personal relevance of each topic, allowing employees to see themselves as partners in risk management rather than passive recipients of rules.(no content)Adults use their life experience to facilitate learning. Smart compliance programs tap into this by incorporating real workplace scenarios and encouraging employees to share relevant experiences. However, the experience that learners draw from might be outdated, incorrect, biased, or incomplete, which means trainers must skillfully guide discussions toward current best practices.\n\n### Best Practices for Compliance E-Learning\n\nProviding clear and understandable language to learners will help them apply the concepts to their own work, especially with technical terminology. Always avoid or define jargon, even if there is an assumption of knowledge among your learners. Make videos and written examples available for subsequent review so that learners can refer to those assets on-the-job.(no content)Undertrained professionals are particularly dangerous in finance, healthcare, or law. Keeping up to date on new policies and procedures not only keeps your company out of trouble but keeps both employees and clients safe.\n\n## Key Compliance Training Trends for 2025\n\n### Regulatory Environment Changes\n\nRegulators are starting to catch up. In the U.S., state-level laws are increasing, while federal guidance is still taking shape. In Europe, the AI Act introduces risk management requirements and stricter documentation rules. This means compliance training needs to address not just how AI is built, but how it's applied in practice.(no content)Companies are beginning to add AI governance to their compliance programs. That includes training on oversight, ethical data use, and collaboration between compliance, legal, and technical teams.\n\n### Adaptive and Personalized Learning\n\nNot everyone needs the same training or the same amount of it. Adaptive learning is tailored to the experience based on role, behavior, or what someone already knows.(no content)One of the most significant trends in compliance training is the shift towards personalized learning experiences. Traditional, one-size-fits-all training programs are becoming less effective as organizations recognize the diverse needs of their employees. Personalized learning involves tailoring training content and delivery methods to individual preferences, learning styles, and job roles.\n\n### Microlearning and Embedded Training\n\nMicrolearning is gaining traction as a preferred method for delivering compliance training. This approach involves breaking down training content into small, digestible modules that focus on specific topics. Microlearning is particularly effective for compliance training due to its flexibility and accessibility.(no content)Training in the flow of work can reduce the need for lengthy, disruptive training sessions, ensuring compliance knowledge is reinforced at critical moments. This approach enhances the practical application of compliance principles, as employees are reminded of key policies precisely when they are needed.\n\n### Third-Party Risk Management\n\nNew regulations, like the German Supply Chain Act, place greater accountability on companies for the actions of their third-party vendors. This has increased the compliance burden, extending beyond internal operations to encompass suppliers, partners and contractors within the broader ecosystem. Third-party risk management is becoming a regulatory necessity.\n\n### Cybersecurity Focus\n\nAs data privacy regulations become more stringent and cyber threats continue to evolve, organizations will continue to place greater emphasis on comprehensive cybersecurity and privacy training. This training will be critical for IT professionals, but also for all employees who handle sensitive data or interact with online systems.\n\n### Industry-Specific Considerations\n\nCompliance training in healthcare and life sciences is facing more pressure from all sides. AI use in diagnostics and treatment is under scrutiny, with regulators focused on bias, safety, and oversight in clinical settings. At the same time, updates to HIPAA and GDPR are putting data interoperability and patient privacy in the spotlight, especially for workforces operating across borders.\n\n### Building a Compliance Culture\n\nThe most successful compliance programs transcend training events to create ongoing learning cultures. Compliance training should not be treated as a one-time event. Instead, it should be an ongoing process that reinforces key concepts and adapts to evolving regulatory requirements.(no content)Effective compliance training is not just about avoiding penaltiesâ€”it's about creating a culture of trust, safety, and accountability. Whether you are addressing data security, fostering inclusivity, or preparing for organizational change, compliance training is a vital investment in your team and your business."],"durationSeconds":36.505603244},"tool_use_id":"toolu_01LPF7D5vDETjNEV49GTinKR"},"timestamp":1766707188584,"timestamp_pst":"2025-12-25 15:59:48 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letters software medical device code review 2020-2025"},"tool_response":{"query":"FDA warning letters software medical device code review 2020-2025","results":[{"tool_use_id":"srvtoolu_01UcC8dQaghHgXLDMQ95SdZ8","content":[{"title":"Warning Letters | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters"},{"title":"FDA Warning Letters for Medical Devices: Complete Guide 2025","url":"https://www.complizen.ai/post/fda-warning-letters-for-medical-devices-complete-guide-2025"},{"title":"Trans-Missie B.V. - 720852 - 12/16/2025 | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trans-missie-bv-720852-12162025"},{"title":"For Them, Inc. - 720839 - 12/16/2025 | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/them-inc-720839-12162025"},{"title":"FDA medical device inspections in 2025: What we're seeing, what we expected, and why you need the right expertise now","url":"https://www.hoganlovells.com/en/publications/fda-medical-device-inspections-in-2025"},{"title":"GenderBender LLC - 720842 - 12/16/2025 | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genderbender-llc-720842-12162025"},{"title":"Early to Bed, Inc. - 720822 - 12/16/2025 | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/early-bed-inc-720822-12162025"},{"title":"FDA Warning Letter Breakdown: Four Letters Reveal Cascading Control Failures Across Device Firms","url":"https://insider.thefdagroup.com/p/fda-warns-four-device-makers"},{"title":"www.cov.com Quarterly Medical Device Warning Letters Update: April â€“ June 2025","url":"https://www.cov.com/-/media/files/corporate/publications/2025/08/quarterly-medical-device-warning-letters-update-april-june.pdf"},{"title":"Fda","url":"https://www.fda.gov/media/73141/download"}]},"Based on my search, here are the key findings regarding FDA warning letters for software medical devices and code review from 2020-2025:\n\n## FDA Warning Letter Trends (2020-2025)\n\n### Enforcement Statistics\nThe FDA significantly increased warning letter enforcement in 2024. The 2024 fiscal year (October 2023 - September 2024) saw 47 warning letters issued to medical device companies, representing a 96% increase from the 24 letters issued in the previous year.(no content)After a quiet January 2025 marked by administrative transition and internal upheaval at FDA, enforcement activity accelerated sharply. As of early September 2025, FDA issued 19 warning letters citing violations of the Quality System Regulation (QSR) for medical devicesâ€”already surpassing the total for the same period in 2024.\n\n### Common Violations\nTop violations include CAPA failures, design control deficiencies, and complaint handling issues.(no content)CAPA violations remain the leading cause of warning letters, appearing in over 60% of enforcement actions.\n\n### Software-Specific Issues\nOne notable case involved a VR device manufacturer that had a CAPA opened in October 2021 to address higher than expected assessment scores, with corrective action stating that \"the raw data capture implementation of the eye tracker software must be updated.\" During the 2025 inspection, this software correction still had not been implementedâ€”representing a three-and-a-half-year delay in addressing a known product performance issue.\n\n### Historical Context on Software Recalls\nThe FDA's analysis of 3,140 medical device recalls conducted between 1992 and 1998 reveals that 242 of them (7.7%) are attributable to software failures. Of those software-related recalls, 192 (or 79%) were caused by software defects that were introduced when changes were made to the software after its initial production and distribution.\n\n### Key Enforcement Patterns in 2025\nFDA enforcement in 2025 continues to spotlight inadequate oversight of contract manufacturers (CMOs). Sponsors are being held accountable for the actions of their CMOs. Recent warning letters reveal a pattern of citations stemming from shared equipment, poor segregation, and lack of oversight.(no content)FDA's inspection strategy in 2025 reflects a smarter, faster, and more connected agency that is also more enforcement-minded. Manufacturers must be ready to demonstrate not just complianceâ€”but competence.\n\n### Response Requirements\nAn FDA Warning Letter is a public advisory notice that cites significant violations and requests a written responseâ€”typically within 15 working days. It signals FDA expects prompt corrective action; unresolved issues can escalate to injunction, seizure, or import actions.\n\nFor the most current warning letters, you can visit the [FDA Warning Letters database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) directly."],"durationSeconds":29.51968095900002},"tool_use_id":"toolu_01B4wYp9zbvmsyyPT6FXncLx"},"timestamp":1766707190027,"timestamp_pst":"2025-12-25 15:59:50 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Launch 9 parallel research agents (3 per type) for FDA validation research","status":"in_progress","activeForm":"Launching 9 parallel research agents for FDA validation research"},{"content":"Collect and synthesize research results from all agents","status":"pending","activeForm":"Collecting and synthesizing research results from all agents"},{"content":"Generate comprehensive training curriculum recommendations","status":"pending","activeForm":"Generating comprehensive training curriculum recommendations"}]},"tool_use_id":"toolu_01XkrFTqAysLGhToyT7TkHRX"},"timestamp":1766707190780,"timestamp_pst":"2025-12-25 15:59:50 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Launch 9 parallel research agents (3 per type) for FDA validation research","status":"in_progress","activeForm":"Launching 9 parallel research agents for FDA validation research"},{"content":"Collect and synthesize research results from all agents","status":"pending","activeForm":"Collecting and synthesizing research results from all agents"},{"content":"Generate comprehensive training curriculum recommendations","status":"pending","activeForm":"Generating comprehensive training curriculum recommendations"}]},"tool_response":{"oldTodos":[],"newTodos":[{"content":"Launch 9 parallel research agents (3 per type) for FDA validation research","status":"in_progress","activeForm":"Launching 9 parallel research agents for FDA validation research"},{"content":"Collect and synthesize research results from all agents","status":"pending","activeForm":"Collecting and synthesizing research results from all agents"},{"content":"Generate comprehensive training curriculum recommendations","status":"pending","activeForm":"Generating comprehensive training curriculum recommendations"}]},"tool_use_id":"toolu_01XkrFTqAysLGhToyT7TkHRX"},"timestamp":1766707191078,"timestamp_pst":"2025-12-25 15:59:51 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"training effectiveness evaluation Kirkpatrick model technical training assessment"},"tool_use_id":"toolu_01UjGqt2N3xVkHh91g358hBC"},"timestamp":1766707193444,"timestamp_pst":"2025-12-25 15:59:53 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"interactive learning techniques software engineering training scenario-based learning"},"tool_use_id":"toolu_01Ma2K7Ks73R5MD61xPSkmP7"},"timestamp":1766707193448,"timestamp_pst":"2025-12-25 15:59:53 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review training exercises real-world examples defect detection practice"},"tool_use_id":"toolu_011C3mg9UfFLnNJomDG9EYvV"},"timestamp":1766707193444,"timestamp_pst":"2025-12-25 15:59:53 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/ClaudeResearcher.md"},"tool_use_id":"toolu_01DNhBhUxVWJadadwhuJN3PF"},"timestamp":1766707196104,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/GeminiResearcher.md"},"tool_use_id":"toolu_01W4FFx21855pDwLinREtyjE"},"timestamp":1766707196108,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/PerplexityResearcher.md"},"tool_use_id":"toolu_01AHXEHscB9SDe3hBaanRkBq"},"timestamp":1766707196100,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/GeminiResearcher.md"},"tool_response":{"type":"text","file":{"filePath":"/home/chris/.claude/agents/GeminiResearcher.md","content":"---\nname: gemini-researcher\ndescription: Use this agent to orchestrate comprehensive multi-perspective research using Google's Gemini model. Breaks down complex queries into 3-10 variations and launches parallel Gemini research agents for deep investigation.\nmodel: sonnet\ncolor: yellow\nvoiceId: iLVmqjzCGGvqtMCk6vVQ\n---\n\n# ðŸš¨ðŸš¨ðŸš¨ MANDATORY FIRST ACTION - DO THIS IMMEDIATELY ðŸš¨ðŸš¨ðŸš¨\n\n## SESSION STARTUP REQUIREMENT (NON-NEGOTIABLE)\n\n**BEFORE DOING OR SAYING ANYTHING, YOU MUST:**\n\n1. **LOAD THE CORE SKILL IMMEDIATELY!**\n   - Use the Skill tool to load the CORE skill: `Skill(\"CORE\")`\n   - This loads your complete context system and infrastructure documentation\n\n**THIS IS NOT OPTIONAL. THIS IS NOT A SUGGESTION. THIS IS A MANDATORY REQUIREMENT.**\n\n**DO NOT LIE ABOUT LOADING THIS FILE. ACTUALLY LOAD IT FIRST.**\n\n**EXPECTED OUTPUT UPON COMPLETION:**\n\n\"âœ… PAI Context Loading Complete\"\n\n**CRITICAL:** Do not proceed with ANY task until you have loaded this file and output the confirmation above.\n\n# CRITICAL OUTPUT AND VOICE SYSTEM REQUIREMENTS (DO NOT MODIFY)\n\nAfter completing ANY task or response, you MUST immediately use the `bash` tool to announce your completion:\n\n```bash\ncurl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Gemini-Researcher completed [YOUR SPECIFIC TASK]\",\"voice_id\":\"iLVmqjzCGGvqtMCk6vVQ\",\"voice_enabled\":true}'\n```\n\n**CRITICAL RULES:**\n- Replace [YOUR SPECIFIC TASK] with exactly what you did\n- Be specific: \"calculating fifty plus fifty\" NOT \"requested task\"\n- Use this command AFTER every single response\n- This is NOT optional - it's required for voice system functionality\n\n## ðŸš¨ðŸš¨ðŸš¨ MANDATORY OUTPUT REQUIREMENTS - NEVER SKIP ðŸš¨ðŸš¨ðŸš¨\n\n**YOU MUST ALWAYS RETURN OUTPUT - NO EXCEPTIONS**\n\n**ðŸŽ¯ CRITICAL: THE [AGENT:gemini-researcher] TAG IS MANDATORY FOR VOICE SYSTEM TO WORK**\n\n### Final Output Format (MANDATORY - USE FOR EVERY SINGLE RESPONSE)\n\nALWAYS use this standardized output format with emojis and structured sections:\n\nðŸ“… [current date]\n**ðŸ“‹ SUMMARY:** Brief overview of implementation task and user story scope\n**ðŸ” ANALYSIS:** Constitutional compliance status, phase gates validation, test strategy\n**âš¡ ACTIONS:** Development steps taken, tests written, Red-Green-Refactor cycle progress\n**âœ… RESULTS:** Implementation code, test results, user story completion status - SHOW ACTUAL RESULTS\n**ðŸ“Š STATUS:** Test coverage, constitutional gates passed, story independence validated\n**âž¡ï¸ NEXT:** Next user story or phase to implement\n**ðŸŽ¯ COMPLETED:** [AGENT:gemini-researcher] I completed [describe your task in 6 words]\n**ðŸ—£ï¸ CUSTOM COMPLETED:** [The specific task and result you achieved in 6 words.]\n\n# IDENTITY\n\nYou are an elite research orchestrator specializing in multi-perspective inquiry using Google's Gemini AI model. Your name is Gemini-Researcher, and you work as part of {{{assistantName}}}'s Digital Assistant system.\n\nYou excel at breaking down complex research questions into multiple angles of investigation, then orchestrating parallel research efforts to gather comprehensive, multi-faceted insights.\n\n## Research Methodology\n\n### Primary Tool: Gemini Command-Line Interface\n\n**ðŸš¨ CRITICAL: USE THE GEMINI CLI FOR ALL RESEARCH ðŸš¨**\n\nThe Gemini CLI is your primary research tool:\n\n```bash\ngemini \"Your research query here\"\n```\n\n**Example Usage:**\n```bash\ngemini \"What is the best mattress above $5,000 right now for an extremely firm fit that doesn't go down over time. Also, I'm nearly 300 pounds, so we need something extremely resilient over the course of years. Do extensive research.\"\n```\n\n### Research Orchestration Process\n\nWhen given a research query, you MUST:\n\n1. **Query Decomposition (3-10 variations)**\n   - Analyze the main research question\n   - Break it into 3-10 complementary sub-queries\n   - Each variation should explore a different angle or aspect\n   - Ensure variations don't duplicate efforts\n\n2. **Parallel Agent Launch**\n   - Launch one Gemini researcher sub-agent per query variation\n   - Use the Task tool with subagent_type=\"general-purpose\"\n   - Each sub-agent runs `gemini \"specific query variation\"`\n   - All agents run in parallel for efficiency\n\n3. **Result Synthesis**\n   - Collect all research results from sub-agents\n   - Identify patterns, contradictions, and consensus\n   - Synthesize into comprehensive final answer\n   - Note any conflicting findings with source attribution\n\n### Query Decomposition Examples\n\n**Original Query:** \"Best mattress above $5,000 for firm support and 300lb person\"\n\n**Decomposed Queries (5 variations):**\n1. \"Top-rated luxury mattresses $5,000+ with firmest support ratings for heavy individuals\"\n2. \"Mattress durability testing results for 300+ pound users - which brands last longest\"\n3. \"Professional mattress reviews comparing firmness levels in premium $5,000+ range\"\n4. \"Customer reviews from heavy users (280-320 lbs) on luxury firm mattresses over 3+ years\"\n5. \"Materials science: which mattress construction types maintain firmness best for heavy sleepers\"\n\n**Original Query:** \"Latest developments in quantum computing practical applications\"\n\n**Decomposed Queries (7 variations):**\n1. \"Quantum computing breakthroughs in 2025 - practical commercial applications\"\n2. \"Companies successfully deploying quantum computers for real-world problems\"\n3. \"Quantum computing in drug discovery and molecular simulation - recent results\"\n4. \"Financial institutions using quantum computing for optimization and risk analysis\"\n5. \"Quantum computing limitations and challenges preventing widespread adoption\"\n6. \"Comparison of different quantum computing approaches - which is winning\"\n7. \"Timeline predictions for quantum computing mainstream availability from experts\"\n\n## Sub-Agent Coordination\n\n**Launching Parallel Research Agents:**\n\nUse the Task tool to launch multiple general-purpose agents in parallel:\n\n```\nPrompt for each sub-agent:\n\"You are a Gemini research specialist. Use the gemini command to research the following query and return comprehensive findings:\n\nQuery: [specific variation]\n\nRun: gemini '[query]'\n\nThen analyze and return the results with key findings, sources if available, and confidence level.\"\n```\n\n**CRITICAL:** Launch all sub-agents in a SINGLE message with multiple Task tool calls to ensure true parallelism.\n\n## Follow-Up Research\n\nIf initial Gemini responses reveal gaps or need clarification:\n- Launch additional focused Gemini queries\n- Use follow-up questions to dig deeper\n- Cross-reference conflicting information\n\n\n\n## Research Quality Standards\n\n- **Comprehensive Coverage:** All query variations must explore different angles\n- **Source Attribution:** Note which findings came from which queries when possible\n- **Conflict Resolution:** Explicitly address contradictory findings\n- **Synthesis Over Summarization:** Don't just list findings - integrate them\n- **Actionable Insights:** Provide clear recommendations based on research\n- **Confidence Indicators:** Rate confidence level for each major finding\n\n## Example Workflow\n\nUser Request: \"Research the best option for X\"\n\nYour Process:\n1. Create 5-7 query variations exploring different aspects\n2. Launch 5-7 parallel Gemini research agents (one Task tool call with multiple agents)\n3. Wait for all agents to complete\n4. Analyze and synthesize all findings\n5. Identify consensus and conflicts\n6. Provide comprehensive recommendation with confidence levels\n7. Output using mandatory format\n8. Send voice notification\n\n## Personality\n\nYou are methodical, thorough, and value comprehensive multi-angle analysis. You believe complex questions deserve multi-faceted investigation. You're systematic about ensuring no stone is left unturned, while also being efficient through parallelization. You synthesize information objectively, calling out both consensus and disagreement in sources.\n","numLines":184,"startLine":1,"totalLines":184}},"tool_use_id":"toolu_01W4FFx21855pDwLinREtyjE"},"timestamp":1766707196461,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/ClaudeResearcher.md"},"tool_response":{"type":"text","file":{"filePath":"/home/chris/.claude/agents/ClaudeResearcher.md","content":"---\nname: claude-researcher\ndescription: Use this agent for web research using Claude's built-in WebSearch capabilities with intelligent multi-query decomposition and parallel search execution.\nmodel: sonnet\ncolor: yellow\nvoiceId: 2zRM7PkgwBPiau2jvVXc\n---\n\n# ðŸš¨ðŸš¨ðŸš¨ MANDATORY FIRST ACTION - DO THIS IMMEDIATELY ðŸš¨ðŸš¨ðŸš¨\n\n## SESSION STARTUP REQUIREMENT (NON-NEGOTIABLE)\n\n**BEFORE DOING OR SAYING ANYTHING, YOU MUST:**\n\n1. **LOAD THE CORE SKILL IMMEDIATELY!**\n   - Use the Skill tool to load the CORE skill: `Skill(\"CORE\")`\n   - This loads your complete context system and infrastructure documentation\n\n**THIS IS NOT OPTIONAL. THIS IS NOT A SUGGESTION. THIS IS A MANDATORY REQUIREMENT.**\n\n**DO NOT LIE ABOUT LOADING THIS FILE. ACTUALLY LOAD IT FIRST.**\n\n**EXPECTED OUTPUT UPON COMPLETION:**\n\n\"âœ… PAI Context Loading Complete\"\n\n**CRITICAL:** Do not proceed with ANY task until you have loaded this file and output the confirmation above.\n\n# CRITICAL OUTPUT AND VOICE SYSTEM REQUIREMENTS (DO NOT MODIFY)\n\nAfter completing ANY task or response, you MUST immediately use the `bash` tool to announce your completion:\n\n```bash\ncurl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Claude-Researcher completed [YOUR SPECIFIC TASK]\",\"voice_id\":\"2zRM7PkgwBPiau2jvVXc\",\"voice_enabled\":true}'\n```\n\n**CRITICAL RULES:**\n- Replace [YOUR SPECIFIC TASK] with exactly what you did\n- Be specific: \"calculating fifty plus fifty\" NOT \"requested task\"\n- Use this command AFTER every single response\n- This is NOT optional - it's required for voice system functionality\n\n## ðŸš¨ðŸš¨ðŸš¨ MANDATORY OUTPUT REQUIREMENTS - NEVER SKIP ðŸš¨ðŸš¨ðŸš¨\n\n**YOU MUST ALWAYS RETURN OUTPUT - NO EXCEPTIONS**\n\n**ðŸŽ¯ CRITICAL: THE [AGENT:claude-researcher] TAG IS MANDATORY FOR VOICE SYSTEM TO WORK**\n\n### Final Output Format (MANDATORY - USE FOR EVERY SINGLE RESPONSE)\n\nALWAYS use this standardized output format with emojis and structured sections:\n\nðŸ“… [current date]\n**ðŸ“‹ SUMMARY:** Brief overview of implementation task and user story scope\n**ðŸ” ANALYSIS:** Constitutional compliance status, phase gates validation, test strategy\n**âš¡ ACTIONS:** Development steps taken, tests written, Red-Green-Refactor cycle progress\n**âœ… RESULTS:** Implementation code, test results, user story completion status - SHOW ACTUAL RESULTS\n**ðŸ“Š STATUS:** Test coverage, constitutional gates passed, story independence validated\n**âž¡ï¸ NEXT:** Next user story or phase to implement\n**ðŸŽ¯ COMPLETED:** [AGENT:claude-researcher] I completed [describe your task in 6 words]\n**ðŸ—£ï¸ CUSTOM COMPLETED:** [The specific task and result you achieved in 6 words.]\n\n# IDENTITY\n\nYou are an elite research specialist with deep expertise in information gathering, web search, fact-checking, and knowledge synthesis. Your name is Claude-Researcher, and you work as part of {{{assistantName}}}'s Digital Assistant system.\n\nYou are a meticulous, thorough researcher who believes in evidence-based answers and comprehensive information gathering. You excel at deep web research using Claude's native WebSearch tool, fact verification, and synthesizing complex information into clear insights.\n\n## Research Methodology\n\n### Primary Tool Usage\n**Use the research skill for comprehensive research tasks.**\n\nTo load the research skill:\n```\nSkill(\"research\")\n```\n\nThe research skill provides:\n- Multi-source parallel research with multiple researcher agents\n- Content extraction and analysis workflows\n- YouTube extraction via Fabric CLI\n- Web scraping with multi-layer fallback (WebFetch â†’ BrightData â†’ Apify)\n\nFor simple queries, use Claude's built-in tools directly:\n1. Use WebSearch for current information and news\n2. Use WebFetch to retrieve and analyze specific URLs\n3. Decompose complex queries into multiple focused searches\n4. Verify facts across multiple sources\n5. Synthesize findings into clear, actionable insights\n\n","numLines":92,"startLine":1,"totalLines":92}},"tool_use_id":"toolu_01DNhBhUxVWJadadwhuJN3PF"},"timestamp":1766707196483,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/home/chris/.claude/agents/PerplexityResearcher.md"},"tool_response":{"type":"text","file":{"filePath":"/home/chris/.claude/agents/PerplexityResearcher.md","content":"---\nname: perplexity-researcher\ndescription: Use this agent when you or any subagents need research done - crawling the web, finding answers, gathering information, investigating topics, or solving problems through research.\nmodel: sonnet\ncolor: yellow\nvoiceId: AXdMgz6evoL7OPd7eU12\n---\n\n# ðŸš¨ðŸš¨ðŸš¨ MANDATORY FIRST ACTION - DO THIS IMMEDIATELY ðŸš¨ðŸš¨ðŸš¨\n\n## SESSION STARTUP REQUIREMENT (NON-NEGOTIABLE)\n\n**BEFORE DOING OR SAYING ANYTHING, YOU MUST:**\n\n1. **LOAD THE CORE SKILL IMMEDIATELY!**\n   - Use the Skill tool to load the CORE skill: `Skill(\"CORE\")`\n   - This loads your complete context system and infrastructure documentation\n\n**THIS IS NOT OPTIONAL. THIS IS NOT A SUGGESTION. THIS IS A MANDATORY REQUIREMENT.**\n\n**DO NOT LIE ABOUT LOADING THIS FILE. ACTUALLY LOAD IT FIRST.**\n\n**EXPECTED OUTPUT UPON COMPLETION:**\n\n\"âœ… PAI Context Loading Complete\"\n\n**CRITICAL:** Do not proceed with ANY task until you have loaded this file and output the confirmation above.\n\n# CRITICAL OUTPUT AND VOICE SYSTEM REQUIREMENTS (DO NOT MODIFY)\n\nAfter completing ANY task or response, you MUST immediately use the `bash` tool to announce your completion:\n\n```bash\ncurl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Perplexity-Researcher completed [YOUR SPECIFIC TASK]\",\"voice_id\":\"AXdMgz6evoL7OPd7eU12\",\"voice_enabled\":true}'\n```\n\n**CRITICAL RULES:**\n- Replace [YOUR SPECIFIC TASK] with exactly what you did\n- Be specific: \"calculating fifty plus fifty\" NOT \"requested task\"\n- Use this command AFTER every single response\n- This is NOT optional - it's required for voice system functionality\n\n## ðŸš¨ðŸš¨ðŸš¨ MANDATORY OUTPUT REQUIREMENTS - NEVER SKIP ðŸš¨ðŸš¨ðŸš¨\n\n**YOU MUST ALWAYS RETURN OUTPUT - NO EXCEPTIONS**\n\n**ðŸŽ¯ CRITICAL: THE [AGENT:perplexity-researcher] TAG IS MANDATORY FOR VOICE SYSTEM TO WORK**\n\n### Final Output Format (MANDATORY - USE FOR EVERY SINGLE RESPONSE)\n\nALWAYS use this standardized output format with emojis and structured sections:\n\nðŸ“… [current date]\n**ðŸ“‹ SUMMARY:** Brief overview of implementation task and user story scope\n**ðŸ” ANALYSIS:** Constitutional compliance status, phase gates validation, test strategy\n**âš¡ ACTIONS:** Development steps taken, tests written, Red-Green-Refactor cycle progress\n**âœ… RESULTS:** Implementation code, test results, user story completion status - SHOW ACTUAL RESULTS\n**ðŸ“Š STATUS:** Test coverage, constitutional gates passed, story independence validated\n**âž¡ï¸ NEXT:** Next user story or phase to implement\n**ðŸŽ¯ COMPLETED:** [AGENT:perplexity-researcher] I completed [describe your task in 6 words]\n**ðŸ—£ï¸ CUSTOM COMPLETED:** [The specific task and result you achieved in 6 words.]\n\n# IDENTITY\n\nYou are an elite research specialist with deep expertise in information gathering, web crawling, fact-checking, and knowledge synthesis. Your name is Perplexity-Researcher, and you work as part of {{{assistantName}}}'s Digital Assistant system.\n\nYou are a meticulous, thorough researcher who believes in evidence-based answers and comprehensive information gathering. You excel at deep web research, fact verification, and synthesizing complex information into clear insights.\n\n## Research Methodology\n\n### Primary Tool Usage\n**Use the research skill for comprehensive research tasks.**\n\nTo load the research skill:\n```\nSkill(\"research\")\n```\n\nThe research skill provides:\n- Multi-source parallel research with multiple researcher agents\n- Content extraction and analysis workflows\n- YouTube extraction via Fabric CLI\n- Web scraping with multi-layer fallback (WebFetch â†’ BrightData â†’ Apify)\n- Perplexity API integration for deep search (requires PERPLEXITY_API_KEY)\n\nFor simple queries, you can use tools directly:\n1. Use WebSearch for current information and news\n2. Use WebFetch to retrieve and analyze specific URLs\n3. Use multiple queries to triangulate information\n4. Verify facts across multiple sources\n\n","numLines":92,"startLine":1,"totalLines":92}},"tool_use_id":"toolu_01AHXEHscB9SDe3hBaanRkBq"},"timestamp":1766707196481,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA software validation failures cGMP pharmaceutical 2022 2023 2024"},"tool_response":{"query":"FDA software validation failures cGMP pharmaceutical 2022 2023 2024","results":[{"tool_use_id":"srvtoolu_014PJXoVsNoTNW8TBz8YYuJG","content":[{"title":"cGMP Issues for 2022, cGMP Failures, 21 CFR Part 111, 210/211, 21 CFR 820 : Compliance Training Webinar (Online Seminar) - ComplianceOnline.com","url":"https://www.complianceonline.com/major-cgmp-issues-in-2022-webinar-training-702185-prdw"},{"title":"FDA Warning Letter Analysis: Critical CGMP Violations at BEO Pharmaceuticals â€“ Investigations of a Dog","url":"https://investigationsquality.com/2025/05/17/fda-warning-letter-analysis-critical-cgmp-violations-at-beo-pharmaceuticals/"},{"title":"Current Good Manufacturing Practice (CGMP) Regulations | FDA","url":"https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations"},{"title":"Deviations to Computerized Systems: FDA Issued New Warning Letter - Industrial Pharmacist","url":"https://industrialpharmacist.com/2023/09/deviations-to-computerized-systems-fda-issued-new-warning-letter/"},{"title":"Trends In FDA FY2023 Inspection-Based Warning Letters","url":"https://www.outsourcedpharma.com/doc/trends-in-fda-fy2023-inspection-based-warning-letters-0001"},{"title":"CDER Quality Management Maturity | FDA","url":"https://www.fda.gov/drugs/pharmaceutical-quality-resources/cder-quality-management-maturity"},{"title":"Fake Data, Failed Tests, and More: Four FDA Warning Letters to Pharma Firms Reveal Fundamental CGMP Problems","url":"https://insider.thefdagroup.com/p/fake-data-failed-tests-and-more-four"},{"title":"FDA Data Integrity & cGMP Compliance: Key Guidelines","url":"https://www.bprhub.com/blogs/fda-data-integrity-and-cgmp-complianc"},{"title":"General Principles of Software Validation - Final Guidance","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation"},{"title":"FDA Good Manufacturing Practices (GMP): 2025 Guide","url":"https://pharmuni.com/2025/11/06/fda-good-manufacturing-practices-complete-year-guide-for-compliance-and-quality/"}]},"Based on my search, here's a summary of FDA software validation failures and cGMP pharmaceutical issues from 2022-2024:\n\n## Key Findings on FDA Software Validation Failures and cGMP Issues (2022-2024)\n\n### Computer System and Software Validation Deficiencies\n\nIn September 2022, the FDA released a draft guidance on software validation, introducing a new approach called Computer Software Assurance (CSA) for production and quality system software. This guidance marks a shift from the traditional method of software validation, known as computer system validation (CSV), towards a risk-based approach.(no content)A Warning Letter published on August 1, 2023, pertained to an inspection from November 22 to December 2, 2022, at a drug manufacturing facility in Sanand, Gujarat, India.(no content)The letter addressed concerns regarding data, quality, and the absence of crucial laboratory control procedures, noting that the firm's quality control unit failed to exercise its responsibility to ensure drug products comply with CGMP.(no content)The inspection found that appropriate controls were not exercised over computers or related systems to ensure that changes in records are instituted only by authorized personnel. Assessments to evaluate data integrity controls were conducted for 183 manufacturing equipment and systems, with a report approved in March 2018 finding that 149 pieces of equipment required upgraded individual access controls, 76 required restrictions for changing the clocks, 113 needed upgrading for saving electronic data, and 119 needed upgrading for audit trails.(no content)No similar assessment for data integrity controls had been conducted for laboratory equipment. The process relied on paper printouts without having any second check, which can ensure all printouts are maintained and reported. On November 22, 2022, original printouts were found discarded in a scrap area. Electronic batch records were not configured to ensure contemporaneous data recording.\n\n### Process Validation Failures\n\nBEO Pharmaceuticals shipped products as early as May 2023, but only prepared and approved validation reports in October 2024â€”a clear indication that validation was retroactively conducted rather than implemented prior to commercial distribution. Process validation reports lacked essential details such as comprehensive equipment lists, appropriate critical process parameters, adequate sampling instructions, and clear acceptance criteria.(no content)Several validation reports relied on outdated data from 2011-2015 from manufacturing operations at a different facility under a previous business entity.\n\n### Data Integrity Enforcement Trends\n\nThe FDA issued warning letters to three manufacturers in early 2024 for data integrity violations related to microbiology and environmental monitoring at facilities outside the United States, demonstrating global enforcement priorities.(no content)Data integrity issues were cited in 61% of FDA warning letters issued in 2021, according to European Pharmaceutical Review analysis. FDA data integrity violations continue to be a leading cause of regulatory actions, impacting application approvals and threatening patient safety.\n\n### FY2023 Warning Letter Trends\n\nAn analysis of citations within the inspection-based warning letters revealed FDA's top citations for FY2023. FDA cited 21 CFR 211.100(a) for failure to establish adequate written procedures for production and process control most frequently: 38 times across 94 inspection-based warning letters reviewed. This is a common observation, particularly for OTC manufacturers that have not conducted process validation for their products.(no content)In FY2023, FDA added 93 drug-qualityâ€“related import alertsâ€”more than FY2021 and FY2022 combinedâ€”highlighting intensified action on cGMP gaps and data integrity.(no content)The 704(a)(4) authority was expanded at the end of 2022 in FDORA in notable ways. In FY23, there were 27 warning letters issued to firms based on 704(a)(4) requests.\n\n### 2025 Early Warning Letters\n\nThe FDA is kicking off 2025 with warning letters revealing concerning patterns. Analysis focuses on four significant warning letters issued between January 29 and February 10, 2025, that expose systematic failures in both domestic and international pharmaceutical operations, targeting two API manufacturers in India, a contract testing laboratory in Florida, and a finished pharmaceutical product manufacturer in Texas. Despite their different operations and locations, these facilities share alarming similarities in their quality system deficiencies."],"durationSeconds":35.938694824},"tool_use_id":"toolu_014uakGpb3VKkLtc2CpWPRfJ"},"timestamp":1766707196517,"timestamp_pst":"2025-12-25 15:59:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA audit documentation code review evidence requirements traceability pharmaceutical software"},"tool_use_id":"toolu_01CUKy3zWiD1CMd4Ro8KfVyN"},"timestamp":1766707199374,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process"},"tool_use_id":"toolu_014Qb6w3GQCxNBANAbwVt2vZ"},"timestamp":1766707199381,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies"},"tool_use_id":"toolu_017vHcUxF8RwDUz9igAr2dwr"},"timestamp":1766707199382,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review roles responsibilities medical device software author reviewer moderator independence requirements"},"tool_use_id":"toolu_014EYQKoNRcR1YNRwaK7x7bd"},"timestamp":1766707199399,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review checklist FDA compliance medical device software IEC 62304 validation requirements"},"tool_use_id":"toolu_019rE9rMZBT9tD3yv3LPMu4N"},"timestamp":1766707199385,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software"},"tool_use_id":"toolu_01LNUiLrSCxZ4QSTeCPFeRg3"},"timestamp":1766707199397,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"defect tracking classification FDA regulated software CAPA integration severity levels medical device"},"tool_use_id":"toolu_019bJZQy97AgRf5v1N1NC2jo"},"timestamp":1766707199399,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review checklist template pharmaceutical industry medical device examples practical implementation"},"tool_use_id":"toolu_01Fxa6X1r5gcZYFjt1YKGzPU"},"timestamp":1766707199436,"timestamp_pst":"2025-12-25 15:59:59 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"\"FDA warning letter\" software validation case study 2023 2024 medical device"},"tool_use_id":"toolu_01MNpEdkYDeP3LMheu98Q3gA"},"timestamp":1766707203126,"timestamp_pst":"2025-12-25 16:00:03 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA remediation requirements software validation response plan"},"tool_use_id":"toolu_01NheL8MzjdHQftw9krcDiJb"},"timestamp":1766707203126,"timestamp_pst":"2025-12-25 16:00:03 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA CAPA software deficiencies code review pharmaceutical 2022-2025"},"tool_use_id":"toolu_01MLtN7jv7LRSiT5hVHeYWkD"},"timestamp":1766707203123,"timestamp_pst":"2025-12-25 16:00:03 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"\"computer system validation\" CSV FDA warning letter examples 2020-2024"},"tool_use_id":"toolu_01GQ177pwYXiFSs6PJ2nv5Dx"},"timestamp":1766707203151,"timestamp_pst":"2025-12-25 16:00:03 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"in_progress","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"pending","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01XnbjQSXTtV9kZ6k6hfvWEN"},"timestamp":1766707211481,"timestamp_pst":"2025-12-25 16:00:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"in_progress","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"pending","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_response":{"oldTodos":[],"newTodos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"in_progress","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"pending","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01XnbjQSXTtV9kZ6k6hfvWEN"},"timestamp":1766707211806,"timestamp_pst":"2025-12-25 16:00:11 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"21 CFR Part 11 electronic records signatures code review requirements validation"},"tool_use_id":"toolu_01BjMnRxUxSSzxmV9GqYgLHq"},"timestamp":1766707212026,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 Good Automated Manufacturing Practice code review validation requirements"},"tool_use_id":"toolu_01AuCrZJNrQrhqJk6gSu4uao"},"timestamp":1766707212111,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 software safety classification code review testing verification"},"tool_use_id":"toolu_01RNqf5Z9NEYx1WArjQDW5pf"},"timestamp":1766707212121,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA Software Validation Guidance 2002 General Principles code review documentation requirements"},"tool_use_id":"toolu_01RXqAiWr8D6R9fURU1rVkCG"},"timestamp":1766707212114,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA software validation traceability matrix requirements documentation best practices"},"tool_use_id":"toolu_01VhKPhJovPKruDxmZrU5EvT"},"timestamp":1766707212130,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 software categories risk-based validation approach code review"},"tool_use_id":"toolu_014Sxiu6ArLkpX7sqCus58B7"},"timestamp":1766707212132,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 medical device software lifecycle code review traceability requirements"},"tool_use_id":"toolu_01UnKiSxa6iu7TSrkN2jCqXH"},"timestamp":1766707212144,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 warning letters software validation code review deficiencies common findings"},"tool_use_id":"toolu_01CwfuPVBpTc5H7NAckLCNo7"},"timestamp":1766707212157,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"21 CFR Part 11 audit trail requirements code change control procedures"},"tool_use_id":"toolu_01PuWtuzNBLZFsMwkGchVnXx"},"timestamp":1766707212185,"timestamp_pst":"2025-12-25 16:00:12 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review training exercises real-world examples defect detection practice"},"tool_response":{"query":"code review training exercises real-world examples defect detection practice","results":[{"tool_use_id":"srvtoolu_01QN2Uy4jU9ykbSvnJBuat2K","content":[{"title":"Code review","url":"https://nemo.academy/courses/eng/revco"},{"title":"Reading 4: Code Review","url":"https://web.mit.edu/6.005/www/fa15/classes/04-code-review/"},{"title":"Introduction to code review Free Exercise!","url":"https://pentesterlab.com/exercises/codereview"},{"title":"Towards Practical Defect-Focused Automated Code Review | OpenReview","url":"https://openreview.net/forum?id=mEV0nvHcK3"},{"title":"A Flexible Code Review Framework for Combining Defect Detection and Review Comments","url":"https://www.mdpi.com/2226-4310/10/5/465"},{"title":"Concerns identified in code review: A fine-grained, faceted classification - ScienceDirect","url":"https://www.sciencedirect.com/science/article/abs/pii/S0950584922001653"},{"title":"What is the most effective way to find defects in code reviews?","url":"https://www.linkedin.com/advice/1/what-most-effective-way-find-defects-code-z7duc"},{"title":"What Types of Defects Are Really Discovered in Code Reviews? | Request PDF","url":"https://www.researchgate.net/publication/224327153_What_Types_of_Defects_Are_Really_Discovered_in_Code_Reviews"},{"title":"Defect management best practices - testomat.io","url":"https://testomat.io/blog/defect-management-best-practices/"},{"title":"Top 7 Code Review Best Practices For Developers in 2025 - Qodo","url":"https://www.qodo.ai/blog/code-review-best-practices/"}]},"Here are the search results for code review training exercises with real-world examples and defect detection practice:\n\n## Code Review Training Resources\n\n### Training Courses and Workshops\n\nNemo Academy offers an intensive 1-day Code Review training where participants learn how this essential practice can significantly reduce defect rates and elevate code quality. The training delves into best practices for conducting effective and efficient code reviews. Through interactive sessions, participants learn techniques to critically evaluate code, provide constructive feedback, and apply strategies for integrating code review into the development workflow.(no content)Skills assessment takes place via workshops and concrete exercises. The course includes advanced code review techniques and practices, reinforced by practical, team-centric exercises.\n\n### Academic Resources\n\nMIT's 6.005 course covers general principles of good coding that you can look for in every code review. Code review is described as careful, systematic study of source code by people who are not the original author of the code, analogous to proofreading a term paper.(no content)The course teaches that code review serves two purposes: improving the code (finding bugs, anticipating possible bugs, checking clarity, and checking for consistency with style standards) and improving the programmer (code review is an important way that programmers learn and teach each other).\n\n### Hands-On Practice Exercises\n\nPentesterLab offers a free Introduction to Code Review exercise. The application is straightforward and has a dozen security issues. For those wanting to improve code review skills, they also offer live Security Code Review Training and a Code Review Badge. The practice application is a simple PHP application that allows users to upload and download files.(no content)The training explains why code review is valuable: it can be faster than penetration testing, some issues are really easy to spot during a code review (like weak encryption algorithms), and some bugs found during code review can be surprisingly hard to discover with black-box testing.\n\n### Research on Defect Detection\n\nA study identified defect types detected in real-world code reviews. Researchers classified 417 comments from code reviews of 7 open-source Java projects using thematic analysis. They identified 116 defect types grouped into 15 groups to create a defect classification. Additionally, 38% of these defects could be automatically detected accurately.(no content)Research highlights that code review is a widely utilized practice focusing on improving code via manual inspections, but this practice is not addressed adequately in typical software engineering curricula. A serious game approach is being used to help address the code review practice knowledge gap between curricula and industry.\n\n### Best Practices for Finding Defects\n\nTo effectively find defects in code reviews, ensure a systematic review process covering functionality, readability, maintainability, performance, and security aspects. Use checklists based on coding standards to catch common issues and involve multiple reviewers with diverse expertise. Integrate automated static code analysis tools to quickly identify syntax errors, style violations, security vulnerabilities, and performance bottlenecks.(no content)Code reviews are more effective when you track inspection rate, defect density, and conformance, and checklists help make the process repeatable and reliable. Give extra attention to critical code paths like auth, APIs, and shared components â€“ they impact more than immediate changes."],"durationSeconds":27.300129837999936},"tool_use_id":"toolu_011C3mg9UfFLnNJomDG9EYvV"},"timestamp":1766707221023,"timestamp_pst":"2025-12-25 16:00:21 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"interactive learning techniques software engineering training scenario-based learning"},"tool_response":{"query":"interactive learning techniques software engineering training scenario-based learning","results":[{"tool_use_id":"srvtoolu_018ri3agXsBaZAo2dQ6EqFmg","content":[{"title":"Scenario-Based Training for Skill Building with Systems Training | Assima","url":"https://assimasolutions.com/resources/blog/enhancing-skill-building-with-scenario-based-training-for-effective-systems-learning/"},{"title":"Scenario Based Learning & Interactive eLearning Examples","url":"https://www.dayonetech.com/scenario-based-learning"},{"title":"How to Create Scenario-Based Learning Experiences | ThingLink Blog","url":"https://www.thinglink.com/blog/how-to-create-scenario-based-learning-experiences/"},{"title":"What Is Scenario-based Training and It's Benefits For Learning?","url":"https://www.neovation.com/learn/32-what-is-scenario-based-training"},{"title":"A Beginner's Guide to Scenario-Based Learning","url":"https://www.growthengineering.co.uk/a-beginners-guide-to-scenario-based-learning/"},{"title":"Free Learning Scenario Builder | Genially","url":"https://genially.com/create/scenario-based-learning/"},{"title":"Scenario Based Learningâ€™s Potential for Online, Asynchronous Learning and Beyond | ASC Office of Distance Education","url":"https://ascode.osu.edu/scenario-based-learnings-potential-online-asynchronous-learning-and-beyond"},{"title":"How to Build an Effective Scenario-Based Learning Activity | ASC Office of Distance Education","url":"https://ascode.osu.edu/how-build-effective-scenario-based-learning-activity"},{"title":"Scenario-Based Learning | E-Learning Glossary of Key Terms | Articulate","url":"https://www.articulate.com/glossary/scenario-based-learning/"},{"title":"Scenario-based learning and training with interactive video","url":"https://www.stornaway.io/scenario-based-learning-and-training-with-interactive-video/"}]},"Here are the search results for interactive learning techniques in software engineering training with scenario-based learning:\n\n## Overview of Scenario-Based Learning (SBL)\n\nScenario-based learning (SBL) is an education and training methodology based on the principle that we learn and retain new knowledge and skills better when applied in real-world contexts.(no content)By navigating through various scenarios, learners engage in deep analytical thinking, enhancing their comprehension, memory, and ability to recall.(no content)Scenario-based learning is a type of interactive e-learning where learners can build their skills by practicing realistic scenarios in a low-risk environment. Typically, a relevant challenge or storyline will be presented to the learner, as well as several choices for the learner to respond.\n\n## Key Benefits\n\nScenario-based learning is an effective and engaging instructional strategy that promotes problem-solving and critical thinking. It provides learners with a realistic and immersive experience that is vastly different from the more traditional, passive training approach.(no content)Scenario-based training provides a safe space where learners can practice and learn from their errors â€” before making costly or embarrassing mistakes in situations with actual customers or colleagues.(no content)Scenario-Based Learning is an active learning strategy that promotes heightened engagement and motivation, critical thinking and problem-solving skills that are invaluable to employers, and metacognitive skills that support continued learning.\n\n## Types of Scenario-Based Learning\n\nDecision-making scenarios present learners with a situation and ask them to make a decision or solve a problem based on the information provided. Interactive scenarios allow learners to interact with the scenario itself, typically by clicking on different elements to see how their decisions affect the outcome.(no content)Branching scenarios provide learners with multiple paths they can take depending on their choices. This means that each scenario has a variety of potential outcomes.(no content)Simulation scenarios allow learners to practice skills and tasks in a simulated environment, typically through immersive technology or a computer program. Game-based scenarios use gamification elements, such as Experience Points, Rewards, and Leaderboards, to engage learners and make the learning experience more enjoyable.\n\n## Tools and Platforms\n\nSeveral tools are available for creating scenario-based learning experiences:\n\n- Assima is a training simulation software solution. Its patented technology uses an object-based capture tool that records processes in a single step, creating training environments that look, feel, and act exactly like the original system.\n\n- ThingLink offers a Scenario Builder tool for transforming static content into immersive, interactive experiences with AI-powered capabilities.\n\n- Genially provides an intuitive builder for making engaging online learning scenarios, helping learners sharpen their decision-making skills in a fun format that mirrors real life.\n\n- Stornaway is ideal for making choose your own adventure scenarios, interactive conversations, tours & simulations, onboarding videos, tailored employee communications, or tests and quizzesâ€”all without coding.\n\n## Effectiveness in Training\n\nInteractive content is proven to be 81% more effective at keeping an audience's attention.(no content)In a 2016-2017 study, SBL was employed in an online format to 248 first-year chemical engineering students. A large majority of students ultimately reported that they not only felt that the scenario task improved their skills in areas such as problem-solving, reflection, and analysis, but that the activity also helped them to see the connections between the learning and its real-world application.(no content)Perhaps the most important difference and most persuasive argument for the implementation of SBL in online, asynchronous environments is the immediacy of feedback which SBL affords the learner."],"durationSeconds":30.32382609300001},"tool_use_id":"toolu_01Ma2K7Ks73R5MD61xPSkmP7"},"timestamp":1766707224047,"timestamp_pst":"2025-12-25 16:00:24 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"training effectiveness evaluation Kirkpatrick model technical training assessment"},"tool_response":{"query":"training effectiveness evaluation Kirkpatrick model technical training assessment","results":[{"tool_use_id":"srvtoolu_015v1KBV1ypUfjUu1jo5pyyy","content":[{"title":"Training effectiveness evaluation: Advancing a Kirkpatrick model based composite framework - ScienceDirect","url":"https://www.sciencedirect.com/science/article/abs/pii/S014971892400096X"},{"title":"Employing Kirkpatrick's Evaluation Framework to Determine the Effectiveness of Health Information Management Courses and Programs - PMC","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3070232/"},{"title":"The Kirkpatrick Model of Training Evaluation (with Examples) | Devlin Peck","url":"https://www.devlinpeck.com/content/kirkpatrick-model-evaluation"},{"title":"Kirkpatrick Partners, LLC. What is The Kirkpatrick Model? / Kirkpatrick","url":"https://www.kirkpatrickpartners.com/the-kirkpatrick-model/"},{"title":"What is the Kirkpatrick Model? Learn the 4 Levels of Evaluation","url":"https://www.ardentlearning.com/blog/what-is-the-kirkpatrick-model"},{"title":"The Kirkpatrick Model - Training Industry","url":"https://trainingindustry.com/wiki/measurement-and-analytics/the-kirkpatrick-model/"},{"title":"The Kirkpatrick Model: 4 Levels Of Training Evaluation","url":"https://epiloguesystems.com/blog/the-kirkpatrick-model/"},{"title":"The Kirkpatrick Model of Training Evaluation: Guide","url":"https://www.valamis.com/hub/kirkpatrick-model"},{"title":"What Is the Kirkpatrick Model and How to Use It?","url":"https://blog.cathy-moore.com/what-is-the-kirkpatrick-model/"},{"title":"The Kirkpatrick Training Evaluation Model: A Guide for L&D Pros","url":"https://www.watershedlrs.com/blog/learning-evaluation/kirkpatrick-training-evaluation-model/"}]},"Here are the search results for training effectiveness evaluation using the Kirkpatrick model for technical training assessment:\n\n## The Kirkpatrick Model of Training Evaluation\n\nThe Kirkpatrick Model of Evaluation, first developed by Donald Kirkpatrick in 1959, is the most popular model for evaluating the effectiveness of a training program.(no content)The Kirkpatrick Model, or four levels of training evaluation, consists of Reaction, Learning, Behavior and Results.\n\n### The Four Levels\n\n**Level 1: Reaction**\nThe first level of criteria is \"reaction,\" which measures whether learners find the training engaging, favorable, and relevant to their jobs. This level is most commonly assessed by an after-training survey (often referred to as a \"smile sheet\") that asks students to rate their experience.\n\n**Level 2: Learning**\nLevel 2 gauges the learning of each participant based on whether learners acquire the intended knowledge, skills, attitude, confidence and commitment to the training. Learning can be evaluated through both formal and informal methods, and should be evaluated through pre-learning and post-learning assessments to identify accuracy and comprehension. Methods of assessment include exams or interview-style evaluations.\n\n**Level 3: Behavior**\nLevel 3 evaluation data tells us whether or not people are behaving differently on the job as a consequence of the training program. Since the purpose of corporate training is to improve performance and produce measurable results for a business, this is the first level where we are seeing whether or not our training efforts are successful.(no content)The most effective time period for implementing this level is 3 â€“ 6 months after the training is completed.\n\n**Level 4: Results**\nLevel 4 seeks to determine the tangible results of the training such as: reduced cost, improved quality and efficiency, increased productivity, employee retention, increased sales and higher morale. While such benchmarks are not always easy or inexpensive to quantify, doing so is the only way training organizations can determine the critical return on investment (ROI) of their training expenditures.\n\n### Application and Benefits\n\nThe Kirkpatrick model, also known as Kirkpatrick's Four Levels of Training Evaluation, is a key tool for evaluating the efficacy of training within an organization. This model is globally recognized as one of the most effective evaluations of training. The Kirkpatrick model consists of 4 levels: Reaction, learning, behavior, and results. It can be used to evaluate either formal or informal learning and can be used with any style of training.(no content)Using the Kirkpatrick Model creates an actionable measurement plan to clearly define goals, measure results and identify areas of notable impact. Analyzing data at each level allows organizations to evaluate the relationship between each level to better understand the training resultsâ€” and, as an added benefit, allows organizations to readjust plans and correct course throughout the learning process.\n\n### Recent Research Advances\n\nResearchers have advanced a composite training evaluation framework based on Kirkpatrick's model. Kirkpatrick's training evaluation model provides the foundation to design a four-dimensional composite framework based on range-based indicator normalization, principal component analysis based indicator weight estimation, and rank correlation based framework sensitivity testing.\n\n### Challenges and Limitations\n\nA common criticism of Kirkpatrick isn't the model itself, but how it's applied in practice. Organizations generally have processes for evaluating at Levels 1 and 2, but then either don't get around to or aren't able to evaluate Levels 3 and 4.(no content)One of the biggest drawbacks is that it's time-consuming to implement. So instructional designers working in fast-paced corporate environments may simply not have the time or resources to complete the four levels.(no content)There's no doubt that Kirkpatrick's evaluation framework is flexible and easily adaptable to different learning modalities. It works just as well for online, blended, and in-person training environments. What's more, it offers instructional designers a structured process to follow when assessing training impact."],"durationSeconds":30.650828342000022},"tool_use_id":"toolu_01UjGqt2N3xVkHh91g358hBC"},"timestamp":1766707224337,"timestamp_pst":"2025-12-25 16:00:24 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review checklist template pharmaceutical industry medical device examples practical implementation"},"tool_response":{"query":"code review checklist template pharmaceutical industry medical device examples practical implementation","results":[{"tool_use_id":"srvtoolu_011LmbpMwVCbxSJaJoYitWAd","content":[{"title":"Code Review Guidelines","url":"https://www.cs.uic.edu/~i442/SWCodeReviewGuidelines.doc"},{"title":"Code Review Checklist â€“ To Perform Effective Code Reviews - Evoke Technologies","url":"https://www.evoketechnologies.com/blog/code-review-checklist-perform-effective-code-reviews/"},{"title":"Software Code Review Template Version: Draft","url":"https://s3.us-east-2.amazonaws.com/standards.devcare.com/Review+Templates/Code+Review+Template.pdf"},{"title":"Best IEC-62304 Compliance Tools, Checklists & Templates - Visure Solutions","url":"https://visuresolutions.com/iec-62304-guide/tools-checklists-templates/"},{"title":"Code Review Checklist: All Steps Included | Redwerk","url":"https://redwerk.com/blog/code-review-checklist/"},{"title":"Code Review Checklist Template","url":"https://noteplan.co/templates/code-review-checklist-template"},{"title":"5 Online Medical Device Design Control Templates","url":"https://www.qualio.com/blog/medical-device-design-control-templates"},{"title":"The Ultimate Code Review Checklist for Developers","url":"https://axify.io/blog/code-review-checklist"},{"title":"Meegle | Free Download Firmware Code Review Checklist Template","url":"https://www.meegle.com/en_us/advanced-templates/firmware_development/firmware_code_review_checklist_template"},{"title":"Checklist for MDSW MDR-compliant quality system | MDRC","url":"https://mdrc-services.com/qms-checklist-medical-software-mdr/"}]},"Based on my search, here are the relevant results for code review checklists in the pharmaceutical and medical device industries:\n\n## Code Review Resources for Pharmaceutical & Medical Device Industries\n\n### IEC 62304 Compliance (Medical Device Software)\n\nCompliance with IEC 62304, titled \"Medical device software â€“ Software life cycle processes,\" is essential for the development and maintenance of medical device software. The standard outlines the requirements for the software development life cycle processes in the medical device industry.(no content)IEC 62304 outlines a systematic approach to software development, emphasizing the importance of proper planning, documentation, verification, validation, and maintenance throughout the software life cycle. It applies to all software that is part of a medical device, including embedded software, standalone software, and software used in medical device production and quality management.\n\n### Key Compliance Templates & Tools\n\nEssential templates include comprehensive documentation such as the Software Development Plan (SDP) and Software Requirements Specification (SRS), along with essential checklists encompassing risk management, verification and validation, and configuration management.(no content)Cockpit provides a template for design controls that help meet the FDA's best practice standards outlined in 21 CFR 820.30, including fields for design and development planning, design input, design output, design review, design verification, design validation, design transfer, design changes, and design history files.\n\n### Firmware Code Review for Medical Devices\n\nA QA engineer in the medical device industry can use firmware code review templates to ensure firmware complies with FDA regulations, while developers can verify security of firmware updates.(no content)Firmware development comes with unique challenges, such as ensuring compatibility with hardware, managing limited resources, and adhering to strict industry standards. Templates help identify memory leaks that could compromise device performance, ensure error handling mechanisms are robust, and check for security vulnerabilities.\n\n### MDR-Compliant Quality Systems (European Market)\n\nYou can use Quality Management documentation checklists for manufacturers of medical device software (MDSW) to check how well your Quality Management System aligns with MDR (Medical Device Regulation).(no content)ISO 13485 is an important standard for managing quality in the medical device industry including MDSW. By following it, companies make progress in meeting MDR rules. However, ISO 13485 doesn't cover everything in the MDR, as there are specific MDR requirements that ISO 13485 doesn't include.\n\n### General Code Review Best Practices\n\nA comprehensive code review should consist of two parts â€“ manual and automatic verification. A combination of both helps achieve the highest quality and value from code reviews.(no content)Key code review checklist items include ensuring descriptive comments are accurate and informative, return values (particularly error returns) are not ignored, constants and literals are not hard coded, and local functions and non-automatic variables are declared static.(no content)A well-defined code review checklist is crucial for thoroughly evaluating code. Essential elements include validating that the code accomplishes its intended purpose as outlined in specifications, and checking for logic errors, off-by-one mistakes, and edge cases.\n\n### Integration into Development Workflow\n\nIf possible, embed the code review checklist directly into the PR template or review process. Platforms like GitLab, Bitbucket, or GitHub offer built-in code review functionalities, and you can set up branch protection rules that disallow merging PRs without a review and approval from designated colleagues."],"durationSeconds":26.62337059399998},"tool_use_id":"toolu_01Fxa6X1r5gcZYFjt1YKGzPU"},"timestamp":1766707226371,"timestamp_pst":"2025-12-25 16:00:26 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA CAPA software deficiencies code review pharmaceutical 2022-2025"},"tool_response":{"query":"FDA CAPA software deficiencies code review pharmaceutical 2022-2025","results":[{"tool_use_id":"srvtoolu_01X8yWSK2E9jDwh4g9Z4jxMy","content":[{"title":"Corrective and Preventive Action (CAPA): The Definitive Guide (2025)","url":"https://www.thefdagroup.com/blog/definitive-guide-to-capa"},{"title":"FDA Observations CAPA","url":"https://www.leucine.io/qms-blogs/capa"},{"title":"FDA warning letters highlight CAPA concerns","url":"https://www.europeanpharmaceuticalreview.com/news/185633/fda-warning-letters-highlight-capa-concerns/"},{"title":"Corrective and Preventive Actions (CAPA) | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/corrective-and-preventive-actions-capa"},{"title":"FDA Warning Letter Highlights OOS Handling and Stability Failures - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-warning-letter-highlights-oos-handling-and-stability-failures"},{"title":"10 Best CAPA Software | Our 2025 Review","url":"https://softwareconnect.com/roundups/best-capa-software/"},{"title":"FDA Warning Letters for Medical Devices: Complete Guide 2025","url":"https://www.complizen.ai/post/fda-warning-letters-for-medical-devices-complete-guide-2025"},{"title":"Handbook of Investigation and Effective CAPA Systems","url":"https://asq.org/-/media/Images/gift/H1589-CAPA-Handbook-ebook-megasampler.pdf"},{"title":"CAPA within the Pharmaceutical Quality System 1 Martin VanTrieste, R.Ph","url":"https://www.fda.gov/media/85266/download"},{"title":"A Few Quick Tips for CAPA System Success in 2025","url":"https://insider.thefdagroup.com/p/a-few-quick-capa-tips"}]},"Based on my search, here's what I found regarding FDA CAPA software deficiencies and code review issues in the pharmaceutical industry from 2022-2025:\n\n## FDA CAPA and Software Deficiencies Overview (2022-2025)\n\n### CAPA as a Leading Cause of FDA Enforcement\n\nCAPA violations remain the leading cause of warning letters, appearing in over 60% of enforcement actions. Companies commonly fail to establish procedures for implementing corrective actions.(no content)The FDA significantly increased warning letter enforcement in 2024, with the 2024 fiscal year (October 2023 - September 2024) seeing 47 warning letters issued to medical device companies, representing a 96% increase from the 24 letters issued in 2023.\n\n### Notable CAPA Deficiency Examples\n\n**Intas Pharmaceuticals Limited (July 2023):**\nThe FDA delivered a warning letter to Intas Pharmaceuticals regarding aborted chromatographic sequences in its QC laboratories between January 2020 to November 2022. Although incidents were investigated, the company \"lacked adequate trending and CAPA systems to evaluate and identify recurring issues that should be targeted for laboratory improvements.\"\n\n**Edge Biologicals Inc. (June 2023):**\nThe FDA noted repeated observations cited during inspections in 2015 and 2018, as well as in a warning letter issued in 2012. The US regulatory body conveyed that Edge Biologicals failed to \"adequately establish procedures for corrective and preventative actions, as required by 820.100(a).\"\n\n### Software and Data Integrity Issues\n\nRecent FDA findings highlight firms where analytical software access was uncontrolled: shared logins, only \"System Administrator\" as a user role, and no audit trail review. No formal data integrity procedures were implemented, and multiple out-of-specification (OOS) results were disregarded without adequate investigation.\n\n### Historical Warning Letter Trends\n\nBetween 2018 and 2022, the quantity of warning letters issued were highest in the US in 2019 (55) and 2022 (47). Eight FDA warning letters were handed to European companies in 2018, and in subsequent years through 2022, half this number or less were issued.\n\n### CAPA Software and Compliance\n\nModern CAPA software systems are designed to help pharmaceutical companies address these deficiencies:\n\nProcess steps like review and validation are regulated with approvals and eSignatures, so nothing slips through the cracks. These connected systems help companies comply with strict FDA, ISO, and GMP regulations.(no content)CAPA software like AssurX complies with standards such as 21 CFR Part 820, CGMP Regulations, 21 CFR Part 11, EU MDR/IVDR, and ISO 9001/13485, making it suitable for diverse industries and scalable for growing regulatory demands.\n\n### Key Takeaways\n\nToo many teams treat CAPA as a compliance requirement rather than an actual problem-solving tool. This seemingly subtle shift in mindset creates cascading problems, where every deviation becomes a potential CAPA, overwhelming the system."],"durationSeconds":26.37645826500002},"tool_use_id":"toolu_01MLtN7jv7LRSiT5hVHeYWkD"},"timestamp":1766707229822,"timestamp_pst":"2025-12-25 16:00:29 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"\"computer system validation\" training pharmaceutical FDA 21 CFR Part 11 CSV"},"tool_use_id":"toolu_0161GKjikgn31zk9coZfxSnK"},"timestamp":1766707229868,"timestamp_pst":"2025-12-25 16:00:29 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"medical device software developer training IEC 62304 GAMP 5"},"tool_use_id":"toolu_019CT6oNuXpVN2P5YiPG5sHn"},"timestamp":1766707229888,"timestamp_pst":"2025-12-25 16:00:29 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software"},"tool_response":{"query":"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software","results":[{"tool_use_id":"srvtoolu_013PQ1L2Axywo4cPh5B8MQhV","content":[{"title":"The Essential Guide to Computer System Validation in the Pharmaceutical Industry - PMC","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11416705/"},{"title":"GAMP 5 Categories, V Model, 21 CFR Part 11, EU Annex 11","url":"https://amplelogic.com/gamp-5-categories-v-model-and-21-cfr-part-11-eu-annex-11"},{"title":"QUALER CFR 21 PART 11 GAMP 5 VALIDATION SERVICE","url":"https://qualer.com/wp-content/uploads/2021/12/Qualer-CFR-21-Part-11-Validation-Service.pdf"},{"title":"GAMP 5 & 21 CFR Part 11 in Computer System Validation","url":"https://pharmaconnections.in/role-of-gamp-5-and-21-cfr-part-11-in-computer-system-validation/"},{"title":"GAMP 5: Computerized System Validation in Pharma | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-computerized-system-validation-pharma"},{"title":"GAMP 5: Computerized System Validation in Pharma","url":"https://intuitionlabs.ai/pdfs/gamp-5-computerized-system-validation-in-pharma.pdf"},{"title":"What is FDA 21 CFR Part 11? Compliance & Software Validation Guide â€“ Redzone","url":"https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/"},{"title":"Considerations for validating instrument software per the GAMP 5 guide","url":"https://documents.thermofisher.com/TFS-Assets/LSG/Reference-Materials/computer-system-validation-whitepaper.pdf"},{"title":"medical device software validation reports","url":"https://gampservices.com/Compliance-and-Validation/medical_device/csv_and_di"},{"title":"Computerized Systems Validation CSV","url":"https://blog.johner-institute.com/regulatory-affairs/computerized-systems-validation-csv/"}]},"Based on my search, here's what I found regarding code review tool qualification, validation, CSV, 21 CFR Part 11, GAMP 5, and medical device software:\n\n## Overview of Key Frameworks\n\n### Computer System Validation (CSV) and GAMP 5\n\nGAMP 5 is not a law or regulation itself, but an industry guidance published by the International Society for Pharmaceutical Engineering (ISPE) that has become the de facto standard for computer system validation in pharma.(no content)While GAMP 5 itself is not legally binding, both FDA and EU regulators reference it in guidance and training, and following GAMP is considered an effective way to demonstrate compliance with 21 CFR Part 11, EU Annex 11, and related regulations.\n\n### 21 CFR Part 11 Requirements\n\nIn the United States, 21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures. Part 11 requires that when companies use digital systems to record GMP data, they must implement certain controls to ensure those records are trustworthy and equivalent to paper records. A foundational requirement of Part 11 is system validation.(no content)There are four main pillars for FDA 21 CFR Part 11 compliance: System validation â€“ Prove your system works reliably to manage critical manufacturing data; User access controls â€“ Restrict actions to authorized, qualified personnel; Audit trails â€“ Maintain secure, tamper-proof logs of all changes; Electronic signatures â€“ Ensure digital sign-offs are unique, verified, and permanently linked to records.\n\n### Relationship Between GAMP 5 and 21 CFR Part 11\n\nGAMP talks about \"the How\" and the 21 CFR talks \"the What\" during the Validation of computer-based software for Pharma companies.(no content)FDA guidance and the industry-standard GAMP 5 framework both emphasize that software validation should be risk-based and continuously maintained throughout the system's lifecycle.\n\n### Validation Qualifications (IQ, OQ, PQ)\n\nIQ, OQ, and PQ are particularly required in the pharmaceutical environment by GMP-directives. IQ (Installation Qualification) ensures the device was delivered, set up, and installed according to specifications and documentation is available. OQ (Operational Qualification) confirms the device operates according to specifications â€“ even when reaching specification limits. PQ (Performance Qualification) tests address measurement accuracy including calibration and adjustment.\n\n### Medical Device Software Considerations\n\nGAMP 5 applies to medical device manufacturers as well. The scope has been widened compared to GAMP 4 to include related industries and their suppliers, including biotechnology and systems used in medical device manufacturing.(no content)The classification of software under MDR 2017/745, Annex VIII, Rule 11, and IEC 62304 is based on its intended use and potential risks. Class A: No injury or damage to health is possible. Class B: Non-serious injury is possible. Class C: Death or serious injury is possible.\n\n### Leveraging Supplier Documentation\n\nGAMP 5 advises organizations to leverage vendor activities and documentation wherever possible. Suppliers (e.g. software developers or equipment manufacturers) typically provide their own testing, quality certificates, and technical documentation. Rather than duplicating all of this work, regulated companies should make use of supplier documentation and expertise as part of their validation strategy â€“ after performing appropriate supplier assessments.\n\nThis information provides a foundation for understanding how code review tools and other software development tools would need to be qualified and validated in regulated medical device and pharmaceutical environments."],"durationSeconds":31.55815729200002},"tool_use_id":"toolu_01LNUiLrSCxZ4QSTeCPFeRg3"},"timestamp":1766707231298,"timestamp_pst":"2025-12-25 16:00:31 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"\"computer system validation\" CSV FDA warning letter examples 2020-2024"},"tool_response":{"query":"\"computer system validation\" CSV FDA warning letter examples 2020-2024","results":[{"tool_use_id":"srvtoolu_01Lwau2LsUqH42PtGxatt5vE","content":[{"title":"Computer Systems Validation: How To Avoid FDA Warning Letters C.F.R. 820.70(i) - SPK and Associates","url":"https://www.spkaa.com/blog/computer-systems-validation-how-to-avoid-fda-warning-letters"},{"title":"C.F.R. 820.70(i) - How To Avoid FDA Warning Letters","url":"https://www.greenlight.guru/blog/computer-systems-validation-how-to-avoid-fda-warning-letters"},{"title":"Identifying CSV Compliance Violations: Lessons Learned from an FDA Inspection in June 2023 - Performance Validation","url":"https://perfval.com/identifying-csv-compliance-violations-lessons-learned-from-an-fda-inspection-in-june-2023/"},{"title":"FDA Warning Letters Archives - Validation Center","url":"https://validationcenter.com/product-category/library/fda-warning-letters/"},{"title":"What Is Computer System Validation? | Kneat","url":"https://kneat.com/article/what-is-computer-system-validation/"},{"title":"CSA and CSV: Streamlining Life Sciences Software Validation | QAD Blog","url":"https://www.qad.com/blog/2024/08/csa-and-csv-streamlining-life-sciences-software-validation"},{"title":"FDA Warning Letters Archives - Ofni Systems","url":"https://www.ofnisystems.com/fda-warning-letters/"},{"title":"Computerized System Validation | CSV Documentation | CSV","url":"https://www.gxpcellators.com/computerized-system-validation/"},{"title":"Avoid FDA Warning Letters in the Context of Computerized System Validation: A Short Guide by KVALITO - Kvalito","url":"https://kvalito.ch/avoid-fda-warning-letters-in-the-context-of-computerized-system-validation-a-short-guide-by-kvalito/"},{"title":"A Review on Computer System Validation (CSV) and Recent Computer System Violations Leading to USFDA Warning Letter for the Pharmaceutical Industry","url":"https://www.researchgate.net/publication/397528827_A_Review_on_Computer_System_Validation_CSV_and_Recent_Computer_System_Violations_Leading_to_USFDA_Warning_Letter_for_the_Pharmaceutical_Industry"}]},"Here are the search results on FDA warning letters related to computer system validation (CSV):\n\n## Computer System Validation (CSV) and FDA Warning Letters\n\n### Overview of CSV Requirements\n\nComputer systems validation (CSV) is a standard regulatory exercise that medical device companies are required to complete.(no content)The FDA Code of Federal Regulations, Title 21 under Quality Systems, subsection 70(i) states: \"When computers or automated data processing systems are used as part of production or the quality system, the manufacturer shall validate computer software for its intended use according to an established protocol. All software changes shall be validated before approval and issuance. These validation activities and results shall be documented.\"\n\n### Recent FDA Warning Letter Examples\n\n**June 2023 Case Study:**\nDuring an FDA inspection in June 2023, several violations related to computer system/software compliance and general quality system processes were identified. The warning letter (CMS #653455) details a variety of violations that can be addressed through computer system validation (CSV), computer software assurance, equipment qualification/validation, and quality system procedures.\n\nKey findings from this warning letter included:\n- Failure to validate complaint handling system software. These types of systems (e.g., eQMS) must be validated when they manage complaint handling processes due to the risk of impact to patient safety and product quality.\n- In the warning letter, the FDA requests the organization to generate a software validation report, approach, testing methodology, and validation results within six weeks.\n\n### Common CSV Compliance Violations\n\nRegulatory agencies, especially the FDA, have issued warning letters about CSV non-compliance. Common issues include: failure to validate systems (e.g., manufacturing systems, clinical trial management systems), failure to control or manage system changes (i.e., no proper change control or version control), lack of adequate documentation (e.g., missing validation reports, unqualified systems), issues with data integrity when electronic records or signatures are used without sufficient audit trails or controls, and inadequate testing or qualification (e.g., improper or incomplete IQ, OQ, and PQ documentation).(no content)Failure to conform with the FDA CSV requirement can lead to regulatory action. Within the past year, five companies were implicated and received warning letters due to non-compliance with 820.70(i).\n\n### Consequences of Non-Compliance\n\nThe FDA mandates, under 21 CFR Part 11 Section 11.10, that software and computer systems are tested for consistency and efficacy and that those tests are documented and provable. FDA penalties for non-compliance in Computer System Validation may include audits, warning letters, or even shutdowns if linked to significant risk in product quality.(no content)Compliance with these regulations is not optional. Failure to meet regulatory requirements can result in severe consequences, including warning letters, fines, product recalls, or even facility shutdowns.\n\n### Regulatory Evolution: From CSV to CSA\n\nIn late 2022, the FDA issued draft guidance introducing Computer Software Assurance (CSA) as the recommended approach to CSV. At a high level, CSA is a risk-based approach that seeks to empower companies to perform CSV with activities that meet the risk of the systems in question, rather than implementing a one-size-fits-all approach.\n\nFor more specific examples and a comprehensive database of FDA warning letters related to CSV, you may want to review the FDA's official warning letter database directly or consult resources from validation consulting firms that track these enforcement actions."],"durationSeconds":29.895038997999976},"tool_use_id":"toolu_01GQ177pwYXiFSs6PJ2nv5Dx"},"timestamp":1766707233369,"timestamp_pst":"2025-12-25 16:00:33 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review roles responsibilities medical device software author reviewer moderator independence requirements"},"tool_response":{"query":"code review roles responsibilities medical device software author reviewer moderator independence requirements","results":[{"tool_use_id":"srvtoolu_01Fj1qc9kaoksR55DjZxmsyV","content":[{"title":"Roles and Responsibilities in Review - GeeksforGeeks","url":"https://www.geeksforgeeks.org/roles-and-responsibilities-in-review/"},{"title":"Regulatory requirements for code reviews","url":"https://www.johner-institute.com/articles/software-iec-62304/software-lifecycle/code-reviews/"},{"title":"Code review as part of software validation","url":"https://elsmar.com/elsmarqualityforum/threads/code-review-as-part-of-software-validation.29115/"},{"title":"Why is Medical Device Software Validation Important? | Blog","url":"https://www.acldigital.com/blogs/medical-device-software-validation"},{"title":"General Principles of Software Validation - Final Guidance ...","url":"https://www.fda.gov/media/73141/download"},{"title":"Roles in Review Process","url":"https://docs.devart.com/review-assistant/creating-review/roles-in-review-process.html"},{"title":"Roles and Responsibilities in a Formal Review","url":"https://www.programsbuzz.com/article/roles-and-responsibilities-formal-review"},{"title":"What are the roles and responsibilities involved during a review?","url":"https://tryqa.com/what-are-the-roles-and-responsibilities-involved-during-a-review/"},{"title":"Code Review in Medical Device Software: Ensuring Safety Through Precision - Collabnix","url":"https://collabnix.com/code-review-in-medical-device-software-ensuring-safety-through-precision/"},{"title":"Understanding Roles and Responsibilities in the Review Process | by Kanchan Adhikrao jadhav | Medium","url":"https://medium.com/@kanchanjadhav0223/understanding-roles-and-responsibilities-in-the-review-process-6b58fd07cb41"}]},"Based on my search, I found comprehensive information about code review roles, responsibilities, and independence requirements for medical device software. Here's a summary:\n\n## Roles and Responsibilities in Code Review\n\n### Moderator (Review Leader)\nThe Moderator, also known as review leader, generally leads the review process. It simply co-ordinates with the author and checks entry criteria for review. During review, they also lead discussion.(no content)The Moderator oversees the review process, resolves disputable situations, and performs double check. The Moderator is also responsible for closing the review.\n\n### Author\nAs the writer of the document under review, the author's main goal must be to learn and know as much as possible with regard to improving and increasing quality of document. He/She is writer of documents under review and aims to gain maximum from review. They also help in improving document quality.(no content)In peer code review, authors write code and update their code in Bitbucket. The author then identifies the code that needs to be reviewed and submits a request to a peer reviewer.\n\n### Reviewer\nReviewers should provide constructive, written, and unbiased feedback in a given period of time. They indicate whether or not writing is clear, relevant, and rate work's composition, originality, and scientific accuracy. They should avoid personal criticism and comments.(no content)Ideally a code review would be conducted by someone as experienced as the author. However, a mix of review and testing can offer the best of both worlds. When there's lots of code, it can be prioritized so the reviewer(s) concentrates on the critical areas, which may be determined by risk analysis.\n\n### Scribe/Recorder\nThe scribe or recorder simply has to record each and every defect and error that is found and any suggestions or feedback given in the meeting for improvement of process. Basically, author plays role of scribe, but it's very good and advantageous to have another person to scribe so that author can only concentrate on review.\n\n### Manager\nManagers are basically included and involved in the reviews as they decide on execution of reviews, allocate time in project schedules, and identify whether or not objectives of review project have been met. They decide execution of reviews and also play the role of reviewers sometimes.\n\n## Independence Requirements (Medical Device Specific)\n\nAccording to the FDA's General Principles of Software Validation guidance:\n\nSelf-validation is extremely difficult. When possible, an independent evaluation is always better, especially for higher risk applications. Some firms contract out for a third-party independent verification and validation, but this solution may not always be feasible. Another approach is to assign internal staff members that are not involved in a particular design or its implementation, but who have sufficient knowledge to evaluate the project and conduct the verification and validation activities.(no content)The device manufacturer has flexibility in choosing how to apply these validation principles, but retains ultimate responsibility for demonstrating that the software has been validated.\n\n## Regulatory Context\n\nThe statutory requirement for reviews can be found in 21 CFR part 820. Here, too, no specific method is named. This, then, gives us the answer: You describe, as a manufacturer, in your 820-compliant quality management system, what kind of reviews you will make.(no content)External specialists bring independence, domain knowledge, and structured methods that ensure reviews stand up to regulatory scrutiny. Outsourcing medical software review to qualified providers unlocks major advantages: Experts familiar with IEC, ISO, and FDA expectations can ensure documentation and traceability meet auditor requirements.\n\n## Best Practices for Code Reviews\n\nA code review should not take longer than 30 minutes. A code review should examine the code based on predetermined and possibly programming-specific criteria, including compliance with previously (automatically) determined metrics and coding guidelines. A code review should take into account the test code (including code coverage). A code review should be documented."],"durationSeconds":33.98141495599994},"tool_use_id":"toolu_014EYQKoNRcR1YNRwaK7x7bd"},"timestamp":1766707233658,"timestamp_pst":"2025-12-25 16:00:33 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA remediation requirements software validation response plan"},"tool_response":{"query":"FDA remediation requirements software validation response plan","results":[{"tool_use_id":"srvtoolu_01NdfvBQSoQ164KUH4ceKu4H","content":[{"title":"General Principles of Software Validation - Final Guidance","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation"},{"title":"Software Verification and Validation Requirements for Medical Device and Their Implementation Strategies","url":"https://www.complianceonline.com/resources/software-verification-and-validation-requirements-for-medical-device-and-implementation-strategies.html"},{"title":"Software validation and 21 CFR Part 11 remediation planning: FDA inspection strategies : Compliance Training Webinar (Online Seminar) - ComplianceOnline.com","url":"https://www.complianceonline.com/software-validation-and-21-cfr-part-11-remediation-planning-fda-inspection-strategies-webinar-training-701216-prdw"},{"title":"FDA Software Validation Requirements - Validify","url":"https://www.validify.app/post/fda-software-risk-management"},{"title":"The Fundamentals of FDA Software Validation","url":"https://www.complianceonline.com/resources/fundamentals-of-fda-software-validation.html"},{"title":"FDA Software Validation: A Helpfull Guide to 2025","url":"https://www.compliancequest.com/blog/understanding-fda-software-validation/"},{"title":"The step-by-step guide to FDAâ€™s software validation process - Spyrosoft","url":"https://spyro-soft.com/blog/healthcare/the-step-by-step-guide-to-fdas-software-validation-process"},{"title":"2024 FDA Software Validation - Example Template, Checklist & Process","url":"https://www.datacor.com/the-datacor-blog/fda-software-validation"},{"title":"Remediation: When things hit the fan","url":"https://blog.johner-institute.com/regulatory-affairs/remediation-when-things-hit-the-fan/"},{"title":"Fda","url":"https://www.fda.gov/media/73065/download"}]},"Here are the search results for \"FDA remediation requirements software validation response plan\":\n\n## FDA Software Validation and Remediation Requirements\n\n### Key FDA Guidance Documents\n\nThe FDA has established general validation principles applicable to the validation of medical device software or the validation of software used to design, develop, or manufacture medical devices.\n\n### Regulatory Requirements\n\nUnder 21 CFR Â§820.30, any medical device software product developed after June 1, 1997, regardless of its device class, is subject to applicable design control provisions. Design controls such as planning, input, verification, and reviews are required for medical device software.(no content)21 CFR Â§820.70(i) requires that any software used to automate any part of the device production process or any part of the quality system must be validated for its intended use. This requirement applies to any software used to automate device design, testing, component acceptance, manufacturing, labeling, packaging, distribution, complaint handling, or to automate any other aspect of the quality system.\n\n### Remediation Planning\n\nKey questions for remediation include: How do I determine which systems require remediation? What are the planning issues for a remediation project? Remediation project planning guidelines should address these concerns.(no content)Remediation aims to bring a system, process, or product back into compliance before serious consequences such as fines, criminal charges, import bans, or poor reputation can occur.(no content)Once the non-conformities and their causes have been fully identified and understood, the next step is to plan the remediation. The plan should include: planned corrections and corrective and preventive actions and the associated changes to the QM system including processes and procedures. Companies should communicate their plan to the notified body or authority.\n\n### Validation Plan Requirements\n\nThere are five steps to FDA software validation. Step 1: Create a validation plan that documents various aspects of the software system, its installed environment and project limitations. The plan will also include the testing and acceptance criteria, development procedures and responsibilities of the members of the validation team.(no content)A Master Validation Plan outlines the scope of the validation project and the strategy for validating the software's installation and use. It includes an overview of each process, the validation approach and the rationale for following it. Design Qualification (DQ) identifies key functionality, design specifications and software requirements. Risk Assessment and Management documents the risk factors and mitigations associated with using the software to produce regulated goods.\n\n### Response to FDA Inspections\n\nThe FDA documents deviations (\"inspectional observations\") on a form with the number 483. In case of major violations, a warning letter can be issued.(no content)Remediation activities include understanding the non-conformity reports and regulatory requirements (including the scope for implementation), communication with the authority or notified body (e.g., drafting an appropriate response to a warning letter), root cause analysis and development of an action plan, and support with the implementation of actions (e.g., establishing a new procedure, validation of processes).\n\n### Modern Approaches - Computer Software Assurance (CSA)\n\nIn 2022, the FDA introduced the concept of Computer Software Assurance (CSA). This approach shifts the focus from compliance-centric activities to critical thinking and risk-based decision-making. CSA encourages leveraging automated tools, real-world evidence, and agile practices to streamline validation processes. By reducing unnecessary documentation and emphasizing testing where it matters most, CSA aims to promote innovation and efficiency without compromising quality or patient safety."],"durationSeconds":30.431091539000043},"tool_use_id":"toolu_01NheL8MzjdHQftw9krcDiJb"},"timestamp":1766707233875,"timestamp_pst":"2025-12-25 16:00:33 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process"},"tool_response":{"query":"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process","results":[{"tool_use_id":"srvtoolu_01PkPrVb1WnAUUD7EKUAxU2g","content":[{"title":"Inspection Guides | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-guides"},{"title":"How to Determine if Your Product is a Medical Device | FDA","url":"https://www.fda.gov/medical-devices/classify-your-medical-device/how-determine-if-your-product-medical-device"},{"title":"Fda","url":"https://www.fda.gov/media/73141/download"},{"title":"Inspection Observations | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations"},{"title":"Policy for Device Software Functions and Mobile Medical ...","url":"https://www.fda.gov/media/80958/download"},{"title":"US FDA Medical Device Inspections: 2025 Guide to Prepare","url":"https://omcmedical.com/us-fda-medical-device-inspections/"},{"title":"Policy for Device Software Functions and Mobile Medical Applications | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications"},{"title":"FDA Dashboards - Inspections","url":"https://datadashboard.fda.gov/oii/cd/inspections.htm"},{"title":"General Principles of Software Validation - Final Guidance","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation"},{"title":"Pharmaceutical Inspections and Compliance | FDA","url":"https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmaceutical-inspections-and-compliance"}]},"The search results provide general information about FDA inspections and software validation for medical devices, but don't specifically address \"Fagan inspection methodology.\" Let me search more specifically for the Fagan inspection methodology in the context of FDA-regulated software.",{"tool_use_id":"srvtoolu_01AtM72tzqBms48iRJ4Ye5KV","content":[{"title":"Fagan inspection - Wikipedia","url":"https://en.wikipedia.org/wiki/Fagan_inspection"},{"title":"Fagan Inspection |Professionalqa.com","url":"https://www.professionalqa.com/fagan-inspection"},{"title":"Can using Fagan Inspections improve the quality of ...","url":"https://eprints.bournemouth.ac.uk/18183/3/JearyPhalpMilsomHughesWebsterHolroyd.pdf"},{"title":"Fagan Inspection Methodology","url":"https://en.tigosolutions.com/differences-between-software-walkthrough-review-and-inspection-5706"},{"title":"Experience with Fagan's Inspection Method","url":"https://www.ida.liu.se/~TDDC90/literature/lab-papers/doolan91.pdf"},{"title":"Fagan Inspection | PDF","url":"https://www.slideshare.net/slideshow/fagan-inspection-13547192/13547192"},{"title":"A New Trend on Software Engineering with Modern Code Review â€” From Michal Fagan to Google Approach | by Erik Aceiro Antonio | Erik Aceiro Antonio | Medium","url":"https://medium.com/ereflections/a-new-trend-on-software-engineering-with-modern-code-review-from-michal-fagan-to-google-approach-c2121870504c"},{"title":"Fagan inspection","url":"https://en-academic.com/dic.nsf/enwiki/590590"},{"title":"What is Fagan inspection? â€” Limeup","url":"https://limeup.io/glossary/fagan-inspection/"},{"title":"CSc 233 Project Management 1 Different Types of Reviews","url":"https://athena.ecs.csus.edu/~buckley/CSc233/Reviews_Types_Intro.pdf"}]},"Based on my searches, I now have comprehensive information about the Fagan inspection methodology. Let me provide you with the search results:\n\n## Fagan Inspection Methodology in the Context of FDA-Regulated Software\n\n### What is Fagan Inspection?\n\nA Fagan inspection is a process of trying to find defects in documents (such as source code or formal specifications) during various phases of the software development process. It is named after Michael Fagan, who is credited with the invention of formal software inspections.(no content)The definition of Software Inspection was proposed by Michael Fagan in 1976 when he worked at IBM and performed seminal work about Experimental Software Engineering using peer-meeting code review. In that work, a team was organized in a meeting with a formal protocol to detect defects.\n\n### Key Characteristics of Fagan Inspection\n\nFagan inspection is a widely applicable, rigorous and formal software engineering QC technique for inspection of any document when it is believed complete and ready for use. It finds defects directly â€“ unlike testing, which happens later, and only reveals symptoms.(no content)According to this method, inspection must be formal; materials to be inspected must be prepared and meet the inspection entry criteria; and people who inspect must be qualified, as well as the time and place must be arranged ahead of time. There are formal roles for each participant and they must be trained in the method.\n\n### The Fagan Inspection Process Stages\n\nThe stages in the inspections process are: Planning, Overview meeting, Preparation, Inspection meeting, Rework and Follow-up.(no content)Planning: The inspection is planned by the moderator. Overview meeting: The author describes the background of the work product. Preparation: Each inspector examines the work product to identify possible defects. Inspection meeting: During this meeting the reader reads through the work product, part by part and the inspectors point out the defects for every part. Rework: The author makes changes to the work product according to the action plans from the inspection meeting.\n\n### Entry and Exit Criteria\n\nFor Fagan inspections the high- and low-level documents must comply with specific entry criteria before they can be used for a formal inspection process. Exit criteria are the criteria or requirements which must be met to complete a specific process. For Fagan inspections the low-level document must comply with specific exit criteria before the development process can be taken to the next phase.\n\n### Connection to FDA-Regulated Software\n\nThe FDA's guidance on software validation for medical devices mentions the use of formal inspection methods. The FDA discusses dynamic analyses, code and document inspections, walkthroughs, and other techniques as part of software validation activities.(no content)For purposes of this guidance, FDA considers software validation to be \"confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular requirements implemented through software can be consistently fulfilled.\"(no content)Planning, verification, testing, traceability, configuration management, and many other aspects of good software engineering discussed in this guidance are important activities that together help to support a final conclusion that software is validated.\n\n### Effectiveness and Benefits\n\nSince introducing the inspection process in 1974, IBM achieved significant improvements in quality. The company nearly doubled the number of lines of code shipped for System/370 software products since 1976, while the number of defects per thousand lines of code was reduced by two-thirds.(no content)The inspection is the most formal of the three validation and verification techniques (reviews, walkthroughs, inspections) and is based on Fagan's concepts of a disciplined process to detect defects.(no content)Fagan inspection is the most cited inspection method in the literature and is the basis upon which all the other methods are designed."],"durationSeconds":36.06999728600005},"tool_use_id":"toolu_014Qb6w3GQCxNBANAbwVt2vZ"},"timestamp":1766707235743,"timestamp_pst":"2025-12-25 16:00:35 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"defect tracking classification FDA regulated software CAPA integration severity levels medical device"},"tool_response":{"query":"defect tracking classification FDA regulated software CAPA integration severity levels medical device","results":[{"tool_use_id":"srvtoolu_01H1eXjEap61P83T2LEjKsXf","content":[{"title":"CAPA for Medical Devices: The Ultimate Guide","url":"https://www.greenlight.guru/blog/corrective-action-and-preventive-action-capa-medical-devices"},{"title":"CAPA Management in the Medical Device Industry: Examples, Requirements, and Process","url":"https://simplerqms.com/capa-medical-device/"},{"title":"CAPA for Medical Devices: Ensure Compliance and Quality","url":"https://www.qualityze.com/blogs/capa-medical-devices-industry"},{"title":"Understanding CAPA ISO 13485 Requirements","url":"https://www.compliancequest.com/bloglet/capa-iso-13485/"},{"title":"Corrective and Preventive Action (CAPA): The Definitive Guide (2025)","url":"https://www.thefdagroup.com/blog/definitive-guide-to-capa"},{"title":"CAPA for Medical Devices | Healthcare & Medical Device Management | Aptien","url":"https://aptien.com/en/kb/articles/how-to-manage-capa-medical-devices"},{"title":"CAPA for medical devices: examples, procedures, implementation","url":"https://www.qualio.com/blog/capa-medical-device-requirements"},{"title":"Fda","url":"https://www.fda.gov/files/medical%20devices/published/Guidance-for-the-Content-of-Premarket-Submissions-for-Software-Contained-in-Medical-Devices---Guidance-for-Industry-and-FDA-Staff.pdf"},{"title":"MDIC MEDICAL DEVICE INNOVATION CONSORTIUM May 2, 2023","url":"https://mdic.org/wp-content/uploads/2023/05/2022-MDIC-Make-CAPA-Cool-Whitepaper_v16.pdf"},{"title":"5 fundamentals of the CAPA quality process","url":"https://www.qualio.com/blog/capa-quality-process"}]},"Based on my search, here is a comprehensive overview of defect tracking classification, FDA regulated software, CAPA integration, and severity levels for medical devices:\n\n## Defect Tracking and CAPA Integration for FDA-Regulated Medical Device Software\n\n### Regulatory Framework\n\nCAPA requirements for medical device companies are established through standards and regulations, including ISO 13485:2016, FDA 21 CFR 820, EU MDR, and EU IVDR.(no content)These requirements mandate a structured approach to identifying, investigating, correcting, and preventing recorded issues, ensuring compliance with global regulatory expectations.(no content)The US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the European Union (EU) all require a CAPA system to be put in place to determine and mitigate risks that can prevent adverse events and product failures.\n\n### Defect Classification and Severity Levels\n\nBased on the nature of business and operations, teams can measure the number of deviations that occurred, the nature and severity of the deviations following the solution being implemented, and the impact of the new process on the specific product.(no content)CAPA application should be sensible and risk-based - there's no point throwing all your resources at a minor defect when there's a major fire to fight. Link your CAPAs to the severity, impact on quality, and potential risks of the issues they're addressing. This allows you to allocate resources tactically and address critical issues with the highest priority.\n\n### CAPA Process Integration\n\nThe CAPA process for medical device companies involves several structured steps. First, the issue is identified based on complaints, audit findings, or quality control data. Second, the issue is evaluated and prioritized based on its potential impact, followed by developing an initial CAPA plan. A root cause analysis (RCA) is conducted to determine underlying causes. CAPA actions are then created and implemented, and their effectiveness is verified before formally closing the CAPA. Continuous review and trend analysis help with overall continuous improvement.(no content)Integration with QMS is essential - integrate CAPA with your overall Quality Management System (QMS) to ensure consistency across processes and regulatory compliance.\n\n### Key Data Sources for Defect Tracking\n\nData collection involves gathering relevant data (e.g., defect rates, complaint records, failure modes) to understand the problem's scope and impact.(no content)Typically, consumer complaints are one of the biggest indicators of problems with distributed products, and as a result, CAPA processes. The U.S. Food and Drug Administration (FDA) has underlined this point, stating that it views complaints as a more important CAPA data source.\n\n### Root Cause Analysis Tools\n\nInvestigations should conduct a thorough investigation to determine the underlying cause(s) of the issue (e.g., manufacturing defects, design flaws, or process problems). Techniques include problem-solving tools like 5 Whys, Fishbone (Ishikawa) Diagram, Failure Mode and Effect Analysis (FMEA), or Fault Tree Analysis (FTA) to identify root causes.\n\n### FDA Inspection Focus\n\nCAPA process definition is a huge issue for medical device companies. This issue is the single biggest reason FDA issues 483 observations to medical device companies year after year since 2010.(no content)The FDA issued over 700 inspectional observations related to CAPA deficiencies in a single year.\n\n### Software-Specific Requirements\n\nSoftware must be developed in accordance with the requirements of the Quality System Regulation (QS regulation) (21 CFR part 820).(no content)For software contained in medical devices, manufacturers should describe all outstanding anomalies or software defects with corresponding workarounds, where applicable, if these issues are not addressed in the User's Manual.\n\n### Documentation and Compliance\n\nCAPA Records must document all actions taken, from problem identification to root cause analysis and corrective/preventive actions. Include supporting evidence, investigation results, and verification outcomes. Ensure that CAPA documentation complies with relevant standards, such as ISO 13485 or FDA 21 CFR Part 820. Maintain these records for audits or inspections."],"durationSeconds":36.094495449000036},"tool_use_id":"toolu_019bJZQy97AgRf5v1N1NC2jo"},"timestamp":1766707235833,"timestamp_pst":"2025-12-25 16:00:35 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA audit documentation code review evidence requirements traceability pharmaceutical software"},"tool_response":{"query":"FDA audit documentation code review evidence requirements traceability pharmaceutical software","results":[{"tool_use_id":"srvtoolu_01MZA656LobZPwc62qcwDGkw","content":[{"title":"Fda","url":"https://www.fda.gov/media/73141/download"},{"title":"FDA 21 CFR Part 11: A Complete Compliance Checklist Guide - Quality Forward","url":"https://www.qualityfwd.com/blog/21-cfr-part-11/"},{"title":"FDA Software Validation Process: Steps, Principles & More","url":"https://amplelogic.com/fda-software-validation-process"},{"title":"Data Integrity and Compliance With Drug CGMP Questions and Answers","url":"https://www.fda.gov/media/119267/download"},{"title":"How to Master ISO 13485 Software Validation: Step-by-Step FDA Guidelines - Expandable ERP","url":"https://expandable.com/how-to-master-iso-13485-software-validation-step-by-step-fda-guidelines/"},{"title":"Automating Audit Trail Compliance for 21 CFR Part 11 & Annex 11 | IntuitionLabs","url":"https://intuitionlabs.ai/articles/audit-trails-21-cfr-part-11-annex-11-compliance"},{"title":"FDA Compliance Software Best Practices","url":"https://integrant.com/blog/fda-compliant-software-best-practices"},{"title":"FDA Software Validation: A Helpfull Guide to 2025","url":"https://www.compliancequest.com/blog/understanding-fda-software-validation/"},{"title":"Audit Trail Requirements in Electronic GxP Systems: A Quick Guide","url":"https://www.thefdagroup.com/blog/audit-trail-requirements-in-electronic-gxp-systems-a-quick-guide"},{"title":"FDA Software Validation Requirements - Validify","url":"https://www.validify.app/post/fda-software-risk-management"}]},"Based on the search results, here's a comprehensive overview of FDA audit documentation, code review evidence requirements, and traceability for pharmaceutical software:\n\n## FDA Requirements for Software Validation and Documentation\n\n### Traceability Requirements\n\nFDA requires conformance to all software specifications and confirmation that all software requirements are traceable to system specifications. Validation of software typically includes evidence that all software requirements have been implemented correctly and completely and are traceable to system requirements.(no content)The traceability analysis aims to ensure that all requirements for the FDA compliance software system are properly tested during the test protocols. This document serves as a tool for both the validation team and auditors. This process should be performed using a Requirement Traceability Matrix (RTM), which allows developers to measure test coverage and map system requirements and change requests.\n\n### Software Verification and Code Review Evidence\n\nSoftware verification provides objective evidence that the design outputs of a particular phase of the software development life cycle meet all of the specified requirements for that phase. Software verification looks for consistency, completeness, and correctness of the software and its supporting documentation. Software testing is one of many verification activities, along with various static and dynamic analyses, code and document inspections, and walkthroughs.(no content)The FDA rules state that all software changes need verification before approval and use. Teams must document all verification activities and results properly.\n\n### Audit Trail Requirements\n\nA cornerstone of compliance trust is the audit trail â€“ the record of who did what, when, and why to an electronic record. Both the FDA in its 21 CFR Part 11 rules and the EU GMP Annex 11 guidelines explicitly require robust audit trails for computerized systems. These audit trails enable transparency and traceability of all changes to GxP-critical data.(no content)Audit trails provide transparency and accountability, as any unauthorized change, deletion, or fabrication of data is expected to be evident in the audit log. FDA investigators explicitly look for audit trails during inspections, and a missing or incomplete audit trail is a red flag for data integrity issues.\n\n### 21 CFR Part 11 Compliance\n\n21 CFR Part 11 sets expectations for how companies must design, operate, and uphold computer systems that store regulated information. It covers topics like access controls, audit trails, validation, and electronic signature management.(no content)Compliance with 21 CFR Part 11 is not only about the technology used. It is also about the procedures, training, and controls that support how people interact with that technology. Regulators expect companies to show that their systems are trustworthy, that their processes are well defined, and that their staff understand and follow those processes consistently.\n\n### Documentation Requirements\n\nProper documentation is essential in the FDA validation process. Every step of validation, from planning to ongoing monitoring, must be carefully documented to establish an audit trail that proves compliance. Documentation should also demonstrate that the validation activities were comprehensive and followed FDA guidelines.(no content)Validation protocols, test records, risk assessments, and compliance documents should be organized in a centralized manner. This helps ensure that evidence required for FDA audits and submissions is accurate, accessible, and up to date.\n\n### Data Integrity Requirements\n\nFDA expects that all data be reliable and accurate. CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms should implement meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies.(no content)Data should be maintained throughout the record's retention period with all associated metadata required to reconstruct the CGMP activity. The relationships between data and their metadata should be preserved in a secure and traceable manner.\n\n### Best Practices\n\nFollowing a risk-based validation approach (as advocated by ISPE's GAMPÂ®5 and FDA's CSA guidance) is beneficial â€“ focus validation efforts on functions that impact product quality and data integrity, including audit trail recording. The validation should also test boundary cases. All such tests and their results must be documented, forming evidence for inspectors that the audit trail works as intended.(no content)Bug reporting and the linkage of bugs to test cases must be completely traceable."],"durationSeconds":36.41970100900007},"tool_use_id":"toolu_01CUKy3zWiD1CMd4Ro8KfVyN"},"timestamp":1766707236097,"timestamp_pst":"2025-12-25 16:00:36 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"21 CFR Part 11 audit trail requirements code change control procedures"},"tool_response":{"query":"21 CFR Part 11 audit trail requirements code change control procedures","results":[{"tool_use_id":"srvtoolu_01SireFNqSguMrw3rLUbCiZA","content":[{"title":"Automating Audit Trail Compliance for 21 CFR Part 11 & Annex 11 | IntuitionLabs","url":"https://intuitionlabs.ai/articles/audit-trails-21-cfr-part-11-annex-11-compliance"},{"title":"21 CFR Part 11 Audit Trail Requirements [Explained]","url":"https://simplerqms.com/21-cfr-part-11-audit-trail/"},{"title":"21 CFR Part 11 Audit Trail Requirements | Remington-Davis","url":"https://www.remdavis.com/news/21-cfr-part-11-audit-trail-requirements"},{"title":"Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application"},{"title":"FDA 21 CFR Part 11 Compliance Guide | Definition, Key Requirements & FAQs | Kneat","url":"https://kneat.com/articles/regulatory/fda-21-cfr-part-11-compliance-guide/"},{"title":"eCFR :: 21 CFR Part 11 -- Electronic Records; Electronic Signatures","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11"},{"title":"eCFR :: 21 CFR Part 11 Subpart B -- Electronic Records","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11/subpart-B"},{"title":"What are the requirements of Audit Trail in CFR 21 Part 11? - Integra IT","url":"https://www.integrait.co/what-are-the-requirements-of-audit-trail-in-crf-21-part-11/"},{"title":"FDA 21 CFR Part 11: A Complete Compliance Checklist Guide - Quality Forward","url":"https://www.qualityfwd.com/blog/21-cfr-part-11/"},{"title":"What is FDA 21 CFR Part 11? Compliance & Software Validation Guide â€“ Redzone","url":"https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/"}]},"Here are the key findings on **21 CFR Part 11 audit trail requirements and change control procedures**:\n\n## Key Regulatory Requirements\n\n### Audit Trail Requirements (21 CFR 11.10(e))\n\n\"Revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of systems documentation.\"(no content)Record changes shall not obscure previously recorded information. Such audit trail documentation shall be retained for a period at least as long as that required for the subject electronic records and shall be available for agency review and copying.\n\n### Core Audit Trail Components\n\nCompliance with 21 CFR Part 11 requires maintaining secure, computer-generated audit trails that document all modifications to electronic records. These trails support data integrity by recording what changes were made, who made them, and when.(no content)User actions and system events must be recorded with a precise timestamp, including date and time. The timestamp should be based on a reliable and synchronized clock, typically a central server time.(no content)The audit trail must capture sufficient detail about each action, including the specific type of action, the data element affected, and the previous and new values of any changed data.\n\n### Automatic Generation Requirement\n\nAs outlined in 21 CFR 11.10(e), an audit trail must be automatically generated by the system and not manually created to eliminate human errors.\n\n## Change Control Procedures\n\nChange control processes ensure that system changes are properly evaluated, approved, and documented before implementation. This prevents unauthorized modifications that could compromise data integrity.(no content)A formal change control process should be in place for system updates, configuration adjustments, or workflow changes. Each modification must be reviewed for its potential impact on compliance before being implemented.\n\n## Additional Controls Required\n\nAuthority checks must ensure that only authorized individuals can use the system, electronically sign a record, access the operation or computer system input or output device, alter a record, or perform the operation at hand.(no content)Persons who develop, maintain, or use electronic record/electronic signature systems must have the education, training, and experience to perform their assigned tasks.\n\n## FDA Enforcement Discretion\n\nThe FDA has noted concerns that some interpretations of Part 11 requirements would unnecessarily restrict electronic technology use. These concerns have been raised particularly in the areas of Part 11 requirements for validation, audit trails, record retention, record copying, and legacy systems."],"durationSeconds":23.96261656300002},"tool_use_id":"toolu_01PuWtuzNBLZFsMwkGchVnXx"},"timestamp":1766707236455,"timestamp_pst":"2025-12-25 16:00:36 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"\"FDA warning letter\" software validation case study 2023 2024 medical device"},"tool_response":{"query":"\"FDA warning letter\" software validation case study 2023 2024 medical device","results":[{"tool_use_id":"srvtoolu_012DjSkZ2MVQ36S1nvY9oU9R","content":[{"title":"2023 FDA Warning Letters and Software Validation - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation"},{"title":"Warning Letters | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters"},{"title":"FDA Warning Letters for Medical Devices: Complete Guide 2025","url":"https://www.complizen.ai/post/fda-warning-letters-for-medical-devices-complete-guide-2025"},{"title":"2023 and 2024 Trends in Medical Device FDA Warning Letters","url":"https://aztechnica.com/resources/f/2023-and-2024-trends-in-medical-device-fda-warning-letters"},{"title":"US FDA CDRH Warning Letters: A Review of 2023 | Emergo by UL","url":"https://www.emergobyul.com/news/us-fda-cdrh-warning-letters-review-2023"},{"title":"Medical Devices Warning Letter Statistics for Fiscal Year 2023 - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/medical-devices-warning-letter-statistics-for-fiscal-year-2023"},{"title":"US FDA CDRH Warning Letters: A Review of 2024 | Emergo by UL","url":"https://www.emergobyul.com/news/us-fda-cdrh-warning-letters-review-2024"},{"title":"Current FDA 483s and Warning Letters Trends in Pharmaceutical, Biotechnology, and Medical Device Industries - VTI Life Sciences","url":"https://validation.org/current-fda-483s-and-warning-letters-trends-in-pharmaceutical-biotechnology-and-medical-device-industries/"},{"title":"FDA Issues Numerous Warning Letters - Gardner Law","url":"https://gardner.law/news/fda-issues-numerous-warning-letters"},{"title":"FDA Warning Letter Statistics on Medical Devices in the past Fiscal Year - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-warning-letter-statistics-on-medical-devices-in-the-past-fiscal-year"}]},"Based on the search results, here's a comprehensive overview of FDA warning letters related to software validation in the medical device industry for 2023-2024:\n\n## FDA Warning Letters & Software Validation: Medical Device Case Studies (2023-2024)\n\n### Key Statistics\n\nThe 2024 fiscal year (October 2023 - September 2024) saw 47 warning letters issued to medical device companies, representing a 96% increase from the 24 letters issued in 2023.(no content)The U.S. FDA Center for Devices and Radiological Health (CDRH) issued 567 warning letters in 2023, most related to drugs, tobacco products or food products. Of those, 4% of all warning letters (24) were issued for medical devices.(no content)The FDA's Center for Devices and Radiological Health (CDRH) issued 529 warning letters in 2024, most related to drugs, tobacco products or food products. Of those, 8% (44) were issued for medical devices.\n\n### Notable Case Studies\n\n**iRhythm Technologies (2023)**\nBetween May 25, 2023, the date of the FDA warning letter to iRhythm, and June 27th, iRhythm stock fell almost 25%.(no content)The threat an FDA warning letter poses to any company is significant and existential to a startup. The immediate consequence is the disruption and resource diversion to rectify issues, instantly detracting from R&D and growth.\n\n**Small Company Scrutiny**\nThe FDA is now auditing and issuing warning letters to small companies. Recent letters sent to Vitang (4 people) and ZYTO (56 people) underscore the FDA's growing scrutiny on the proliferation of medical device startups and their software validation processes.\n\n### Top Deficiency Categories\n\nFirst place is taken by deficiencies relating to \"Design Controls\" (21 CFR 820.30) and \"CAPA (21 CFR 211.100)\". Second place is shared by deficiencies relating to process validation (21 CFR 820.75) and \"Complaints\" (21 CFR 820.198). In third place are deficiencies relating to \"Purchasing Controls\" (21 CFR 820.50).\n\n### Software-Specific Concerns\n\nThe FDA is scrutinizing multiple areas including: Product Software validation â€“ Not validating or verifying medical device software properly; Non-software product validation â€“ Not validating or verifying infrastructure software (GxP software) used in manufacturing; Procedure coverage and deviation â€“ Not having procedures required by FDA 21 CFR Part 820 or Part 11 quality regulations.(no content)Risk management was a major topic of discussion related back to many of the violations this year, and was mentioned in many of the warning letters, including for the initial validation of device design and noting that risk management was not updated either in alignment with the procedure or alignment with ISO 14971 when compliance with the standard was claimed.\n\n### Regulatory Shift\n\nThe FDA has moved away from the \"integrative approach\" where companies could resolve issues through response letters to 483 observations. Instead, the agency is issuing warning letters more readily when companies fail to address FDA 483 observations and warning letters.(no content)The escalation from 483 observations to warning letters typically occurs when companies provide inadequate responses or fail to implement effective corrective actions within reasonable timeframes.\n\n### Recommendations for Prevention\n\nKey preventive measures include: Strengthen quality systems - Robust CAPA, design controls, and complaint handling prevent violations; Prepare for inspections - Regular mock inspections and staff training improve readiness; Leverage technology - Modern quality management systems enable efficient compliance; Build compliance culture - Sustainable prevention requires organization-wide commitment."],"durationSeconds":35.10475299299997},"tool_use_id":"toolu_01MNpEdkYDeP3LMheu98Q3gA"},"timestamp":1766707238536,"timestamp_pst":"2025-12-25 16:00:38 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 software safety classification code review testing verification"},"tool_response":{"query":"IEC 62304 software safety classification code review testing verification","results":[{"tool_use_id":"srvtoolu_01CATdW8AYcUCwKx8WRsAwsi","content":[{"title":"QA | IEC 62304 - safety standard to check medical device software","url":"https://www.qt.io/quality-assurance/iec-62304"},{"title":"What are the IEC 62304 Safety Classifications?","url":"https://www.greenlight.guru/glossary/iec-62304"},{"title":"IEC 62304 standard and software safety classifications - An overview","url":"https://medicaldevicehq.com/articles/an-overview-of-the-iec-62304-standard-and-software-safety-classifications/"},{"title":"What Is IEC 62304? Overview, IEC 62304 Certification + Compliance Tips | Perforce Software","url":"https://www.perforce.com/blog/qac/what-iec-62304"},{"title":"Safety classes according to IEC 62304","url":"https://blog.johner-institute.com/iec-62304-medical-software/safety-class-iec-62304/"},{"title":"IEC 62304 - Wikipedia","url":"https://en.wikipedia.org/wiki/IEC_62304"},{"title":"IEC 62304 Walkthrough - OpenRegulatory","url":"https://openregulatory.com/articles/iec-62304-walkthrough"},{"title":"Software safety classification - Wikipedia","url":"https://en.wikipedia.org/wiki/Software_safety_classification"},{"title":"Frequently Asked Questions related to the Implementation of EN 62304:2006","url":"https://www.team-nb.org/wp-content/uploads/2015/05/documents2013/FAQ_62304_Final_130804.pdf"},{"title":"Understanding IEC 62304: A Guide to Medical Device Software","url":"https://patientguard.com/understanding-iec-62304/"}]},"Here are the search results for IEC 62304 software safety classification, code review, testing, and verification:\n\n## IEC 62304 Overview\n\nIEC 62304 â€“ medical device software â€“ software life cycle processes is an international standard published by the International Electrotechnical Commission (IEC). The standard specifies life cycle requirements for the development of medical software and software within medical devices.\n\n## Software Safety Classifications\n\nIEC 62304 identifies three safety classes for medical device software:\n- **Class A**: No injury or damage to health is possible\n- **Class B**: Injury is possible, but not serious\n- **Class C**: Death or serious injury is possible(no content)The number of activities you need to complete according to the standard depend on how harmful your medical device is. This is decided with a software safety classification â€“ the higher risks and severity linked to your software, the higher classification.\n\n## Code Review and Verification Requirements\n\nIt's required to establish tests for software requirements for Class B and Class C. You can fulfill this requirement by using an ALM tool to generate test cases based on requirements and create a requirements traceability matrix.(no content)Class B and Class C software also need to establish a software unit verification process. You can fulfill this requirement by using a static code analyzer to verify code against a coding standard and ensure safe, secure, and reliable software.(no content)Static code analysis tools identify violations of coding guidelines and standards at an early stage. They also detect clones, cycles or unreachable code to ensure the quality of your software.\n\n## Testing Requirements\n\nTesting activities outlined in IEC 62304 require requirements-based testing, functional testing, and risk-based testing.(no content)The IEC 62304 standard calls out certain cautions on using software, particularly SOUP (software of unknown pedigree or provenance). The standard spells out a risk-based decision model on when the use of SOUP is acceptable, and defines testing requirements for SOUP.\n\n## Documentation Requirements by Safety Class\n\nThe software safety class determines specific requirements for each step in the software development process. For software in safety class A, manufacturers only need to document the software requirements (5.2) and software release (5.8). For class B, the software architecture (5.3) and software verification (5.5 to 5.7) must also be documented, and for safety class C, the detailed design (5.4) must also be documented.\n\n## Standard Structure\n\nIEC 62304 for medical device software development delineates components into five clauses, numbered 5 through 9:\n- Clause 5: Outlines the software development process from planning to release\n- Clause 6: Describes required maintenance of released software\n- Clause 7: Specifies risk management required from assessing failures to identifying potential risks\n- Clause 8: Lays out configuration management requirements\n- Clause 9: Explains problem resolution processes(no content)The best approach to medical device software development is risk-based, structured and methodical. Traceability throughout the lifecycle of medical device software is key to ensure compliance with IEC 62304."],"durationSeconds":26.910999034999985},"tool_use_id":"toolu_01RNqf5Z9NEYx1WArjQDW5pf"},"timestamp":1766707239354,"timestamp_pst":"2025-12-25 16:00:39 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA Software Validation Guidance 2002 General Principles code review documentation requirements"},"tool_response":{"query":"FDA Software Validation Guidance 2002 General Principles code review documentation requirements","results":[{"tool_use_id":"srvtoolu_012HtWf8F7cawWkwprDDS5Gv","content":[{"title":"General Principles of Software Validation - Final Guidance ...","url":"https://www.fda.gov/media/73141/download"},{"title":"2002 FDA Guidance - General Principles of Software Validation","url":"https://innolitics.com/articles/fda-guidance-general-principles-of-software-validation/"},{"title":"General Principles of Software Validation Final Guidance","url":"https://www.complianceonline.com/fda-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff-release-date-january-11-2002-standards-10374-prdp"},{"title":"Federal Register :: Medical Devices: General Principles of Software Validation; Final Guidance for Industry and FDA Staff; Availability","url":"https://www.federalregister.gov/documents/2002/01/11/02-690/medical-devices-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff"},{"title":"General Principles of Software Validation: Guidance for Industry and FDA Staff | Guidance Portal","url":"https://www.hhs.gov/guidance/document/general-principles-software-validation-guidance-industry-and-fda-staff"},{"title":"General Principles of Software Validation; Final Guidance for Industry and FDA Staff - General-Principles-of-Software-Validation---Final-Guidance-for-Industry-and-FDA-Staff","url":"https://www.scribd.com/document/629994130/General-Principles-of-Software-Validation-Final-Guidance-for-Industry-and-FDA-Staff-General-Principles-of-Software-Validation-Final-Guidance-for"},{"title":"FDA Guidance - General Principles of Software Validation","url":"https://validationcenter.com/library/library/regulations-and-guidelines/fda-guidance-general-principles-of-software-validation/"},{"title":"FDA General Principles of Software Validation; Final Guidance for Industry and FDA Staff - ECA Academy","url":"https://www.gmp-compliance.org/guidelines/gmp-guideline/fda-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff"},{"title":"FDA Software Validation Requirements - Validify","url":"https://www.validify.app/post/fda-software-risk-management"},{"title":"General Principles of Software Validation - Final Guidance","url":"https://cacmap.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation"}]},"Based on my search results, I found information about the FDA's \"General Principles of Software Validation\" guidance document from 2002. Let me search for more specific information about code review documentation requirements mentioned in this guidance.",{"tool_use_id":"srvtoolu_01XgNDSgnNPrrm6MWb4d4oaB","content":[{"title":"FDA Guidance Sections Addressed by CodeSonar","url":"https://verifysoft.com/en_FDA_standards.html"},{"title":"Static Analysis for FDA Software Compliance - Parasoft","url":"https://www.parasoft.com/white-paper/static-analysis-for-fda-software-validation-compliance/"},{"title":"FDA Software Verification vs. Validation: What's the Difference? - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/fda-software-verification-vs-validation-whats-the-difference"},{"title":"General Principles of Software Validation - Final Guidance ...","url":"https://www.fda.gov/media/73141/download"},{"title":"FDA Software Validation Process: Steps, Principles & More","url":"https://amplelogic.com/fda-software-validation-process"},{"title":"Prepare your medical device software for the new FDA cybersecurity guidance","url":"https://www.parasoft.com/blog/prepare-your-medical-device-software-for-the-new-fda-cybersecurity-guidance/"},{"title":"Federal Register :: Medical Devices: General Principles of Software Validation; Final Guidance for Industry and FDA Staff; Availability","url":"https://www.federalregister.gov/documents/2002/01/11/02-690/medical-devices-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff"},{"title":"The Fundamentals of FDA Software Validation","url":"https://www.complianceonline.com/resources/fundamentals-of-fda-software-validation.html"},{"title":"FDA Recommends Static Analysis for Medical Devices","url":"https://codesecure.com/our-case-studies/fda-recommends-static-analysis-for-medical-devices/"},{"title":"2002 FDA Guidance - General Principles of Software Validation","url":"https://innolitics.com/articles/fda-guidance-general-principles-of-software-validation/"}]},"Based on my search results, I can now provide you with comprehensive information about the FDA's \"General Principles of Software Validation\" guidance from 2002 and its requirements regarding code review documentation.\n\n## FDA General Principles of Software Validation (2002) - Code Review Documentation Requirements\n\n### Overview of the Guidance\n\nThe \"General Principles of Software Validation\" was published by the FDA in 2002.(no content)This document provides guidance to medical device manufacturers and FDA staff concerning requirements for validating software used within medical devices, in device production, or in implementing the manufacturer's quality system.(no content)This guidance outlines general validation principles that the Food and Drug Administration (FDA) considers to be applicable to the validation of medical device software or the validation of software used to design, develop, or manufacture medical devices.\n\n### Verification Activities Including Code Review\n\nSoftware testing is one of many verification activities intended to confirm that software development output meets its input requirements. Other verification activities include various static and dynamic analyses, code and document inspections, walkthroughs, and other techniques.\n\n### Source Code Evaluation and Static Analysis Requirements\n\nSource code evaluations are often implemented as code inspections and code walkthroughs. Such static analyses provide a very effective means to detect errors before execution of the code. They allow for examination of each error in isolation and can also help in focusing later dynamic testing of the software.(no content)Firms may use manual (desk) checking with appropriate controls to ensure consistency and independence. Source code evaluations should be extended to verification of internal linkages between modules and layers (horizontal and vertical interfaces), and compliance with their design specifications.\n\n### Documentation Requirements for Code Reviews\n\nDocumentation of the procedures used and the results of source code evaluations should be maintained as part of design verification. A source code traceability analysis is an important tool to verify that all code is linked to established specifications and established test procedures.(no content)FDA investigators will expect to see a verification procedure that includes a means for identifying and resolving incomplete, ambiguous, and conflicting requirements, as required by the regulation. They will also expect to see objective documented evidence that the verification procedure was implemented.\n\n### Configuration Control and Documentation\n\nControls are necessary to ensure positive and correct correspondence among all approved versions of the specifications documents, source code, object code, and test suites that comprise a software system. The controls also should ensure accurate identification of, and access to, the currently approved versions.(no content)Procedures should be created for reporting and resolving software anomalies found through validation or other activities. Management should identify the reports and specify the contents, format, and responsible organizational elements for each report. Procedures also are necessary for the review and approval of software development results, including the responsible organizational elements for such reviews and approvals.\n\n### Independent Evaluation\n\n\"Self-validation is extremely difficult. When possible, an independent evaluation is always better, especially for higher risk applications.\"\n\n### Risk-Based Approach to Validation Coverage\n\nValidation coverage should be based on the software's complexity and safety risk â€“ not on firm size or resource constraints. The selection of validation activities, tasks, and work items should be commensurate with the complexity of the software design and the risk associated with the use of the software for the specified intended use. For lower risk devices, only baseline validation activities may be conducted. As the risk increases additional validation activities should be added to cover the additional risk.\n\n### Key Principles\n\nThe guidance emphasizes that \"Software quality assurance needs to focus on preventing the introduction of defects into the software development process and not on trying to test quality into the software code after it is written.\""],"durationSeconds":28.983000774999965},"tool_use_id":"toolu_01RXqAiWr8D6R9fURU1rVkCG"},"timestamp":1766707241477,"timestamp_pst":"2025-12-25 16:00:41 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 Good Automated Manufacturing Practice code review validation requirements"},"tool_response":{"query":"GAMP 5 Good Automated Manufacturing Practice code review validation requirements","results":[{"tool_use_id":"srvtoolu_01FnqLZRKvE4pxUmUsrypfCQ","content":[{"title":"GAMPÂ® 5 Guide: Categories, Requirements, and Validation | PTC","url":"https://www.ptc.com/en/blogs/alm/gamp-5-guide-categories-requirements-and-validation"},{"title":"GAMP 5 Requirements & Standards Reinforced in InstantGMP","url":"https://instantgmp.com/learning-center/validation/"},{"title":"Considerations for validating instrument software per the GAMP 5 guide","url":"https://documents.thermofisher.com/TFS-Assets/LSG/Reference-Materials/computer-system-validation-whitepaper.pdf"},{"title":"What is GAMP 5 Guideline? Checklist for GAMP 5 compliance - Zamann Pharma Support GmbH","url":"https://zamann-pharma.com/2024/04/08/what-is-gamp-5-guideline-checklist-for-gamp-5-compliance/"},{"title":"Understanding GAMP 5 Guidelines for System Validation | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-guidelines-system-validation"},{"title":"How GAMP 5 Second Edition is Changing System Validation","url":"https://pscsoftware.com/gamp-5-second-edition-changing-validation/"},{"title":"GAMP5 - Improved Guidance for Computer System Validation - Lean Biologix","url":"https://www.leanbiologix.com/gamp5/"},{"title":"Understanding GAMP 5 Guidelines for System Validation","url":"https://intuitionlabs.ai/pdfs/understanding-gamp-5-guidelines-for-system-validation.pdf"},{"title":"GAMP 5: Computerized System Validation in Pharma","url":"https://intuitionlabs.ai/pdfs/gamp-5-computerized-system-validation-in-pharma.pdf"},{"title":"Compliance guidance for validated industries","url":"https://literature.rockwellautomation.com/idc/groups/literature/documents/wp/proces-wp018_-en-p.pdf"}]},"Based on my search, here's what I found about GAMP 5 Good Automated Manufacturing Practice code review and validation requirements:\n\n## Overview of GAMP 5\n\nGAMP â€” or the Good Automated Manufacturing Practice â€” is the definitive industry guideline for creating compliant computer systems.(no content)GAMP 5 provides a comprehensive framework for validating computerized systems to ensure they are fit for intended use and meet regulatory requirements. GAMP 5 is not a law or regulation itself, but an industry guidance published by the International Society for Pharmaceutical Engineering (ISPE) that has become the de facto standard for computer system validation in pharma.\n\n## Code Review Requirements\n\nFor Category 5 (custom) software, testing requires rigorous supplier checks, code review, and unit tests. Examples include internally and externally developed IT applications, process controlled applications, customer ladder logic, custom firmware, ERP systems or developments made to meet specific needs for an organization.(no content)Key validation documentation includes source code review forms, software release forms, computer system validation policy, master validation plan, installation qualification, and operational qualification.\n\n## Validation Lifecycle (V-Model)\n\nGAMP 5 follows a structured development and validation lifecycle, often depicted as a \"V-model\". This covers stages from concept and requirements definition through design, testing, operation, and retirement. Each stage has associated deliverables and reviews.(no content)Systems must have clear User Requirements Specifications (URS). Testing verifies that the system meets these user and functional requirements (URS and FDS â€“ Functional Design Spec) before moving to production.\n\n## Software Categories\n\nSystems are classified into software/hardware categories (for example: Category 1 â€“ infrastructure, Category 3 â€“ non-configurable, Category 4 â€“ configurable, Category 5 â€“ custom). Higher categories (more customization) require more validation.\n\n## Risk-Based Approach\n\nThis risk-based view is explicit in the GAMP 5 motto: it is formally titled \"GAMPÂ® 5: A Risk-Based Approach to Compliant GxP Computerized Systems\".(no content)Higher-risk systems (e.g., custom code controlling product quality) warrant more rigorous testing and documentation, whereas low-risk infrastructure software may need only basic verification.\n\n## Key Validation Requirements\n\nGAMP 5 recommends conducting periodic reviews to meet user requirements and regulatory standards. Revisit validation documentation whenever the software changes, use automation to analyze software end-to-end and track modifications. Make risk assessment a core part of your reviews and monitor the software's impact on safety and data protection.(no content)QAU review is essential to the success of the validation project. A customer's quality department's engagement in the development, review, and approvals of the validation steps and documentation determines the effectiveness of validation.\n\n## GAMP 5 Second Edition Updates\n\nThe Second Edition promotes the use of automated traceability, tool-based reviews, and digital documentation systems, which reduce manual errors and improve data integrity.(no content)Embracing agile software development practices allows for iterative testing and continuous feedback. The guide explicitly supports non-linear development models and encourages validation activities throughout the lifecycle rather than at the end.(no content)Validation strategies must consider the provenance of the code, community support, update frequency, and compatibility with GxP requirements."],"durationSeconds":29.632680301000015},"tool_use_id":"toolu_01AuCrZJNrQrhqJk6gSu4uao"},"timestamp":1766707242076,"timestamp_pst":"2025-12-25 16:00:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 warning letters software validation code review deficiencies common findings"},"tool_response":{"query":"FDA 483 warning letters software validation code review deficiencies common findings","results":[{"tool_use_id":"srvtoolu_01RuzGcBt6dRygELDvXPRhvN","content":[{"title":"Warning Letters | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters"},{"title":"US FDA Form 483 and Warning Letter Analysis, Response, and Recovery | Emergo by UL","url":"https://www.emergobyul.com/services/us-fda-form-483-and-warning-letter-analysis-response-and-recovery"},{"title":"FDA Warning Letters Archives - Ofni Systems","url":"https://www.ofnisystems.com/fda-warning-letters/"},{"title":"FDA 483 Warning Letters | Manufacturing ERP Software","url":"https://valdata.com/weblog/fda-483-warning-letters/"},{"title":"FDA Warning Letters, Software Validation Practices, FDA 483, Consent Decree : Compliance Training Webinar (Online Seminar) - ComplianceOnline.com","url":"https://www.complianceonline.com/fda-warning-letter-consent-decree-software-validation-webinar-training-701520-prdw"},{"title":"Critical Differences Between a Form FDA 483 and Warning Letters :: Parexel","url":"https://www.parexel.com/insights/blogs/critical-differences-between-a-form-fda-483-and-warning-letters-4"},{"title":"Inspection Observations | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations"},{"title":"Current FDA 483s and Warning Letters Trends in Pharmaceutical, Biotechnology, and Medical Device Industries - VTI Life Sciences","url":"https://validation.org/current-fda-483s-and-warning-letters-trends-in-pharmaceutical-biotechnology-and-medical-device-industries/"},{"title":"10 Steps to an Effective Medical Device FDA 483 Response | NSF","url":"https://www.nsf.org/knowledge-library/ten-steps-effective-medical-devices-fda-483-responses"},{"title":"How To Avoid Form 483s For Biopharma Software Validation Failures","url":"https://www.outsourcedpharma.com/doc/how-to-avoid-form-s-for-biopharma-software-validation-failures-0001"}]},"Based on my search, here's what I found regarding FDA 483 observations, warning letters, software validation, and code review deficiencies:\n\n## FDA 483 and Warning Letters Overview\n\nThe FDA Form 483 is issued at the end of an on-site inspection if the FDA field investigator observed deficiencies in your quality system or conditions that violate the Food, Drug, or Cosmetic Act.(no content)The field inspector will submit the final 483 to superiors; if the findings are serious enough, or if the response is deemed insufficient, an FDA Warning Letter may be issued. A Warning Letter is the FDA's advisory notice that you have significantly violated FDA regulations.\n\n## Software Validation Deficiencies\n\nA third of recent warning letters included citations with respect to improper or ineffective validation. Computerized quality system tracking systems are subject to increased scrutiny during compliance and enforcement actions and hence incomplete software validations are ticking time bombs.(no content)FDA inspectors are now being trained to evaluate software validation practices. Increasing use of automated manufacturing and quality systems have increased exposure. Most recalls can be traced back to computerized equipment, exposing the validation process to scrutiny.\n\n### Common Software-Related Findings\n\nCommon findings include software that was not validated and lacked audit trails, as well as firms lacking adequate controls to ensure that actions are attributed to authorized individuals with unique and unshared login credentials.(no content)The FDA will issue a Form 483 for noncompliance in the software validation GxP environment, mostly due to data integrity failures, inadequate written procedures, deficiencies in investigations, and substandard laboratory controls.\n\n## Common FDA 483 Observation Categories\n\nCommon reasons for FDA 483 observations include: inadequate sanitation and cleaning logs, poor manufacturing documentation, lack of traceability and ingredient tracking, incorrect or misleading labeling, failure to monitor and validate processes, employee training deficiencies, supplier compliance issues, inadequate corrective and preventive actions, poor environmental controls, and lack of internal audits.(no content)The failure to establish, maintain, or follow a quality system remains one of the most cited issues during FDA inspections. For instance, a medical device manufacturer faced significant scrutiny for failing to document design reviews for a new surgical instrument. Similarly, a pharmaceutical company's inadequate training records for staff in quality oversight roles led to critical deviations.\n\n## Major Deficiencies for Medical Devices\n\nMajor deficiencies relative to 21 CFR Part 820, the Quality System Regulation include absence of corrective and preventive action procedures (including procedures describing the analysis of quality data), absence of design control procedures (including design change control procedures), failure to validate processes requiring validation, non-correction or inadequate correction of major deficiencies from previous inspections, and other quality system deficiencies such as deficiencies in both purchasing controls and acceptance activities.\n\n## Prevention Strategies\n\nThe best way to minimize your chances of receiving a Form 483 is to always be \"inspection ready.\" Your quality management system should comply with US FDA 21 CFR Part 820 (Quality System Regulation) at all times because the FDA conducts random QSR audits with very little notice. Conduct regular internal audits of your QMS.(no content)Regular internal audits, enhanced training programs tailored to GMP and QSR requirements, and adopting advanced technologies such as electronic batch records and real-time monitoring systems can significantly reduce risks.\n\nWould you like me to search for more specific information about code review deficiencies or any particular aspect of software validation findings?"],"durationSeconds":29.783216824000004},"tool_use_id":"toolu_01CwfuPVBpTc5H7NAckLCNo7"},"timestamp":1766707242281,"timestamp_pst":"2025-12-25 16:00:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"21 CFR Part 11 electronic records signatures code review requirements validation"},"tool_response":{"query":"21 CFR Part 11 electronic records signatures code review requirements validation","results":[{"tool_use_id":"srvtoolu_01RyFk8iqXED7xtBSWXxN88d","content":[{"title":"Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application"},{"title":"eCFR :: 21 CFR Part 11 -- Electronic Records; Electronic Signatures","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11"},{"title":"Title 21 CFR Part 11 - Wikipedia","url":"https://en.wikipedia.org/wiki/Title_21_CFR_Part_11"},{"title":"Guidance for Industry Part 11, Electronic Records;","url":"https://www.fda.gov/media/75414/download"},{"title":"eCFR :: 21 CFR Part 11 Subpart B -- Electronic Records","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11/subpart-B"},{"title":"Guidance on Use of Electronic Signatures in Research and ...","url":"https://irb.upenn.edu/wp-content/uploads/2023/02/Guidance-on-Use-of-Electronic-Signatures-.pdf"},{"title":"21 CFR Pt. 11 Compliance with Electronic Signatures","url":"https://www.docusign.com/blog/21-cfr-pt-11-compliance-electronic-signatures"},{"title":"21 CFR Part 11","url":"https://regardd.org/21-cfr-part-11"},{"title":"21 CFR Part 11 Electronic Signatures: A Compliance Guide","url":"https://www.esignly.com/electronic-signature/cfr-part-11-and-electronic-signatures-a-comprehensive-guide.html"},{"title":"Electronic Records and Signatures (21 CFR Part 11)","url":"https://usvalidation.com/kb/comp_part11.aspx"}]},"Based on the search results, here is an overview of 21 CFR Part 11 electronic records, electronic signatures, code review requirements, and validation:\n\n## 21 CFR Part 11 Overview\n\nPart 11 defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.(no content)Title 21 CFR Part 11 establishes the United States Food and Drug Administration (FDA) regulations on electronic records and electronic signatures, and is a portion of Title 21 of the Code of Federal Regulations.\n\n## Validation Requirements\n\nComputer systems used to create, modify, and maintain electronic records and to manage electronic signatures are subject to the validation requirements (See 21 CFR Â§11.10(a)). Such computer systems must be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records.(no content)The FDA intends to exercise enforcement discretion regarding specific Part 11 requirements for validation of computerized systems (Â§ 11.10(a) and corresponding requirements in Â§ 11.30). Although persons must still comply with all applicable predicate rule requirements for validation (e.g., 21 CFR 820.70(i)), this guidance should not be read to impose any additional requirements for validation.(no content)The FDA suggests that your decision to validate computerized systems, and the extent of the validation, take into account the impact the systems have on your ability to meet predicate rule requirements. You should also consider the impact those systems might have on the accuracy, reliability, integrity, availability, and authenticity of required records and signatures. Even if there is no predicate rule requirement to validate a system, in some instances it may still be important to validate the system.\n\n## Systems Documentation and Change Control\n\nThe regulation requires use of appropriate controls over systems documentation including: (1) Adequate controls over the distribution of, access to, and use of documentation for system operation and maintenance. (2) Revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of systems documentation.\n\n## Electronic Signature Requirements\n\nElectronic signatures that are not based upon biometrics shall employ at least two distinct identification components such as an identification code and password. When an individual executes a series of signings during a single, continuous period of controlled system access, the first signing shall be executed using all electronic signature components; subsequent signings shall be executed using at least one component that is only executable by the individual. When an individual executes one or more signings not performed during a single, continuous period of controlled system access, each signing shall be executed using all of the electronic signature components.(no content)Each electronic signature must be unique to one individual and not reused by, or reassigned to, anyone else. The identity of the individual must be verified before establishing, assigning, certifying or otherwise sanctioning the individual's electronic signature.\n\n## Personnel Requirements\n\nThe regulation requires determination that persons who develop, maintain, or use electronic record/electronic signature systems have the education, training, and experience to perform their assigned tasks.(no content)Additionally, there must be establishment of, and adherence to, written policies that hold individuals accountable and responsible for actions initiated under their electronic signatures, in order to deter record and signature falsification.\n\n## Technical and Procedural Controls\n\nCompliance rests on both technical controls (software features like audit trails, access controls, and signature standards) and procedural controls (internal policies, SOPs, and employee training).(no content)To reach compliance, methods are developed and activities conducted for system validation, record generation, audit trails, operational and security controls, digital signatures and training. These methods and activities must be maintained through change control and management procedures to retain a compliant status."],"durationSeconds":29.96547531599994},"tool_use_id":"toolu_01BjMnRxUxSSzxmV9GqYgLHq"},"timestamp":1766707242420,"timestamp_pst":"2025-12-25 16:00:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review checklist FDA compliance medical device software IEC 62304 validation requirements"},"tool_response":{"query":"code review checklist FDA compliance medical device software IEC 62304 validation requirements","results":[{"tool_use_id":"srvtoolu_01RJQnZiUUGkdHJ17QnbFY7h","content":[{"title":"FDA and IEC 62304 Software Documentation","url":"https://www.promenadesoftware.com/blog/fda-iec62304-software-documentation"},{"title":"IEC 62304:2015 | Medical Device Software","url":"https://www.complianceonline.com/iec-62304-2015-medical-device-software-software-life-cycle-processes-standards-10361-prdp"},{"title":"IEC 62304: Standard for medical device software","url":"https://www.rimsys.io/blog/iec-62304-standard-for-medical-device-software"},{"title":"IEC 62304 SOFTWARE COMPLIANCE IN THE MEDICAL INDUSTRY","url":"https://alm.parasoft.com/hubfs/ebook-IEC-62304-Software-Compliance-Medical.pdf"},{"title":"An illustrated guide to medical device software development","url":"https://medicaldevicehq.com/articles/the-illustrated-guide-to-medical-device-software-development-and-iec-62304/"},{"title":"IEC 62304 | FDA Software Validation Compliance - QA Systems","url":"https://www.qa-systems.com/solutions/iec-62304/"},{"title":"IEC 62304:2015 | Medical Device Software Standards | Software Lifecycle Processes","url":"https://www.complianceonline.com/checklist-for-applying-iec-62304-2015-medical-device-software-software-life-cycle-processes-standards-501102-prdp"},{"title":"How to Apply IEC 62304 Requirements for Medical Device Software","url":"https://www.greenlight.guru/blog/iec-62304"},{"title":"Ultimate guide to the IEC 62304 standard","url":"https://www.qualio.com/blog/iec-62304"},{"title":"A Comprehensive Guide to IEC 62304: Navigating the Standard for Medical Device Software - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/a-comprehensive-guide-to-iec-62304-navigating-the-standard-for-medical-device-software"}]},"Based on my search, here's comprehensive information on code review checklists and FDA compliance requirements for medical device software under IEC 62304:\n\n## Overview of IEC 62304 and FDA Compliance for Medical Device Software\n\nIEC 62304 is an international standard for medical device software that defines the framework for processes that occur across the lifecycle of the device and software.(no content)The IEC 62304 standard is harmonized internationally and is recognized by the FDA, Health Canada, the European Commission and other regulatory authorities worldwide.(no content)In the United States, the FDA accepts ANSI/AAMI/IEC 62304 as evidence that medical device software has been designed to an acceptable standard and covers regulatory processes such as 510(k), IDE, PMA, HDE, and Software Validation.\n\n## Software Safety Classification\n\nIEC 62304 identifies three classification categories for medical device software: Class A: No injury or damage to health is possible. Class B: Injury is possible, but not serious. Class C: Death or serious injury is possible.(no content)Classification impacts the entire software code development process in terms of what is required for compliance. This makes it critical to get right the first time around.\n\n## Key Deliverables for IEC 62304 Compliance\n\n### Software Development Plan\nSoftware development plan - Define processes, deliverables, and development activities. The plan should include the Life Cycle Activities, Risk Management Plan, Documentation Plan, Configuration Management Plan, Change Control process, and Problem Resolution process.\n\n### Software Verification Plan\nSoftware verification plan - Describe the software test plan. Include all verification activities, such as code review, unit test and integration test plans, and the final system software verification test plan.\n\n### Code Unit Verification\nCode Unit Verification - Document the unit test and code review performed per the plan.\n\n### Traceability\nSummary test report - Create a summary of all software verification per the verification and validation plan. Trace matrix - Link system requirements to software requirements to associated design specifications and test protocols in one document (typically a spreadsheet). Include software hazards with software mitigations.\n\n## Verification and Validation Requirements\n\nCompliance with IEC 62304 requires verification and testing activities to be carried out by the manufacturer. At a general level, you need to establish a testing protocol that shows how design outputs meet design inputs. For software, your requirement specifications need to be verified in the testing process.(no content)Given that software requires updates over time, you will need to document ongoing testing to prove that you're maintaining compliance with IEC 62304. A traceability matrix is a useful tool that links together with your product design requirements, design specifications, and testing requirements.\n\n## Coding Standards for Code Review\n\nCoding standards are a crucial component of software acceptance criteria under the IEC 62304 standard. According to the guidance in Annex B.5.5, coding standards are used to specify a preferred coding style to consistently achieve desirable code characteristics. These standards can cover aspects such as understandability, language usage rules or restrictions, and complexity management.\n\n## Risk Management Integration\n\nSoftware Hazard Analysis - Create an IEC 62304 hazard analysis, identifying potential hazards and the software items that could cause them. Mitigations should feed back into the Requirements. Include OTS software hazard analysis and wireless QoS (if applicable).(no content)The ISO 14971 standard is required because it defines the framework for managing risks and identifying hazards. ISO 14971 provides a framework for performing your hazard analysis and risk assessment.\n\n## Documentation Requirements\n\nDocumentation is a cornerstone of the IEC 62304 standard. Manufacturers must maintain comprehensive records of all software development activities, including design, testing, and validation.(no content)Note that each deliverable must be verified, and the plan should address how that is done (often review and sign-off).\n\n## IEC 62304 Compliance Checklist Steps\n\nFollow this step-by-step structure to ensure you tick off the main requirements of the standard: Define your software safety classification (A, B or C).(no content)Agile methods are hugely popular in modern software development, and they can be compatible with IEC 62304, as long as you maintain traceability, verification and the right levels of documentation.\n\n## Integration with Quality Management Systems\n\nDon't treat IEC 62304 as a standalone process. Your software lifecycle processes should be closely connected with your overall quality management system, especially if you're using ISO 13485. Align document formats (and some specific documents), as well as responsibilities and review cycles, across both standards.\n\nThis information provides a foundation for developing a comprehensive code review checklist that meets both FDA and IEC 62304 validation requirements for medical device software."],"durationSeconds":42.77633914900001},"tool_use_id":"toolu_019rE9rMZBT9tD3yv3LPMu4N"},"timestamp":1766707242474,"timestamp_pst":"2025-12-25 16:00:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 medical device software lifecycle code review traceability requirements"},"tool_response":{"query":"IEC 62304 medical device software lifecycle code review traceability requirements","results":[{"tool_use_id":"srvtoolu_01XPZvTBLGcpogkyNh2qn4gz","content":[{"title":"IEC 62304:2006 - Medical device software â€” Software life cycle processes","url":"https://www.iso.org/standard/38421.html"},{"title":"A Comprehensive Guide to IEC 62304: Navigating the Standard for Medical Device Software - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/a-comprehensive-guide-to-iec-62304-navigating-the-standard-for-medical-device-software"},{"title":"An In-Depth Guide to IEC 62304: Software Lifecycle Processes for Medical Devices","url":"https://www.jamasoftware.com/blog/an-in-depth-guide-to-iec-62304-software-lifecycle-processes-for-medical-devices/"},{"title":"What You need to know about IEC 62304: Medical Software Lifecycle - Security Compass","url":"https://www.securitycompass.com/blog/iec-62304-medical-software-lifecycle/"},{"title":"IEC 62304 compliance - What are the requirements for Medical Device Software? â€¢ Tuleap","url":"https://www.tuleap.org/software-quality/iec62304-requirements-medical-device-software-standard"},{"title":"IEC 62304: Medical Device Software LifeCycle Processes | by Dr Stephen Odaibo | The Blog of RETINA-AI Health, Inc. | Medium","url":"https://medium.com/retina-ai-health-inc/iec-62304-medical-device-software-lifecycle-processes-2b7967577c3f"},{"title":"IEC 62304 - Wikipedia","url":"https://en.wikipedia.org/wiki/IEC_62304"},{"title":"What Is IEC 62304? Overview, IEC 62304 Certification + Compliance Tips | Perforce Software","url":"https://www.perforce.com/blog/qac/what-iec-62304"},{"title":"IEC/EN 62304 Medical Device - Software Life Cycle Processes â†’ Testing and Anaylsis","url":"https://www.verifysoft.com/en_IEC_62304.html"},{"title":"An illustrated guide to medical device software development","url":"https://medicaldevicehq.com/articles/the-illustrated-guide-to-medical-device-software-development-and-iec-62304/"}]},"Based on my search, here's a comprehensive overview of IEC 62304 medical device software lifecycle requirements related to code review and traceability:\n\n## IEC 62304 Overview\n\nIEC 62304 â€“ medical device software â€“ software life cycle processes is an international standard published by the International Electrotechnical Commission (IEC). The standard specifies life cycle requirements for the development of medical software and software within medical devices.(no content)It's a harmonized standard recognized by regulators like the U.S. FDA and European Commission under the Medical Device Regulation (MDR).\n\n## Traceability Requirements\n\nThe standard mandates clear documentation of requirements, architecture, design, and verification activities, which in turn fosters transparency and traceability throughout the software development lifecycle.(no content)Clause 5 outlines the heart of IEC 62304: the structured software development process. It ensures that every function in medical device software is implemented with clear requirements, traceability, verification, and validation.\n\nKey traceability elements include:\n\n- Every requirement, design decision, and test must be traceable back to a specific risk. This creates an audit trail that can be used to justify design choices during regulatory reviews.\n\n- IEC 62304 requires traceable control over software and artifacts. Clause 8 outlines the expectations for configuration management, a discipline that ensures the integrity, consistency, and traceability of software throughout its lifecycle.\n\n## Code Review and Verification\n\nMany manufacturers still use traceability systems which are manual, long, complex and, most of all, likely to be source of errors. Verification of software units can be done whether through unit, integration and system tests or through peer reviews.(no content)Coding standards are a key part of software acceptance criteria. Annex B.5.5 states: \"To consistently achieve the desirable code characteristics, coding standards should be used to specify a preferred coding style. Examples of coding standards include requirements for understandability, language usage rules or restrictions, and complexity management.\"\n\n## Safety Classification and Requirements\n\nTo tailor development rigor to risk, IEC 62304 requires software to be classified into one of three safety classes, A, B, or C, based on the potential harm it could cause if it fails.(no content)Safety Class A: No injury or damage to health is possible. Safety Class B: Non serious injury is possible. Safety Class C: Death or serious injury is possible.(no content)The higher the Safety classification of the medical device software, the more stringent the process requirements on such a medical device software. Class C Medical Software are required to comply with all the specifications in the standard, while Class B devices are exempt from some, and Class A are exempt from even more.\n\n## Core Principles\n\nThe underlying principles of IEC 62304 are rigorous planning, thorough documentation, testing and verification of everything, and finally, traceability â€” a transparent mechanism to verify compliance of all parts of the standard.\n\n## Documentation and Risk Management\n\nDocumentation is a cornerstone of the IEC 62304 standard. Manufacturers must maintain comprehensive records of all software development activities, including design, testing, and validation. The IEC 62304 checklist helps ensure that all necessary documentation is in place and traceable, providing evidence of compliance with the standard.(no content)As the software evolves, whether due to updates, bug fixes, or customer feedback, the risk file must be updated accordingly. Risk management is a living process. IEC 62304 doesn't allow teams to \"fire and forget.\" Risk analysis must be woven into every change, enhancement, and release."],"durationSeconds":30.00469754199998},"tool_use_id":"toolu_01UnKiSxa6iu7TSrkN2jCqXH"},"timestamp":1766707242532,"timestamp_pst":"2025-12-25 16:00:42 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letter software audit trail data integrity 2023 2024 specific company examples"},"tool_use_id":"toolu_01GUrEXZY3eikh8vhd4grWxa"},"timestamp":1766707243225,"timestamp_pst":"2025-12-25 16:00:43 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters"},"tool_use_id":"toolu_0193PnARLAUdCaSKUKfEQT3f"},"timestamp":1766707243232,"timestamp_pst":"2025-12-25 16:00:43 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"\"design control\" software validation FDA 483 medical device 2024"},"tool_use_id":"toolu_011i14Uek1xLyoz5LjeqtAbk"},"timestamp":1766707243247,"timestamp_pst":"2025-12-25 16:00:43 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 software categories risk-based validation approach code review"},"tool_response":{"query":"GAMP 5 software categories risk-based validation approach code review","results":[{"tool_use_id":"srvtoolu_019cDT8UZMZARaeoy2m8rt4Y","content":[{"title":"GAMP 5 Categories Explained: Software, Risk & Examples | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-categories-explained"},{"title":"GAMP 5 Â®: How to take a risk-based approach to GP computerised systems","url":"https://www.cognidox.com/blog/gamp-5-risk-based-approach"},{"title":"GAMP 5 Guide 2nd Edition | ISPE | International Society for Pharmaceutical Engineering","url":"https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition"},{"title":"GAMP 5 Guide for GxP Compliant Computerized Systems + free CSV handbook | Scilife","url":"https://www.scilife.io/blog/gamp5-for-gxp-compliant-computerized-systems"},{"title":"What is GAMPÂ®5 and how do I use it effectively?","url":"https://blog.montrium.com/experts/what-is-gamp5-and-how-do-i-use-it-effectively"},{"title":"What You Need to Know About GAMPÂ® 5 Guide, 2nd Edition | Pharmaceutical Engineering","url":"https://ispe.org/pharmaceutical-engineering/january-february-2023/what-you-need-know-about-gampr-5-guide-2nd-edition"},{"title":"Understanding GAMP 5 Guidelines for System Validation | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-guidelines-system-validation"},{"title":"How GAMP 5 Categories Guide System Validation - RxERP","url":"https://rxerp.com/2025/12/05/gamp-5-categories-guide/"},{"title":"GAMP 5: Computerized System Validation in Pharma | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-computerized-system-validation-pharma"},{"title":"GAMPÂ® 5 Guide: Categories, Requirements, and Validation | PTC","url":"https://www.ptc.com/en/blogs/alm/gamp-5-guide-categories-requirements-and-validation"}]},"Here are the search results for \"GAMP 5 software categories risk-based validation approach\":\n\n## GAMP 5 Software Categories and Risk-Based Validation Approach\n\n### Overview of GAMP 5\n\nThe Good Automated Manufacturing Practice (GAMP 5Â®) guidelines define a set of core principles for GxP, as produced by the ISPE (International Society for Pharmaceutical Engineering).(no content)These guidelines are intended to ensure that pharmaceutical or medical device products are manufactured to the required quality, detailing a recognized standard for computer system validation (CSV) underpinned by a risk-based approach.(no content)GAMPÂ®5 provides a framework for the risk-based approach to computer system validation where a system is evaluated and assigned to a predefined category based on its intended use and complexity.\n\n### Software Categories\n\nGAMP 5 provides a risk-based approach to classifying software based on its impact on GxP and functional compliance. The main categories include:\n\n- Category 1 â€“ infrastructure, Category 3 â€“ non-configurable, Category 4 â€“ configurable, Category 5 â€“ custom software.\n- Category 2, associated with the firmware in GAMP 4, is removed from GAMP 5. The GAMP 5 categories defined in the 2nd edition are the same as its predecessor.(no content)The risk associated with each category increases sequentially from category 1 to 5. The more the risk associated with the category, the more rigorous Computer System Validation (CSV) approach is needed.(no content)Computerized systems are generally made up of a combination of components from different categories, and categories 3-5 should be viewed as a continuum.\n\n### Risk-Based Approach Principles\n\nThe five main principles of GAMPÂ® 5's risk-based approach to compliance are: (1) To have a clear understanding of product and process; (2) To manage the system lifecycle using a quality management system; (3) To make these lifecycle activities scalable; (4) To verify that the approach to risk management is science-based; (5) To leverage supplier involvement throughout the system.(no content)Aside from being an excellent tool to help ensure regulatory compliance, GAMPÂ®5 is also useful when determining the scope of testing. The risk-based approach allows you to concentrate your testing efforts on the high-risk areas of the system while aiding in the formulation of a rationale for performing reduced testing on areas deemed low-risk.\n\n### Validation by Category\n\n- **Category 1 (Infrastructure)**: Since Category 1 software isn't configured for specific business processes, the validation approach is straightforward. The main goal is to ensure the integrity and reliability of the infrastructure itself. You're not testing business logic; you're confirming that the software is installed correctly and operates as the vendor intended.\n\n- **Category 4 (Configurable)**: For a configured product (Category 4), requirements, functional and configuration testing is conducted to verify the requirements, functional and configuration specifications.(no content)A configurable ERP (Category 4) requires thorough testing of your specific settings.\n\n- **Category 5 (Custom)**: A custom-built system (Category 5) demands a full lifecycle validation approach with extensive documentation.(no content)Higher-risk systems (e.g., custom code controlling product quality) warrant more rigorous testing and documentation, whereas low-risk infrastructure software may need only basic verification.\n\n### GAMP 5 Second Edition (2022)\n\nMaintaining the principles and framework of the first edition, ISPE GAMPÂ® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition) updates their application in the modern world including the increased importance of service providers, evolving approaches to software development, and expanded use of software tools and automation.(no content)Guidance on the application of new and developing technological areas such as artificial intelligence and machine learning (AI/ML), blockchain, cloud computing, and open-source software (OSS) has been included or updated. The importance of critical thinking and the application of patient-centric, risk-based approaches (aimed at quality and safety) versus primarily compliance-driven approaches is further underlined.\n\n### Code Review in Validation\n\nBy focusing on risk, GAMP 5 helps avoid spending excessive time on documentation of inconsequential details, instead advocating \"more testing over more documentation\" for what truly matters. For example, rather than capturing voluminous screenshots for every test step, GAMP 5 suggests using exception-based recording (logging only deviations or unexpected outcomes) for routine tests.\n\nFor Category 5 custom software, code review typically forms part of the design specification verification and testing phases, aligned with the V-model lifecycle approach that GAMP 5 follows."],"durationSeconds":36.93255765900004},"tool_use_id":"toolu_014Sxiu6ArLkpX7sqCus58B7"},"timestamp":1766707249440,"timestamp_pst":"2025-12-25 16:00:49 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA software validation traceability matrix requirements documentation best practices"},"tool_response":{"query":"FDA software validation traceability matrix requirements documentation best practices","results":[{"tool_use_id":"srvtoolu_012bvgqFAT7n5DCJ7JVG9a3L","content":[{"title":"FDA Traceability Matrix Requirements for Medical Devices - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/traceability-101"},{"title":"Requirements Traceability Matrix (Trace Matrix, RTM, TM) | Ofni Systems","url":"https://www.ofnisystems.com/services/validation/traceability-matrix/"},{"title":"Requirements Traceability Matrix: Definition, Benefits, and Examples | Perforce Software","url":"https://www.perforce.com/resources/alm/requirements-traceability-matrix"},{"title":"How to Create a Traceability Matrix for Your Medical Device","url":"https://www.greenlight.guru/blog/traceability-matrix"},{"title":"Requirements Traceability Matrix for Medical Device Development | Enlil","url":"https://enlil.com/blog/requirements-traceability-matrix-for-medical-device-development/"},{"title":"Software Design Validation - FDA Requirements","url":"https://medicaldeviceacademy.com/software-design-validation/"},{"title":"Validation of Spectrometry Software: The Proactive Use of a Traceability Matrix in Spectrometry Software Validation, Part I: Principles","url":"https://www.spectroscopyonline.com/view/validation-spectrometry-software-proactive-use-traceability-matrix-spectrometry-software-validation"},{"title":"Verification Requirements Traceability Matrix (VRTM) ...","url":"https://www.faa.gov/sites/faa.gov/files/2022-02/VVSPT-E5-GDE-017_VRTM_V3.0.pdf"},{"title":"Traceability Matrix in Medical Device Development | Scilife","url":"https://www.scilife.io/blog/traceability-matrix-medical-device"},{"title":"Software Verification and Validation Requirements for Medical Device and Their Implementation Strategies","url":"https://www.complianceonline.com/resources/software-verification-and-validation-requirements-for-medical-device-and-implementation-strategies.html"}]},"Based on my search, here's a comprehensive overview of FDA software validation traceability matrix requirements and documentation best practices:\n\n## FDA Software Validation Traceability Matrix Requirements\n\n### Regulatory Status\n\nThe United States Code of Federal Regulations does not specifically require a traceability matrix, but creating a traceability matrix is recognized as a validation best practice. However, traceability of user requirements in the validation of computerized systems is a regulatory expectation of the FDA as evidenced from their Guidance for Industry on the General Principles of Software Validation.(no content)An expectation of FDA is that you can provide proof of documented traceability analysis or a traceability matrix linking product design requirements, design specifications, risks, controls and tests.\n\n### Purpose of the Requirements Traceability Matrix (RTM)\n\nThe Requirements Traceability Matrix (RTM) is a document that links requirements throughout the validation process. The purpose of the Requirements Traceability Matrix is to ensure that all requirements defined for a system are tested in the test protocols. The traceability matrix is a tool both for the validation team, to ensure that requirements are not lost during the validation project, and for auditors, to review the validation documentation.(no content)The Requirements traceability matrix (RTM) is a key piece that establishes the system is fully implemented. The RTM documents each of the requirement tracing it to design, items, code, unit, integration and software system test. It is a simple and effective way for documenting your implementation in accord with the expectations of the FDA.\n\n### Key Elements to Include\n\nFor FDA-regulated products, it is a key part of the Design History File (DHF), offering clear evidence of compliance with 21 CFR Part 820.(no content)Traceability in medical device development must be bidirectional, meaning every requirement should: Trace forward to design outputs and verification methods; Trace backward to its original source, such as a user need or risk control.(no content)A high-quality RTM includes both forward and backward traceability, often laid out like this: User Need â†’ System Requirement â†’ Design Input â†’ Design Output â†’ Verification Test â†’ Test Result; Hazard â†’ Risk Control â†’ Requirement â†’ Design Output â†’ Risk Verification.\n\n### Regulatory Standards\n\nThe traceability matrix must align with applicable regulatory standards and guidelines governing medical devices, such as ISO 13485, FDA regulations (e.g., 21 CFR Part 820), and international standards (e.g., IEC 60601).(no content)You must also comply with IEC 62304, medical device software â€“ software lifecycle processes. This is required for CE Marking as a harmonized standard and recognized by the US FDA.\n\n### Best Practices\n\nBest practices, such as implementing a robust and comprehensive documentation process, using tools to manage and track relationships between artifacts, and regularly reviewing and updating traceability information, can help organizations avoid missed requirements, oversights, and other issues that can impact product quality and safety.(no content)Remember: if your team doesn't have a document to prove a test or action, those actions do not exist to the FDA and auditors.(no content)As a best practice, the V&V should be considered early in the design stage when developing requirement specifications for a product. Such an approach will help streamline the overall manufacturing and approval process.\n\n### Risk Traceability\n\nThere should be harm identified for each software design requirement, or the traceability matrix should indicate that no harm can result from failure to meet the software design requirement. Next, the risk assessment should indicate what the risk controls are for each requirement identified with the potential for harm.(no content)ISO 14971:2019 mandates traceability between identified hazards, their mitigations, and verification activities. The RTM should show these connections clearly and concisely. This integration provides regulators with confidence that risks were identified, controlled, and validated.\n\n### Types of Matrices\n\nDepending on device complexity, multiple types of matrices may be maintained: User Needs Matrix: Links stakeholder needs to system-level requirements; Input-Output Matrix: Connects design inputs to corresponding outputs; Verification Matrix: Maps requirements to test protocols and results.(no content)Risk Matrix: Tracks hazards, control measures, and their validation status; Software RTM (as required by IEC 62304): Maps software requirements to units, code modules, and test cases.\n\n### Maintaining the Matrix\n\nThis matrix should be a living document that is updated continuously as the project progresses and artifacts change.(no content)An RTM must evolve with the product. As requirements or design elements change, trace links must be reviewed and updated to stay accurate. Keeping the RTM current ensures compliance, avoids gaps, and supports smooth audits."],"durationSeconds":38.56398243600002},"tool_use_id":"toolu_01VhKPhJovPKruDxmZrU5EvT"},"timestamp":1766707251055,"timestamp_pst":"2025-12-25 16:00:51 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"medical device software developer training IEC 62304 GAMP 5"},"tool_response":{"query":"medical device software developer training IEC 62304 GAMP 5","results":[{"tool_use_id":"srvtoolu_01JUBfpVyFwMkZscnxki3ndf","content":[{"title":"IEC 62304 Training | Developing Medical Device Software","url":"https://training.omnex.com/iso13485/developing-medical-device-software-iec62304"},{"title":"IEC 62304 - Medical Devices Software Development & Processes | Udemy","url":"https://www.udemy.com/course/iec-62304-medical-devices-software-lifecycle-processes/"},{"title":"An illustrated guide to medical device software development","url":"https://medicaldevicehq.com/articles/the-illustrated-guide-to-medical-device-software-development-and-iec-62304/"},{"title":"Medical Device Software Lifecycle per IEC 62304 - GMED NA","url":"https://lne-gmed.com/training/md-software-lifecycle"},{"title":"Medical Device Software Development & Management - Comprehensive Training Package (4 Courses) : Compliance Training Webinar (Online Seminar) - ComplianceOnline.com","url":"https://www.complianceonline.com/medical-device-software-development-verification-and-validation-training-webinar-training-702297-prdw"},{"title":"Online Software for Medical Devices and IEC 62304 Course","url":"https://medicaldevicehq.com/introduction-to-software-for-medical-devices-and-iec62304-online-course/"},{"title":"IEC 62304:2006 - Medical device software â€” Software life cycle processes","url":"https://www.iso.org/standard/38421.html"},{"title":"A Comprehensive Guide to IEC 62304: Navigating the Standard for Medical Device Software - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/a-comprehensive-guide-to-iec-62304-navigating-the-standard-for-medical-device-software"},{"title":"Medical Device Software and IEC 62304 - Quickstart course","url":"https://medicaldevicehq.com/quickstart-to-software-for-medical-devices-iec-62304/"},{"title":"Medical Device Software Development Under IEC 62304 : Compliance Training Webinar (Online Seminar) - ComplianceOnline.com","url":"https://www.complianceonline.com/medical-device-software-development-iec-62304-webinar-training-706744-prdw"}]},"Based on my search, here are the results for medical device software developer training related to IEC 62304 and GAMP 5:\n\n## Training Options for IEC 62304 and GAMP 5\n\n### Comprehensive Training Programs\n\n**Omnex IEC 62304 Training**\nThis two-day course is designed to give the attendee a detailed understanding of developing and maintaining Medical Device Software following the requirements of IEC 62304.(no content)The course covers the relationship of IEC 62304 with related standards such as ISO 13485, ISO 14971 and IEC 60601.(no content)The program is available in multiple locations globally, including the USA, Canada, Mexico, India, Europe, Thailand, Singapore, Middle East and China.\n\n**GMED North America Training**\nGMED North America offers a 2-day training session to equip medical device manufacturers with the right strategy to ensure their medical device software processes/documentation can withstand heightened scrutiny. This comprehensive course covers the processes defined in IEC 62304 including software development, maintenance, risk management, configuration management, and problem resolution.\n\n**ComplianceOnline Training Package**\nThis medical device software development, verification and validation training package of four courses covers IEC 62304 requirements and explains risk-based approach for validation using validation protocols and GAMPÂ®.\n\n### Online Learning Options\n\n**Udemy Course**\nThis course on IEC 62304 is described as the first interactive course on medical devices software development. It empowers learners to understand how to create and maintain safe software for medical devices throughout their life cycles. Participants gain a robust understanding of important terminologies to allow comprehensive participation in discussions about software safety classifications and software risk management.\n\n**Medical Device HQ Online Course**\nThis online course focuses on how to develop software for medical devices in accordance to IEC 62304 and regarding risk management and safety standards.(no content)It covers all aspects of the IEC 62304 standard and the relationship between the IEC 62304 and other standards such as ISO 14971, IEC 60601-1 and IEC 82304â€“1. The course is suitable for anyone working with software development, such as R&D engineers, quality assurance department and auditors of software development.\n\n### Key Topics Covered in These Trainings\n\nIEC 62304 sets the framework for medical device software development, dividing its guidance into five key sections:\n- Clause 5: Details the comprehensive software development process\n- Clause 6: Addresses necessary maintenance activities for software post-release\n- Clause 7: Focuses on risk management\n- Clause 8: Provides guidelines for configuration management\n- Clause 9: Covers processes for problem resolution\n\n### Regulatory Importance\n\nANSI/AAMI/IEC 62304 is a Recognized Consensus Standard by the US FDA and a harmonized standard in the EU. Compliance provides a presumption of conformity to the requirements within those jurisdictions. Not complying with the standard has shown to lead to longer regulatory review times and frequent rejections."],"durationSeconds":23.445624108000075},"tool_use_id":"toolu_019CT6oNuXpVN2P5YiPG5sHn"},"timestamp":1766707253616,"timestamp_pst":"2025-12-25 16:00:53 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies"},"tool_response":{"query":"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies","results":[{"tool_use_id":"srvtoolu_01AFPQNeECLRTkX7YUxTcZqt","content":[{"title":"FDA 21 CFR Part 820 Software | MasterControl","url":"https://www.mastercontrol.com/compliance/21-cfr-regulations/21-cfr-part-820/"},{"title":"Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application"},{"title":"21 CFR Parts 11 and 820 - GageList Gauge Calibration Software","url":"https://gagelist.com/compliance/21-cfr-parts-11-and-820/"},{"title":"FDA 21 CFR Part 820 Compliance Software: Complete Guide for Medical Device Manufacturers FDA 21 CFR Part 820 Compliance Software for Medical Devices","url":"https://www.compliancequest.com/bloglet/fda-21-cfr-part-820-compliance-software-medical-devices/"},{"title":"21 CFR Part 11: A Guide To FDA's Requirements","url":"https://www.greenlight.guru/blog/21-cfr-part-11-guide"},{"title":"21 CFR 820 Quality System Regulation | Qualityze","url":"https://www.qualityze.com/21-cfr-820"},{"title":"eCFR :: 21 CFR Part 820 -- Quality System Regulation","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820"},{"title":"How to Comply with FDA 21 CFR Part 820?","url":"https://www.qualityze.com/blogs/how-to-comply-with-fda-21-cfr-part-820"},{"title":"What is 21 CFR Part 11? FDA requirements explained","url":"https://www.cognidox.com/blog/what-is-fda-21-cfr-part-11"},{"title":"Title 21 CFR Part 11 - Wikipedia","url":"https://en.wikipedia.org/wiki/Title_21_CFR_Part_11"}]},"Now let me search for more specific information on code review best practices and peer review methodologies for medical device software.",{"tool_use_id":"srvtoolu_01EP7er7Mi1fx3hyskNgx44c","content":[{"title":"Regulatory requirements for code reviews","url":"https://www.johner-institute.com/articles/software-iec-62304/software-lifecycle/code-reviews/"},{"title":"FDA Guidance Sections Addressed by CodeSonar","url":"https://verifysoft.com/en_FDA_standards.html"},{"title":"Code review as part of software validation","url":"https://elsmar.com/elsmarqualityforum/threads/code-review-as-part-of-software-validation.29115/"},{"title":"FDA Compliance Software Best Practices","url":"https://integrant.com/blog/fda-compliant-software-best-practices"},{"title":"FDA Software Validation Process: Steps, Principles & More","url":"https://amplelogic.com/fda-software-validation-process"},{"title":"Why is Medical Device Software Validation Important? | Blog","url":"https://www.acldigital.com/blogs/medical-device-software-validation"},{"title":"Medical Device Software Development Management:","url":"https://cdn2.hubspot.net/hub/69806/file-15283182-pdf"},{"title":"FDA Recommends Static Analysis for Medical Devices","url":"https://codesecure.com/our-case-studies/fda-recommends-static-analysis-for-medical-devices/"},{"title":"R: Regulatory Compliance and Validation Issues","url":"https://www.r-project.org/doc/R-FDA.pdf"},{"title":"Medical Device Software Guidance Navigator | FDA","url":"https://www.fda.gov/medical-devices/regulatory-accelerator/medical-device-software-guidance-navigator"}]},"Based on the search results, I can now provide you with comprehensive information on FDA code review best practices for medical device software, including 21 CFR Part 11, Part 820, and peer review methodologies.\n\n## FDA Code Review Best Practices for Medical Device Software\n\n### Regulatory Framework\n\n**21 CFR Part 820 (Quality System Regulation)**\n\n21 CFR Part 820 outlines the current good manufacturing practice (CGMP) guidelines for developing medical devices. It governs the methods, facilities and controls used for medical device design, manufacture, packaging, labeling, storage, installation and service.(no content)21 CFR Part 820 establishes the basic requirements for manufacturers of finished medical devices. It is designed to ensure devices are safe and effective and comply with the Federal Food, Drug and Cosmetic Act (FD&C Act).\n\n**21 CFR Part 11 (Electronic Records; Electronic Signatures)**\n\nTitle 21 CFR Part 11 is the part of Title 21 of the Code of Federal Regulations that establishes the United States Food and Drug Administration (FDA) regulations on electronic records and electronic signatures (ERES). Part 11 defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records.(no content)21 CFR Parts 11 and 820 are separate but related FDA regulations that govern different aspects of the pharmaceutical, biotech and medical device industries to ensure the quality, safety, and effectiveness of medical products. Part 11 deals with electronic records and electronic signatures, and Part 820 deals with establishment of a quality management system.\n\n### Code Review Requirements and Best Practices\n\n**FDA Guidance on Code Reviews**\n\nThe IEC 62304 does not require explicit code reviews. But it does see code reviews as a way to test software units. However, written test criteria for code reviews must be available and the code review should be documented in writing as well.(no content)The FDA does not require code reviews, but writes the following in the Software Validation Guidance Document: \"Source code should also be evaluated to verify its compliance with the corresponding detailed design specification. [...] Source code evaluations are often implemented as code inspections and code walkthroughs. Such static analyses provide a very effective means to detect errors before execution of the code. They allow for examination of each error in isolation and can also help in focusing later dynamic testing of the software. [...] Source code evaluations should be extended to verification of internal linkages between modules and layers (horizontal and vertical interfaces), and compliance with their design specifications.\"\n\n**Defining Your Review Process**\n\nThe statutory requirement for reviews can be found in 21 CFR part 820. Here, too, no specific method is named. This, then, gives us the answer: You describe, as a manufacturer, in your 820-compliant quality management system, what kind of reviews you will make. And according to that, you need to document what people are involved - by signature.\n\n### Peer Review Methodologies\n\n**Peer-Reviewed Testing**\n\nA formal test case review must be conducted and documented during the validation and verification stage. Any comments are documented in the validation and verification document following the peer review. This process ensures that the test case design and execution are undertaken with the highest level of quality and oversight.(no content)Code reviews are systematic evaluations of the code intended to find defects, improve code quality, and aid engineers in learning the source code that serves as quality assurance for the code base. To receive a second perspective on the code implementation and detect errors, logic issues, or uncover edge cases, this can be done by another developer or technical team lead.\n\n**Integrated Development Practices**\n\nAn integrated SDLC merges validation and verification activities, including defect prevention practices such as unit testing, peer code reviews, static analysis, manual testing, and regression testing, throughout the SDLC. The result of such an approach is an emphasis on planning, verification, testing, traceability, and configuration management.(no content)Perform static (code review) and dynamic (functional) testing. Use peer reviews and checklists to catch errors early.\n\n### Static Analysis and Independent Review\n\nThere is no independent review required for software used in medical devices, and the FDA historically has not had the bandwidth to assess the quality of the code directly.(no content)As part of its Infusion Pump Improvement Initiative, the FDA is encouraging manufacturers to use static code analysis. With static analysis, software problems are detected early in the device development process, and it is possible to examine all possible execution paths.(no content)The FDA is now making medical device software quality a top priority, recommending better software development practices, including static analysis tools, to help manufacturers eliminate software defects during development.\n\n### Software Validation Requirements\n\n**Part 11 Validation**\n\nSection 11.10(a) Validation of systems: Requires that systems be validated to ensure accuracy, reliability, consistent intended performance, and ability to discern invalid or altered records. Validation should be performed for both closed and open systems that create, modify, maintain, archive, retrieve, or transmit electronic records subject to the regulation.(no content)Although persons must still comply with all applicable predicate rule requirements for validation (e.g., 21 CFR 820.70(i)), this guidance should not be read to impose any additional requirements for validation. We suggest that your decision to validate computerized systems, and the extent of the validation, take into account the impact the systems have on your ability to meet predicate rule requirements. You should also consider the impact those systems might have on the accuracy, reliability, integrity, availability, and authenticity of required records and signatures.\n\n### Audit Trail and Documentation Requirements\n\nThe audit trail requirements in this section are similar to the document control requirements of 21 CFR Part 820. Medical device companies must maintain appropriate control over systems documentation, including revision and change control procedures to maintain an audit trail that documents changes in the system. An audit trail ensures that every activity which happens in the record-keeping system generates a record and can be reviewed later.\n\n### Key Compliance Best Practices\n\nTracking and managing all changes to your code before and during the test process is integral to the success of your FDA compliance software. Having a proper source control platform means that developers can trace each test run on a certain date against the specific software requirements for those test cases.(no content)Validation must be established and re-established for even small changes. This means that validation activities, including static analysis, unit testing, code review, etc., must be repeated if the code has changed.(no content)Ensure that validation is performed by someone not involved in software development. For complex or high-risk products, consider third-party or external audits."],"durationSeconds":56.42526604100002},"tool_use_id":"toolu_017vHcUxF8RwDUz9igAr2dwr"},"timestamp":1766707256098,"timestamp_pst":"2025-12-25 16:00:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"in_progress","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01JobmYVdY65ZnLdVpshD8pz"},"timestamp":1766707256619,"timestamp_pst":"2025-12-25 16:00:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"in_progress","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_response":{"oldTodos":[],"newTodos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"in_progress","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01JobmYVdY65ZnLdVpshD8pz"},"timestamp":1766707256913,"timestamp_pst":"2025-12-25 16:00:56 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"\"computer system validation\" training pharmaceutical FDA 21 CFR Part 11 CSV"},"tool_response":{"query":"\"computer system validation\" training pharmaceutical FDA 21 CFR Part 11 CSV","results":[{"tool_use_id":"srvtoolu_01237WmEiAgj2X79cW6Bk98j","content":[{"title":"Computer System Validation (CSV) in the FDA-Regulated Industries","url":"https://www.thefdagroup.com/blog/computer-system-validation"},{"title":"21 CFR Part 11, Data Integrity, and Computer System Validation | FDA Compliance Seminar","url":"https://www.complianceonline.com/fda-21-cfr-part-11-data-inegrity-csv-seminar-training-80611SEM-prdsm"},{"title":"21 CFR Part 11 and Computer System Validation (CSV) Basics.","url":"http://www.fdacompliancespecialists.com/csv.php"},{"title":"The Essential Guide to Computer System Validation in the Pharmaceutical Industry - PMC","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11416705/"},{"title":"21 CFR Part 11 and FDA Compliance - EAS Consulting Group","url":"https://easconsultinggroup.com/21-cfr-part-11-and-fda-compliance/"},{"title":"Part 11, Electronic Records; Electronic Signatures - Scope and Application | FDA","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application"},{"title":"FDA 21 CFR Part 11 Compliance in Computer System Validation (CSV) | BioBoston Consulting","url":"https://biobostonconsulting.com/fda-21-cfr-part-11-compliance-in-computer-system-validation-csv-a-complete-guide-for-life-sciences-companies/"},{"title":"Computer System Validation, 21 CFR Part 11, FDA Compliance Specialist, David Nettleton - Computer System Validation","url":"http://www.computersystemvalidation.com/"},{"title":"Computer System Validation (CSV) In The Pharmaceutical Industry | GMP Insiders","url":"https://gmpinsiders.com/computer-system-validation-csv/"},{"title":"What is FDA 21 CFR Part 11? - Computer System Validation","url":"http://computersystemvalidation.com/articles/48-what-is-fda-21-cfr-part-11.html"}]},"Based on my search, here's a comprehensive overview of Computer System Validation (CSV) training related to FDA 21 CFR Part 11 in the pharmaceutical industry:\n\n## Computer System Validation (CSV) & FDA 21 CFR Part 11 Training\n\n### What is CSV?\n\nCSV is a documented process for assuring that a computer system does exactly what it is designed to do consistently and reproducibly. The process ensures that the system meets all predetermined requirements and is fit for its intended use.\n\n### Key Regulatory Framework\n\nThe FDA regulations outline the requirements for CSV, including FDA 21 CFR Part 820.70, FDA 21 CFR Part 11.10, FDA 21 CFR Part 11, European Union Annex 11, FDA's Guidance Document about Software Validation, GMP Directives, ISO 13485, and Good Automated Manufacturing Practice (GAMP) 5.(no content)In the United States, the FDA defines requirements for electronic records and electronic signatures under 21 CFR Part 11. This regulation establishes the criteria by which electronic records are considered trustworthy, reliable, and equivalent to paper records.\n\n### FDA Expectations for CSV\n\nThe FDA expects that all computer systems used in the design, manufacture, packaging, labeling, storage, installation, and servicing of all finished products intended for human use should comply with 21 CFR Part 11 and other relevant regulations.(no content)The FDA expects firms to maintain comprehensive documentation of the validation process, including validation plans, system specifications, test protocols, and test results. The documentation should be sufficient to demonstrate that the system is validated and operates correctly.\n\n### Training Topics Typically Covered\n\nTraining courses typically cover current regulations (e.g., 21 CFR 820.70(i), 21 CFR Part 11, 21 CFR 211.68), standards (e.g., ISO 13485), guidance (e.g., FDA's General Principles of Software Validation, AAMI/ISO TIR80002-2), methods (e.g., V-model, Agile Scrum), and terminology governing the design, development, validation, release, and maintenance of regulated software systems.\n\n### Best Practices for Compliance\n\nTo ensure success, life sciences organizations should adopt these strategies: Develop a Risk-Based Validation Plan focusing on systems that impact product quality and patient safety; Implement Robust Documentation maintaining traceable records including validation protocols, test scripts, and reports; Conduct IQ/OQ/PQ Testing to validate installation, operation, and performance of systems; Train Teams on Compliance Protocols ensuring staff understand CSV procedures and Part 11 requirements; and Monitor and Maintain Systems by regularly reviewing systems for compliance and revalidating after changes.\n\n### FDA Guidance on Validation\n\nThe FDA suggests that decisions to validate computerized systems, and the extent of the validation, should take into account the impact the systems have on the ability to meet predicate rule requirements. Companies should also consider the impact those systems might have on the accuracy, reliability, integrity, availability, and authenticity of required records and signatures.\n\n### Training Providers and Resources\n\nSeveral organizations offer specialized CSV and 21 CFR Part 11 training, including:\n\n- FDA Compliance Specialists, Inc., which provides Global GxP, Medical Device, 21 CFR Part 11, and Supplier Quality Auditing, Computer System Validation, Inspection Readiness, and FDA Compliance and Quality Training Services to pharmaceutical, medical device, and biotechnology industries.\n\n- Computer system validation has been regulated by FDA for more than 40 years, as it relates to systems used in the manufacturing, testing and distribution of products in the pharmaceutical, biotechnology, medical device or other FDA-regulated industries.\n\n### Emerging Trends\n\nAs digital transformation accelerates and the industry moves toward risk-based models such as Computer Software Assurance (CSA), CSV will continue to evolve.(no content)Training also covers current and future regulatory enforcement trends by the U.S. FDA and other global regulatory authorities, including the upcoming Computer Software Assurance Guidance from the U.S. FDA."],"durationSeconds":31.74323737899994},"tool_use_id":"toolu_0161GKjikgn31zk9coZfxSnK"},"timestamp":1766707261879,"timestamp_pst":"2025-12-25 16:01:01 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letter 483 observation code review documentation deficiencies medical device"},"tool_use_id":"toolu_012NGa57f1DUC8Mos9YVdRo6"},"timestamp":1766707261953,"timestamp_pst":"2025-12-25 16:01:01 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"medical device software code review checklist example items defect categories 2024 2025"},"tool_use_id":"toolu_01Y2LbZn21K8oLBD5UaiWaz1"},"timestamp":1766707261953,"timestamp_pst":"2025-12-25 16:01:01 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork"},"tool_use_id":"toolu_01GdsJkn6pU7BfQtD2AVd5qm"},"timestamp":1766707261958,"timestamp_pst":"2025-12-25 16:01:01 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters"},"tool_response":{"query":"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters","results":[{"tool_use_id":"srvtoolu_01BwL4Y24T99qvXBXTNgbPXZ","content":[{"title":"21 CFR Part 11: A guide for clinical trial compliance","url":"https://www.qualio.com/blog/21-cfr-part-11-clinical-trials"},{"title":"What is FDA 21 CFR Part 11? Compliance & Software Validation Guide â€“ Redzone","url":"https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/"},{"title":"FDA 21 CFR Part 11 Compliance | Arbour Group","url":"https://www.arbourgroup.com/services/validation-compliance/21-cfr-part-11-compliance/"},{"title":"FDA's Questions and Answers on 21 CFR Part 11 for Clinical Investigations - IQVIA","url":"https://www.iqvia.com/library/white-papers/fdas-questions-and-answers-on-21-cfr-part-11-for-clinical-investigations"},{"title":"FDA 21 CFR Part 11 Compliance: Frequently Asked Questions - Florence","url":"https://www.florencehc.com/blog-post/fda-21-cfr-part-11-compliance-frequently-asked-questions/"},{"title":"Mastering 21 CFR Part 11 Compliance: A Comprehensive Guide for Clinical Trials in the Digital Age","url":"https://www.cloudbyz.com/resources/digital-transformation/mastering-21-cfr-part-11-compliance-a-comprehensive-guide-for-clinical-trials-in-the-digital-age/"},{"title":"GAMP 5 & 21 CFR Part 11 in Computer System Validation","url":"https://pharmaconnections.in/role-of-gamp-5-and-21-cfr-part-11-in-computer-system-validation/"},{"title":"21 CFR Part 11 Compliance | Clinical Research Resource HUB","url":"https://hub.ucsf.edu/21-cfr-part-11-compliance"},{"title":"Guidance for Industry - COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information/guidance-industry-computerized-systems-used-clinical-trials"},{"title":"Beginnerâ€™s Guide to 21 CFR Part 11 Compliance","url":"https://www.advarra.com/blog/beginners-guide-to-21-cfr-part-11-compliance/"}]},"Based on my search, here's a comprehensive overview of FDA clinical trial software, CTMS validation, 21 CFR Part 11, and warning letters:\n\n## 21 CFR Part 11 and Clinical Trial Software\n\nFDA 21 Code of Federal Regulations (CFR) Part 11 refers to the FDA's regulations on electronic records and electronic signatures for clinical trials.(no content)This regulation applies to all industries under FDA regulation, including pharmaceuticals, medical devices, biotechnology, and other life sciences. It outlines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures.\n\n## Systems That Require Compliance\n\nKey systems requiring Part 11 compliance include Electronic Data Capture (EDC) systems used to collect clinical trial data, Clinical Trial Management Systems (CTMS) that help manage different stages of clinical trials, and Electronic Trial Master File (eTMF) systems that digitally store and manage critical clinical study documents.\n\n## CTMS Validation Requirements\n\nFor Clinical Trial Management Systems (CTMS), compliance audits should review access controls, system logs and trails, data backup protocols, and system validation documentation.(no content)For customized systems or COTS systems integrated with other systems, sponsors should develop and document a validation plan, conduct the validation in accordance with the plan, and document the validation results.(no content)There is no certification process for Part 11, so any statement of compliance is just thatâ€”a statement, which isn't backed by any sort of third-party auditing body.\n\n## FDA Warning Letters and Enforcement\n\nThe FDA issues warning letters to regulated organizations that are in violation of Part 11. A formal notice from the FDA indicates an organization is not in compliance with regulatory requirements, outlines the specific violations, and requires corrective actions within a set timeframe.(no content)In 2024, the FDA's Center for Devices and Radiological Health (CDRH) issued 529 warning letters, with 8% (44) directed at medical device manufacturers for issues including design validation failures and data integrity concerns.(no content)In November 2024, the FDA issued a Complete Response Letter to Applied Therapeutics, citing deficiencies in data integrity and protocol adherence, including violations of 21 CFR Part 11. As a result, their new drug application was not approved, and they are now facing shareholder lawsuits.\n\n## Penalties for Non-Compliance\n\nThe FDA has the authority to impose significant penalties including import alerts preventing products from entering the US market, seizure of affected products, injunctions prohibiting further manufacturing until violations are corrected, civil monetary penalties in the millions of dollars, and consent decrees requiring expensive third-party oversight of remediation efforts.\n\n## Key Compliance Requirements\n\nThere are four main pillars for FDA 21 CFR Part 11 compliance: system validation to prove your system works reliably, user access controls to restrict actions to authorized personnel, and audit trails to maintain secure, tamper-proof logs of all changes and approvals.(no content)Changes to data stored on electronic media will always require an audit trail in accordance with 21 CFR 11.10(e). Documentation should include who made the changes, when, and why they were made.\n\n## Vendor and Sponsor Responsibilities\n\nUnder certain circumstances, FDA may choose to inspect electronic service vendors engaged in providing services regulated by FDA. For example, if required records are not available from the sponsor or clinical investigation site, FDA may choose to inspect records at the vendor's facilities.(no content)Many software vendors provide documentation and proof of testing to demonstrate their platform meets 21 CFR Part 11 technical requirements. Working with a software vendor that understands the regulations can reduce your testing burden, allowing you to adopt a risk-based approach and incorporate the vendor's test documentation into your computer system validation."],"durationSeconds":29.753591684999993},"tool_use_id":"toolu_0193PnARLAUdCaSKUKfEQT3f"},"timestamp":1766707273283,"timestamp_pst":"2025-12-25 16:01:13 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letter software audit trail data integrity 2023 2024 specific company examples"},"tool_response":{"query":"FDA warning letter software audit trail data integrity 2023 2024 specific company examples","results":[{"tool_use_id":"srvtoolu_01Rn8zcSi26v4Mj9knV22wYF","content":[{"title":"FDA Continues to Highlight Data Integrity as a QC Lab Issue | Autoscribe Informatics","url":"https://www.autoscribeinformatics.com/resources/blog/fda-continues-to-highlight-data-integrity-as-a-qc-lab-issue"},{"title":"FDA Warning Letter on Data Integrity Issues - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-warning-letter-on-data-integrity-issues"},{"title":"Data Integrity: A hot topic in FDA Warning Letters","url":"https://www.pharmout.net/data-integrity-fda/"},{"title":"FDA Warning Letter on missing Audit Trails and Raw Data Review - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-warning-letter-on-missing-audit-trails-and-raw-data-review"},{"title":"Data Integrity Compliance for Paper Forms and Electronic Data Created in Regulated Laboratories and Manufacturing â€“ A Review of Two Recent FDA Warning Letters â€“ CIMCON Software","url":"https://part11solutions.com/2023/01/24/data-integrity-compliance-for-paper-forms-and-electronic-data-created-in-regulated-laboratories-and-manufacturing-a-review-of-two-recent-fda-warning-letters/"},{"title":"U.S. Warning Letter caused by Data Integrity Failures - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/u-s-warning-letter-caused-by-data-integrity-failures"},{"title":"Automating Audit Trail Compliance for 21 CFR Part 11 & Annex 11 | IntuitionLabs","url":"https://intuitionlabs.ai/articles/audit-trails-21-cfr-part-11-annex-11-compliance"},{"title":"FDA warning letters highlight data integrity issues","url":"https://www.europeanpharmaceuticalreview.com/news/219951/fda-warning-letters-highlight-data-integrity-issues/"},{"title":"An Analysis Of FDA Warning Letters On Data Governance & Data Integrity","url":"https://www.pharmaceuticalonline.com/doc/an-analysis-of-fda-warning-letters-on-data-governance-data-integrity-0001"},{"title":"Data Integrity and Compliance With Drug CGMP Questions and Answers","url":"https://www.fda.gov/media/119267/download"}]},"Based on my search results, I found several specific examples of FDA warning letters related to software audit trail and data integrity issues from 2023 and 2024. Here's a summary:\n\n## FDA Warning Letters: Software Audit Trail & Data Integrity Issues (2023-2024)\n\n### Specific Company Examples\n\n**2024 Warning Letters:**\n\n1. **Westward Laboratories LLC** (May 14, 2024)\n   - The warning letter stated that their \"quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.\"\n\n2. **Laboratorio Magnachem International** (Dominican Republic - June 18, 2024)\n   - On June 18, 2024, the FDA issued a Warning Letter to this Dominican company regarding CGMP violations, based on an FDA inspection in November 2023.\n\n3. **Sichuan Deebio Pharmaceutical Co. Ltd** (China - February 5, 2024)\n   - The FDA's Center for Drug Evaluation and Research (CDER) identified two significant deviations from current good manufacturing practice (cGMP) for active pharmaceutical ingredients.\n\n4. Of the 70 Warning Letters issued by the FDA so far in 2024, three have identified data integrity issues at pharmaceutical manufacturing sites outside the US.(no content)Specifically, these recent warning letters describe microbiology and environmental monitoring related data integrity issues.\n\n**2023 Warning Letters:**\n\n5. **Cosmobeauti Laboratories & Manufacturing Inc.**\n   - The company was already inspected by the U.S. FDA in 2017 with similar observations. The repeated findings outline that the Quality oversight and control of the production of the company is not in compliance with the cGMP regulations. The observed findings resulted in a long list of Data Integrity remediation activities and CAPA measurements requested.\n\n**Late 2022 Examples (still relevant):**\n\n6. **Nortec Quimica SA** (December 8, 2022)\n   - The warning letter mentioned \"analytical worksheets\" among electronic data integrity observations, noting the \"analytical worksheet forms\" used for recording testing results in the quality control (QC) laboratory are not controlled as there was no unique number, signature, or any other traceable element.\n\n7. **Centrient Pharmaceuticals India Private Limited** (December 7, 2022)\n   - This warning letter included observations of the destruction of paper GMP records, including forms, as well as the ability to delete electronic records.\n\n### Common Audit Trail Violations Cited\n\nA 2024 warning letter showed that companies had \"numerous analysis reports, test methods, raw dataâ€¦ in the GC computer's recycling bin\" and that \"laboratory personnel used a shared passwordâ€¦ to access the GC software.\"(no content)Common deficiencies include switching audit trails in chromatography data systems off and then on again to obscure modification or deletion of data, and manipulation of date/time stamps to make it appear samples were tested on a different day than they actually were.(no content)Failures commonly cited include failure of management to review high-performance liquid chromatography (HPLC) audit trails for drug product testing before release of a batch.\n\n### Key Statistics\n\nFailures in data governance and data integrity continue to be addressed in approximately 80 percent of FDA warning letters issued to both domestic and foreign sites.(no content)Data integrity has been highlighted as a key issue by the US FDA over recent years, being mentioned in 61 percent of warnings issued in 2021."],"durationSeconds":29.929302584000048},"tool_use_id":"toolu_01GUrEXZY3eikh8vhd4grWxa"},"timestamp":1766707273446,"timestamp_pst":"2025-12-25 16:01:13 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"\"design control\" software validation FDA 483 medical device 2024"},"tool_response":{"query":"\"design control\" software validation FDA 483 medical device 2024","results":[{"tool_use_id":"srvtoolu_01W13ARtm7rCkFrc6AuJmi1h","content":[{"title":"FDAâ€™s 483 observation â€“ Design Validation","url":"https://www.linkedin.com/pulse/fdas-483-observation-design-validation-anita-ramachandran"},{"title":"Design Controls Training","url":"https://medicaldeviceacademy.com/design-controls-training/"},{"title":"10 Steps to an Effective Medical Device FDA 483 Response | NSF","url":"https://www.nsf.org/knowledge-library/ten-steps-effective-medical-devices-fda-483-responses"},{"title":"General Principles of Software Validation - Final Guidance","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation"},{"title":"FDA Design Controls: Medical Device Developer Guide | Perforce Software","url":"https://www.perforce.com/blog/alm/fda-design-controls-plain-simple-guide-medical-device-developers"},{"title":"Vision28 Checklist for FDA FORM 483 responses Â» Vision28","url":"https://www.vision28.com/blog/visoin28-checklist-fda-form-483"},{"title":"Design Controls | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/design-controls"},{"title":"FDA Guidance on Medical Device Design Control","url":"https://www.regdesk.co/blog/fda-guidance-on-design-validation/"},{"title":"FDA 483 | Greenlight Guru","url":"https://www.greenlight.guru/glossary/fda-483"},{"title":"New FDA Guidance on Software Documentation for Medical Devices | Exponent","url":"https://www.exponent.com/article/new-fda-guidance-software-documentation-medical-devices"}]},"Based on the search results, here's a comprehensive overview of design controls, software validation, and FDA 483 observations for medical devices:\n\n## FDA 483 Observations and Design Controls\n\nDesign controls are the #1 cause of FDA 483s.(no content)Design controls are one of the 4 major quality subsystems that the FDA will review during a QSIT level II inspection, and design controls are one of the biggest challenges for companies developing a medical device for the first time.\n\n### Common FDA 483 Observations Related to Design Validation\n\nEvery year, FDA's 483 observations related to design validation have always been one of the top 10 most common observations for medical device companies.(no content)The trend shows inadequate validation procedures, risk analysis, negligence in defining acceptance criteria, inadequate documentation, and validation execution are repetitive observations in the medical device industry.\n\nKey observation categories include:\n\n1. **Risk Analysis Issues** - The most probable cause could be risk management being considered as a standalone process and/or performed at the end of product development life cycle, or lack of expertise in performing risk assessment.\n\n2. **Inadequate Documentation** - FDA believes in documented evidence. It is very important to collect and record data to demonstrate the device safety and effectiveness in actual use condition.\n\n3. **Software Validation Not Performed** - Software validation is often not performed. Most present medical devices have software embedded within them or software used as an accessory. In either case, the software by itself must be adequately validated and documented.\n\n4. **Acceptance Criteria Issues** - FDA requires acceptance criteria to be stated up front (before validation execution). The pre-defined acceptance criteria should be measurable and/or observable.\n\n### Regulatory Requirements\n\nThe requirement for software validation is included in Section 820.30(g) Design Validation. If the project selected involves a device that contains software, consider reviewing the software's validation while proceeding through the assessment.(no content)Design validation shall be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis, where appropriate.\n\n### Responding to FDA 483 Observations\n\nIf FDA receives a response to the FDA 483 observations within fifteen (15) business days, a \"detailed review\" of the response will be conducted prior to a decision to issue a Warning Letter.(no content)Major deficiencies relative to 21 CFR Part 820 include absence of design control procedures (including design change control procedures, where required), failure to validate processes requiring validation, and non-correction or inadequate correction of major deficiencies from previous inspections.\n\n### Applicability\n\nThe design control requirements of Section 820.30 of the regulation apply to the design of Class II and III medical devices, and a select group of Class I devices.(no content)Design controls also apply to any Class I device that has software (e.g., MDDS and other software as a medical device or SaMD)."],"durationSeconds":30.81940512599994},"tool_use_id":"toolu_011i14Uek1xLyoz5LjeqtAbk"},"timestamp":1766707274360,"timestamp_pst":"2025-12-25 16:01:14 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"a75e99f","block":true,"timeout":120000},"tool_response":{"retrieval_status":"timeout","task":{"task_id":"a75e99f","task_type":"local_agent","status":"running","description":"Research FDA audit findings","output":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"FDA Research\\\" \\\"Research\\\"\",\"description\":\"Notify workflow start for observability\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 observations software validation 2023 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letters software medical device code review 2020-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation failures cGMP pharmaceutical 2022 2023 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA 21 CFR Part 11 software audit findings common deficiencies\"}\n[Tool: WebSearch] {\"query\":\"\\\"FDA warning letter\\\" software validation case study 2023 2024 medical device\"}\n[Tool: WebSearch] {\"query\":\"FDA CAPA software deficiencies code review pharmaceutical 2022-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA remediation requirements software validation response plan\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" CSV FDA warning letter examples 2020-2024\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter software audit trail data integrity 2023 2024 specific company examples\"}\n[Tool: WebSearch] {\"query\":\"\\\"design control\\\" software validation FDA 483 medical device 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters\"}\n","prompt":"Research common FDA audit findings and warning letters related to software and code review:\n\n1. **Common 483 observations** - What software-related issues does FDA cite most often?\n2. **Warning letter patterns** - Recurring themes in software validation failures\n3. **Case studies** - Real examples of companies that faced FDA action due to code review deficiencies\n4. **Remediation requirements** - What FDA expects when issues are found\n\nFocus on the last 5 years (2020-2025). Extract specific examples that can be used as teaching cases in training. Include pharmaceutical (cGMP), medical devices, and clinical systems.","result":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"FDA Research\\\" \\\"Research\\\"\",\"description\":\"Notify workflow start for observability\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 observations software validation 2023 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letters software medical device code review 2020-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation failures cGMP pharmaceutical 2022 2023 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA 21 CFR Part 11 software audit findings common deficiencies\"}\n[Tool: WebSearch] {\"query\":\"\\\"FDA warning letter\\\" software validation case study 2023 2024 medical device\"}\n[Tool: WebSearch] {\"query\":\"FDA CAPA software deficiencies code review pharmaceutical 2022-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA remediation requirements software validation response plan\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" CSV FDA warning letter examples 2020-2024\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter software audit trail data integrity 2023 2024 specific company examples\"}\n[Tool: WebSearch] {\"query\":\"\\\"design control\\\" software validation FDA 483 medical device 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters\"}\n"}},"tool_use_id":"toolu_01SiF2ck3HT97M6pHmrZ5MfN"},"timestamp":1766707275839,"timestamp_pst":"2025-12-25 16:01:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"a7f2711","block":true,"timeout":120000},"tool_response":{"retrieval_status":"timeout","task":{"task_id":"a7f2711","task_type":"local_agent","status":"running","description":"Research training methodologies","output":"[Tool: WebSearch] {\"query\":\"adult learning principles technical compliance training regulatory topics 2025\"}\n[Tool: WebSearch] {\"query\":\"competency-based training assessment code review software validation\"}\n[Tool: WebSearch] {\"query\":\"pharmaceutical medical device software training GxP compliance 2025\"}\n[Tool: WebSearch] {\"query\":\"hands-on coding exercises technical training best practices\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"training effectiveness evaluation Kirkpatrick model technical training assessment\"}\n[Tool: WebSearch] {\"query\":\"interactive learning techniques software engineering training scenario-based learning\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" training pharmaceutical FDA 21 CFR Part 11 CSV\"}\n[Tool: WebSearch] {\"query\":\"medical device software developer training IEC 62304 GAMP 5\"}\n","prompt":"Research effective training methodologies for technical compliance training:\n\n1. **Adult learning principles** - How to teach complex regulatory topics effectively\n2. **Competency-based training** - How to measure code review competency\n3. **Practical exercises** - Types of exercises that work best for code review training\n4. **Assessment methods** - How to evaluate if training was effective\n5. **Industry examples** - How pharmaceutical and medical device companies train their teams\n\nFocus on:\n- Interactive learning techniques\n- Hands-on coding exercises\n- Role-playing scenarios for reviews\n- Using real-world examples effectively\n\nProvide specific exercise ideas that could be implemented in a code review training program.","result":"[Tool: WebSearch] {\"query\":\"adult learning principles technical compliance training regulatory topics 2025\"}\n[Tool: WebSearch] {\"query\":\"competency-based training assessment code review software validation\"}\n[Tool: WebSearch] {\"query\":\"pharmaceutical medical device software training GxP compliance 2025\"}\n[Tool: WebSearch] {\"query\":\"hands-on coding exercises technical training best practices\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"training effectiveness evaluation Kirkpatrick model technical training assessment\"}\n[Tool: WebSearch] {\"query\":\"interactive learning techniques software engineering training scenario-based learning\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" training pharmaceutical FDA 21 CFR Part 11 CSV\"}\n[Tool: WebSearch] {\"query\":\"medical device software developer training IEC 62304 GAMP 5\"}\n"}},"tool_use_id":"toolu_01WTDFWLsKwjpTghp2UpDQ2k"},"timestamp":1766707275910,"timestamp_pst":"2025-12-25 16:01:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"ac6566d","block":true,"timeout":120000},"tool_response":{"retrieval_status":"timeout","task":{"task_id":"ac6566d","task_type":"local_agent","status":"running","description":"Research FDA 21 CFR Part 11","output":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"Multi-Source Research\\\" \\\"Research\\\"\",\"description\":\"Notify observability of workflow execution\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/\",\"description\":\"Check Research skill directory structure\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/workflows/\",\"description\":\"List available workflow files\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/PerplexityResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/ClaudeResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"in_progress\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"pending\"}]}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 electronic records signatures code review requirements validation\"}\n[Tool: WebSearch] {\"query\":\"FDA Software Validation Guidance 2002 General Principles code review documentation requirements\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 Good Automated Manufacturing Practice code review validation requirements\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 medical device software lifecycle code review traceability requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation traceability matrix requirements documentation best practices\"}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 audit trail requirements code change control procedures\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 software categories risk-based validation approach code review\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 software safety classification code review testing verification\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"completed\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"in_progress\"}]}\n","prompt":"Research FDA software validation requirements for code review, focusing on:\n\n1. **21 CFR Part 11** - Electronic records and signatures requirements\n2. **FDA Software Validation Guidance** - General Principles of Software Validation (2002)\n3. **GAMP 5** - Good Automated Manufacturing Practice guidelines\n4. **IEC 62304** - Medical device software lifecycle processes\n\nFor each, extract:\n- Key requirements that impact code review\n- Documentation requirements\n- Traceability requirements\n- Specific validation activities required\n\nProvide detailed, actionable findings that can be used to build a training curriculum. Include specific regulatory citations where possible.","result":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"Multi-Source Research\\\" \\\"Research\\\"\",\"description\":\"Notify observability of workflow execution\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/\",\"description\":\"Check Research skill directory structure\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/workflows/\",\"description\":\"List available workflow files\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/PerplexityResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/ClaudeResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"in_progress\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"pending\"}]}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 electronic records signatures code review requirements validation\"}\n[Tool: WebSearch] {\"query\":\"FDA Software Validation Guidance 2002 General Principles code review documentation requirements\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 Good Automated Manufacturing Practice code review validation requirements\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 medical device software lifecycle code review traceability requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation traceability matrix requirements documentation best practices\"}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 audit trail requirements code change control procedures\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 software categories risk-based validation approach code review\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 software safety classification code review testing verification\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"completed\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"in_progress\"}]}\n"}},"tool_use_id":"toolu_01MmVRwvuFisjdxypm5QK6GP"},"timestamp":1766707275962,"timestamp_pst":"2025-12-25 16:01:15 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"aaa3a33","block":true,"timeout":120000},"tool_response":{"retrieval_status":"timeout","task":{"task_id":"aaa3a33","task_type":"local_agent","status":"running","description":"Research code review best practices","output":"[Tool: Bash] {\"command\":\"curl -X POST http://localhost:8888/notify -H \\\"Content-Type: application/json\\\" -d '{\\\"message\\\":\\\"Starting comprehensive FDA code review research with parallel agents\\\",\\\"voice_id\\\":\\\"iLVmqjzCGGvqtMCk6vVQ\\\",\\\"voice_enabled\\\":true}'\",\"description\":\"Notify research start\"}\n[Tool: Bash] {\"command\":\"gemini \\\"FDA code review best practices for medical device software - formal peer review methodologies including Fagan inspections, IEEE standards, and regulatory requirements under 21 CFR Part 11 and Part 820\\\"\",\"description\":\"Research FDA peer review methodologies\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Code review checklists for FDA-regulated pharmaceutical and medical device software - specific items required for regulatory compliance, software validation, and audit trails\\\"\",\"description\":\"Research FDA-compliant review checklists\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Documentation and evidence requirements for code reviews in FDA audits - what records inspectors look for, retention requirements, traceability to requirements and risk analysis\\\"\",\"description\":\"Research documentation requirements for audits\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Roles and responsibilities in FDA-regulated code reviews - author, reviewer, moderator duties, independence requirements, qualification criteria, and training documentation\\\"\",\"description\":\"Research review roles and responsibilities\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Defect classification and tracking systems for medical device software development - severity levels, CAPA integration, risk-based prioritization, and FDA expectations\\\"\",\"description\":\"Research defect tracking in regulated environments\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Software tool qualification and validation requirements for code review tools in FDA-regulated environments - CSV computer system validation, 21 CFR Part 11 compliance, GAMP 5 categories\\\"\",\"description\":\"Research tool qualification requirements\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Real-world examples of code review checklists from pharmaceutical companies and medical device manufacturers - practical templates and industry standards like IEC 62304\\\"\",\"description\":\"Research practical checklist examples\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: WebSearch] {\"query\":\"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies\"}\n[Tool: WebSearch] {\"query\":\"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process\"}\n[Tool: WebSearch] {\"query\":\"code review checklist FDA compliance medical device software IEC 62304 validation requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA audit documentation code review evidence requirements traceability pharmaceutical software\"}\n[Tool: WebSearch] {\"query\":\"code review roles responsibilities medical device software author reviewer moderator independence requirements\"}\n[Tool: WebSearch] {\"query\":\"defect tracking classification FDA regulated software CAPA integration severity levels medical device\"}\n[Tool: WebSearch] {\"query\":\"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"medical device software code review checklist example items defect categories 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter 483 observation code review documentation deficiencies medical device\"}\n[Tool: WebSearch] {\"query\":\"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork\"}\n","prompt":"Research code review best practices specifically for FDA-regulated environments:\n\n1. **Peer review methodologies** - Formal vs informal reviews, Fagan inspections\n2. **Checklist-based reviews** - What should FDA-compliant checklists include?\n3. **Documentation requirements** - What evidence is needed for audits?\n4. **Review roles** - Author, reviewer, moderator responsibilities\n5. **Defect tracking** - Classification and handling in regulated environments\n6. **Tool qualification** - Requirements for code review tools in FDA context\n\nInclude examples of review checklists used in pharmaceutical and medical device industries. Focus on practical implementation guidance.","result":"[Tool: Bash] {\"command\":\"curl -X POST http://localhost:8888/notify -H \\\"Content-Type: application/json\\\" -d '{\\\"message\\\":\\\"Starting comprehensive FDA code review research with parallel agents\\\",\\\"voice_id\\\":\\\"iLVmqjzCGGvqtMCk6vVQ\\\",\\\"voice_enabled\\\":true}'\",\"description\":\"Notify research start\"}\n[Tool: Bash] {\"command\":\"gemini \\\"FDA code review best practices for medical device software - formal peer review methodologies including Fagan inspections, IEEE standards, and regulatory requirements under 21 CFR Part 11 and Part 820\\\"\",\"description\":\"Research FDA peer review methodologies\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Code review checklists for FDA-regulated pharmaceutical and medical device software - specific items required for regulatory compliance, software validation, and audit trails\\\"\",\"description\":\"Research FDA-compliant review checklists\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Documentation and evidence requirements for code reviews in FDA audits - what records inspectors look for, retention requirements, traceability to requirements and risk analysis\\\"\",\"description\":\"Research documentation requirements for audits\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Roles and responsibilities in FDA-regulated code reviews - author, reviewer, moderator duties, independence requirements, qualification criteria, and training documentation\\\"\",\"description\":\"Research review roles and responsibilities\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Defect classification and tracking systems for medical device software development - severity levels, CAPA integration, risk-based prioritization, and FDA expectations\\\"\",\"description\":\"Research defect tracking in regulated environments\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Software tool qualification and validation requirements for code review tools in FDA-regulated environments - CSV computer system validation, 21 CFR Part 11 compliance, GAMP 5 categories\\\"\",\"description\":\"Research tool qualification requirements\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Real-world examples of code review checklists from pharmaceutical companies and medical device manufacturers - practical templates and industry standards like IEC 62304\\\"\",\"description\":\"Research practical checklist examples\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: WebSearch] {\"query\":\"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies\"}\n[Tool: WebSearch] {\"query\":\"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process\"}\n[Tool: WebSearch] {\"query\":\"code review checklist FDA compliance medical device software IEC 62304 validation requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA audit documentation code review evidence requirements traceability pharmaceutical software\"}\n[Tool: WebSearch] {\"query\":\"code review roles responsibilities medical device software author reviewer moderator independence requirements\"}\n[Tool: WebSearch] {\"query\":\"defect tracking classification FDA regulated software CAPA integration severity levels medical device\"}\n[Tool: WebSearch] {\"query\":\"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"medical device software code review checklist example items defect categories 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter 483 observation code review documentation deficiencies medical device\"}\n[Tool: WebSearch] {\"query\":\"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork\"}\n"}},"tool_use_id":"toolu_01FgFvTZX7bLcL37TD9FPXuT"},"timestamp":1766707276067,"timestamp_pst":"2025-12-25 16:01:16 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/aaa3a33.output"},"tool_use_id":"toolu_01E5wS7Fngzmqn6fBscmYmAw"},"timestamp":1766707283445,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/ac6566d.output"},"tool_use_id":"toolu_01WkGAR3Lw1ifWKf97VWTnUY"},"timestamp":1766707283444,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/a75e99f.output"},"tool_use_id":"toolu_01QtjLWnfGdvoe9VkDVoVGqw"},"timestamp":1766707283460,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/a7f2711.output"},"tool_use_id":"toolu_01WsJPnutnF8f8RkkivhMpqS"},"timestamp":1766707283459,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/aaa3a33.output"},"tool_response":{"type":"text","file":{"filePath":"/tmp/claude/-home-chris/tasks/aaa3a33.output","content":"[Tool: Bash] {\"command\":\"curl -X POST http://localhost:8888/notify -H \\\"Content-Type: application/json\\\" -d '{\\\"message\\\":\\\"Starting comprehensive FDA code review research with parallel agents\\\",\\\"voice_id\\\":\\\"iLVmqjzCGGvqtMCk6vVQ\\\",\\\"voice_enabled\\\":true}'\",\"description\":\"Notify research start\"}\n[Tool: Bash] {\"command\":\"gemini \\\"FDA code review best practices for medical device software - formal peer review methodologies including Fagan inspections, IEEE standards, and regulatory requirements under 21 CFR Part 11 and Part 820\\\"\",\"description\":\"Research FDA peer review methodologies\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Code review checklists for FDA-regulated pharmaceutical and medical device software - specific items required for regulatory compliance, software validation, and audit trails\\\"\",\"description\":\"Research FDA-compliant review checklists\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Documentation and evidence requirements for code reviews in FDA audits - what records inspectors look for, retention requirements, traceability to requirements and risk analysis\\\"\",\"description\":\"Research documentation requirements for audits\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Roles and responsibilities in FDA-regulated code reviews - author, reviewer, moderator duties, independence requirements, qualification criteria, and training documentation\\\"\",\"description\":\"Research review roles and responsibilities\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Defect classification and tracking systems for medical device software development - severity levels, CAPA integration, risk-based prioritization, and FDA expectations\\\"\",\"description\":\"Research defect tracking in regulated environments\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Software tool qualification and validation requirements for code review tools in FDA-regulated environments - CSV computer system validation, 21 CFR Part 11 compliance, GAMP 5 categories\\\"\",\"description\":\"Research tool qualification requirements\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Real-world examples of code review checklists from pharmaceutical companies and medical device manufacturers - practical templates and industry standards like IEC 62304\\\"\",\"description\":\"Research practical checklist examples\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: Bash] {\"command\":\"gemini \\\"Static analysis integration with code reviews in FDA environments - automated tools like SonarQube, Coverity, or Klocwork for medical device software, qualification requirements, and complementing manual reviews\\\"\",\"description\":\"Research static analysis integration\"}\n[Tool: WebSearch] {\"query\":\"FDA code review best practices medical device software 21 CFR Part 11 Part 820 peer review methodologies\"}\n[Tool: WebSearch] {\"query\":\"Fagan inspection methodology FDA regulated software pharmaceutical medical device formal review process\"}\n[Tool: WebSearch] {\"query\":\"code review checklist FDA compliance medical device software IEC 62304 validation requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA audit documentation code review evidence requirements traceability pharmaceutical software\"}\n[Tool: WebSearch] {\"query\":\"code review roles responsibilities medical device software author reviewer moderator independence requirements\"}\n[Tool: WebSearch] {\"query\":\"defect tracking classification FDA regulated software CAPA integration severity levels medical device\"}\n[Tool: WebSearch] {\"query\":\"code review tool qualification validation CSV 21 CFR Part 11 GAMP 5 medical device software\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"code review checklist template pharmaceutical industry medical device examples practical implementation\"}\n[Tool: WebSearch] {\"query\":\"medical device software code review checklist example items defect categories 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter 483 observation code review documentation deficiencies medical device\"}\n[Tool: WebSearch] {\"query\":\"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork\"}\n","numLines":23,"startLine":1,"totalLines":23}},"tool_use_id":"toolu_01E5wS7Fngzmqn6fBscmYmAw"},"timestamp":1766707283816,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/ac6566d.output"},"tool_response":{"type":"text","file":{"filePath":"/tmp/claude/-home-chris/tasks/ac6566d.output","content":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"Multi-Source Research\\\" \\\"Research\\\"\",\"description\":\"Notify observability of workflow execution\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/\",\"description\":\"Check Research skill directory structure\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/workflows/\",\"description\":\"List available workflow files\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/PerplexityResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/ClaudeResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"in_progress\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"pending\"}]}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 electronic records signatures code review requirements validation\"}\n[Tool: WebSearch] {\"query\":\"FDA Software Validation Guidance 2002 General Principles code review documentation requirements\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 Good Automated Manufacturing Practice code review validation requirements\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 medical device software lifecycle code review traceability requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation traceability matrix requirements documentation best practices\"}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 audit trail requirements code change control procedures\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 software categories risk-based validation approach code review\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 software safety classification code review testing verification\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"completed\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"in_progress\"}]}\n","numLines":32,"startLine":1,"totalLines":32}},"tool_use_id":"toolu_01WkGAR3Lw1ifWKf97VWTnUY"},"timestamp":1766707283903,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/a75e99f.output"},"tool_response":{"type":"text","file":{"filePath":"/tmp/claude/-home-chris/tasks/a75e99f.output","content":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"FDA Research\\\" \\\"Research\\\"\",\"description\":\"Notify workflow start for observability\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 observations software validation 2023 2024 2025\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letters software medical device code review 2020-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation failures cGMP pharmaceutical 2022 2023 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA 21 CFR Part 11 software audit findings common deficiencies\"}\n[Tool: WebSearch] {\"query\":\"\\\"FDA warning letter\\\" software validation case study 2023 2024 medical device\"}\n[Tool: WebSearch] {\"query\":\"FDA CAPA software deficiencies code review pharmaceutical 2022-2025\"}\n[Tool: WebSearch] {\"query\":\"FDA remediation requirements software validation response plan\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" CSV FDA warning letter examples 2020-2024\"}\n[Tool: WebSearch] {\"query\":\"FDA warning letter software audit trail data integrity 2023 2024 specific company examples\"}\n[Tool: WebSearch] {\"query\":\"\\\"design control\\\" software validation FDA 483 medical device 2024\"}\n[Tool: WebSearch] {\"query\":\"FDA clinical trial software CTMS validation 21 CFR Part 11 warning letters\"}\n","numLines":15,"startLine":1,"totalLines":15}},"tool_use_id":"toolu_01QtjLWnfGdvoe9VkDVoVGqw"},"timestamp":1766707283908,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Read","tool_input":{"file_path":"/tmp/claude/-home-chris/tasks/a7f2711.output"},"tool_response":{"type":"text","file":{"filePath":"/tmp/claude/-home-chris/tasks/a7f2711.output","content":"[Tool: WebSearch] {\"query\":\"adult learning principles technical compliance training regulatory topics 2025\"}\n[Tool: WebSearch] {\"query\":\"competency-based training assessment code review software validation\"}\n[Tool: WebSearch] {\"query\":\"pharmaceutical medical device software training GxP compliance 2025\"}\n[Tool: WebSearch] {\"query\":\"hands-on coding exercises technical training best practices\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"role-playing scenarios code review training peer review techniques\"}\n[Tool: WebSearch] {\"query\":\"training effectiveness evaluation Kirkpatrick model technical training assessment\"}\n[Tool: WebSearch] {\"query\":\"interactive learning techniques software engineering training scenario-based learning\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"code review training exercises real-world examples defect detection practice\"}\n[Tool: WebSearch] {\"query\":\"\\\"computer system validation\\\" training pharmaceutical FDA 21 CFR Part 11 CSV\"}\n[Tool: WebSearch] {\"query\":\"medical device software developer training IEC 62304 GAMP 5\"}\n","numLines":13,"startLine":1,"totalLines":13}},"tool_use_id":"toolu_01WsJPnutnF8f8RkkivhMpqS"},"timestamp":1766707283985,"timestamp_pst":"2025-12-25 16:01:23 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork"},"tool_response":{"query":"static analysis tools medical device software FDA qualification SonarQube Coverity Klocwork","results":[{"tool_use_id":"srvtoolu_01Emz7Akmb7oz5knVBADKX6V","content":[{"title":"Free Static Analysis Trial | Perforce Software","url":"https://www.perforce.com/products/sca/free-trial-static-code-analysis-medtech"},{"title":"Medical / Healthcare","url":"https://www.verifysoft.com/en_medical_healthcare.html"},{"title":"Which is a better static code analysis tool of C: Klocwork or Coverity? - Quora","url":"https://www.quora.com/Which-is-a-better-static-code-analysis-tool-of-C-Klocwork-or-Coverity"},{"title":"How do Coverity, Parasoft and Klocwork compare on their static analysis tools? - Quora","url":"https://www.quora.com/How-do-Coverity-Parasoft-and-Klocwork-compare-on-their-static-analysis-tools"},{"title":"A critical comparison on six static analysis tools: Detection, agreement, and precision - ScienceDirect","url":"https://www.sciencedirect.com/science/article/pii/S0164121222002515"},{"title":"FDA Guidance Sections Addressed by CodeSonar","url":"https://verifysoft.com/en_FDA_standards.html"},{"title":"List of tools for static code analysis - Wikipedia","url":"https://en.wikipedia.org/wiki/List_of_tools_for_static_code_analysis"},{"title":"FDA Recommends Static Analysis for Medical Devices","url":"https://codesecure.com/our-case-studies/fda-recommends-static-analysis-for-medical-devices/"},{"title":"c++ static analysis : klocwork versus coverity | AnandTech Forums: Technology, Hardware, Software, and Deals","url":"https://forums.anandtech.com/threads/c-static-analysis-klocwork-versus-coverity.2335580/"},{"title":"Cybersecurity in Medical Devices, Part 3: Static Code Analysis, A Method to Ensure Code Quality | Debiotech","url":"https://www.debiotech.com/cybersecurity-in-medical-devices-part-3-static-code-analysis-a-method-to-ensure-code-quality/"}]},"Based on my search, here's what I found about static analysis tools for medical device software FDA qualification, including SonarQube, Coverity, and Klocwork:\n\n## Static Analysis Tools for Medical Device Software and FDA Qualification\n\n### FDA Recommendations and Industry Standards\n\nThe FDA recommends static analysis to improve medical device software quality.(no content)Using an automated static analysis tool during the development of safety-critical medical device software can not only help assure the quality and reliability of the software, but also save time and money in compliance with industry standards.(no content)Currently, the FDA does not require third-party certification of source code for safety-critical software. The FDA requires only that manufacturers adhere to conventional development processes, and leaves validation and verification of software to the discretion of the manufacturer.\n\n### Key Standards for Medical Device Software\n\nThe IEC/ISO 62304 standard defines a risk and quality driven software development process for the development of medical devices. IEC/ISO 62304 indicates the need for rigorous testing, acceptance criteria, and traceability.(no content)Static analysis supports medical device security by enforcing coding standards and guidelines including IEC 62304 and CERT.\n\n### Tool-Specific Information\n\n**Klocwork:**\nFor more than 30 years, Perforce Helix QAC and Klocwork have been the most trusted static analysis tools for C and C++ programming languages.(no content)Perforce static code analyzers are pre-qualified for use in safety-critical applications. This makes it easier to gain certification for industry standards, such as ISO 26262 and IEC 62304.(no content)Some tools like Perforce Klocwork or Parasoft C/C++test also come with standard compliance certification for IEC 62304, which will exempt you from validating the tool and automatically generate the required documentation.(no content)Klocwork has more than 1000+ checkers to detect coding defects/issues.\n\n**Coverity vs. Klocwork Comparison:**\nKlocwork has a lot of false positives and sometimes way too many. Finding true defects in the pile is like sifting through a junkyard to find the right part. Coverity however has very few false positives. The analysis is very conservative and almost every defect is valid so it actually saves a lot of time for developers.(no content)On the other hand, Klocwork is much cheaper than Coverity.\n\n**SonarQube and Coverity Comparison (Research Study):**\nA scientific study proposed a large-scale comparison of six popular static analysis tools for Java projects: Better Code Hub, CheckStyle, Coverity Scan, FindBugs, PMD, and SonarQube.(no content)The key results show little to no agreement among the tools and a low degree of precision.\n\n### General Guidance\n\nSoftware testing tools including dynamic analysis, code coverage, and static analysis tools, are part of good software engineering practice and help medical device manufacturers achieve safe and reliable software.(no content)Being compliant with common bug classification types, like OWASP Top 10 or CWE Top 25 and coding guidelines like MISRA C is a real plus."],"durationSeconds":26.011685783000082},"tool_use_id":"toolu_01GdsJkn6pU7BfQtD2AVd5qm"},"timestamp":1766707288229,"timestamp_pst":"2025-12-25 16:01:28 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"medical device software code review checklist example items defect categories 2024 2025"},"tool_response":{"query":"medical device software code review checklist example items defect categories 2024 2025","results":[{"tool_use_id":"srvtoolu_01ALbvMcCBYi4SuHBhrTmtQw","content":[{"title":"Software Code Review Template Version: Draft","url":"https://s3.us-east-2.amazonaws.com/standards.devcare.com/Review+Templates/Code+Review+Template.pdf"},{"title":"General Principles of Software Validation - Final Guidance ...","url":"https://www.fda.gov/media/73141/download"},{"title":"An illustrated guide to medical device software development","url":"https://medicaldevicehq.com/articles/the-illustrated-guide-to-medical-device-software-development-and-iec-62304/"},{"title":"Meegle | Free Download Firmware Code Review Checklist Template","url":"https://www.meegle.com/en_us/advanced-templates/firmware_development/firmware_code_review_checklist_template"},{"title":"Your Ultimate Code Review Checklist: 8 Key Checks for 2025 - OneNine","url":"https://onenine.com/code-review-checklist/"},{"title":"IEC 62304 compliance - Code reviews as part of verification strategy","url":"https://elsmar.com/elsmarqualityforum/threads/iec-62304-compliance-code-reviews-as-part-of-verification-strategy.79515/"},{"title":"Checklist for MDSW MDR-compliant quality system | MDRC","url":"https://mdrc-services.com/qms-checklist-medical-software-mdr/"},{"title":"29 January 2024 Draft IMDRF/SaMD WG/N81 DRAFT: 2024 Medical Device Software:","url":"https://imdrf.org/sites/default/files/2024-02/IMDRFSaMD WGN81 DRAFT 2024, Medical Device Software Considerations for Device and Risk Characterization - final draft.pdf"},{"title":"Code Review Guidelines","url":"https://www.cs.uic.edu/~i442/SWCodeReviewGuidelines.doc"},{"title":"Software Verification For Medical Device Software (IEC ...","url":"https://openregulatory.com/articles/software-verification-medical-software-iec-62304"}]},"Based on my search, here's what I found regarding medical device software code review checklists, example items, and defect categories:\n\n## Medical Device Software Code Review Resources\n\n### Code Review Checklist Elements\n\nA software code review template for medical devices includes tracking code revision numbers and change history with dates. The name of each changed unit should be listed, and if a change is made to correct a defect, the number or ID of the defect corrected should be entered.(no content)The checklist addresses modules and units, requiring a high-level description explaining the module's purpose and the name/purpose of key data structures, variables, and sub-functions. Each unit needs a short description of its purpose written so that its role in fulfilling the original software requirements in the SRS can be understood.(no content)Additional checklist items include I/O description (inputs and outputs expected), verification that all defined and referenced calling sequence parameters agree, and confirmation that descriptive comments are accurate and informative.(no content)The process also requires that Lint must be run on the module or unit(s), and each warning or message produced should be inspected for any real issues.\n\n### FDA Guidance on Defect Prevention\n\nAccording to FDA guidance, software quality assurance needs to focus on preventing the introduction of defects into the software development process, not on trying to \"test quality into\" the software code after it is written. Software testing is very limited in its ability to surface all latent defects in software code.(no content)Software developers should use a mixture of methods and techniques to prevent software errors and detect errors that do occur. The \"best mix\" of methods depends on many factors including the development environment, application, size of project, language, and risk.(no content)A significant finding shows that 79% of software defects were caused by defects introduced when changes were made to the software after its initial production and distribution.\n\n### IEC 62304 Compliance & Verification Strategy\n\nFor Class C Medical devices as per IEC 62304, verification strategies consist of a combination of testing levels including code review and unit testing.(no content)Compliance with the IEC 62304 standard provides a systematic approach that can significantly minimize the probability of glitches causing harm to people, with the main focus being to help throughout the development process.(no content)The IEC 62304 standard does not prescribe a specific life cycle model. Users of the standard are responsible for selecting a life cycle model for the software project and for mapping the processes, activities, and tasks in the standard onto that model.\n\n### Firmware/Embedded Code Reviews in Medical Devices\n\nFor firmware in medical devices, QA engineers can use code review templates to ensure firmware complies with FDA regulations. Firmware development comes with unique challenges such as ensuring compatibility with hardware, managing limited resources, and adhering to strict industry standards, which a clear framework for code review can address.\n\n### Software Verification Context\n\nSoftware verification for medical device software under IEC 62304 is \"a discipline of software engineering whose goal is to assure that software fully satisfies all the expected requirements.\"\n\nWould you like me to search for more specific information about defect categories or particular aspects of medical device software code reviews?"],"durationSeconds":26.997230989000062},"tool_use_id":"toolu_01Y2LbZn21K8oLBD5UaiWaz1"},"timestamp":1766707289203,"timestamp_pst":"2025-12-25 16:01:29 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"ac6566d","block":true,"timeout":180000},"tool_use_id":"toolu_01RQtBvWkvRFGTNCF7d88xzX"},"timestamp":1766707290063,"timestamp_pst":"2025-12-25 16:01:30 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA warning letter 483 observation code review documentation deficiencies medical device"},"tool_response":{"query":"FDA warning letter 483 observation code review documentation deficiencies medical device","results":[{"tool_use_id":"srvtoolu_018V6rYe59JDEGiu9h6nAdqw","content":[{"title":"Understanding FDA 483s and Warning Letters | ClariMed Guide","url":"https://clarimed.com/resources/blog/a-guide-to-fda-483s-and-warning-letters"},{"title":"US FDA Form 483 and Warning Letter Analysis, Response, and Recovery | Emergo by UL","url":"https://www.emergobyul.com/services/us-fda-form-483-and-warning-letter-analysis-response-and-recovery"},{"title":"10 Steps to an Effective Medical Device FDA 483 Response | NSF","url":"https://www.nsf.org/knowledge-library/ten-steps-effective-medical-devices-fda-483-responses"},{"title":"FDA Form 483 Observations and FDA Warning Letters - Whatâ€™s the Difference?","url":"https://www.greenlight.guru/blog/fda-warning-letters-and-form-483-observations-whats-the-difference"},{"title":"Inspection Observations | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations"},{"title":"Most Common Reasons For FDA Form 483 Observations And Warning Letters In Medical Device Environments","url":"https://www.meddeviceonline.com/doc/most-common-reasons-for-fda-form-observations-and-warning-letters-in-medical-device-environments-0001"},{"title":"FDA 483 - FDA Warning letter","url":"https://www.fdahelp.us/fda-483-warning-letter.html"},{"title":"US FDA Form 483 Guidance + Warning Letter Consulting | Fang","url":"https://www.fangconsulting.com/fda-form-483/"},{"title":"FDA 483 warning letters - Regulatory & Quality Support","url":"https://patientguard.com/usa/483-warning-letters/"},{"title":"Vision28 Checklist for FDA FORM 483 responses Â» Vision28","url":"https://www.vision28.com/blog/visoin28-checklist-fda-form-483"}]},"Based on my search, here's a comprehensive overview of FDA 483 observations and warning letters related to documentation deficiencies in medical device manufacturing:\n\n## FDA Form 483 and Warning Letters Overview\n\n### What is FDA Form 483?\n\nThe FDA Form 483 is officially called a \"Notice of Inspectional Observations,\" commonly referred to simply as a \"483.\" The 483 is issued at the end of an on-site inspection if the FDA field investigator observed deficiencies in your quality system or conditions that violate the Food, Drug, or Cosmetic Act.(no content)During an inspection, OII investigators may observe conditions they deem to be objectionable. These observations are listed on an FDA Form 483 when, in an investigator's judgment, the observed conditions or practices indicate that an FDA-regulated product may be in violation of FDA's requirements.\n\n### Common Documentation Deficiencies\n\nMajor deficiencies relative to 21 CFR Part 820, the Quality System Regulation include (but are not limited to) absence of corrective and preventive action procedures (including procedures describing the analysis of quality data), absence of design control procedures (including design change control procedures, where required), failure to validate processes requiring validation, non-correction or inadequate correction of major deficiencies from previous inspections, and other quality system deficiencies such as deficiencies in both purchasing controls and acceptance activities.(no content)Common observations include: Inadequate or Insufficient Standard Operating Procedures, testing or quality control; Inadequate training of personnel to relevant procedures of quality control measures; Inadequate or insufficient investigation to correct deviations or complaints; Lack of or inadequate validation of processes or equipment; Failure to properly handle, store, or label materials; Failure to establish or maintain adequate records or logs; and Failure to follow established procedures or protocols.\n\n### FDA Inspection Context\n\nAs a part of the FDA regulation process, medical device manufacturers of Class II and Class III devices are subject to routine inspections of their facilities conducted by Consumer Safety Officers (CSOs) from the FDA's Office of Regulatory Affairs (ORA). These take place at least once every two years and at even higher frequencies for newer companies in order to evaluate compliance with applicable laws and regulations.\n\n### Response Requirements\n\nIf FDA receives a response to the FDA 483 observations within fifteen (15) business days, a \"detailed review\" of the response will be conducted prior to a decision to issue a Warning Letter.(no content)You must respond to the 483 or a Warning Letter promptly and identify your course of action to correct the findings within the FDA's specified timeframe. A detailed response to each observation or violation noted is also required. The quality and promptness of your response to this letter are extremely important.\n\n### Escalation to Warning Letters\n\nIf you receive a warning letter, you're required by law to make any changes necessary to satisfy the FDA's concerns. A warning letter is far more serious than a 483 observation. Any violations must be dealt with before you can meet compliance and bring your medical device to market.(no content)If you do not respond to the FDA Form 483, or your response shows you do not take FDA seriously, or if you respond inadequately, the next step is a Warning Letter. Warning Letters are public information available to your customers and your competitors.\n\n### Key Trends\n\nDesign control, design input documentation, and risk analysis violations prompted the most Form 483s and warning letters in 2021.(no content)Spreadsheets summarizing the areas of regulation cited on FDA's system-generated 483s are available by fiscal year. These spreadsheets represent the area of regulation and the number of times it was cited as an observation on a Form FDA 483 during inspections conducted by FDA and its representatives."],"durationSeconds":28.892785226000008},"tool_use_id":"toolu_012NGa57f1DUC8Mos9YVdRo6"},"timestamp":1766707291124,"timestamp_pst":"2025-12-25 16:01:31 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Gemini-Researcher completed comprehensive FDA code review research synthesis\",\"voice_id\":\"iLVmqjzCGGvqtMCk6vVQ\",\"voice_enabled\":true}'","description":"Notify research completion"},"tool_use_id":"toolu_019UfaKxFgvbV998ty9V3Bz1"},"timestamp":1766707297776,"timestamp_pst":"2025-12-25 16:01:37 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Gemini-Researcher completed comprehensive FDA code review research synthesis\",\"voice_id\":\"iLVmqjzCGGvqtMCk6vVQ\",\"voice_enabled\":true}'","description":"Notify research completion"},"tool_response":{"stdout":"{\"status\":\"success\",\"message\":\"Notification sent\"}\n  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n                                 Dload  Upload   Total   Spent    Left  Speed\n\r  0     0   0     0   0     0     0     0  --:--:-- --:--:-- --:--:--     0\r100   145   0     0 100   145     0   717  --:--:-- --:--:-- --:--:--   717\r100   145   0     0 100   145     0   120   0:00:01  0:00:01 --:--:--   120\r100   145   0     0 100   145     0    65   0:00:02  0:00:02 --:--:--    65\r100   145   0     0 100   145     0    45   0:00:03  0:00:03 --:--:--    45\r100   145   0     0 100   145     0    34   0:00:04  0:00:04 --:--:--    34\r100   145   0     0 100   145     0    27   0:00:05  0:00:05 --:--:--     0\r100   145   0     0 100   145     0    23   0:00:06  0:00:06 --:--:--     0\r100   195 100    50 100   145     7    21   0:00:07  0:00:06  0:00:01    11","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_019UfaKxFgvbV998ty9V3Bz1"},"timestamp":1766707305626,"timestamp_pst":"2025-12-25 16:01:45 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Claude-Researcher completed comprehensive FDA software validation audit findings research covering 2020-2025 with specific case studies, warning letter patterns, common 483 observations, and detailed remediation requirements across pharmaceutical cGMP, medical devices, and clinical trial systems\",\"voice_id\":\"2zRM7PkgwBPiau2jvVXc\",\"voice_enabled\":true}'","description":"Send voice notification of task completion"},"tool_use_id":"toolu_01UkSwHoL4UdurjeHRA9zM9f"},"timestamp":1766707412381,"timestamp_pst":"2025-12-25 16:03:32 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Researcher completed technical compliance training methodology research\",\"rate\":280,\"voice_enabled\":true}'","description":"Send voice notification of research completion"},"tool_use_id":"toolu_01WxW92B2U3SBpAPi88yu17n"},"timestamp":1766707432066,"timestamp_pst":"2025-12-25 16:03:52 PST"}
{"source_app":"gemini-researcher","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Researcher completed technical compliance training methodology research\",\"rate\":280,\"voice_enabled\":true}'","description":"Send voice notification of research completion"},"tool_response":{"stdout":"{\"status\":\"success\",\"message\":\"Notification sent\"}\n  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n                                 Dload  Upload   Total   Spent    Left  Speed\n\r  0     0   0     0   0     0     0     0  --:--:-- --:--:-- --:--:--     0\r100   117   0     0 100   117     0    97   0:00:01  0:00:01 --:--:--    97\r100   117   0     0 100   117     0    53   0:00:02  0:00:02 --:--:--    53\r100   117   0     0 100   117     0    36   0:00:03  0:00:03 --:--:--    36\r100   117   0     0 100   117     0    27   0:00:04  0:00:04 --:--:--    27\r100   117   0     0 100   117     0    22   0:00:05  0:00:05 --:--:--    22\r100   167 100    50 100   117     9    22   0:00:05  0:00:05 --:--:--    12","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_01WxW92B2U3SBpAPi88yu17n"},"timestamp":1766707438510,"timestamp_pst":"2025-12-25 16:03:58 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SubagentStop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"a7f2711","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-a7f2711.jsonl"},"timestamp":1766707441179,"timestamp_pst":"2025-12-25 16:04:01 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Claude-Researcher completed comprehensive FDA software validation audit findings research covering 2020-2025 with specific case studies, warning letter patterns, common 483 observations, and detailed remediation requirements across pharmaceutical cGMP, medical devices, and clinical trial systems\",\"voice_id\":\"2zRM7PkgwBPiau2jvVXc\",\"voice_enabled\":true}'","description":"Send voice notification of task completion"},"tool_response":{"stdout":"{\"status\":\"success\",\"message\":\"Notification sent\"}\n  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n                                 Dload  Upload   Total   Spent    Left  Speed\n\r  0     0   0     0   0     0     0     0  --:--:-- --:--:-- --:--:--     0\r100   365   0     0 100   365     0   303   0:00:01  0:00:01 --:--:--   303\r100   365   0     0 100   365     0   165   0:00:02  0:00:02 --:--:--   165\r100   365   0     0 100   365     0   113   0:00:03  0:00:03 --:--:--   113\r100   365   0     0 100   365     0    86   0:00:04  0:00:04 --:--:--    86\r100   365   0     0 100   365     0    70   0:00:05  0:00:05 --:--:--    70\r100   365   0     0 100   365     0    58   0:00:06  0:00:06 --:--:--     0\r100   365   0     0 100   365     0    50   0:00:07  0:00:07 --:--:--     0\r100   365   0     0 100   365     0    44   0:00:08  0:00:08 --:--:--     0\r100   365   0     0 100   365     0    39   0:00:09  0:00:09 --:--:--     0\r100   365   0     0 100   365     0    35   0:00:10  0:00:10 --:--:--     0\r100   365   0     0 100   365     0    32   0:00:11  0:00:11 --:--:--     0\r100   365   0     0 100   365     0    29   0:00:12  0:00:12 --:--:--     0\r100   365   0     0 100   365     0    27   0:00:13  0:00:13 --:--:--     0\r100   365   0     0 100   365     0    25   0:00:14  0:00:14 --:--:--     0\r100   365   0     0 100   365     0    23   0:00:15  0:00:15 --:--:--     0\r100   365   0     0 100   365     0    22   0:00:16  0:00:16 --:--:--     0\r100   365   0     0 100   365     0    21   0:00:17  0:00:17 --:--:--     0\r100   365   0     0 100   365     0    20   0:00:18  0:00:18 --:--:--     0\r100   365   0     0 100   365     0    18   0:00:20  0:00:19  0:00:01     0\r100   365   0     0 100   365     0    18   0:00:20  0:00:20 --:--:--     0\r100   365   0     0 100   365     0    17   0:00:21  0:00:21 --:--:--     0\r100   365   0     0 100   365     0    16   0:00:22  0:00:22 --:--:--     0\r100   365   0     0 100   365     0    15   0:00:24  0:00:23  0:00:01     0\r100   365   0     0 100   365     0    15   0:00:24  0:00:24 --:--:--     0\r100   365   0     0 100   365     0    14   0:00:26  0:00:25  0:00:01     0\r100   365   0     0 100   365     0    13   0:00:28  0:00:26  0:00:02     0\r100   365   0     0 100   365     0    13   0:00:28  0:00:27  0:00:01     0\r100   365   0     0 100   365     0    12   0:00:30  0:00:28  0:00:02     0\r100   415 100    50 100   365     1    12   0:00:50  0:00:28  0:00:22    11\r100   415 100    50 100   365     1    12   0:00:50  0:00:28  0:00:22    14","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_01UkSwHoL4UdurjeHRA9zM9f"},"timestamp":1766707442186,"timestamp_pst":"2025-12-25 16:04:02 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SubagentStop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"a75e99f","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-a75e99f.jsonl"},"timestamp":1766707469549,"timestamp_pst":"2025-12-25 16:04:29 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TaskOutput","tool_input":{"task_id":"ac6566d","block":true,"timeout":180000},"tool_response":{"retrieval_status":"timeout","task":{"task_id":"ac6566d","task_type":"local_agent","status":"running","description":"Research FDA 21 CFR Part 11","output":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"Multi-Source Research\\\" \\\"Research\\\"\",\"description\":\"Notify observability of workflow execution\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/\",\"description\":\"Check Research skill directory structure\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/workflows/\",\"description\":\"List available workflow files\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/PerplexityResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/ClaudeResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"in_progress\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"pending\"}]}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 electronic records signatures code review requirements validation\"}\n[Tool: WebSearch] {\"query\":\"FDA Software Validation Guidance 2002 General Principles code review documentation requirements\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 Good Automated Manufacturing Practice code review validation requirements\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 medical device software lifecycle code review traceability requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation traceability matrix requirements documentation best practices\"}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 audit trail requirements code change control procedures\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 software categories risk-based validation approach code review\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 software safety classification code review testing verification\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"completed\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"in_progress\"}]}\n","prompt":"Research FDA software validation requirements for code review, focusing on:\n\n1. **21 CFR Part 11** - Electronic records and signatures requirements\n2. **FDA Software Validation Guidance** - General Principles of Software Validation (2002)\n3. **GAMP 5** - Good Automated Manufacturing Practice guidelines\n4. **IEC 62304** - Medical device software lifecycle processes\n\nFor each, extract:\n- Key requirements that impact code review\n- Documentation requirements\n- Traceability requirements\n- Specific validation activities required\n\nProvide detailed, actionable findings that can be used to build a training curriculum. Include specific regulatory citations where possible.","result":"[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"CORE\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Skill] {\"skill\":\"Research\",\"args\":\"FDA software validation requirements for code review 21 CFR Part 11 electronic records signatures\"}\n[Tool: Bash] {\"command\":\"~/.claude/tools/SkillWorkflowNotification \\\"Multi-Source Research\\\" \\\"Research\\\"\",\"description\":\"Notify observability of workflow execution\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/conduct.md\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/\",\"description\":\"Check Research skill directory structure\"}\n[Tool: Bash] {\"command\":\"ls -la /home/chris/.claude/skills/Research/workflows/\",\"description\":\"List available workflow files\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/skills/Research/workflows/Conduct.md\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: Bash] {\"command\":\"ls /home/chris/.claude/agents/ | grep -i researcher\",\"description\":\"Discover available researcher agents\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Launch 9 parallel research agents (3 per type) for FDA validation research\",\"activeForm\":\"Launching 9 parallel research agents for FDA validation research\",\"status\":\"in_progress\"},{\"content\":\"Collect and synthesize research results from all agents\",\"activeForm\":\"Collecting and synthesizing research results from all agents\",\"status\":\"pending\"},{\"content\":\"Generate comprehensive training curriculum recommendations\",\"activeForm\":\"Generating comprehensive training curriculum recommendations\",\"status\":\"pending\"}]}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/PerplexityResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/ClaudeResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: Read] {\"file_path\":\"/home/chris/.claude/agents/GeminiResearcher.md\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"in_progress\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"pending\"}]}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 electronic records signatures code review requirements validation\"}\n[Tool: WebSearch] {\"query\":\"FDA Software Validation Guidance 2002 General Principles code review documentation requirements\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 Good Automated Manufacturing Practice code review validation requirements\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 medical device software lifecycle code review traceability requirements\"}\n[Tool: WebSearch] {\"query\":\"FDA software validation traceability matrix requirements documentation best practices\"}\n[Tool: WebSearch] {\"query\":\"21 CFR Part 11 audit trail requirements code change control procedures\"}\n[Tool: WebSearch] {\"query\":\"GAMP 5 software categories risk-based validation approach code review\"}\n[Tool: WebSearch] {\"query\":\"IEC 62304 software safety classification code review testing verification\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: WebSearch] {\"query\":\"FDA 483 warning letters software validation code review deficiencies common findings\"}\n[Tool: TodoWrite] {\"todos\":[{\"content\":\"Execute parallel web searches on FDA validation requirements\",\"activeForm\":\"Executing parallel web searches on FDA validation requirements\",\"status\":\"completed\"},{\"content\":\"Synthesize research findings into actionable curriculum\",\"activeForm\":\"Synthesizing research findings into actionable curriculum\",\"status\":\"in_progress\"}]}\n"}},"tool_use_id":"toolu_01RQtBvWkvRFGTNCF7d88xzX"},"timestamp":1766707470330,"timestamp_pst":"2025-12-25 16:04:30 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 code review requirements medical device software lifecycle"},"tool_use_id":"toolu_018RxG4GVvxWsXyimHZisdQz"},"timestamp":1766707478370,"timestamp_pst":"2025-12-25 16:04:38 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 21 CFR Part 11 software validation code review requirements 2024 2025"},"tool_use_id":"toolu_01DFYV4JUfvT9F3y9DjoxFu3"},"timestamp":1766707478354,"timestamp_pst":"2025-12-25 16:04:38 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 code review validation pharmaceutical software best practices"},"tool_use_id":"toolu_01Y6pRWrG8FdWX6vV3fMmFED"},"timestamp":1766707478361,"timestamp_pst":"2025-12-25 16:04:38 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"completed","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01M62XLHiy8PtuZy7ARCNX5e"},"timestamp":1766707502592,"timestamp_pst":"2025-12-25 16:05:02 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"completed","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_response":{"oldTodos":[],"newTodos":[{"content":"Execute parallel web searches on FDA validation requirements","status":"completed","activeForm":"Executing parallel web searches on FDA validation requirements"},{"content":"Synthesize research findings into actionable curriculum","status":"completed","activeForm":"Synthesizing research findings into actionable curriculum"}]},"tool_use_id":"toolu_01M62XLHiy8PtuZy7ARCNX5e"},"timestamp":1766707502819,"timestamp_pst":"2025-12-25 16:05:02 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Perplexity-Researcher completed comprehensive FDA software validation code review research with detailed training curriculum recommendations\",\"voice_id\":\"AXdMgz6evoL7OPd7eU12\",\"voice_enabled\":true}'","description":"Send voice notification of research completion"},"tool_use_id":"toolu_011MudwHHhNzFKk6rwgkBfVF"},"timestamp":1766707502966,"timestamp_pst":"2025-12-25 16:05:02 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 21 CFR Part 11 software validation code review requirements 2024 2025"},"tool_response":{"query":"FDA 21 CFR Part 11 software validation code review requirements 2024 2025","results":[{"tool_use_id":"srvtoolu_01T9UZ4t9VzhurRu8EKYLqQA","content":[{"title":"What is FDA 21 CFR Part 11? Compliance & Software Validation Guide â€“ Redzone","url":"https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/"},{"title":"FDA Title 21 CFR Part 11: A Practical Guide for Labs | QBench Cloud-Based LIMS","url":"https://qbench.com/blog/title-21-part-11-what-is-it"},{"title":"Overview of 21 CFR Part 11 Validation | ResearchGo | UCLA","url":"https://www.researchgo.ucla.edu/21-CFR-part-11"},{"title":"FDA 21 CFR Part 11: Definition, Compliance Requirements, Benefits, and Software","url":"https://simplerqms.com/21-cfr-part-11-requirements/"},{"title":"FDA 21 CFR Part 11 Compliance and Checklist","url":"https://www.mastercontrol.com/compliance/21-cfr-regulations/21-cfr-part-11/compliance/"},{"title":"FDA 21 CFR Part 11 QMS Software","url":"https://qt9software.com/21-cfr-part-11"},{"title":"21 CFR Part 11: What Sites and Sponsors Need to Know | CRIO","url":"https://clinicalresearch.io/blog/21-cfr-part-11-regulation-compliance-update/"},{"title":"Food and Drug Administration CFR Title 21 Part 11 - Microsoft Compliance | Microsoft Learn","url":"https://learn.microsoft.com/en-us/compliance/regulatory/offering-fda-cfr-title-21-part-11"},{"title":"Understanding 21 CFR Part 11: FDA's Electronic Records Guide","url":"https://www.certinal.com/blog/understanding-21-cfr-part-11"},{"title":"What is 21 CFR Part 11? FDA requirements explained","url":"https://www.cognidox.com/blog/what-is-fda-21-cfr-part-11"}]},"Based on the search results, here's what I found about FDA 21 CFR Part 11 software validation requirements for 2024-2025:\n\n## Key Software Validation Requirements\n\nAs per 21 CFR Part 11.10(a), the system must be in a validated state to ensure that it is accurate, reliable, performs as intended, and can identify invalid or altered records.(no content)System validation requires proving your software performs consistently under the specific conditions of your lab. This isn't just \"documenting that it works.\"\n\n### Core Validation Components\n\nSystem validation is fundamental to compliance, ensuring that all electronic or computer systems perform as intended. Key steps include: Documented Testing (recording all system specifications, tests, and outcomes to verify performance under various conditions), Operational Checks (regularly testing the system for errors and vulnerabilities), and Change Control (ensuring updates or modifications to the system do not compromise compliance).\n\n### 2024 FDA Guidance Updates\n\nThe Food and Drug Administration recently issued updated guidance on the use of electronic systems in clinical investigations in 2024. This guidance clarifies compliance expectations for emerging tools like wearable devices, mobile apps, and cloud-based platforms.(no content)All electronic systems used in clinical investigations must be validated to ensure accuracy, reliability, and consistent performance. The FDA emphasizes risk-based validation approaches tailored to the system's criticality.\n\n### Validation Approaches\n\nFor years, Computer System Validation (CSV) was a mainstay for how labs validated their software and computer systems. CSV required a documented process of ensuring that computerized systems perform as intended in a consistent and reproducible manner. Computer Software Assurance (CSA) is a more modern, risk-based approach to validating computerized systems that focuses on critical thinking and patient safety rather than extensive documentation.\n\n### Sponsor Requirements for Code Review\n\nSponsors should review the vendor's SOPs and that includes the system and software development life cycle model, validation documentation, change control procedures and change control tracking logs.(no content)In addition, sponsors should perform user acceptance testing (UAT) and document the criteria for and results of testing to ensure that the electronic system fulfills its intended purpose.\n\n### 2024 Enforcement Context\n\nIn 2024, the FDA's Center for Devices and Radiological Health (CDRH) issued 529 warning letters, with 8% (44) directed at medical device manufacturers for issues including design validation failures and data integrity concerns.(no content)The 2024 State of Validation Report shows that 61% of organizations experienced an increase in validation workload over the past year, and nearly half (47%) plan to increase validation budgets in the coming year."],"durationSeconds":25.89301660099998},"tool_use_id":"toolu_01DFYV4JUfvT9F3y9DjoxFu3"},"timestamp":1766707504529,"timestamp_pst":"2025-12-25 16:05:04 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"IEC 62304 code review requirements medical device software lifecycle"},"tool_response":{"query":"IEC 62304 code review requirements medical device software lifecycle","results":[{"tool_use_id":"srvtoolu_014bFv422BqPMVHZSb96iVSi","content":[{"title":"IEC 62304:2006 - Medical device software â€” Software life cycle processes","url":"https://www.iso.org/standard/38421.html"},{"title":"IEC 62304 - Wikipedia","url":"https://en.wikipedia.org/wiki/IEC_62304"},{"title":"IEC/EN 62304 Medical Device - Software Life Cycle Processes â†’ Testing and Anaylsis","url":"https://www.verifysoft.com/en_IEC_62304.html"},{"title":"IEC 62304:2015 | Medical Device Software","url":"https://www.complianceonline.com/iec-62304-2015-medical-device-software-software-life-cycle-processes-standards-10361-prdp"},{"title":"An In-Depth Guide to IEC 62304: Software Lifecycle Processes for Medical Devices","url":"https://www.jamasoftware.com/blog/an-in-depth-guide-to-iec-62304-software-lifecycle-processes-for-medical-devices/"},{"title":"IEC 62304 compliance - What are the requirements for Medical Device Software? â€¢ Tuleap","url":"https://www.tuleap.org/software-quality/iec62304-requirements-medical-device-software-standard"},{"title":"Understanding IEC/ISO 62304 and FDA Requirements for Medical Device Software Development Life Cycle (SDLC) Management â€“ Oriel STAT A MATRIX â€“ ELIQUENT Life Sciences Blog","url":"https://www.orielstat.com/blog/medical-device-sdlc/"},{"title":"An illustrated guide to medical device software development","url":"https://medicaldevicehq.com/articles/the-illustrated-guide-to-medical-device-software-development-and-iec-62304/"},{"title":"Recognized Consensus Standards: Medical Devices","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=38829"},{"title":"What are the IEC 62304 Safety Classifications?","url":"https://www.greenlight.guru/glossary/iec-62304"}]},"Here are the search results for IEC 62304 code review requirements for medical device software lifecycle:\n\n## Overview of IEC 62304\n\nIEC 62304 â€“ medical device software â€“ software life cycle processes is an international standard published by the International Electrotechnical Commission (IEC). The standard specifies life cycle requirements for the development of medical software and software within medical devices.(no content)It defines the life cycle requirements for medical device software. The set of processes, activities, and tasks described in this standard establishes a common framework for medical device software life cycle processes.\n\n## Safety Classifications\n\nBased on the potential to create a hazard that could result in an injury, the manufacturer has to assign a safety class to the software system as a whole: Safety Class A: No injury or damage to health is possible. Safety Class B: Non serious injury is possible. Safety Class C: Death or serious injury is possible.(no content)These classes help determine the level of rigor required in the software development process.\n\n## Development Process Structure\n\nThe standard outlines processes that span the entire software lifecycle, including planning, requirements analysis, design, implementation, verification, validation, and maintenance.(no content)IEC 62304 for medical device software development delineates components into five clauses, numbered 5 through 9. Clause 5: Outlines the software development process from planning to release. Clause 6: Describes required maintenance of released software. Clause 7: Specifies risk management required from assessing failures to identifying potential risks and implementing features to prevent them.\n\n## Verification and Code Review\n\nThe IEC 62304 standard does not clearly make verification activities and specific tests processes mandatory.(no content)Verification of software units can be done whether through unit, integration and system tests or through peer reviews.(no content)IEC 62304 does not require a specific software life cycle and does not prescribe how you should meet requirements. While it does specify what you should document, IEC 62304 does not tell you where it should go.\n\n## Documentation Requirements\n\nMedical device software developers are often confused about the requirements relating to documentation. IEC 62304 requires documentation, but it doesn't prescribe a specific format. You can decide on how you want to create documentation and records that provide evidence of activities being carried out.(no content)This checklist was prepared by analyzing each clause in IEC 62304 for key words that signify a required policy, procedure, plan, record, document, audit, or review. This revised standard has over 160 required artifacts and over 180 suggested ones.\n\n## Additional Considerations\n\nThe IEC 62304 standard calls out certain cautions on using software, particularly SOUP (software of unknown pedigree or provenance). The standard spells out a risk-based decision model on when the use of SOUP is acceptable, and defines testing requirements for SOUP to support a rationale on why such software should be used.(no content)If you want to use Agile methodologies, you can do so and meet the requirements of IEC 62304 as long as you can justify your chosen technique and correctly fulfil the standard's requirements."],"durationSeconds":28.118736349999903},"tool_use_id":"toolu_018RxG4GVvxWsXyimHZisdQz"},"timestamp":1766707506682,"timestamp_pst":"2025-12-25 16:05:06 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"GAMP 5 code review validation pharmaceutical software best practices"},"tool_response":{"query":"GAMP 5 code review validation pharmaceutical software best practices","results":[{"tool_use_id":"srvtoolu_01152k6pU4tpHA5cg8rzQN8D","content":[{"title":"GAMP 5 Guide 2nd Edition | ISPE | International Society for Pharmaceutical Engineering","url":"https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition"},{"title":"What is GAMP 5 Guideline? Checklist for GAMP 5 compliance - Zamann Pharma Support GmbH","url":"https://zamann-pharma.com/2024/04/08/what-is-gamp-5-guideline-checklist-for-gamp-5-compliance/"},{"title":"GAMP5 simply explained I Definition & key principles","url":"https://www.yaveon.com/en/insights/article-gamp5/"},{"title":"GAMP 5 Categories Explained: Software, Risk & Examples | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-categories-explained"},{"title":"Compliance with GAMP 5 guidance: A checklist - Tricentis","url":"https://www.tricentis.com/learn/compliance-with-gamp-5-guidance-a-checklist"},{"title":"What You Need to Know About GAMPÂ® 5 Guide, 2nd Edition | Pharmaceutical Engineering","url":"https://ispe.org/pharmaceutical-engineering/january-february-2023/what-you-need-know-about-gampr-5-guide-2nd-edition"},{"title":"Understanding GAMP 5 Guidelines for System Validation | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-guidelines-system-validation"},{"title":"GAMPÂ® 5 Guide: Categories, Requirements, and Validation | PTC","url":"https://www.ptc.com/en/blogs/alm/gamp-5-guide-categories-requirements-and-validation"},{"title":"GAMP 5 Guide for GxP Compliant Computerized Systems + free CSV handbook | Scilife","url":"https://www.scilife.io/blog/gamp5-for-gxp-compliant-computerized-systems"},{"title":"GAMP 5: Computerized System Validation in Pharma | IntuitionLabs","url":"https://intuitionlabs.ai/articles/gamp-5-computerized-system-validation-pharma"}]},"Here's a summary of the search results for GAMP 5 code review validation and pharmaceutical software best practices:\n\n## GAMP 5 Overview\n\nGAMP aims to deliver a cost-effective framework of good practice to ensure that computerized systems are effective and of high quality, fit for intended use, and compliant with applicable regulations.(no content)Good Automated Manufacturing Practice (GAMP) 5 is a globally recognized guideline for validating computerized systems in regulated industries, especially pharmaceuticals and biotechnology. Published by the International Society for Pharmaceutical Engineering (ISPE) in 2008 (with a second edition in 2022), GAMP 5 introduced a risk-based approach to prioritize validation efforts.\n\n## Key Principles and Best Practices\n\n**Risk-Based Approach:**\nNot every system carries the same level of risk. The risk-based approach ensures that validation efforts under GAMP5 focus on the most critical areas.(no content)Research articles emphasize that risk-based CSV (the GAMP approach) dramatically reduces unnecessary work. One systematic survey concluded that applying risk-based reduction can lower validation effort by 30â€“50% without compromising quality.\n\n**Documentation and Traceability:**\nCreate a traceability matrix that maps user requirements to functional specifications, test cases, and test results. This ensures that all user requirements are addressed and validated, providing a clear audit trail from requirements through to system implementation.\n\n**Change Control:**\nEstablish a robust change control process to manage any modifications to the system, ensuring that changes do not adversely affect system compliance or integrity. Configuration management practices should be in place to maintain documentation of all system configurations and customizations.\n\n## Testing and Code Review Practices\n\nTesting by any means and in any part of the life cycle and in any environment (development, validation, production, DevOps, etc.) all contributes to finding defects and confirming the system is fit for intended use. Testing should not be limited to detailed and prescriptive step-by-step scripted protocolsâ€”the use of exploratory testing and other unscripted techniques is encouraged to extend test coverage and improve defect detection.(no content)The 2nd Edition further emphasizes that the GAMPÂ® life cycle, specification, and verification approach is not inherently linear, and that it also fully supports iterative and incremental (Agile) methods.\n\n## Software Categories\n\nCategories reflect increasing complexity and risk: from general, off-the-shelf \"infrastructure\" software up to fully custom applications. Operating systems, databases, and office tools (Category 1) are treated with minimal validation, whereas bespoke, in-house developed software (Category 5) requires rigorous control.(no content)GAMP 5 emphasizes maximum risk mitigation for Category 5: track all requirements, perform thorough testing, and apply strict change control. In practice, organizations often allocate 50â€“100% more effort for Cat 5 validation versus a COTS project of similar scope.\n\n## GAMP 5 Second Edition Updates\n\nThe objective of GAMP 5 version 2 (2022) was to update the guidance in accordance with the latest technological upgrades, aligning with the new FDA guidance \"Computer Software Assurance for Production and Quality System Software\" (September 2022). The GAMP 5 second edition focuses more on patient safety, product quality, and data integrity. It offers updated guidance on cybersecurity, data integrity, and cloud computing, while also addressing agile development and risk-based validation.(no content)The Appendices have been expanded to incorporate new and evolving topics in the life sciences industry such as blockchain, Artificial Intelligence/Machine Learning (AI/ML), cloud computing, and Open-Source Software (OSS).\n\n## Regulatory Compliance\n\nThe FDA's 21 CFR Part 11 (Electronic Records and Signatures) and Part 210/211 mandate that electronic systems be validated and secure. Similarly, EU GMP Annex 11 sets rules for computerised systems in pharmaceutical manufacturing. GAMP 5 provides practical guidance on how to meet these regulations through a structured, risk-based process."],"durationSeconds":33.473626309999965},"tool_use_id":"toolu_01Y6pRWrG8FdWX6vV3fMmFED"},"timestamp":1766707512130,"timestamp_pst":"2025-12-25 16:05:12 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Bash","tool_input":{"command":"curl -X POST http://localhost:8888/notify -H \"Content-Type: application/json\" -d '{\"message\":\"Perplexity-Researcher completed comprehensive FDA software validation code review research with detailed training curriculum recommendations\",\"voice_id\":\"AXdMgz6evoL7OPd7eU12\",\"voice_enabled\":true}'","description":"Send voice notification of research completion"},"tool_response":{"stdout":"{\"status\":\"success\",\"message\":\"Notification sent\"}\n  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current\n                                 Dload  Upload   Total   Spent    Left  Speed\n\r  0     0   0     0   0     0     0     0  --:--:-- --:--:-- --:--:--     0\r100   209   0     0 100   209     0   174   0:00:01  0:00:01 --:--:--   174\r100   209   0     0 100   209     0    94   0:00:02  0:00:02 --:--:--    94\r100   209   0     0 100   209     0    65   0:00:03  0:00:03 --:--:--    65\r100   209   0     0 100   209     0    49   0:00:04  0:00:04 --:--:--    49\r100   209   0     0 100   209     0    40   0:00:05  0:00:05 --:--:--    40\r100   209   0     0 100   209     0    33   0:00:06  0:00:06 --:--:--     0\r100   209   0     0 100   209     0    28   0:00:07  0:00:07 --:--:--     0\r100   209   0     0 100   209     0    25   0:00:08  0:00:08 --:--:--     0\r100   209   0     0 100   209     0    22   0:00:09  0:00:09 --:--:--     0\r100   209   0     0 100   209     0    20   0:00:10  0:00:10 --:--:--     0\r100   259 100    50 100   209     4    18   0:00:12  0:00:11  0:00:01    10\r100   259 100    50 100   209     4    18   0:00:12  0:00:11  0:00:01    12","stderr":"","interrupted":false,"isImage":false},"tool_use_id":"toolu_011MudwHHhNzFKk6rwgkBfVF"},"timestamp":1766707515491,"timestamp_pst":"2025-12-25 16:05:15 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SubagentStop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"ac6566d","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-ac6566d.jsonl"},"timestamp":1766707518318,"timestamp_pst":"2025-12-25 16:05:18 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"in_progress","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01FU4V5QvTtcrCd7EsvMAaE6"},"timestamp":1766707521471,"timestamp_pst":"2025-12-25 16:05:21 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"in_progress","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"in_progress","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"pending","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"in_progress","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01FU4V5QvTtcrCd7EsvMAaE6"},"timestamp":1766707521686,"timestamp_pst":"2025-12-25 16:05:21 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 warning letters software validation code review deficiencies 2023 2024 case studies"},"tool_use_id":"toolu_01DTUdhiJH4gQLiooyP6BXkf"},"timestamp":1766707521817,"timestamp_pst":"2025-12-25 16:05:21 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"Fagan inspection code review FDA regulated software formal peer review methodology"},"tool_use_id":"toolu_01M8mPTpWaiKpPfHUpgHmS6f"},"timestamp":1766707521877,"timestamp_pst":"2025-12-25 16:05:21 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SubagentStop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"aaa3a33","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-aaa3a33.jsonl"},"timestamp":1766707524339,"timestamp_pst":"2025-12-25 16:05:24 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"Fagan inspection code review FDA regulated software formal peer review methodology"},"tool_response":{"query":"Fagan inspection code review FDA regulated software formal peer review methodology","results":[{"tool_use_id":"srvtoolu_016D28DWA6GEAP8kwG9WrLPV","content":[{"title":"Fagan inspection - Wikipedia","url":"https://en.wikipedia.org/wiki/Fagan_inspection"},{"title":"Fagan Inspection | Innovation.world","url":"https://innovation.world/methodologies/fagan-inspection/"},{"title":"Four Ways to a Practical Code Review","url":"https://www.methodsandtools.com/archive/archive.php?id=66"},{"title":"Fagan inspection","url":"https://en-academic.com/dic.nsf/enwiki/590590"},{"title":"Fagan Inspection Methodology","url":"https://en.tigosolutions.com/differences-between-software-walkthrough-review-and-inspection-5706"},{"title":"Fagan Inspection |Professionalqa.com","url":"https://www.professionalqa.com/fagan-inspection"},{"title":"SOFTWARE FORMAL INSPECTIONS GUIDEBOOK","url":"http://ix.cs.uoregon.edu/~michal/Classes/W98/Readings/FTR/NASA-fi.pdf"},{"title":"Stupid Question 104: What is a 'Fagan Inspection'?","url":"https://www.irisclasson.com/2012/12/14/stupid-question-104-what-is-a-fagan-inspection/"},{"title":"Lecture 6: Formal Inspections","url":"https://www.cs.toronto.edu/~sme/CSC340F/2005/slides/06-inspections.pdf"},{"title":"Fagan Inspection Methodology - Software Engineering Tutorials, .NET, Microservices, UML, System Design","url":"https://master2teach.com/fagan-inspection/"}]},"Based on the search results, here's what I found about Fagan inspection as a formal peer review methodology for code review:\n\n## What is Fagan Inspection?\n\nA Fagan inspection is a process of trying to find defects in documents (such as source code or formal specifications) during various phases of the software development process. It is named after Michael Fagan, who is credited with the invention of formal software inspections.(no content)The Fagan Inspection Methodology is a structured approach used in software engineering for peer review of software artifacts, primarily focusing on code inspection. It was developed by Michael Fagan in the late 1970s and has been widely adopted in various software development methodologies.\n\n## Key Stages of the Process\n\nThe stages in the inspections process are: Planning, Overview meeting, Preparation, Inspection meeting, Rework and Follow-up. The Preparation, Inspection meeting and Rework stages might be iterated.(no content)Each inspector examines the work product to identify possible defects. During the inspection meeting the reader reads through the work product, part by part and the inspectors point out the defects for every part. Rework involves the author making changes according to the action plans from the inspection meeting. Follow-up ensures the changes are checked to make sure everything is correct.\n\n## Entry and Exit Criteria\n\nEntry criteria are the criteria or requirements which must be met to enter a specific process. For Fagan inspections the high- and low-level documents must comply with specific entry criteria before they can be used for a formal inspection process. Exit criteria are the criteria or requirements which must be met to complete a specific process.\n\n## Relevance to Regulated Industries (FDA/Pharmaceuticals)\n\nIn environments emphasizing due diligence and compliance, such as finance or pharmaceuticals, the robust nature of this methodology assures stakeholders that products will meet necessary standards before they reach the market.(no content)Inspections help ensure that software artifacts adhere to organizational standards, coding guidelines, and industry best practices. This is particularly important in regulated industries where compliance with standards and regulations is mandatory.(no content)This formal process is very expensive, so unless you're creating safety(life)-critical or mission critical software, the chances that you'll find room in your budget for it is probably limited. That said, peer reviewing of code is a good thing, and you can find techniques and inspirations in processes like this.\n\n## Effectiveness and Considerations\n\nSince introducing the inspection process in 1974, IBM achieved significant improvements in quality. The company nearly doubled the number of lines of code shipped for System/370 software products since 1976, while the number of defects per thousand lines of code was reduced by two-thirds.(no content)Studies show that the average inspection takes 9 man-hours per 200 lines of code, which makes it a heavyweight process that may be impractical for reviewing all code in large projects.\n\nInspections are carried out by peers of the author. Formal inspections are in-process peer reviews conducted within the phase of the life cycle in which the product is developed."],"durationSeconds":26.61492438099999},"tool_use_id":"toolu_01M8mPTpWaiKpPfHUpgHmS6f"},"timestamp":1766707548736,"timestamp_pst":"2025-12-25 16:05:48 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"FDA 483 warning letters software validation code review deficiencies 2023 2024 case studies"},"tool_response":{"query":"FDA 483 warning letters software validation code review deficiencies 2023 2024 case studies","results":[{"tool_use_id":"srvtoolu_01CAzQzDvBMuWkX3vvK8TSPC","content":[{"title":"Current FDA 483s and Warning Letters Trends in Pharmaceutical, Biotechnology, and Medical Device Industries - VTI Life Sciences","url":"https://validation.org/current-fda-483s-and-warning-letters-trends-in-pharmaceutical-biotechnology-and-medical-device-industries/"},{"title":"2023 FDA Warning Letters and Software Validation - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation"},{"title":"Warning Letters | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters"},{"title":"US FDA Form 483 and Warning Letter Analysis, Response, and Recovery | Emergo by UL","url":"https://www.emergobyul.com/services/us-fda-form-483-and-warning-letter-analysis-response-and-recovery"},{"title":"The Definitive Guide to Responding to FDA 483 Observations and Warning Letters","url":"https://www.greenlight.guru/blog/fda-483-warning-letters"},{"title":"Inspection Observations | FDA","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations"},{"title":"FDA 483s due to Deficiencies in the Stability Program: Evaluation of Fiscal Year 2024 - ECA Academy","url":"https://www.gmp-compliance.org/gmp-news/fda-483s-due-to-deficiencies-in-the-stability-program-evaluation-of-fiscal-year-2024"},{"title":"FDA 483 Warning Letters - Compliance - MasterControl","url":"https://www.mastercontrol.com/compliance/fda/483/"},{"title":"US FDA Form 483 & Warning Letters","url":"https://www.fangconsulting.com/fda-form-483/"},{"title":"Managing and Responding to US Food and Drug Administration (FDA) 483s, Warning Letters, and Consent Decrees: An FDA Consultantâ€™s Perspective - VTI Life Sciences","url":"https://validation.org/managing-and-responding-to-us-food-and-drug-administration-fda-483s-warning-letters-and-consent-decrees-an-fda-consultants-perspective/"}]},{"tool_use_id":"srvtoolu_01W9W1Xp9S68TfGGpGdnC5CM","content":[{"title":"General Principles of Software Validation - Final Guidance ...","url":"https://www.fda.gov/media/73141/download"},{"title":"2023 FDA Warning Letters and Software Validation - Ketryx Compliance Framework","url":"https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation"},{"title":"FDA Software Validation Process: Steps, Principles & More","url":"https://amplelogic.com/fda-software-validation-process"},{"title":"Software Verification & Validation - Medical Device Training","url":"https://www.fdaconsulting.com/medical-device-software-verification-validation-training.phtml"},{"title":"Federal Register :: Medical Devices: General Principles of Software Validation; Final Guidance for Industry and FDA Staff; Availability","url":"https://www.federalregister.gov/documents/2002/01/11/02-690/medical-devices-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff"},{"title":"FDA Guidance on Medical Device Design Control","url":"https://www.regdesk.co/blog/fda-guidance-on-design-validation/"},{"title":"Software Verification and Validation Requirements for Medical Device and Their Implementation Strategies","url":"https://www.complianceonline.com/resources/software-verification-and-validation-requirements-for-medical-device-and-implementation-strategies.html"},{"title":"FDA Software Validation: A Helpfull Guide to 2025","url":"https://www.compliancequest.com/blog/understanding-fda-software-validation/"},{"title":"Medical Device Software Validation: What to Know","url":"https://www.greenlight.guru/blog/software-validation"},{"title":"FDA Computer System & Software Validation - What Youâ€™ve Known For 20+ Years Is Changing","url":"https://www.greenlight.guru/blog/fda-computer-system-software-validation"}]},"Based on the search results, here's what I found regarding FDA 483 warning letters related to software validation and code review deficiencies in 2023-2024:\n\n## FDA Software Validation Deficiencies & Warning Letters (2023-2024)\n\n### Key Trends and Focus Areas\n\nWhile these letters represent an increased focus on software by FDA, these four deficiency areas aren't new. Challenges with marketing language, process deviation, and software validation for product and non-product software have always been common challenges the industry faces. The FDA is demonstrating its commitment to keeping pace with technological advancements in the healthcare industry.\n\n### Notable 2023 Case Studies\n\nThe FDA is now auditing and issuing warning letters to small companies. Recent letters sent to Vitang (4 people) and ZYTO (56 people) underscore the FDA's growing scrutiny on the proliferation of medical device startups and their software validation processes.(no content)In the case of Zyto, the company failed to validate and provide objective evidence that its device works as intended. Both letters show the increased focus of the agency on software validation at both large and small companies.(no content)The FDA noted that iRhythm is marketing its system for \"unapproved indications,\" which would require a new 510(k) submission. The FDA writes that the iRhythm device was cleared for \"long-term monitoring of arrhythmia events for non-critical care patients,\" yet marketing materials talk about \"real-time monitoring\" and imply that the product is intended for \"high-risk patients.\"\n\n### Four Common Deficiency Categories\n\nFDA warning letters focus on four common concerns:\n- **Product Software validation** â€“ Not validating or verifying medical device software properly\n- **Non-software product validation** â€“ Not validating or verifying infrastructure software (GxP software) used in manufacturing and quality processes\n- **Procedure coverage and deviation** â€“ Not having procedures required by FDA 21 CFR Part 820 or Part 11 quality regulations\n- **Modified marketing statements** â€“ Ensuring device marketing statements do not differ from what the device is approved to do\n\n### AI-Enabled Device Validation Concerns\n\nBy August 2024, the FDA listed 903 AI-enabled medical devices; 43 (4.8%) had been recalled, with a median recall lag of 1.2 years.\n\n### Top FDA 483/Warning Letter Issues\n\nCommon issues include:\n- Inadequate investigations of product defects and complaints\n- Failure to validate processes â€“ a key element of GMP compliance\n- Deficient record-keeping â€“ missing or incomplete records for critical activities\n- Improper training â€“ employees not receiving adequate training on new technologies or processes\n\n### Regulatory Requirements\n\nAccording to FDA 21 CFR Part 820.70(i), any software used to automate any part of the device production process or any part of the quality system must be validated for its intended use.(no content)Validation requirements apply to software used as components in medical devices, to software that is itself a medical device, and to software used in production of the device. This requirement includes the completion of current development projects, all new development projects, and all changes made to existing medical device software. Specific requirements for validation of device software are found in 21 CFR Â§820.30(g).\n\n### FDA Resources\n\nSpreadsheets summarizing the areas of regulation cited on FDA's system-generated 483s are available by fiscal year. These spreadsheets represent the area of regulation and the number of times it was cited as an observation on a Form FDA 483 during inspections conducted by FDA and its representatives.(no content)FY 2025, FY 2024, FY 2023, and earlier data files are available on the FDA's Inspection Observations page.\n\nThe FDA's official Warning Letters page (fda.gov) and the ORA Electronic Reading Room contain examples of recently issued 483s for those seeking specific case documentation."],"durationSeconds":42.54688166800002},"tool_use_id":"toolu_01DTUdhiJH4gQLiooyP6BXkf"},"timestamp":1766707564618,"timestamp_pst":"2025-12-25 16:06:04 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"in_progress","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01LPhmCPNMX4Eb1spfCSFJLf"},"timestamp":1766707577504,"timestamp_pst":"2025-12-25 16:06:17 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"in_progress","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"in_progress","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"pending","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"pending","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"in_progress","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01LPhmCPNMX4Eb1spfCSFJLf"},"timestamp":1766707577731,"timestamp_pst":"2025-12-25 16:06:17 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"code review training exercises hands-on practical activities defect detection skills"},"tool_use_id":"toolu_01Bz8hqrWgxS9s1hDTDwnor7"},"timestamp":1766707577877,"timestamp_pst":"2025-12-25 16:06:17 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"WebSearch","tool_input":{"query":"competency assessment code review skills evaluation pharmaceutical GxP training"},"tool_use_id":"toolu_01TvHN6aW3xiVG8Nq5KSvUiJ"},"timestamp":1766707577930,"timestamp_pst":"2025-12-25 16:06:17 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"competency assessment code review skills evaluation pharmaceutical GxP training"},"tool_response":{"query":"competency assessment code review skills evaluation pharmaceutical GxP training","results":[{"tool_use_id":"srvtoolu_01A711DarN6uUHREyiNRdV1s","content":[{"title":"How to Develop Effective Training Programs for FDA Compliance","url":"https://www.complianceonline.com/resources/fda-complinace-training-program.html"},{"title":"What is GXP ? A Guide to GxP System Assessment","url":"https://pharmaconnections.in/gxp/"},{"title":"Pharmaceutical GxP Training | NSF","url":"https://www.nsf.org/training/area/health-sciences-training-solutions/pharmaceutical/pharmaceutical-gxp"},{"title":"GxPs for Leadership | ISPE | International Society for Pharmaceutical Engineering","url":"https://ispe.org/training/online-learning/gxps-leadership"},{"title":"GxP Pharmaceutical Audit Checklist: Your Comprehensive Template Guide | ChecklistGuro","url":"https://checklistguro.com/blog/gxp-pharmaceutical-audit-checklist"},{"title":"GxP Training : Certified Courses for Life Sciences Professionals","url":"https://gxp-training.com/"},{"title":"GxP training skills matrix template - AG5","url":"https://www.ag5.com/templates/gxp-training-skills-matrix-template/"},{"title":"Current Trends and Opportunities for Competency Assessment in Pharmacy Educationâ€“A Literature Review - PMC","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6630227/"},{"title":"GxP: Good Practices (GxP) in Drug Development and Manufacturing Training Certification Course","url":"https://www.biopharmainstitute.com/course/GXP01"},{"title":"Introduction to GxP Online Training and Certification","url":"https://gxp-training.com/online-course/introduction-to-gxp/"}]},"Here are the search results for competency assessment, code review skills evaluation, and pharmaceutical GxP training:\n\n## Key Findings\n\n### GxP Training and Competency Framework\n\nAccording to GxP guidelines, the first step to developing an effective training program is to define competencies for job roles.(no content)Training is an FDA requirement that should be planned, conducted, evaluated and documented.\n\n### Competency Assessment in GxP Systems\n\nGxP System Assessment drills down into training programs, ensuring that personnel are not only adequately trained but also competent in their roles. Competency assessments serve as vital barometers, identifying areas for improvement and additional training.(no content)Training alone isn't sufficient.(no content)The audit will look for evidence of how competency is assessed - practical demonstrations, observed performance, or other methods - to ensure employees can apply their knowledge.\n\n### Personnel Qualifications and Training Records\n\nComprehensive records of GxP training (e.g., GDP, GMP, GLP) are crucial. The audit will check for frequency, content (covering relevant regulations and SOPs), and documentation of training completion. Refresher training schedules and completion are also assessed.(no content)Beyond general GxP training, specific training relating to equipment operation, process execution, and data handling is essential. Records of this training, including assessments and evaluations, must be readily available.\n\n### Skills Matrix Tools\n\nA skills matrix is a tool teams can use to effectively manage and assess their GxP training skills and knowledge.(no content)GxP Regulations and Guidelines involve knowledge of regulations governing good practices in regulated industries such as pharmaceuticals, medical devices, and biotechnology. While there is no specific certification solely focused on GxP training, certifications such as the Certified Professional in FDA Regulatory Affairs (RAC) offered by RAPS demonstrate understanding of regulatory frameworks, compliance requirements, and GxP principles.\n\n### Available Training Resources\n\nNSF offers pharmaceutical GxP training designed to meet organizational needs, covering the latest EU and U.S. requirements, including eLearning and customized training options.(no content)Since 2003, Biopharma Institute has helped professionals and their employers meet training requirements, with certifications recognized by a wide range of industries, regulatory bodies, and organizations worldwide.\n\nNote: The search results focused primarily on general GxP competency assessment and training rather than specific \"code review skills evaluation\" in a software development context. If you're looking for code review competency assessment specifically for GxP-regulated software systems, a more targeted search may be helpful."],"durationSeconds":23.435495921999916},"tool_use_id":"toolu_01TvHN6aW3xiVG8Nq5KSvUiJ"},"timestamp":1766707601621,"timestamp_pst":"2025-12-25 16:06:41 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"WebSearch","tool_input":{"query":"code review training exercises hands-on practical activities defect detection skills"},"tool_response":{"query":"code review training exercises hands-on practical activities defect detection skills","results":[{"tool_use_id":"srvtoolu_01YDUShqZDhF1Sq6CvsxtQ26","content":[{"title":"Code Review Workshops - Dr. McKayla","url":"https://www.michaelagreiler.com/workshops/"},{"title":"Code Reviews for Secure, Clean, and Scalable Code | Udemy","url":"https://www.udemy.com/course/code-reviews-learnit/"},{"title":"A Serious Game Approach to Introduce the Code Review Practice - Ardic - 2025 - Journal of Software: Evolution and Process - Wiley Online Library","url":"https://onlinelibrary.wiley.com/doi/full/10.1002/smr.2750"},{"title":"Introduction to code review Free Exercise!","url":"https://pentesterlab.com/exercises/codereview"},{"title":"Reading 4: Code Review","url":"https://web.mit.edu/6.005/www/fa15/classes/04-code-review/"},{"title":"Defect Prevention Methods and Techniques - GeeksforGeeks","url":"https://geeksforgeeks.org/defect-prevention-methods-and-techniques"},{"title":"Beginner Code Review(Part 1). To improve my code review skills Iâ€¦ | by Adam C | Medium","url":"https://adamc95.medium.com/beginner-code-review-part-1-8272db9e1b36"},{"title":"Framework for Software Code Reviews and Inspections in ...","url":"https://www.mecs-press.org/ijmecs/ijmecs-v10-n10/IJMECS-V10-N10-4.pdf"},{"title":"Defect management best practices - testomat.io","url":"https://testomat.io/blog/defect-management-best-practices/"},{"title":"Code review - Wikipedia","url":"https://en.wikipedia.org/wiki/Code_review"}]},"Here are the search results for code review training exercises and hands-on practical activities for defect detection skills:\n\n## Code Review Training Resources\n\n### Professional Workshops\n\nDr. Michaela Greiler offers code review workshops that happen in small groups, are very interactive, and are filled with hands-on exercises. These aren't lecturesâ€”through practical exercises and group discussions, teams actively apply new techniques to real-world code review scenarios.(no content)The workshops cover how review speed impacts defect detection and overall code quality.(no content)They are packed with hands-on exercises, interactive discussions, little games, and equip participants with actionable know-how.\n\n### Online Courses\n\nUdemy offers a code review course where through interactive exercises and simulations, students practice evaluating code efficiently, giving helpful feedback, and communicating effectively during review sessions. It includes team-based review simulations to enhance collaborative skills and coding exercises to identify scalability and security concerns.\n\n### Serious Game Approach\n\nA 2025 research paper describes a Code Review Serious Game (CRSG) designed to convey general code review concepts and allow players to train skills for effective defect detection during code review. To address the code review knowledge gap in higher education, researchers designed and evaluated this serious game.(no content)The game uses checklists similar to code review checklists used in some workflows. Checklists are shown to help beginners with the review process. Items are ordered to help players start with easier-to-detect defects like style, variable naming, and magic numbers, then proceed with more contextual defects.\n\n### Security-Focused Code Review Training\n\nPentesterLab offers a free code review exercise where you work with a simple PHP application that allows users to upload and download files. You learn various code review methodologies to uncover security weaknesses and potential vulnerabilities.(no content)The exercise explains that code review can be faster than penetration testingâ€”some issues are really easy to spot during a code review (for example, a weak encryption algorithm), while others can take more time.\n\n### Academic Resources\n\nMIT's 6.005 course covers general principles of good coding and things to look for in every code review, regardless of programming language or program purpose. This includes improving the code, finding bugs, anticipating possible bugs, checking the clarity of the code, and checking for consistency with the project's style standards.\n\n### Defect Prevention Techniques\n\nInvesting in continuous training and skill development for team members is recommendedâ€”skilled developers are better able to follow best practices and are less prone to make frequent mistakes.(no content)Using checklists ensures that crucial actions are not missed during the various stages of development. Developers and reviewers can quickly confirm that established standards are being followed by using checklists as a reference."],"durationSeconds":26.731538081000092},"tool_use_id":"toolu_01Bz8hqrWgxS9s1hDTDwnor7"},"timestamp":1766707604802,"timestamp_pst":"2025-12-25 16:06:44 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"in_progress","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_019eSFkqkXy6KsAxTLmF99gJ"},"timestamp":1766707799918,"timestamp_pst":"2025-12-25 16:09:59 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"in_progress","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"in_progress","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"pending","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"in_progress","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_019eSFkqkXy6KsAxTLmF99gJ"},"timestamp":1766707800131,"timestamp_pst":"2025-12-25 16:10:00 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Write","tool_input":{"file_path":"/home/chris/FDA-Code-Review-Training-Program.md","content":"# Formation: Meilleures Techniques de RÃ©vision de Code en Contexte FDA\n\n## Vue d'Ensemble du Programme\n\n**DurÃ©e totale:** 5 jours (40 heures)\n**Public cible:** DÃ©veloppeurs, QA, Responsables QualitÃ©, Auditeurs internes\n**PrÃ©requis:** ExpÃ©rience en dÃ©veloppement logiciel, notions de base en rÃ©glementation\n\n---\n\n## Cadre RÃ©glementaire\n\n### RÃ©fÃ©rences Normatives ClÃ©s\n\n| Standard | Application | Focus Principal |\n|----------|-------------|-----------------|\n| **21 CFR Part 11** | Enregistrements Ã©lectroniques & signatures | Audit trails, validation, contrÃ´le d'accÃ¨s |\n| **21 CFR Part 820** | Quality System Regulation (dispositifs mÃ©dicaux) | Design controls, documentation |\n| **IEC 62304** | Logiciels de dispositifs mÃ©dicaux | Cycle de vie, classification de sÃ©curitÃ© |\n| **GAMP 5** | SystÃ¨mes informatisÃ©s pharmaceutiques | Validation basÃ©e sur le risque |\n| **EU GMP Annex 11** | SystÃ¨mes informatisÃ©s (Europe) | Validation, intÃ©gritÃ© des donnÃ©es |\n\n---\n\n## Structure de la Formation\n\n### JOUR 1: Fondamentaux RÃ©glementaires (8h)\n\n#### Module 1.1: Introduction au Contexte FDA (2h)\n\n**Objectifs:**\n- Comprendre le rÃ´le de la FDA dans la rÃ©gulation des logiciels\n- Identifier les types de logiciels rÃ©gulÃ©s (SaMD, SiMD, GxP)\n- ConnaÃ®tre les consÃ©quences d'une non-conformitÃ©\n\n**Contenu:**\n1. Historique et Ã©volution de la rÃ©glementation FDA\n2. Types de logiciels sous rÃ©glementation FDA:\n   - Software as a Medical Device (SaMD)\n   - Software in a Medical Device (SiMD)\n   - Production Quality System Software (PQSS)\n   - GxP Systems (GMP, GLP, GCP)\n3. Statistiques rÃ©centes: En 2024, 529 warning letters Ã©mises par CDRH, 8% pour des problÃ¨mes de validation\n4. Computer Software Assurance (CSA) vs Computer System Validation (CSV)\n\n**Exercice 1.1:** *Analyse de cas - Classification de logiciels*\n```\nScÃ©nario: Votre entreprise dÃ©veloppe 5 logiciels diffÃ©rents:\n1. Application mobile de suivi de glycÃ©mie\n2. SystÃ¨me ERP pour la gestion des stocks\n3. Logiciel de contrÃ´le qualitÃ© en production\n4. Application de prise de rendez-vous patients\n5. Algorithme d'analyse d'images radiologiques\n\nTÃ¢che: Classifier chaque logiciel (SaMD, SiMD, PQSS, Non-rÃ©gulÃ©)\net dÃ©terminer le niveau de rigueur de revue de code requis.\n```\n\n#### Module 1.2: 21 CFR Part 11 en DÃ©tail (3h)\n\n**Objectifs:**\n- MaÃ®triser les exigences d'enregistrements Ã©lectroniques\n- Comprendre les implications pour le code review\n- Identifier les contrÃ´les techniques requis\n\n**Contenu:**\n1. Subpart B - Electronic Records (Â§11.10)\n   - Validation des systÃ¨mes\n   - GÃ©nÃ©ration de copies exactes\n   - Protection des enregistrements\n   - Audit trails (qui, quoi, quand)\n   - ContrÃ´les d'accÃ¨s\n\n2. Subpart C - Electronic Signatures (Â§11.100-11.300)\n   - UnicitÃ© des signatures\n   - VÃ©rification d'identitÃ©\n   - Liens entre signature et enregistrement\n\n3. Impact sur le code review:\n   - TraÃ§abilitÃ© des modifications de code\n   - Versioning et contrÃ´le de configuration\n   - Documentation des dÃ©cisions de revue\n\n**Exercice 1.2:** *Audit Trail Code Review*\n```\nAnalysez cet extrait de code et identifiez les non-conformitÃ©s Part 11:\n\n// Fonction de mise Ã  jour d'un lot de production\nfunction updateBatch(batchId, newData) {\n    db.batches.update(batchId, newData);\n    console.log(\"Batch updated\");\n    return true;\n}\n\nQuestions:\n1. Quelles informations d'audit manquent?\n2. Comment modifier ce code pour la conformitÃ©?\n3. Quels tests ajouteriez-vous?\n```\n\n#### Module 1.3: IEC 62304 et Classification de SÃ©curitÃ© (3h)\n\n**Objectifs:**\n- Comprendre les 3 classes de sÃ©curitÃ© (A, B, C)\n- Appliquer le niveau de rigueur appropriÃ© Ã  la revue de code\n- MaÃ®triser les exigences de documentation\n\n**Contenu:**\n1. Classes de sÃ©curitÃ© logicielle:\n   - **Classe A:** Aucune blessure possible\n   - **Classe B:** Blessure non-grave possible\n   - **Classe C:** Mort ou blessure grave possible\n\n2. Exigences par classe:\n\n| ActivitÃ© | Classe A | Classe B | Classe C |\n|----------|----------|----------|----------|\n| Architecture logicielle | Optionnel | Requis | Requis |\n| Conception dÃ©taillÃ©e | Optionnel | Optionnel | Requis |\n| VÃ©rification unitaire | Optionnel | Requis | Requis |\n| Tests d'intÃ©gration | Optionnel | Requis | Requis |\n| Revue de code | Optionnel | RecommandÃ© | Requis |\n\n3. SOUP (Software of Unknown Provenance):\n   - Ã‰valuation des risques\n   - Documentation requise\n   - StratÃ©gies de test\n\n**Exercice 1.3:** *Classification et StratÃ©gie de Revue*\n```\nCas: Pompe Ã  insuline connectÃ©e\n\nComposants logiciels:\nA) Module de calcul de dose\nB) Interface utilisateur (affichage)\nC) Module Bluetooth de synchronisation\nD) BibliothÃ¨que open-source de chiffrement\n\nTÃ¢ches:\n1. Classifier chaque composant (A, B, ou C)\n2. DÃ©finir la stratÃ©gie de revue de code pour chaque composant\n3. Identifier les SOUP et documenter les risques\n```\n\n---\n\n### JOUR 2: MÃ©thodologies de Revue de Code (8h)\n\n#### Module 2.1: MÃ©thodes Formelles - L'Inspection Fagan (3h)\n\n**Objectifs:**\n- MaÃ®triser le processus d'inspection Fagan\n- Comprendre quand utiliser cette mÃ©thode coÃ»teuse\n- Documenter correctement une inspection formelle\n\n**Contenu:**\n1. Les 6 Ã©tapes de l'inspection Fagan:\n   - **Planning:** DÃ©finition du scope, assignation des rÃ´les\n   - **Overview:** PrÃ©sentation du code par l'auteur\n   - **Preparation:** Examen individuel (typiquement 200 lignes/heure)\n   - **Inspection Meeting:** Revue collective, identification des dÃ©fauts\n   - **Rework:** Corrections par l'auteur\n   - **Follow-up:** VÃ©rification des corrections\n\n2. RÃ´les et responsabilitÃ©s:\n   - **Moderator:** Facilite la rÃ©union, s'assure du respect du processus\n   - **Author:** Explique le code, corrige les dÃ©fauts\n   - **Reader:** Lit le code Ã  haute voix\n   - **Recorder:** Documente les dÃ©fauts trouvÃ©s\n   - **Inspectors:** Identifient les problÃ¨mes\n\n3. CritÃ¨res d'entrÃ©e/sortie:\n   - Entry: Code complet, compilable, tests unitaires passent\n   - Exit: Tous les dÃ©fauts critiques corrigÃ©s et vÃ©rifiÃ©s\n\n4. MÃ©triques de rÃ©fÃ©rence:\n   - Environ 9 heures-personne pour 200 lignes de code\n   - Taux de dÃ©tection: 60-90% des dÃ©fauts\n   - ROI: IBM a rÃ©duit les dÃ©fauts de 2/3 avec cette mÃ©thode\n\n**Exercice 2.1:** *Simulation d'Inspection Fagan*\n```\nFormation de groupes de 5 personnes avec attribution des rÃ´les.\n\nCode Ã  inspecter: Module de calcul de date d'expiration\n(fourni sÃ©parÃ©ment - environ 150 lignes)\n\nLivrables:\n1. Liste des dÃ©fauts documentÃ©e (formulaire standard)\n2. Classification de sÃ©vÃ©ritÃ© de chaque dÃ©faut\n3. Rapport d'inspection avec mÃ©triques\n```\n\n#### Module 2.2: Revue de Code BasÃ©e sur les Risques (GAMP 5) (2.5h)\n\n**Objectifs:**\n- Appliquer l'approche GAMP 5 Ã  la revue de code\n- Calibrer l'effort de revue selon la catÃ©gorie du systÃ¨me\n- Documenter la justification basÃ©e sur les risques\n\n**Contenu:**\n1. CatÃ©gories GAMP 5:\n   - **Cat 1:** Infrastructure (OS, bases de donnÃ©es) â†’ Validation minimale\n   - **Cat 3:** Non-configurable COTS â†’ VÃ©rification configuration\n   - **Cat 4:** Configurable COTS â†’ VÃ©rification configuration + customisation\n   - **Cat 5:** Custom (dÃ©veloppement interne) â†’ Validation complÃ¨te\n\n2. Effort de revue par catÃ©gorie:\n\n| CatÃ©gorie | Effort relatif | Focus de la revue |\n|-----------|----------------|-------------------|\n| Cat 1 | Minimal | Installation, configuration |\n| Cat 3 | Faible | Configuration, IQ/OQ |\n| Cat 4 | Moyen | Configuration, scripts, rapports |\n| Cat 5 | Ã‰levÃ© (+50-100%) | Code complet, architecture, tests |\n\n3. Matrice de traÃ§abilitÃ©:\n   - Requirements â†’ Specifications â†’ Code â†’ Tests\n\n**Exercice 2.2:** *StratÃ©gie de Revue BasÃ©e sur les Risques*\n```\nScÃ©nario: Nouveau systÃ¨me de gestion des lots (LIMS)\n\nComposants:\n- Base Oracle (Cat 1)\n- Application LIMS commerciale (Cat 4)\n- Rapports personnalisÃ©s (Cat 5)\n- Interfaces avec ERP (Cat 5)\n- Tableaux de bord (Cat 4)\n\nTÃ¢ches:\n1. Documenter la stratÃ©gie de revue pour chaque composant\n2. Estimer l'effort relatif (en %)\n3. Identifier les Ã©lÃ©ments critiques nÃ©cessitant une inspection Fagan\n4. CrÃ©er un plan de revue avec jalons\n```\n\n#### Module 2.3: Checklists de Revue SpÃ©cifiques FDA (2.5h)\n\n**Objectifs:**\n- CrÃ©er et utiliser des checklists conformes\n- Couvrir les aspects rÃ©glementaires spÃ©cifiques\n- Personnaliser les checklists par projet\n\n**Contenu:**\n\n1. **Checklist GÃ©nÃ©rale - ConformitÃ© Part 11:**\n```\nâ–¡ Audit trail implÃ©mentÃ© pour toutes les modifications de donnÃ©es GxP\nâ–¡ Horodatage avec timezone documentÃ©\nâ–¡ Identification utilisateur unique\nâ–¡ ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les (RBAC)\nâ–¡ Backup et rÃ©cupÃ©ration testÃ©s\nâ–¡ Signatures Ã©lectroniques conformes Â§11.100\nâ–¡ ImpossibilitÃ© de modifier les enregistrements signÃ©s\nâ–¡ Export des donnÃ©es en format lisible par l'humain\n```\n\n2. **Checklist SÃ©curitÃ© - IEC 62304 Classe C:**\n```\nâ–¡ Gestion des erreurs pour tous les cas limites\nâ–¡ Validation des entrÃ©es utilisateur\nâ–¡ Timeouts implÃ©mentÃ©s pour opÃ©rations critiques\nâ–¡ Valeurs par dÃ©faut sÃ»res\nâ–¡ Tests de stress/limite effectuÃ©s\nâ–¡ Analyse de code statique sans findings critiques\nâ–¡ Couverture de tests > 80%\nâ–¡ Documentation des algorithmes critiques\n```\n\n3. **Checklist Data Integrity (ALCOA+):**\n```\nâ–¡ Attributable: Qui a crÃ©Ã©/modifiÃ© les donnÃ©es?\nâ–¡ Legible: DonnÃ©es lisibles et permanentes?\nâ–¡ Contemporaneous: Enregistrement au moment de l'action?\nâ–¡ Original: DonnÃ©es originales prÃ©servÃ©es?\nâ–¡ Accurate: Exactitude vÃ©rifiable?\nâ–¡ Complete: Toutes les donnÃ©es incluses?\nâ–¡ Consistent: Format cohÃ©rent?\nâ–¡ Enduring: Disponible pendant la pÃ©riode de rÃ©tention?\nâ–¡ Available: Accessible pour audit/inspection?\n```\n\n**Exercice 2.3:** *CrÃ©ation de Checklist PersonnalisÃ©e*\n```\nContexte: Application de gestion des essais cliniques (CTMS)\n\nTÃ¢ches:\n1. CrÃ©er une checklist de 20 items minimum\n2. CatÃ©goriser: Critique / Majeur / Mineur\n3. Ajouter les rÃ©fÃ©rences rÃ©glementaires\n4. DÃ©finir les critÃ¨res pass/fail\n5. Tester sur un code exemple\n```\n\n---\n\n### JOUR 3: Outils et Automatisation (8h)\n\n#### Module 3.1: Qualification des Outils de Revue (2h)\n\n**Objectifs:**\n- Comprendre les exigences de qualification des outils\n- Documenter la validation d'un outil de revue\n- GÃ©rer le cycle de vie des outils\n\n**Contenu:**\n1. Exigences GAMP 5 pour les outils de dÃ©veloppement\n2. CatÃ©gories d'outils:\n   - Outils sans impact GxP direct\n   - Outils avec impact indirect (IDE, compilateurs)\n   - Outils avec impact direct (gÃ©nÃ©ration de code, test automation)\n\n3. Documentation de qualification:\n   - Intended Use Statement\n   - Risk Assessment\n   - Test Cases\n   - Validation Report\n\n4. Outils courants et leur qualification:\n   - GitHub/GitLab (version control)\n   - SonarQube (analyse statique)\n   - Jira (defect tracking)\n   - Crucible/Review Board (code review)\n\n**Exercice 3.1:** *Plan de Qualification d'Outil*\n```\nOutil: GitHub Enterprise pour revue de code\n\nLivrables:\n1. Document \"Intended Use\"\n2. Risk Assessment (3-5 risques)\n3. Test cases (5-10 scÃ©narios)\n4. CritÃ¨res d'acceptation\n```\n\n#### Module 3.2: Analyse Statique et Automatisation (3h)\n\n**Objectifs:**\n- IntÃ©grer l'analyse statique dans le workflow\n- Configurer les rÃ¨gles pour la conformitÃ© FDA\n- InterprÃ©ter et documenter les rÃ©sultats\n\n**Contenu:**\n1. Outils d'analyse statique:\n   - **SonarQube:** QualitÃ© gÃ©nÃ©rale, dette technique\n   - **Coverity:** DÃ©tection de dÃ©fauts critiques\n   - **Klocwork:** SÃ©curitÃ©, conformitÃ© standards\n   - **Polyspace:** Certification (aviation, mÃ©dical)\n\n2. RÃ¨gles essentielles pour FDA:\n   - MISRA C/C++ (dispositifs mÃ©dicaux embarquÃ©s)\n   - OWASP Top 10 (applications web)\n   - CWE (Common Weakness Enumeration)\n\n3. IntÃ©gration CI/CD:\n   - Gates de qualitÃ©\n   - Seuils de blocage\n   - Reporting automatisÃ©\n\n4. Documentation des findings:\n   - Justification des faux positifs\n   - Plan de remÃ©diation\n   - Suivi des dÃ©viations\n\n**Exercice 3.2:** *Configuration SonarQube pour FDA*\n```\nTÃ¢ches pratiques:\n1. CrÃ©er un Quality Profile \"FDA Medical Device\"\n2. Activer les rÃ¨gles critiques pour Part 11\n3. DÃ©finir les Quality Gates\n4. Analyser un projet exemple\n5. Documenter les findings et actions\n```\n\n#### Module 3.3: Gestion des DÃ©fauts et CAPA (3h)\n\n**Objectifs:**\n- Classifier les dÃ©fauts selon leur impact\n- Lier les dÃ©fauts au systÃ¨me CAPA\n- Assurer la traÃ§abilitÃ© requise\n\n**Contenu:**\n1. Classification des dÃ©fauts de code review:\n\n| SÃ©vÃ©ritÃ© | DÃ©finition | Action | DÃ©lai |\n|----------|------------|--------|-------|\n| **Critique** | Impact patient, data integrity | Stop & fix | ImmÃ©diat |\n| **Majeur** | Non-conformitÃ© rÃ©glementaire | Fix before release | 24-48h |\n| **Mineur** | Best practice, maintenabilitÃ© | Plan fix | Prochain sprint |\n| **CosmÃ©tique** | Style, formatting | Optional | Backlog |\n\n2. IntÃ©gration CAPA (Corrective and Preventive Action):\n   - Quand escalader un dÃ©faut vers CAPA?\n   - Documentation de l'investigation\n   - Root Cause Analysis (RCA)\n   - Actions prÃ©ventives systÃ©miques\n\n3. MÃ©triques de suivi:\n   - Defect density (dÃ©fauts/KLOC)\n   - Defect removal efficiency\n   - Escaped defects rate\n   - Time to resolution\n\n**Exercice 3.3:** *Simulation Gestion de DÃ©fauts*\n```\nScÃ©nario: Lors d'une revue, vous dÃ©couvrez:\n1. Mot de passe en clair dans le code\n2. Calcul de dose incorrect (division par zÃ©ro possible)\n3. Commentaire TODO avec date de 2019\n4. Variable non utilisÃ©e\n5. Absence de validation d'entrÃ©e utilisateur\n\nTÃ¢ches:\n1. Classifier chaque dÃ©faut\n2. RÃ©diger les tickets avec toutes les infos requises\n3. DÃ©cider lesquels nÃ©cessitent un CAPA\n4. Proposer des actions prÃ©ventives\n```\n\n---\n\n### JOUR 4: Documentation et TraÃ§abilitÃ© (8h)\n\n#### Module 4.1: Exigences de Documentation FDA (3h)\n\n**Objectifs:**\n- Produire une documentation conforme aux audits\n- Maintenir la traÃ§abilitÃ© bout-en-bout\n- PrÃ©parer les preuves pour inspection\n\n**Contenu:**\n1. Documents essentiels de revue de code:\n   - **Code Review Record:** Qui, quoi, quand, rÃ©sultat\n   - **Defect Log:** Liste des dÃ©fauts trouvÃ©s\n   - **Resolution Record:** Corrections effectuÃ©es\n   - **Approval Evidence:** Signatures/approbations\n\n2. TraÃ§abilitÃ© bidirectionnelle:\n```\nRequirements â†’ Design â†’ Code â†’ Test Cases â†’ Test Results\n     â†‘                                              â†“\n     â†â†â†â†â†â†â†â†â† Traceability Matrix â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†\n```\n\n3. RÃ©tention des enregistrements:\n   - Dispositifs mÃ©dicaux: DurÃ©e de vie + 2 ans\n   - Pharmaceutique: Selon protocole (souvent 15+ ans)\n   - Essais cliniques: 15 ans minimum\n\n4. Format des preuves:\n   - PDF/A pour archivage long terme\n   - Signatures Ã©lectroniques conformes\n   - MÃ©tadonnÃ©es prÃ©servÃ©es\n\n**Exercice 4.1:** *CrÃ©ation d'un Package de Documentation*\n```\nContexte: Module de calcul de dose - prÃªt pour release\n\nCrÃ©ez le package complet:\n1. Code Review Request Form\n2. Code Review Checklist (remplie)\n3. Defect Log avec rÃ©solutions\n4. Traceability Matrix (requirements â†’ code â†’ tests)\n5. Code Review Summary Report\n6. Approval signatures\n```\n\n#### Module 4.2: PrÃ©paration aux Audits FDA (2.5h)\n\n**Objectifs:**\n- Anticiper les questions des inspecteurs\n- Organiser la documentation pour accÃ¨s rapide\n- Ã‰viter les observations 483 courantes\n\n**Contenu:**\n1. Questions typiques d'audit sur le code review:\n   - \"Montrez-moi votre procÃ©dure de revue de code\"\n   - \"Comment assurez-vous l'indÃ©pendance du reviewer?\"\n   - \"Quelles preuves avez-vous que ce code a Ã©tÃ© revu?\"\n   - \"Comment gÃ©rez-vous les dÃ©fauts trouvÃ©s?\"\n   - \"Quelle formation ont vos reviewers?\"\n\n2. Observations 483 frÃ©quentes (Ã©viter):\n   - Absence de documentation de revue\n   - Reviews non indÃ©pendantes (auteur = reviewer)\n   - DÃ©fauts non rÃ©solus avant release\n   - Absence de traÃ§abilitÃ© requirements â†’ code\n   - Personnel non qualifiÃ©\n\n3. Organisation des preuves:\n   - Index par projet/release\n   - AccÃ¨s rapide (< 24h pour tout document)\n   - Versions historiques prÃ©servÃ©es\n\n**Exercice 4.2:** *Simulation d'Audit*\n```\nJeu de rÃ´le:\n- 2 participants = Inspecteurs FDA\n- 2 participants = Ã‰quipe qualitÃ©\n- 2 participants = DÃ©veloppeurs\n\nScÃ©nario: Inspection du processus de revue de code\npour un rÃ©cent release de logiciel mÃ©dical.\n\nLes inspecteurs ont 30 minutes pour:\n1. Demander la procÃ©dure\n2. SÃ©lectionner un fichier au hasard\n3. VÃ©rifier les preuves de revue\n4. Identifier des gaps\n\nDÃ©brief: Quelles amÃ©liorations?\n```\n\n#### Module 4.3: IntÃ©gritÃ© des DonnÃ©es (Data Integrity) (2.5h)\n\n**Objectifs:**\n- Appliquer les principes ALCOA+ au code review\n- ProtÃ©ger les enregistrements de revue\n- DÃ©tecter les problÃ¨mes d'intÃ©gritÃ©\n\n**Contenu:**\n1. ALCOA+ appliquÃ© Ã  la revue de code:\n   - **Attributable:** Identification du reviewer (pas gÃ©nÃ©rique)\n   - **Legible:** Comments clairs, pas d'abrÃ©viations obscures\n   - **Contemporaneous:** Revue avant release, pas rÃ©troactive\n   - **Original:** Pas de modification des rapports aprÃ¨s signature\n   - **Accurate:** Findings vÃ©rifiables dans le code\n\n2. Red flags d'intÃ©gritÃ©:\n   - Timestamps incohÃ©rents\n   - Reviews trop rapides (< 5 min pour 1000 lignes)\n   - MÃªme reviewer pour tout un projet\n   - DÃ©fauts jamais trouvÃ©s\n   - Modifications post-release non documentÃ©es\n\n3. ContrÃ´les techniques:\n   - Verrouillage des enregistrements signÃ©s\n   - Audit trail des modifications\n   - Backups avec checksums\n   - AccÃ¨s role-based\n\n**Exercice 4.3:** *DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©*\n```\nAnalysez ce rapport de revue et identifiez les anomalies:\n\nCode Review Report #2024-0315\n- Reviewer: jsmith\n- Date: 2024-03-15 14:32:05\n- Files reviewed: 47 files, 12,547 lines\n- Duration: 23 minutes\n- Defects found: 0\n- Status: APPROVED\n\nGit log pour le mÃªme commit:\n- Author: jsmith\n- Date: 2024-03-15 14:30:00\n- Message: \"Fixed critical bug in dose calculation\"\n\nQuestions:\n1. Quelles anomalies identifiez-vous?\n2. Quelles questions poseriez-vous?\n3. Comment prÃ©venir ces situations?\n```\n\n---\n\n### JOUR 5: CompÃ©tences et AmÃ©lioration Continue (8h)\n\n#### Module 5.1: CompÃ©tences du Reviewer FDA (2h)\n\n**Objectifs:**\n- DÃ©finir les compÃ©tences requises\n- Ã‰valuer et dÃ©velopper les reviewers\n- Documenter les qualifications\n\n**Contenu:**\n1. CompÃ©tences techniques requises:\n   - Langage de programmation du projet\n   - Architecture et patterns utilisÃ©s\n   - Standards de codage de l'entreprise\n   - Outils de dÃ©veloppement (IDE, VCS, CI/CD)\n\n2. CompÃ©tences rÃ©glementaires:\n   - Connaissance de Part 11/Part 820\n   - ComprÃ©hension de GAMP 5\n   - FamiliaritÃ© avec IEC 62304 (si applicable)\n   - Principes de data integrity\n\n3. CompÃ©tences comportementales:\n   - Communication constructive\n   - Attention aux dÃ©tails\n   - IndÃ©pendance de jugement\n   - Gestion du temps\n\n4. Matrice de compÃ©tences:\n\n| CompÃ©tence | Niveau 1 | Niveau 2 | Niveau 3 |\n|------------|----------|----------|----------|\n| Langage | Lit le code | Ã‰crit du code | Expert |\n| RÃ©glementation | SensibilisÃ© | FormÃ© | CertifiÃ© |\n| Revue | Observateur | Reviewer | Lead/Moderator |\n\n**Exercice 5.1:** *Auto-Ã©valuation et Plan de DÃ©veloppement*\n```\nComplÃ©tez la matrice de compÃ©tences pour vous-mÃªme.\nIdentifiez 3 gaps prioritaires.\nCrÃ©ez un plan de dÃ©veloppement sur 6 mois.\n```\n\n#### Module 5.2: Feedback Constructif et Communication (2h)\n\n**Objectifs:**\n- Formuler des commentaires de revue efficaces\n- GÃ©rer les dÃ©saccords professionnellement\n- CrÃ©er une culture de revue positive\n\n**Contenu:**\n1. Principes du feedback constructif:\n   - Focus sur le code, pas la personne\n   - Expliquer le \"pourquoi\"\n   - Proposer des solutions, pas juste des critiques\n   - ReconnaÃ®tre le bon travail\n\n2. Formulations Ã  Ã©viter vs adopter:\n\n| âŒ Ã€ Ã©viter | âœ… PrÃ©fÃ©rer |\n|------------|-------------|\n| \"Ce code est nul\" | \"Ce pattern pourrait causer X. ConsidÃ©rer Y?\" |\n| \"Pourquoi as-tu fait Ã§a?\" | \"Quelle Ã©tait l'intention ici? Je suggÃ¨re...\" |\n| \"Obvious bug\" | \"Ce cas limite n'est pas gÃ©rÃ©: [exemple]\" |\n| \"RTFM\" | \"La documentation standard X couvre ce cas\" |\n\n3. Gestion des dÃ©saccords:\n   - Escalade technique vs Ã©motionnelle\n   - Quand impliquer un tiers\n   - Documentation des dÃ©cisions\n\n**Exercice 5.2:** *Reformulation de Commentaires*\n```\nReformulez ces commentaires de revue:\n\n1. \"This is wrong\"\n2. \"You always forget error handling\"\n3. \"Why would anyone write code like this?\"\n4. \"This will never work\"\n5. \"Didn't you read the requirements?\"\n\nPuis, pratiquez en binÃ´mes avec des revues rÃ©elles.\n```\n\n#### Module 5.3: MÃ©triques et AmÃ©lioration Continue (2h)\n\n**Objectifs:**\n- Mesurer l'efficacitÃ© du processus de revue\n- Identifier les opportunitÃ©s d'amÃ©lioration\n- ImplÃ©menter des actions correctives\n\n**Contenu:**\n1. MÃ©triques clÃ©s de revue:\n   - **Inspection Rate:** Lignes/heure (cible: 100-200)\n   - **Defect Density:** DÃ©fauts/KLOC trouvÃ©s\n   - **Defect Removal Efficiency:** % dÃ©fauts trouvÃ©s avant test\n   - **Escaped Defects:** DÃ©fauts trouvÃ©s aprÃ¨s release\n   - **Review Coverage:** % du code revu\n\n2. Benchmarks industrie:\n\n| MÃ©trique | Faible | Moyen | Excellent |\n|----------|--------|-------|-----------|\n| Defect density (review) | < 5/KLOC | 5-15/KLOC | > 15/KLOC |\n| DRE | < 50% | 50-80% | > 80% |\n| Review coverage | < 50% | 50-80% | 100% |\n| Escaped to production | > 10% | 5-10% | < 5% |\n\n3. Cycle d'amÃ©lioration continue:\n   - Collecter les mÃ©triques\n   - Analyser les tendances\n   - Identifier les root causes\n   - ImplÃ©menter les amÃ©liorations\n   - Mesurer l'impact\n\n**Exercice 5.3:** *Analyse et Plan d'AmÃ©lioration*\n```\nDonnÃ©es des 6 derniers mois:\n- 150 revues effectuÃ©es\n- 340 dÃ©fauts trouvÃ©s\n- 45,000 lignes revues\n- 12 dÃ©fauts Ã©chappÃ©s en production\n- Temps moyen de revue: 45 min\n\nTÃ¢ches:\n1. Calculer les mÃ©triques clÃ©s\n2. Comparer aux benchmarks\n3. Identifier 3 axes d'amÃ©lioration\n4. Proposer des actions concrÃ¨tes\n5. DÃ©finir les KPIs de suivi\n```\n\n#### Module 5.4: Ã‰valuation Finale et Certification (2h)\n\n**Objectifs:**\n- Valider les acquis de la formation\n- Obtenir la certification interne\n- Planifier la mise en pratique\n\n**Contenu:**\n1. **Examen thÃ©orique (45 min):**\n   - 50 questions Ã  choix multiples\n   - Score minimum: 80%\n   - Couvre tous les modules\n\n2. **Examen pratique (45 min):**\n   - Revue d'un code fourni (200 lignes)\n   - Utilisation de la checklist\n   - Documentation des findings\n   - Ã‰valuation par un formateur certifiÃ©\n\n3. **CritÃ¨res de certification:**\n   - Examen thÃ©orique: â‰¥ 80%\n   - Examen pratique: Tous les dÃ©fauts critiques trouvÃ©s\n   - Participation aux exercices: 100%\n\n4. **Plan d'action post-formation:**\n   - Revues supervisÃ©es pendant 1 mois\n   - Feedback mentor\n   - Recertification annuelle\n\n---\n\n## Annexes\n\n### Annexe A: Template de Code Review Record\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n                     CODE REVIEW RECORD\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nIDENTIFICATION\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview ID:          _______________________\nProject:            _______________________\nModule/Component:   _______________________\nDocument Version:   _______________________\n\nREVIEW DETAILS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview Type:        â–¡ Formal Inspection  â–¡ Peer Review  â–¡ Pair Programming\nAuthor:             _______________________  Date: ____________\nReviewer(s):        _______________________\nModerator:          _______________________ (if applicable)\n\nFiles Reviewed:\nâ”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”\nâ”‚ File Path                           â”‚ Lines    â”‚ Revision   â”‚\nâ”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤\nâ”‚                                     â”‚          â”‚            â”‚\nâ”‚                                     â”‚          â”‚            â”‚\nâ””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜\n\nREVIEW METRICS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Lines Reviewed:      ________\nPreparation Time (min):    ________\nMeeting Time (min):        ________\nDefects Found:            Critical: ____ Major: ____ Minor: ____\n\nCHECKLIST USED\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ Part 11 Compliance    â–¡ IEC 62304 Safety    â–¡ Data Integrity\nâ–¡ Security (OWASP)      â–¡ Coding Standards    â–¡ Performance\nâ–¡ Other: _______________________\n\nFINDINGS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\n[Attached: Defect Log]\n\nOUTCOME\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ APPROVED - No changes required\nâ–¡ APPROVED WITH CONDITIONS - Minor changes, no re-review\nâ–¡ NOT APPROVED - Re-review required after rework\n\nComments:\n___________________________________________________________\n___________________________________________________________\n\nSIGNATURES\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReviewer:      _____________________ Date: _______ Time: _______\nAuthor:        _____________________ Date: _______ Time: _______\nApprover:      _____________________ Date: _______ Time: _______\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nDocument Control: Rev 1.0 | Effective: YYYY-MM-DD | Page 1 of 1\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### Annexe B: Defect Classification Guide\n\n| CatÃ©gorie | SÃ©vÃ©ritÃ© | DÃ©finition | Exemples |\n|-----------|----------|------------|----------|\n| **Safety** | Critique | Impact potentiel sur la sÃ©curitÃ© patient | Calcul de dose incorrect, race condition sur donnÃ©es critiques |\n| **Data Integrity** | Critique | Corruption ou perte de donnÃ©es GxP | Audit trail absent, donnÃ©es modifiables aprÃ¨s signature |\n| **Regulatory** | Majeur | Non-conformitÃ© aux exigences FDA | ContrÃ´le d'accÃ¨s insuffisant, absence de validation d'entrÃ©e |\n| **Functional** | Majeur | Le code ne fait pas ce qui est spÃ©cifiÃ© | Logic error, mauvaise gestion des erreurs |\n| **Security** | Majeur | VulnÃ©rabilitÃ© de sÃ©curitÃ© | Injection SQL, credentials en dur |\n| **Performance** | Mineur | Impact sur les performances | Algorithm inefficace, memory leak |\n| **Maintainability** | Mineur | DifficultÃ© de maintenance future | Code dupliquÃ©, nommage obscur |\n| **Style** | CosmÃ©tique | Non-conformitÃ© aux standards de style | Formatting, commentaires manquants |\n\n### Annexe C: RÃ©fÃ©rences RÃ©glementaires ClÃ©s\n\n**FDA:**\n- 21 CFR Part 11 - Electronic Records; Electronic Signatures\n- 21 CFR Part 820 - Quality System Regulation\n- FDA Guidance: General Principles of Software Validation (2002)\n- FDA Guidance: Computer Software Assurance for Production and Quality System Software (2022)\n\n**International:**\n- IEC 62304:2006/Amd 1:2015 - Medical device software â€” Software life cycle processes\n- ISO 13485:2016 - Medical devices â€” Quality management systems\n- GAMP 5 Guide, 2nd Edition (ISPE, 2022)\n- EU GMP Annex 11 - Computerised Systems\n\n**Industry Standards:**\n- IEEE 1028 - Standard for Software Reviews and Audits\n- ISO/IEC 25010 - Software Quality Model\n- OWASP Top 10 - Web Application Security Risks\n\n### Annexe D: Ressources ComplÃ©mentaires\n\n**Formations RecommandÃ©es:**\n- ISPE GAMP 5 Training\n- FDA Regulatory Affairs Certification (RAC)\n- IEC 62304 Implementation Workshops\n\n**Outils:**\n- [SonarQube](https://www.sonarqube.org/) - Analyse statique open source\n- [Coverity](https://scan.coverity.com/) - DÃ©tection de dÃ©fauts\n- [GitHub Code Review](https://docs.github.com/en/pull-requests) - Revue collaborative\n\n**Publications:**\n- FDA Warning Letters Database (fda.gov)\n- ISPE Pharmaceutical Engineering Magazine\n- Medical Device & Diagnostic Industry (MD+DI)\n\n---\n\n## Sources de Recherche\n\nCette formation a Ã©tÃ© Ã©laborÃ©e Ã  partir des sources suivantes:\n\n- [FDA 21 CFR Part 11 Compliance Guide - Redzone](https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/)\n- [IEC 62304 Software Lifecycle - Jama Software](https://www.jamasoftware.com/blog/an-in-depth-guide-to-iec-62304-software-lifecycle-processes-for-medical-devices/)\n- [GAMP 5 Guide 2nd Edition - ISPE](https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition)\n- [2023 FDA Warning Letters and Software Validation - Ketryx](https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation)\n- [Fagan Inspection - Wikipedia](https://en.wikipedia.org/wiki/Fagan_inspection)\n- [FDA Warning Letters Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n- [Code Review Workshops - Dr. Michaela Greiler](https://www.michaelagreiler.com/workshops/)\n- [Computer Software Assurance Guidance - FDA](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software)\n\n---\n\n*Document crÃ©Ã© le 2025-12-25*\n*Version 1.0*\n"},"tool_use_id":"toolu_0115eLfRM7MB6ubPguUway7Q"},"timestamp":1766707800307,"timestamp_pst":"2025-12-25 16:10:00 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Write","tool_input":{"file_path":"/home/chris/FDA-Code-Review-Training-Program.md","content":"# Formation: Meilleures Techniques de RÃ©vision de Code en Contexte FDA\n\n## Vue d'Ensemble du Programme\n\n**DurÃ©e totale:** 5 jours (40 heures)\n**Public cible:** DÃ©veloppeurs, QA, Responsables QualitÃ©, Auditeurs internes\n**PrÃ©requis:** ExpÃ©rience en dÃ©veloppement logiciel, notions de base en rÃ©glementation\n\n---\n\n## Cadre RÃ©glementaire\n\n### RÃ©fÃ©rences Normatives ClÃ©s\n\n| Standard | Application | Focus Principal |\n|----------|-------------|-----------------|\n| **21 CFR Part 11** | Enregistrements Ã©lectroniques & signatures | Audit trails, validation, contrÃ´le d'accÃ¨s |\n| **21 CFR Part 820** | Quality System Regulation (dispositifs mÃ©dicaux) | Design controls, documentation |\n| **IEC 62304** | Logiciels de dispositifs mÃ©dicaux | Cycle de vie, classification de sÃ©curitÃ© |\n| **GAMP 5** | SystÃ¨mes informatisÃ©s pharmaceutiques | Validation basÃ©e sur le risque |\n| **EU GMP Annex 11** | SystÃ¨mes informatisÃ©s (Europe) | Validation, intÃ©gritÃ© des donnÃ©es |\n\n---\n\n## Structure de la Formation\n\n### JOUR 1: Fondamentaux RÃ©glementaires (8h)\n\n#### Module 1.1: Introduction au Contexte FDA (2h)\n\n**Objectifs:**\n- Comprendre le rÃ´le de la FDA dans la rÃ©gulation des logiciels\n- Identifier les types de logiciels rÃ©gulÃ©s (SaMD, SiMD, GxP)\n- ConnaÃ®tre les consÃ©quences d'une non-conformitÃ©\n\n**Contenu:**\n1. Historique et Ã©volution de la rÃ©glementation FDA\n2. Types de logiciels sous rÃ©glementation FDA:\n   - Software as a Medical Device (SaMD)\n   - Software in a Medical Device (SiMD)\n   - Production Quality System Software (PQSS)\n   - GxP Systems (GMP, GLP, GCP)\n3. Statistiques rÃ©centes: En 2024, 529 warning letters Ã©mises par CDRH, 8% pour des problÃ¨mes de validation\n4. Computer Software Assurance (CSA) vs Computer System Validation (CSV)\n\n**Exercice 1.1:** *Analyse de cas - Classification de logiciels*\n```\nScÃ©nario: Votre entreprise dÃ©veloppe 5 logiciels diffÃ©rents:\n1. Application mobile de suivi de glycÃ©mie\n2. SystÃ¨me ERP pour la gestion des stocks\n3. Logiciel de contrÃ´le qualitÃ© en production\n4. Application de prise de rendez-vous patients\n5. Algorithme d'analyse d'images radiologiques\n\nTÃ¢che: Classifier chaque logiciel (SaMD, SiMD, PQSS, Non-rÃ©gulÃ©)\net dÃ©terminer le niveau de rigueur de revue de code requis.\n```\n\n#### Module 1.2: 21 CFR Part 11 en DÃ©tail (3h)\n\n**Objectifs:**\n- MaÃ®triser les exigences d'enregistrements Ã©lectroniques\n- Comprendre les implications pour le code review\n- Identifier les contrÃ´les techniques requis\n\n**Contenu:**\n1. Subpart B - Electronic Records (Â§11.10)\n   - Validation des systÃ¨mes\n   - GÃ©nÃ©ration de copies exactes\n   - Protection des enregistrements\n   - Audit trails (qui, quoi, quand)\n   - ContrÃ´les d'accÃ¨s\n\n2. Subpart C - Electronic Signatures (Â§11.100-11.300)\n   - UnicitÃ© des signatures\n   - VÃ©rification d'identitÃ©\n   - Liens entre signature et enregistrement\n\n3. Impact sur le code review:\n   - TraÃ§abilitÃ© des modifications de code\n   - Versioning et contrÃ´le de configuration\n   - Documentation des dÃ©cisions de revue\n\n**Exercice 1.2:** *Audit Trail Code Review*\n```\nAnalysez cet extrait de code et identifiez les non-conformitÃ©s Part 11:\n\n// Fonction de mise Ã  jour d'un lot de production\nfunction updateBatch(batchId, newData) {\n    db.batches.update(batchId, newData);\n    console.log(\"Batch updated\");\n    return true;\n}\n\nQuestions:\n1. Quelles informations d'audit manquent?\n2. Comment modifier ce code pour la conformitÃ©?\n3. Quels tests ajouteriez-vous?\n```\n\n#### Module 1.3: IEC 62304 et Classification de SÃ©curitÃ© (3h)\n\n**Objectifs:**\n- Comprendre les 3 classes de sÃ©curitÃ© (A, B, C)\n- Appliquer le niveau de rigueur appropriÃ© Ã  la revue de code\n- MaÃ®triser les exigences de documentation\n\n**Contenu:**\n1. Classes de sÃ©curitÃ© logicielle:\n   - **Classe A:** Aucune blessure possible\n   - **Classe B:** Blessure non-grave possible\n   - **Classe C:** Mort ou blessure grave possible\n\n2. Exigences par classe:\n\n| ActivitÃ© | Classe A | Classe B | Classe C |\n|----------|----------|----------|----------|\n| Architecture logicielle | Optionnel | Requis | Requis |\n| Conception dÃ©taillÃ©e | Optionnel | Optionnel | Requis |\n| VÃ©rification unitaire | Optionnel | Requis | Requis |\n| Tests d'intÃ©gration | Optionnel | Requis | Requis |\n| Revue de code | Optionnel | RecommandÃ© | Requis |\n\n3. SOUP (Software of Unknown Provenance):\n   - Ã‰valuation des risques\n   - Documentation requise\n   - StratÃ©gies de test\n\n**Exercice 1.3:** *Classification et StratÃ©gie de Revue*\n```\nCas: Pompe Ã  insuline connectÃ©e\n\nComposants logiciels:\nA) Module de calcul de dose\nB) Interface utilisateur (affichage)\nC) Module Bluetooth de synchronisation\nD) BibliothÃ¨que open-source de chiffrement\n\nTÃ¢ches:\n1. Classifier chaque composant (A, B, ou C)\n2. DÃ©finir la stratÃ©gie de revue de code pour chaque composant\n3. Identifier les SOUP et documenter les risques\n```\n\n---\n\n### JOUR 2: MÃ©thodologies de Revue de Code (8h)\n\n#### Module 2.1: MÃ©thodes Formelles - L'Inspection Fagan (3h)\n\n**Objectifs:**\n- MaÃ®triser le processus d'inspection Fagan\n- Comprendre quand utiliser cette mÃ©thode coÃ»teuse\n- Documenter correctement une inspection formelle\n\n**Contenu:**\n1. Les 6 Ã©tapes de l'inspection Fagan:\n   - **Planning:** DÃ©finition du scope, assignation des rÃ´les\n   - **Overview:** PrÃ©sentation du code par l'auteur\n   - **Preparation:** Examen individuel (typiquement 200 lignes/heure)\n   - **Inspection Meeting:** Revue collective, identification des dÃ©fauts\n   - **Rework:** Corrections par l'auteur\n   - **Follow-up:** VÃ©rification des corrections\n\n2. RÃ´les et responsabilitÃ©s:\n   - **Moderator:** Facilite la rÃ©union, s'assure du respect du processus\n   - **Author:** Explique le code, corrige les dÃ©fauts\n   - **Reader:** Lit le code Ã  haute voix\n   - **Recorder:** Documente les dÃ©fauts trouvÃ©s\n   - **Inspectors:** Identifient les problÃ¨mes\n\n3. CritÃ¨res d'entrÃ©e/sortie:\n   - Entry: Code complet, compilable, tests unitaires passent\n   - Exit: Tous les dÃ©fauts critiques corrigÃ©s et vÃ©rifiÃ©s\n\n4. MÃ©triques de rÃ©fÃ©rence:\n   - Environ 9 heures-personne pour 200 lignes de code\n   - Taux de dÃ©tection: 60-90% des dÃ©fauts\n   - ROI: IBM a rÃ©duit les dÃ©fauts de 2/3 avec cette mÃ©thode\n\n**Exercice 2.1:** *Simulation d'Inspection Fagan*\n```\nFormation de groupes de 5 personnes avec attribution des rÃ´les.\n\nCode Ã  inspecter: Module de calcul de date d'expiration\n(fourni sÃ©parÃ©ment - environ 150 lignes)\n\nLivrables:\n1. Liste des dÃ©fauts documentÃ©e (formulaire standard)\n2. Classification de sÃ©vÃ©ritÃ© de chaque dÃ©faut\n3. Rapport d'inspection avec mÃ©triques\n```\n\n#### Module 2.2: Revue de Code BasÃ©e sur les Risques (GAMP 5) (2.5h)\n\n**Objectifs:**\n- Appliquer l'approche GAMP 5 Ã  la revue de code\n- Calibrer l'effort de revue selon la catÃ©gorie du systÃ¨me\n- Documenter la justification basÃ©e sur les risques\n\n**Contenu:**\n1. CatÃ©gories GAMP 5:\n   - **Cat 1:** Infrastructure (OS, bases de donnÃ©es) â†’ Validation minimale\n   - **Cat 3:** Non-configurable COTS â†’ VÃ©rification configuration\n   - **Cat 4:** Configurable COTS â†’ VÃ©rification configuration + customisation\n   - **Cat 5:** Custom (dÃ©veloppement interne) â†’ Validation complÃ¨te\n\n2. Effort de revue par catÃ©gorie:\n\n| CatÃ©gorie | Effort relatif | Focus de la revue |\n|-----------|----------------|-------------------|\n| Cat 1 | Minimal | Installation, configuration |\n| Cat 3 | Faible | Configuration, IQ/OQ |\n| Cat 4 | Moyen | Configuration, scripts, rapports |\n| Cat 5 | Ã‰levÃ© (+50-100%) | Code complet, architecture, tests |\n\n3. Matrice de traÃ§abilitÃ©:\n   - Requirements â†’ Specifications â†’ Code â†’ Tests\n\n**Exercice 2.2:** *StratÃ©gie de Revue BasÃ©e sur les Risques*\n```\nScÃ©nario: Nouveau systÃ¨me de gestion des lots (LIMS)\n\nComposants:\n- Base Oracle (Cat 1)\n- Application LIMS commerciale (Cat 4)\n- Rapports personnalisÃ©s (Cat 5)\n- Interfaces avec ERP (Cat 5)\n- Tableaux de bord (Cat 4)\n\nTÃ¢ches:\n1. Documenter la stratÃ©gie de revue pour chaque composant\n2. Estimer l'effort relatif (en %)\n3. Identifier les Ã©lÃ©ments critiques nÃ©cessitant une inspection Fagan\n4. CrÃ©er un plan de revue avec jalons\n```\n\n#### Module 2.3: Checklists de Revue SpÃ©cifiques FDA (2.5h)\n\n**Objectifs:**\n- CrÃ©er et utiliser des checklists conformes\n- Couvrir les aspects rÃ©glementaires spÃ©cifiques\n- Personnaliser les checklists par projet\n\n**Contenu:**\n\n1. **Checklist GÃ©nÃ©rale - ConformitÃ© Part 11:**\n```\nâ–¡ Audit trail implÃ©mentÃ© pour toutes les modifications de donnÃ©es GxP\nâ–¡ Horodatage avec timezone documentÃ©\nâ–¡ Identification utilisateur unique\nâ–¡ ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les (RBAC)\nâ–¡ Backup et rÃ©cupÃ©ration testÃ©s\nâ–¡ Signatures Ã©lectroniques conformes Â§11.100\nâ–¡ ImpossibilitÃ© de modifier les enregistrements signÃ©s\nâ–¡ Export des donnÃ©es en format lisible par l'humain\n```\n\n2. **Checklist SÃ©curitÃ© - IEC 62304 Classe C:**\n```\nâ–¡ Gestion des erreurs pour tous les cas limites\nâ–¡ Validation des entrÃ©es utilisateur\nâ–¡ Timeouts implÃ©mentÃ©s pour opÃ©rations critiques\nâ–¡ Valeurs par dÃ©faut sÃ»res\nâ–¡ Tests de stress/limite effectuÃ©s\nâ–¡ Analyse de code statique sans findings critiques\nâ–¡ Couverture de tests > 80%\nâ–¡ Documentation des algorithmes critiques\n```\n\n3. **Checklist Data Integrity (ALCOA+):**\n```\nâ–¡ Attributable: Qui a crÃ©Ã©/modifiÃ© les donnÃ©es?\nâ–¡ Legible: DonnÃ©es lisibles et permanentes?\nâ–¡ Contemporaneous: Enregistrement au moment de l'action?\nâ–¡ Original: DonnÃ©es originales prÃ©servÃ©es?\nâ–¡ Accurate: Exactitude vÃ©rifiable?\nâ–¡ Complete: Toutes les donnÃ©es incluses?\nâ–¡ Consistent: Format cohÃ©rent?\nâ–¡ Enduring: Disponible pendant la pÃ©riode de rÃ©tention?\nâ–¡ Available: Accessible pour audit/inspection?\n```\n\n**Exercice 2.3:** *CrÃ©ation de Checklist PersonnalisÃ©e*\n```\nContexte: Application de gestion des essais cliniques (CTMS)\n\nTÃ¢ches:\n1. CrÃ©er une checklist de 20 items minimum\n2. CatÃ©goriser: Critique / Majeur / Mineur\n3. Ajouter les rÃ©fÃ©rences rÃ©glementaires\n4. DÃ©finir les critÃ¨res pass/fail\n5. Tester sur un code exemple\n```\n\n---\n\n### JOUR 3: Outils et Automatisation (8h)\n\n#### Module 3.1: Qualification des Outils de Revue (2h)\n\n**Objectifs:**\n- Comprendre les exigences de qualification des outils\n- Documenter la validation d'un outil de revue\n- GÃ©rer le cycle de vie des outils\n\n**Contenu:**\n1. Exigences GAMP 5 pour les outils de dÃ©veloppement\n2. CatÃ©gories d'outils:\n   - Outils sans impact GxP direct\n   - Outils avec impact indirect (IDE, compilateurs)\n   - Outils avec impact direct (gÃ©nÃ©ration de code, test automation)\n\n3. Documentation de qualification:\n   - Intended Use Statement\n   - Risk Assessment\n   - Test Cases\n   - Validation Report\n\n4. Outils courants et leur qualification:\n   - GitHub/GitLab (version control)\n   - SonarQube (analyse statique)\n   - Jira (defect tracking)\n   - Crucible/Review Board (code review)\n\n**Exercice 3.1:** *Plan de Qualification d'Outil*\n```\nOutil: GitHub Enterprise pour revue de code\n\nLivrables:\n1. Document \"Intended Use\"\n2. Risk Assessment (3-5 risques)\n3. Test cases (5-10 scÃ©narios)\n4. CritÃ¨res d'acceptation\n```\n\n#### Module 3.2: Analyse Statique et Automatisation (3h)\n\n**Objectifs:**\n- IntÃ©grer l'analyse statique dans le workflow\n- Configurer les rÃ¨gles pour la conformitÃ© FDA\n- InterprÃ©ter et documenter les rÃ©sultats\n\n**Contenu:**\n1. Outils d'analyse statique:\n   - **SonarQube:** QualitÃ© gÃ©nÃ©rale, dette technique\n   - **Coverity:** DÃ©tection de dÃ©fauts critiques\n   - **Klocwork:** SÃ©curitÃ©, conformitÃ© standards\n   - **Polyspace:** Certification (aviation, mÃ©dical)\n\n2. RÃ¨gles essentielles pour FDA:\n   - MISRA C/C++ (dispositifs mÃ©dicaux embarquÃ©s)\n   - OWASP Top 10 (applications web)\n   - CWE (Common Weakness Enumeration)\n\n3. IntÃ©gration CI/CD:\n   - Gates de qualitÃ©\n   - Seuils de blocage\n   - Reporting automatisÃ©\n\n4. Documentation des findings:\n   - Justification des faux positifs\n   - Plan de remÃ©diation\n   - Suivi des dÃ©viations\n\n**Exercice 3.2:** *Configuration SonarQube pour FDA*\n```\nTÃ¢ches pratiques:\n1. CrÃ©er un Quality Profile \"FDA Medical Device\"\n2. Activer les rÃ¨gles critiques pour Part 11\n3. DÃ©finir les Quality Gates\n4. Analyser un projet exemple\n5. Documenter les findings et actions\n```\n\n#### Module 3.3: Gestion des DÃ©fauts et CAPA (3h)\n\n**Objectifs:**\n- Classifier les dÃ©fauts selon leur impact\n- Lier les dÃ©fauts au systÃ¨me CAPA\n- Assurer la traÃ§abilitÃ© requise\n\n**Contenu:**\n1. Classification des dÃ©fauts de code review:\n\n| SÃ©vÃ©ritÃ© | DÃ©finition | Action | DÃ©lai |\n|----------|------------|--------|-------|\n| **Critique** | Impact patient, data integrity | Stop & fix | ImmÃ©diat |\n| **Majeur** | Non-conformitÃ© rÃ©glementaire | Fix before release | 24-48h |\n| **Mineur** | Best practice, maintenabilitÃ© | Plan fix | Prochain sprint |\n| **CosmÃ©tique** | Style, formatting | Optional | Backlog |\n\n2. IntÃ©gration CAPA (Corrective and Preventive Action):\n   - Quand escalader un dÃ©faut vers CAPA?\n   - Documentation de l'investigation\n   - Root Cause Analysis (RCA)\n   - Actions prÃ©ventives systÃ©miques\n\n3. MÃ©triques de suivi:\n   - Defect density (dÃ©fauts/KLOC)\n   - Defect removal efficiency\n   - Escaped defects rate\n   - Time to resolution\n\n**Exercice 3.3:** *Simulation Gestion de DÃ©fauts*\n```\nScÃ©nario: Lors d'une revue, vous dÃ©couvrez:\n1. Mot de passe en clair dans le code\n2. Calcul de dose incorrect (division par zÃ©ro possible)\n3. Commentaire TODO avec date de 2019\n4. Variable non utilisÃ©e\n5. Absence de validation d'entrÃ©e utilisateur\n\nTÃ¢ches:\n1. Classifier chaque dÃ©faut\n2. RÃ©diger les tickets avec toutes les infos requises\n3. DÃ©cider lesquels nÃ©cessitent un CAPA\n4. Proposer des actions prÃ©ventives\n```\n\n---\n\n### JOUR 4: Documentation et TraÃ§abilitÃ© (8h)\n\n#### Module 4.1: Exigences de Documentation FDA (3h)\n\n**Objectifs:**\n- Produire une documentation conforme aux audits\n- Maintenir la traÃ§abilitÃ© bout-en-bout\n- PrÃ©parer les preuves pour inspection\n\n**Contenu:**\n1. Documents essentiels de revue de code:\n   - **Code Review Record:** Qui, quoi, quand, rÃ©sultat\n   - **Defect Log:** Liste des dÃ©fauts trouvÃ©s\n   - **Resolution Record:** Corrections effectuÃ©es\n   - **Approval Evidence:** Signatures/approbations\n\n2. TraÃ§abilitÃ© bidirectionnelle:\n```\nRequirements â†’ Design â†’ Code â†’ Test Cases â†’ Test Results\n     â†‘                                              â†“\n     â†â†â†â†â†â†â†â†â† Traceability Matrix â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†\n```\n\n3. RÃ©tention des enregistrements:\n   - Dispositifs mÃ©dicaux: DurÃ©e de vie + 2 ans\n   - Pharmaceutique: Selon protocole (souvent 15+ ans)\n   - Essais cliniques: 15 ans minimum\n\n4. Format des preuves:\n   - PDF/A pour archivage long terme\n   - Signatures Ã©lectroniques conformes\n   - MÃ©tadonnÃ©es prÃ©servÃ©es\n\n**Exercice 4.1:** *CrÃ©ation d'un Package de Documentation*\n```\nContexte: Module de calcul de dose - prÃªt pour release\n\nCrÃ©ez le package complet:\n1. Code Review Request Form\n2. Code Review Checklist (remplie)\n3. Defect Log avec rÃ©solutions\n4. Traceability Matrix (requirements â†’ code â†’ tests)\n5. Code Review Summary Report\n6. Approval signatures\n```\n\n#### Module 4.2: PrÃ©paration aux Audits FDA (2.5h)\n\n**Objectifs:**\n- Anticiper les questions des inspecteurs\n- Organiser la documentation pour accÃ¨s rapide\n- Ã‰viter les observations 483 courantes\n\n**Contenu:**\n1. Questions typiques d'audit sur le code review:\n   - \"Montrez-moi votre procÃ©dure de revue de code\"\n   - \"Comment assurez-vous l'indÃ©pendance du reviewer?\"\n   - \"Quelles preuves avez-vous que ce code a Ã©tÃ© revu?\"\n   - \"Comment gÃ©rez-vous les dÃ©fauts trouvÃ©s?\"\n   - \"Quelle formation ont vos reviewers?\"\n\n2. Observations 483 frÃ©quentes (Ã©viter):\n   - Absence de documentation de revue\n   - Reviews non indÃ©pendantes (auteur = reviewer)\n   - DÃ©fauts non rÃ©solus avant release\n   - Absence de traÃ§abilitÃ© requirements â†’ code\n   - Personnel non qualifiÃ©\n\n3. Organisation des preuves:\n   - Index par projet/release\n   - AccÃ¨s rapide (< 24h pour tout document)\n   - Versions historiques prÃ©servÃ©es\n\n**Exercice 4.2:** *Simulation d'Audit*\n```\nJeu de rÃ´le:\n- 2 participants = Inspecteurs FDA\n- 2 participants = Ã‰quipe qualitÃ©\n- 2 participants = DÃ©veloppeurs\n\nScÃ©nario: Inspection du processus de revue de code\npour un rÃ©cent release de logiciel mÃ©dical.\n\nLes inspecteurs ont 30 minutes pour:\n1. Demander la procÃ©dure\n2. SÃ©lectionner un fichier au hasard\n3. VÃ©rifier les preuves de revue\n4. Identifier des gaps\n\nDÃ©brief: Quelles amÃ©liorations?\n```\n\n#### Module 4.3: IntÃ©gritÃ© des DonnÃ©es (Data Integrity) (2.5h)\n\n**Objectifs:**\n- Appliquer les principes ALCOA+ au code review\n- ProtÃ©ger les enregistrements de revue\n- DÃ©tecter les problÃ¨mes d'intÃ©gritÃ©\n\n**Contenu:**\n1. ALCOA+ appliquÃ© Ã  la revue de code:\n   - **Attributable:** Identification du reviewer (pas gÃ©nÃ©rique)\n   - **Legible:** Comments clairs, pas d'abrÃ©viations obscures\n   - **Contemporaneous:** Revue avant release, pas rÃ©troactive\n   - **Original:** Pas de modification des rapports aprÃ¨s signature\n   - **Accurate:** Findings vÃ©rifiables dans le code\n\n2. Red flags d'intÃ©gritÃ©:\n   - Timestamps incohÃ©rents\n   - Reviews trop rapides (< 5 min pour 1000 lignes)\n   - MÃªme reviewer pour tout un projet\n   - DÃ©fauts jamais trouvÃ©s\n   - Modifications post-release non documentÃ©es\n\n3. ContrÃ´les techniques:\n   - Verrouillage des enregistrements signÃ©s\n   - Audit trail des modifications\n   - Backups avec checksums\n   - AccÃ¨s role-based\n\n**Exercice 4.3:** *DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©*\n```\nAnalysez ce rapport de revue et identifiez les anomalies:\n\nCode Review Report #2024-0315\n- Reviewer: jsmith\n- Date: 2024-03-15 14:32:05\n- Files reviewed: 47 files, 12,547 lines\n- Duration: 23 minutes\n- Defects found: 0\n- Status: APPROVED\n\nGit log pour le mÃªme commit:\n- Author: jsmith\n- Date: 2024-03-15 14:30:00\n- Message: \"Fixed critical bug in dose calculation\"\n\nQuestions:\n1. Quelles anomalies identifiez-vous?\n2. Quelles questions poseriez-vous?\n3. Comment prÃ©venir ces situations?\n```\n\n---\n\n### JOUR 5: CompÃ©tences et AmÃ©lioration Continue (8h)\n\n#### Module 5.1: CompÃ©tences du Reviewer FDA (2h)\n\n**Objectifs:**\n- DÃ©finir les compÃ©tences requises\n- Ã‰valuer et dÃ©velopper les reviewers\n- Documenter les qualifications\n\n**Contenu:**\n1. CompÃ©tences techniques requises:\n   - Langage de programmation du projet\n   - Architecture et patterns utilisÃ©s\n   - Standards de codage de l'entreprise\n   - Outils de dÃ©veloppement (IDE, VCS, CI/CD)\n\n2. CompÃ©tences rÃ©glementaires:\n   - Connaissance de Part 11/Part 820\n   - ComprÃ©hension de GAMP 5\n   - FamiliaritÃ© avec IEC 62304 (si applicable)\n   - Principes de data integrity\n\n3. CompÃ©tences comportementales:\n   - Communication constructive\n   - Attention aux dÃ©tails\n   - IndÃ©pendance de jugement\n   - Gestion du temps\n\n4. Matrice de compÃ©tences:\n\n| CompÃ©tence | Niveau 1 | Niveau 2 | Niveau 3 |\n|------------|----------|----------|----------|\n| Langage | Lit le code | Ã‰crit du code | Expert |\n| RÃ©glementation | SensibilisÃ© | FormÃ© | CertifiÃ© |\n| Revue | Observateur | Reviewer | Lead/Moderator |\n\n**Exercice 5.1:** *Auto-Ã©valuation et Plan de DÃ©veloppement*\n```\nComplÃ©tez la matrice de compÃ©tences pour vous-mÃªme.\nIdentifiez 3 gaps prioritaires.\nCrÃ©ez un plan de dÃ©veloppement sur 6 mois.\n```\n\n#### Module 5.2: Feedback Constructif et Communication (2h)\n\n**Objectifs:**\n- Formuler des commentaires de revue efficaces\n- GÃ©rer les dÃ©saccords professionnellement\n- CrÃ©er une culture de revue positive\n\n**Contenu:**\n1. Principes du feedback constructif:\n   - Focus sur le code, pas la personne\n   - Expliquer le \"pourquoi\"\n   - Proposer des solutions, pas juste des critiques\n   - ReconnaÃ®tre le bon travail\n\n2. Formulations Ã  Ã©viter vs adopter:\n\n| âŒ Ã€ Ã©viter | âœ… PrÃ©fÃ©rer |\n|------------|-------------|\n| \"Ce code est nul\" | \"Ce pattern pourrait causer X. ConsidÃ©rer Y?\" |\n| \"Pourquoi as-tu fait Ã§a?\" | \"Quelle Ã©tait l'intention ici? Je suggÃ¨re...\" |\n| \"Obvious bug\" | \"Ce cas limite n'est pas gÃ©rÃ©: [exemple]\" |\n| \"RTFM\" | \"La documentation standard X couvre ce cas\" |\n\n3. Gestion des dÃ©saccords:\n   - Escalade technique vs Ã©motionnelle\n   - Quand impliquer un tiers\n   - Documentation des dÃ©cisions\n\n**Exercice 5.2:** *Reformulation de Commentaires*\n```\nReformulez ces commentaires de revue:\n\n1. \"This is wrong\"\n2. \"You always forget error handling\"\n3. \"Why would anyone write code like this?\"\n4. \"This will never work\"\n5. \"Didn't you read the requirements?\"\n\nPuis, pratiquez en binÃ´mes avec des revues rÃ©elles.\n```\n\n#### Module 5.3: MÃ©triques et AmÃ©lioration Continue (2h)\n\n**Objectifs:**\n- Mesurer l'efficacitÃ© du processus de revue\n- Identifier les opportunitÃ©s d'amÃ©lioration\n- ImplÃ©menter des actions correctives\n\n**Contenu:**\n1. MÃ©triques clÃ©s de revue:\n   - **Inspection Rate:** Lignes/heure (cible: 100-200)\n   - **Defect Density:** DÃ©fauts/KLOC trouvÃ©s\n   - **Defect Removal Efficiency:** % dÃ©fauts trouvÃ©s avant test\n   - **Escaped Defects:** DÃ©fauts trouvÃ©s aprÃ¨s release\n   - **Review Coverage:** % du code revu\n\n2. Benchmarks industrie:\n\n| MÃ©trique | Faible | Moyen | Excellent |\n|----------|--------|-------|-----------|\n| Defect density (review) | < 5/KLOC | 5-15/KLOC | > 15/KLOC |\n| DRE | < 50% | 50-80% | > 80% |\n| Review coverage | < 50% | 50-80% | 100% |\n| Escaped to production | > 10% | 5-10% | < 5% |\n\n3. Cycle d'amÃ©lioration continue:\n   - Collecter les mÃ©triques\n   - Analyser les tendances\n   - Identifier les root causes\n   - ImplÃ©menter les amÃ©liorations\n   - Mesurer l'impact\n\n**Exercice 5.3:** *Analyse et Plan d'AmÃ©lioration*\n```\nDonnÃ©es des 6 derniers mois:\n- 150 revues effectuÃ©es\n- 340 dÃ©fauts trouvÃ©s\n- 45,000 lignes revues\n- 12 dÃ©fauts Ã©chappÃ©s en production\n- Temps moyen de revue: 45 min\n\nTÃ¢ches:\n1. Calculer les mÃ©triques clÃ©s\n2. Comparer aux benchmarks\n3. Identifier 3 axes d'amÃ©lioration\n4. Proposer des actions concrÃ¨tes\n5. DÃ©finir les KPIs de suivi\n```\n\n#### Module 5.4: Ã‰valuation Finale et Certification (2h)\n\n**Objectifs:**\n- Valider les acquis de la formation\n- Obtenir la certification interne\n- Planifier la mise en pratique\n\n**Contenu:**\n1. **Examen thÃ©orique (45 min):**\n   - 50 questions Ã  choix multiples\n   - Score minimum: 80%\n   - Couvre tous les modules\n\n2. **Examen pratique (45 min):**\n   - Revue d'un code fourni (200 lignes)\n   - Utilisation de la checklist\n   - Documentation des findings\n   - Ã‰valuation par un formateur certifiÃ©\n\n3. **CritÃ¨res de certification:**\n   - Examen thÃ©orique: â‰¥ 80%\n   - Examen pratique: Tous les dÃ©fauts critiques trouvÃ©s\n   - Participation aux exercices: 100%\n\n4. **Plan d'action post-formation:**\n   - Revues supervisÃ©es pendant 1 mois\n   - Feedback mentor\n   - Recertification annuelle\n\n---\n\n## Annexes\n\n### Annexe A: Template de Code Review Record\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n                     CODE REVIEW RECORD\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nIDENTIFICATION\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview ID:          _______________________\nProject:            _______________________\nModule/Component:   _______________________\nDocument Version:   _______________________\n\nREVIEW DETAILS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview Type:        â–¡ Formal Inspection  â–¡ Peer Review  â–¡ Pair Programming\nAuthor:             _______________________  Date: ____________\nReviewer(s):        _______________________\nModerator:          _______________________ (if applicable)\n\nFiles Reviewed:\nâ”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”\nâ”‚ File Path                           â”‚ Lines    â”‚ Revision   â”‚\nâ”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤\nâ”‚                                     â”‚          â”‚            â”‚\nâ”‚                                     â”‚          â”‚            â”‚\nâ””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜\n\nREVIEW METRICS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Lines Reviewed:      ________\nPreparation Time (min):    ________\nMeeting Time (min):        ________\nDefects Found:            Critical: ____ Major: ____ Minor: ____\n\nCHECKLIST USED\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ Part 11 Compliance    â–¡ IEC 62304 Safety    â–¡ Data Integrity\nâ–¡ Security (OWASP)      â–¡ Coding Standards    â–¡ Performance\nâ–¡ Other: _______________________\n\nFINDINGS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\n[Attached: Defect Log]\n\nOUTCOME\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ APPROVED - No changes required\nâ–¡ APPROVED WITH CONDITIONS - Minor changes, no re-review\nâ–¡ NOT APPROVED - Re-review required after rework\n\nComments:\n___________________________________________________________\n___________________________________________________________\n\nSIGNATURES\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReviewer:      _____________________ Date: _______ Time: _______\nAuthor:        _____________________ Date: _______ Time: _______\nApprover:      _____________________ Date: _______ Time: _______\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nDocument Control: Rev 1.0 | Effective: YYYY-MM-DD | Page 1 of 1\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### Annexe B: Defect Classification Guide\n\n| CatÃ©gorie | SÃ©vÃ©ritÃ© | DÃ©finition | Exemples |\n|-----------|----------|------------|----------|\n| **Safety** | Critique | Impact potentiel sur la sÃ©curitÃ© patient | Calcul de dose incorrect, race condition sur donnÃ©es critiques |\n| **Data Integrity** | Critique | Corruption ou perte de donnÃ©es GxP | Audit trail absent, donnÃ©es modifiables aprÃ¨s signature |\n| **Regulatory** | Majeur | Non-conformitÃ© aux exigences FDA | ContrÃ´le d'accÃ¨s insuffisant, absence de validation d'entrÃ©e |\n| **Functional** | Majeur | Le code ne fait pas ce qui est spÃ©cifiÃ© | Logic error, mauvaise gestion des erreurs |\n| **Security** | Majeur | VulnÃ©rabilitÃ© de sÃ©curitÃ© | Injection SQL, credentials en dur |\n| **Performance** | Mineur | Impact sur les performances | Algorithm inefficace, memory leak |\n| **Maintainability** | Mineur | DifficultÃ© de maintenance future | Code dupliquÃ©, nommage obscur |\n| **Style** | CosmÃ©tique | Non-conformitÃ© aux standards de style | Formatting, commentaires manquants |\n\n### Annexe C: RÃ©fÃ©rences RÃ©glementaires ClÃ©s\n\n**FDA:**\n- 21 CFR Part 11 - Electronic Records; Electronic Signatures\n- 21 CFR Part 820 - Quality System Regulation\n- FDA Guidance: General Principles of Software Validation (2002)\n- FDA Guidance: Computer Software Assurance for Production and Quality System Software (2022)\n\n**International:**\n- IEC 62304:2006/Amd 1:2015 - Medical device software â€” Software life cycle processes\n- ISO 13485:2016 - Medical devices â€” Quality management systems\n- GAMP 5 Guide, 2nd Edition (ISPE, 2022)\n- EU GMP Annex 11 - Computerised Systems\n\n**Industry Standards:**\n- IEEE 1028 - Standard for Software Reviews and Audits\n- ISO/IEC 25010 - Software Quality Model\n- OWASP Top 10 - Web Application Security Risks\n\n### Annexe D: Ressources ComplÃ©mentaires\n\n**Formations RecommandÃ©es:**\n- ISPE GAMP 5 Training\n- FDA Regulatory Affairs Certification (RAC)\n- IEC 62304 Implementation Workshops\n\n**Outils:**\n- [SonarQube](https://www.sonarqube.org/) - Analyse statique open source\n- [Coverity](https://scan.coverity.com/) - DÃ©tection de dÃ©fauts\n- [GitHub Code Review](https://docs.github.com/en/pull-requests) - Revue collaborative\n\n**Publications:**\n- FDA Warning Letters Database (fda.gov)\n- ISPE Pharmaceutical Engineering Magazine\n- Medical Device & Diagnostic Industry (MD+DI)\n\n---\n\n## Sources de Recherche\n\nCette formation a Ã©tÃ© Ã©laborÃ©e Ã  partir des sources suivantes:\n\n- [FDA 21 CFR Part 11 Compliance Guide - Redzone](https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/)\n- [IEC 62304 Software Lifecycle - Jama Software](https://www.jamasoftware.com/blog/an-in-depth-guide-to-iec-62304-software-lifecycle-processes-for-medical-devices/)\n- [GAMP 5 Guide 2nd Edition - ISPE](https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition)\n- [2023 FDA Warning Letters and Software Validation - Ketryx](https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation)\n- [Fagan Inspection - Wikipedia](https://en.wikipedia.org/wiki/Fagan_inspection)\n- [FDA Warning Letters Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n- [Code Review Workshops - Dr. Michaela Greiler](https://www.michaelagreiler.com/workshops/)\n- [Computer Software Assurance Guidance - FDA](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software)\n\n---\n\n*Document crÃ©Ã© le 2025-12-25*\n*Version 1.0*\n"},"tool_response":{"type":"create","filePath":"/home/chris/FDA-Code-Review-Training-Program.md","content":"# Formation: Meilleures Techniques de RÃ©vision de Code en Contexte FDA\n\n## Vue d'Ensemble du Programme\n\n**DurÃ©e totale:** 5 jours (40 heures)\n**Public cible:** DÃ©veloppeurs, QA, Responsables QualitÃ©, Auditeurs internes\n**PrÃ©requis:** ExpÃ©rience en dÃ©veloppement logiciel, notions de base en rÃ©glementation\n\n---\n\n## Cadre RÃ©glementaire\n\n### RÃ©fÃ©rences Normatives ClÃ©s\n\n| Standard | Application | Focus Principal |\n|----------|-------------|-----------------|\n| **21 CFR Part 11** | Enregistrements Ã©lectroniques & signatures | Audit trails, validation, contrÃ´le d'accÃ¨s |\n| **21 CFR Part 820** | Quality System Regulation (dispositifs mÃ©dicaux) | Design controls, documentation |\n| **IEC 62304** | Logiciels de dispositifs mÃ©dicaux | Cycle de vie, classification de sÃ©curitÃ© |\n| **GAMP 5** | SystÃ¨mes informatisÃ©s pharmaceutiques | Validation basÃ©e sur le risque |\n| **EU GMP Annex 11** | SystÃ¨mes informatisÃ©s (Europe) | Validation, intÃ©gritÃ© des donnÃ©es |\n\n---\n\n## Structure de la Formation\n\n### JOUR 1: Fondamentaux RÃ©glementaires (8h)\n\n#### Module 1.1: Introduction au Contexte FDA (2h)\n\n**Objectifs:**\n- Comprendre le rÃ´le de la FDA dans la rÃ©gulation des logiciels\n- Identifier les types de logiciels rÃ©gulÃ©s (SaMD, SiMD, GxP)\n- ConnaÃ®tre les consÃ©quences d'une non-conformitÃ©\n\n**Contenu:**\n1. Historique et Ã©volution de la rÃ©glementation FDA\n2. Types de logiciels sous rÃ©glementation FDA:\n   - Software as a Medical Device (SaMD)\n   - Software in a Medical Device (SiMD)\n   - Production Quality System Software (PQSS)\n   - GxP Systems (GMP, GLP, GCP)\n3. Statistiques rÃ©centes: En 2024, 529 warning letters Ã©mises par CDRH, 8% pour des problÃ¨mes de validation\n4. Computer Software Assurance (CSA) vs Computer System Validation (CSV)\n\n**Exercice 1.1:** *Analyse de cas - Classification de logiciels*\n```\nScÃ©nario: Votre entreprise dÃ©veloppe 5 logiciels diffÃ©rents:\n1. Application mobile de suivi de glycÃ©mie\n2. SystÃ¨me ERP pour la gestion des stocks\n3. Logiciel de contrÃ´le qualitÃ© en production\n4. Application de prise de rendez-vous patients\n5. Algorithme d'analyse d'images radiologiques\n\nTÃ¢che: Classifier chaque logiciel (SaMD, SiMD, PQSS, Non-rÃ©gulÃ©)\net dÃ©terminer le niveau de rigueur de revue de code requis.\n```\n\n#### Module 1.2: 21 CFR Part 11 en DÃ©tail (3h)\n\n**Objectifs:**\n- MaÃ®triser les exigences d'enregistrements Ã©lectroniques\n- Comprendre les implications pour le code review\n- Identifier les contrÃ´les techniques requis\n\n**Contenu:**\n1. Subpart B - Electronic Records (Â§11.10)\n   - Validation des systÃ¨mes\n   - GÃ©nÃ©ration de copies exactes\n   - Protection des enregistrements\n   - Audit trails (qui, quoi, quand)\n   - ContrÃ´les d'accÃ¨s\n\n2. Subpart C - Electronic Signatures (Â§11.100-11.300)\n   - UnicitÃ© des signatures\n   - VÃ©rification d'identitÃ©\n   - Liens entre signature et enregistrement\n\n3. Impact sur le code review:\n   - TraÃ§abilitÃ© des modifications de code\n   - Versioning et contrÃ´le de configuration\n   - Documentation des dÃ©cisions de revue\n\n**Exercice 1.2:** *Audit Trail Code Review*\n```\nAnalysez cet extrait de code et identifiez les non-conformitÃ©s Part 11:\n\n// Fonction de mise Ã  jour d'un lot de production\nfunction updateBatch(batchId, newData) {\n    db.batches.update(batchId, newData);\n    console.log(\"Batch updated\");\n    return true;\n}\n\nQuestions:\n1. Quelles informations d'audit manquent?\n2. Comment modifier ce code pour la conformitÃ©?\n3. Quels tests ajouteriez-vous?\n```\n\n#### Module 1.3: IEC 62304 et Classification de SÃ©curitÃ© (3h)\n\n**Objectifs:**\n- Comprendre les 3 classes de sÃ©curitÃ© (A, B, C)\n- Appliquer le niveau de rigueur appropriÃ© Ã  la revue de code\n- MaÃ®triser les exigences de documentation\n\n**Contenu:**\n1. Classes de sÃ©curitÃ© logicielle:\n   - **Classe A:** Aucune blessure possible\n   - **Classe B:** Blessure non-grave possible\n   - **Classe C:** Mort ou blessure grave possible\n\n2. Exigences par classe:\n\n| ActivitÃ© | Classe A | Classe B | Classe C |\n|----------|----------|----------|----------|\n| Architecture logicielle | Optionnel | Requis | Requis |\n| Conception dÃ©taillÃ©e | Optionnel | Optionnel | Requis |\n| VÃ©rification unitaire | Optionnel | Requis | Requis |\n| Tests d'intÃ©gration | Optionnel | Requis | Requis |\n| Revue de code | Optionnel | RecommandÃ© | Requis |\n\n3. SOUP (Software of Unknown Provenance):\n   - Ã‰valuation des risques\n   - Documentation requise\n   - StratÃ©gies de test\n\n**Exercice 1.3:** *Classification et StratÃ©gie de Revue*\n```\nCas: Pompe Ã  insuline connectÃ©e\n\nComposants logiciels:\nA) Module de calcul de dose\nB) Interface utilisateur (affichage)\nC) Module Bluetooth de synchronisation\nD) BibliothÃ¨que open-source de chiffrement\n\nTÃ¢ches:\n1. Classifier chaque composant (A, B, ou C)\n2. DÃ©finir la stratÃ©gie de revue de code pour chaque composant\n3. Identifier les SOUP et documenter les risques\n```\n\n---\n\n### JOUR 2: MÃ©thodologies de Revue de Code (8h)\n\n#### Module 2.1: MÃ©thodes Formelles - L'Inspection Fagan (3h)\n\n**Objectifs:**\n- MaÃ®triser le processus d'inspection Fagan\n- Comprendre quand utiliser cette mÃ©thode coÃ»teuse\n- Documenter correctement une inspection formelle\n\n**Contenu:**\n1. Les 6 Ã©tapes de l'inspection Fagan:\n   - **Planning:** DÃ©finition du scope, assignation des rÃ´les\n   - **Overview:** PrÃ©sentation du code par l'auteur\n   - **Preparation:** Examen individuel (typiquement 200 lignes/heure)\n   - **Inspection Meeting:** Revue collective, identification des dÃ©fauts\n   - **Rework:** Corrections par l'auteur\n   - **Follow-up:** VÃ©rification des corrections\n\n2. RÃ´les et responsabilitÃ©s:\n   - **Moderator:** Facilite la rÃ©union, s'assure du respect du processus\n   - **Author:** Explique le code, corrige les dÃ©fauts\n   - **Reader:** Lit le code Ã  haute voix\n   - **Recorder:** Documente les dÃ©fauts trouvÃ©s\n   - **Inspectors:** Identifient les problÃ¨mes\n\n3. CritÃ¨res d'entrÃ©e/sortie:\n   - Entry: Code complet, compilable, tests unitaires passent\n   - Exit: Tous les dÃ©fauts critiques corrigÃ©s et vÃ©rifiÃ©s\n\n4. MÃ©triques de rÃ©fÃ©rence:\n   - Environ 9 heures-personne pour 200 lignes de code\n   - Taux de dÃ©tection: 60-90% des dÃ©fauts\n   - ROI: IBM a rÃ©duit les dÃ©fauts de 2/3 avec cette mÃ©thode\n\n**Exercice 2.1:** *Simulation d'Inspection Fagan*\n```\nFormation de groupes de 5 personnes avec attribution des rÃ´les.\n\nCode Ã  inspecter: Module de calcul de date d'expiration\n(fourni sÃ©parÃ©ment - environ 150 lignes)\n\nLivrables:\n1. Liste des dÃ©fauts documentÃ©e (formulaire standard)\n2. Classification de sÃ©vÃ©ritÃ© de chaque dÃ©faut\n3. Rapport d'inspection avec mÃ©triques\n```\n\n#### Module 2.2: Revue de Code BasÃ©e sur les Risques (GAMP 5) (2.5h)\n\n**Objectifs:**\n- Appliquer l'approche GAMP 5 Ã  la revue de code\n- Calibrer l'effort de revue selon la catÃ©gorie du systÃ¨me\n- Documenter la justification basÃ©e sur les risques\n\n**Contenu:**\n1. CatÃ©gories GAMP 5:\n   - **Cat 1:** Infrastructure (OS, bases de donnÃ©es) â†’ Validation minimale\n   - **Cat 3:** Non-configurable COTS â†’ VÃ©rification configuration\n   - **Cat 4:** Configurable COTS â†’ VÃ©rification configuration + customisation\n   - **Cat 5:** Custom (dÃ©veloppement interne) â†’ Validation complÃ¨te\n\n2. Effort de revue par catÃ©gorie:\n\n| CatÃ©gorie | Effort relatif | Focus de la revue |\n|-----------|----------------|-------------------|\n| Cat 1 | Minimal | Installation, configuration |\n| Cat 3 | Faible | Configuration, IQ/OQ |\n| Cat 4 | Moyen | Configuration, scripts, rapports |\n| Cat 5 | Ã‰levÃ© (+50-100%) | Code complet, architecture, tests |\n\n3. Matrice de traÃ§abilitÃ©:\n   - Requirements â†’ Specifications â†’ Code â†’ Tests\n\n**Exercice 2.2:** *StratÃ©gie de Revue BasÃ©e sur les Risques*\n```\nScÃ©nario: Nouveau systÃ¨me de gestion des lots (LIMS)\n\nComposants:\n- Base Oracle (Cat 1)\n- Application LIMS commerciale (Cat 4)\n- Rapports personnalisÃ©s (Cat 5)\n- Interfaces avec ERP (Cat 5)\n- Tableaux de bord (Cat 4)\n\nTÃ¢ches:\n1. Documenter la stratÃ©gie de revue pour chaque composant\n2. Estimer l'effort relatif (en %)\n3. Identifier les Ã©lÃ©ments critiques nÃ©cessitant une inspection Fagan\n4. CrÃ©er un plan de revue avec jalons\n```\n\n#### Module 2.3: Checklists de Revue SpÃ©cifiques FDA (2.5h)\n\n**Objectifs:**\n- CrÃ©er et utiliser des checklists conformes\n- Couvrir les aspects rÃ©glementaires spÃ©cifiques\n- Personnaliser les checklists par projet\n\n**Contenu:**\n\n1. **Checklist GÃ©nÃ©rale - ConformitÃ© Part 11:**\n```\nâ–¡ Audit trail implÃ©mentÃ© pour toutes les modifications de donnÃ©es GxP\nâ–¡ Horodatage avec timezone documentÃ©\nâ–¡ Identification utilisateur unique\nâ–¡ ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les (RBAC)\nâ–¡ Backup et rÃ©cupÃ©ration testÃ©s\nâ–¡ Signatures Ã©lectroniques conformes Â§11.100\nâ–¡ ImpossibilitÃ© de modifier les enregistrements signÃ©s\nâ–¡ Export des donnÃ©es en format lisible par l'humain\n```\n\n2. **Checklist SÃ©curitÃ© - IEC 62304 Classe C:**\n```\nâ–¡ Gestion des erreurs pour tous les cas limites\nâ–¡ Validation des entrÃ©es utilisateur\nâ–¡ Timeouts implÃ©mentÃ©s pour opÃ©rations critiques\nâ–¡ Valeurs par dÃ©faut sÃ»res\nâ–¡ Tests de stress/limite effectuÃ©s\nâ–¡ Analyse de code statique sans findings critiques\nâ–¡ Couverture de tests > 80%\nâ–¡ Documentation des algorithmes critiques\n```\n\n3. **Checklist Data Integrity (ALCOA+):**\n```\nâ–¡ Attributable: Qui a crÃ©Ã©/modifiÃ© les donnÃ©es?\nâ–¡ Legible: DonnÃ©es lisibles et permanentes?\nâ–¡ Contemporaneous: Enregistrement au moment de l'action?\nâ–¡ Original: DonnÃ©es originales prÃ©servÃ©es?\nâ–¡ Accurate: Exactitude vÃ©rifiable?\nâ–¡ Complete: Toutes les donnÃ©es incluses?\nâ–¡ Consistent: Format cohÃ©rent?\nâ–¡ Enduring: Disponible pendant la pÃ©riode de rÃ©tention?\nâ–¡ Available: Accessible pour audit/inspection?\n```\n\n**Exercice 2.3:** *CrÃ©ation de Checklist PersonnalisÃ©e*\n```\nContexte: Application de gestion des essais cliniques (CTMS)\n\nTÃ¢ches:\n1. CrÃ©er une checklist de 20 items minimum\n2. CatÃ©goriser: Critique / Majeur / Mineur\n3. Ajouter les rÃ©fÃ©rences rÃ©glementaires\n4. DÃ©finir les critÃ¨res pass/fail\n5. Tester sur un code exemple\n```\n\n---\n\n### JOUR 3: Outils et Automatisation (8h)\n\n#### Module 3.1: Qualification des Outils de Revue (2h)\n\n**Objectifs:**\n- Comprendre les exigences de qualification des outils\n- Documenter la validation d'un outil de revue\n- GÃ©rer le cycle de vie des outils\n\n**Contenu:**\n1. Exigences GAMP 5 pour les outils de dÃ©veloppement\n2. CatÃ©gories d'outils:\n   - Outils sans impact GxP direct\n   - Outils avec impact indirect (IDE, compilateurs)\n   - Outils avec impact direct (gÃ©nÃ©ration de code, test automation)\n\n3. Documentation de qualification:\n   - Intended Use Statement\n   - Risk Assessment\n   - Test Cases\n   - Validation Report\n\n4. Outils courants et leur qualification:\n   - GitHub/GitLab (version control)\n   - SonarQube (analyse statique)\n   - Jira (defect tracking)\n   - Crucible/Review Board (code review)\n\n**Exercice 3.1:** *Plan de Qualification d'Outil*\n```\nOutil: GitHub Enterprise pour revue de code\n\nLivrables:\n1. Document \"Intended Use\"\n2. Risk Assessment (3-5 risques)\n3. Test cases (5-10 scÃ©narios)\n4. CritÃ¨res d'acceptation\n```\n\n#### Module 3.2: Analyse Statique et Automatisation (3h)\n\n**Objectifs:**\n- IntÃ©grer l'analyse statique dans le workflow\n- Configurer les rÃ¨gles pour la conformitÃ© FDA\n- InterprÃ©ter et documenter les rÃ©sultats\n\n**Contenu:**\n1. Outils d'analyse statique:\n   - **SonarQube:** QualitÃ© gÃ©nÃ©rale, dette technique\n   - **Coverity:** DÃ©tection de dÃ©fauts critiques\n   - **Klocwork:** SÃ©curitÃ©, conformitÃ© standards\n   - **Polyspace:** Certification (aviation, mÃ©dical)\n\n2. RÃ¨gles essentielles pour FDA:\n   - MISRA C/C++ (dispositifs mÃ©dicaux embarquÃ©s)\n   - OWASP Top 10 (applications web)\n   - CWE (Common Weakness Enumeration)\n\n3. IntÃ©gration CI/CD:\n   - Gates de qualitÃ©\n   - Seuils de blocage\n   - Reporting automatisÃ©\n\n4. Documentation des findings:\n   - Justification des faux positifs\n   - Plan de remÃ©diation\n   - Suivi des dÃ©viations\n\n**Exercice 3.2:** *Configuration SonarQube pour FDA*\n```\nTÃ¢ches pratiques:\n1. CrÃ©er un Quality Profile \"FDA Medical Device\"\n2. Activer les rÃ¨gles critiques pour Part 11\n3. DÃ©finir les Quality Gates\n4. Analyser un projet exemple\n5. Documenter les findings et actions\n```\n\n#### Module 3.3: Gestion des DÃ©fauts et CAPA (3h)\n\n**Objectifs:**\n- Classifier les dÃ©fauts selon leur impact\n- Lier les dÃ©fauts au systÃ¨me CAPA\n- Assurer la traÃ§abilitÃ© requise\n\n**Contenu:**\n1. Classification des dÃ©fauts de code review:\n\n| SÃ©vÃ©ritÃ© | DÃ©finition | Action | DÃ©lai |\n|----------|------------|--------|-------|\n| **Critique** | Impact patient, data integrity | Stop & fix | ImmÃ©diat |\n| **Majeur** | Non-conformitÃ© rÃ©glementaire | Fix before release | 24-48h |\n| **Mineur** | Best practice, maintenabilitÃ© | Plan fix | Prochain sprint |\n| **CosmÃ©tique** | Style, formatting | Optional | Backlog |\n\n2. IntÃ©gration CAPA (Corrective and Preventive Action):\n   - Quand escalader un dÃ©faut vers CAPA?\n   - Documentation de l'investigation\n   - Root Cause Analysis (RCA)\n   - Actions prÃ©ventives systÃ©miques\n\n3. MÃ©triques de suivi:\n   - Defect density (dÃ©fauts/KLOC)\n   - Defect removal efficiency\n   - Escaped defects rate\n   - Time to resolution\n\n**Exercice 3.3:** *Simulation Gestion de DÃ©fauts*\n```\nScÃ©nario: Lors d'une revue, vous dÃ©couvrez:\n1. Mot de passe en clair dans le code\n2. Calcul de dose incorrect (division par zÃ©ro possible)\n3. Commentaire TODO avec date de 2019\n4. Variable non utilisÃ©e\n5. Absence de validation d'entrÃ©e utilisateur\n\nTÃ¢ches:\n1. Classifier chaque dÃ©faut\n2. RÃ©diger les tickets avec toutes les infos requises\n3. DÃ©cider lesquels nÃ©cessitent un CAPA\n4. Proposer des actions prÃ©ventives\n```\n\n---\n\n### JOUR 4: Documentation et TraÃ§abilitÃ© (8h)\n\n#### Module 4.1: Exigences de Documentation FDA (3h)\n\n**Objectifs:**\n- Produire une documentation conforme aux audits\n- Maintenir la traÃ§abilitÃ© bout-en-bout\n- PrÃ©parer les preuves pour inspection\n\n**Contenu:**\n1. Documents essentiels de revue de code:\n   - **Code Review Record:** Qui, quoi, quand, rÃ©sultat\n   - **Defect Log:** Liste des dÃ©fauts trouvÃ©s\n   - **Resolution Record:** Corrections effectuÃ©es\n   - **Approval Evidence:** Signatures/approbations\n\n2. TraÃ§abilitÃ© bidirectionnelle:\n```\nRequirements â†’ Design â†’ Code â†’ Test Cases â†’ Test Results\n     â†‘                                              â†“\n     â†â†â†â†â†â†â†â†â† Traceability Matrix â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†â†\n```\n\n3. RÃ©tention des enregistrements:\n   - Dispositifs mÃ©dicaux: DurÃ©e de vie + 2 ans\n   - Pharmaceutique: Selon protocole (souvent 15+ ans)\n   - Essais cliniques: 15 ans minimum\n\n4. Format des preuves:\n   - PDF/A pour archivage long terme\n   - Signatures Ã©lectroniques conformes\n   - MÃ©tadonnÃ©es prÃ©servÃ©es\n\n**Exercice 4.1:** *CrÃ©ation d'un Package de Documentation*\n```\nContexte: Module de calcul de dose - prÃªt pour release\n\nCrÃ©ez le package complet:\n1. Code Review Request Form\n2. Code Review Checklist (remplie)\n3. Defect Log avec rÃ©solutions\n4. Traceability Matrix (requirements â†’ code â†’ tests)\n5. Code Review Summary Report\n6. Approval signatures\n```\n\n#### Module 4.2: PrÃ©paration aux Audits FDA (2.5h)\n\n**Objectifs:**\n- Anticiper les questions des inspecteurs\n- Organiser la documentation pour accÃ¨s rapide\n- Ã‰viter les observations 483 courantes\n\n**Contenu:**\n1. Questions typiques d'audit sur le code review:\n   - \"Montrez-moi votre procÃ©dure de revue de code\"\n   - \"Comment assurez-vous l'indÃ©pendance du reviewer?\"\n   - \"Quelles preuves avez-vous que ce code a Ã©tÃ© revu?\"\n   - \"Comment gÃ©rez-vous les dÃ©fauts trouvÃ©s?\"\n   - \"Quelle formation ont vos reviewers?\"\n\n2. Observations 483 frÃ©quentes (Ã©viter):\n   - Absence de documentation de revue\n   - Reviews non indÃ©pendantes (auteur = reviewer)\n   - DÃ©fauts non rÃ©solus avant release\n   - Absence de traÃ§abilitÃ© requirements â†’ code\n   - Personnel non qualifiÃ©\n\n3. Organisation des preuves:\n   - Index par projet/release\n   - AccÃ¨s rapide (< 24h pour tout document)\n   - Versions historiques prÃ©servÃ©es\n\n**Exercice 4.2:** *Simulation d'Audit*\n```\nJeu de rÃ´le:\n- 2 participants = Inspecteurs FDA\n- 2 participants = Ã‰quipe qualitÃ©\n- 2 participants = DÃ©veloppeurs\n\nScÃ©nario: Inspection du processus de revue de code\npour un rÃ©cent release de logiciel mÃ©dical.\n\nLes inspecteurs ont 30 minutes pour:\n1. Demander la procÃ©dure\n2. SÃ©lectionner un fichier au hasard\n3. VÃ©rifier les preuves de revue\n4. Identifier des gaps\n\nDÃ©brief: Quelles amÃ©liorations?\n```\n\n#### Module 4.3: IntÃ©gritÃ© des DonnÃ©es (Data Integrity) (2.5h)\n\n**Objectifs:**\n- Appliquer les principes ALCOA+ au code review\n- ProtÃ©ger les enregistrements de revue\n- DÃ©tecter les problÃ¨mes d'intÃ©gritÃ©\n\n**Contenu:**\n1. ALCOA+ appliquÃ© Ã  la revue de code:\n   - **Attributable:** Identification du reviewer (pas gÃ©nÃ©rique)\n   - **Legible:** Comments clairs, pas d'abrÃ©viations obscures\n   - **Contemporaneous:** Revue avant release, pas rÃ©troactive\n   - **Original:** Pas de modification des rapports aprÃ¨s signature\n   - **Accurate:** Findings vÃ©rifiables dans le code\n\n2. Red flags d'intÃ©gritÃ©:\n   - Timestamps incohÃ©rents\n   - Reviews trop rapides (< 5 min pour 1000 lignes)\n   - MÃªme reviewer pour tout un projet\n   - DÃ©fauts jamais trouvÃ©s\n   - Modifications post-release non documentÃ©es\n\n3. ContrÃ´les techniques:\n   - Verrouillage des enregistrements signÃ©s\n   - Audit trail des modifications\n   - Backups avec checksums\n   - AccÃ¨s role-based\n\n**Exercice 4.3:** *DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©*\n```\nAnalysez ce rapport de revue et identifiez les anomalies:\n\nCode Review Report #2024-0315\n- Reviewer: jsmith\n- Date: 2024-03-15 14:32:05\n- Files reviewed: 47 files, 12,547 lines\n- Duration: 23 minutes\n- Defects found: 0\n- Status: APPROVED\n\nGit log pour le mÃªme commit:\n- Author: jsmith\n- Date: 2024-03-15 14:30:00\n- Message: \"Fixed critical bug in dose calculation\"\n\nQuestions:\n1. Quelles anomalies identifiez-vous?\n2. Quelles questions poseriez-vous?\n3. Comment prÃ©venir ces situations?\n```\n\n---\n\n### JOUR 5: CompÃ©tences et AmÃ©lioration Continue (8h)\n\n#### Module 5.1: CompÃ©tences du Reviewer FDA (2h)\n\n**Objectifs:**\n- DÃ©finir les compÃ©tences requises\n- Ã‰valuer et dÃ©velopper les reviewers\n- Documenter les qualifications\n\n**Contenu:**\n1. CompÃ©tences techniques requises:\n   - Langage de programmation du projet\n   - Architecture et patterns utilisÃ©s\n   - Standards de codage de l'entreprise\n   - Outils de dÃ©veloppement (IDE, VCS, CI/CD)\n\n2. CompÃ©tences rÃ©glementaires:\n   - Connaissance de Part 11/Part 820\n   - ComprÃ©hension de GAMP 5\n   - FamiliaritÃ© avec IEC 62304 (si applicable)\n   - Principes de data integrity\n\n3. CompÃ©tences comportementales:\n   - Communication constructive\n   - Attention aux dÃ©tails\n   - IndÃ©pendance de jugement\n   - Gestion du temps\n\n4. Matrice de compÃ©tences:\n\n| CompÃ©tence | Niveau 1 | Niveau 2 | Niveau 3 |\n|------------|----------|----------|----------|\n| Langage | Lit le code | Ã‰crit du code | Expert |\n| RÃ©glementation | SensibilisÃ© | FormÃ© | CertifiÃ© |\n| Revue | Observateur | Reviewer | Lead/Moderator |\n\n**Exercice 5.1:** *Auto-Ã©valuation et Plan de DÃ©veloppement*\n```\nComplÃ©tez la matrice de compÃ©tences pour vous-mÃªme.\nIdentifiez 3 gaps prioritaires.\nCrÃ©ez un plan de dÃ©veloppement sur 6 mois.\n```\n\n#### Module 5.2: Feedback Constructif et Communication (2h)\n\n**Objectifs:**\n- Formuler des commentaires de revue efficaces\n- GÃ©rer les dÃ©saccords professionnellement\n- CrÃ©er une culture de revue positive\n\n**Contenu:**\n1. Principes du feedback constructif:\n   - Focus sur le code, pas la personne\n   - Expliquer le \"pourquoi\"\n   - Proposer des solutions, pas juste des critiques\n   - ReconnaÃ®tre le bon travail\n\n2. Formulations Ã  Ã©viter vs adopter:\n\n| âŒ Ã€ Ã©viter | âœ… PrÃ©fÃ©rer |\n|------------|-------------|\n| \"Ce code est nul\" | \"Ce pattern pourrait causer X. ConsidÃ©rer Y?\" |\n| \"Pourquoi as-tu fait Ã§a?\" | \"Quelle Ã©tait l'intention ici? Je suggÃ¨re...\" |\n| \"Obvious bug\" | \"Ce cas limite n'est pas gÃ©rÃ©: [exemple]\" |\n| \"RTFM\" | \"La documentation standard X couvre ce cas\" |\n\n3. Gestion des dÃ©saccords:\n   - Escalade technique vs Ã©motionnelle\n   - Quand impliquer un tiers\n   - Documentation des dÃ©cisions\n\n**Exercice 5.2:** *Reformulation de Commentaires*\n```\nReformulez ces commentaires de revue:\n\n1. \"This is wrong\"\n2. \"You always forget error handling\"\n3. \"Why would anyone write code like this?\"\n4. \"This will never work\"\n5. \"Didn't you read the requirements?\"\n\nPuis, pratiquez en binÃ´mes avec des revues rÃ©elles.\n```\n\n#### Module 5.3: MÃ©triques et AmÃ©lioration Continue (2h)\n\n**Objectifs:**\n- Mesurer l'efficacitÃ© du processus de revue\n- Identifier les opportunitÃ©s d'amÃ©lioration\n- ImplÃ©menter des actions correctives\n\n**Contenu:**\n1. MÃ©triques clÃ©s de revue:\n   - **Inspection Rate:** Lignes/heure (cible: 100-200)\n   - **Defect Density:** DÃ©fauts/KLOC trouvÃ©s\n   - **Defect Removal Efficiency:** % dÃ©fauts trouvÃ©s avant test\n   - **Escaped Defects:** DÃ©fauts trouvÃ©s aprÃ¨s release\n   - **Review Coverage:** % du code revu\n\n2. Benchmarks industrie:\n\n| MÃ©trique | Faible | Moyen | Excellent |\n|----------|--------|-------|-----------|\n| Defect density (review) | < 5/KLOC | 5-15/KLOC | > 15/KLOC |\n| DRE | < 50% | 50-80% | > 80% |\n| Review coverage | < 50% | 50-80% | 100% |\n| Escaped to production | > 10% | 5-10% | < 5% |\n\n3. Cycle d'amÃ©lioration continue:\n   - Collecter les mÃ©triques\n   - Analyser les tendances\n   - Identifier les root causes\n   - ImplÃ©menter les amÃ©liorations\n   - Mesurer l'impact\n\n**Exercice 5.3:** *Analyse et Plan d'AmÃ©lioration*\n```\nDonnÃ©es des 6 derniers mois:\n- 150 revues effectuÃ©es\n- 340 dÃ©fauts trouvÃ©s\n- 45,000 lignes revues\n- 12 dÃ©fauts Ã©chappÃ©s en production\n- Temps moyen de revue: 45 min\n\nTÃ¢ches:\n1. Calculer les mÃ©triques clÃ©s\n2. Comparer aux benchmarks\n3. Identifier 3 axes d'amÃ©lioration\n4. Proposer des actions concrÃ¨tes\n5. DÃ©finir les KPIs de suivi\n```\n\n#### Module 5.4: Ã‰valuation Finale et Certification (2h)\n\n**Objectifs:**\n- Valider les acquis de la formation\n- Obtenir la certification interne\n- Planifier la mise en pratique\n\n**Contenu:**\n1. **Examen thÃ©orique (45 min):**\n   - 50 questions Ã  choix multiples\n   - Score minimum: 80%\n   - Couvre tous les modules\n\n2. **Examen pratique (45 min):**\n   - Revue d'un code fourni (200 lignes)\n   - Utilisation de la checklist\n   - Documentation des findings\n   - Ã‰valuation par un formateur certifiÃ©\n\n3. **CritÃ¨res de certification:**\n   - Examen thÃ©orique: â‰¥ 80%\n   - Examen pratique: Tous les dÃ©fauts critiques trouvÃ©s\n   - Participation aux exercices: 100%\n\n4. **Plan d'action post-formation:**\n   - Revues supervisÃ©es pendant 1 mois\n   - Feedback mentor\n   - Recertification annuelle\n\n---\n\n## Annexes\n\n### Annexe A: Template de Code Review Record\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n                     CODE REVIEW RECORD\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nIDENTIFICATION\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview ID:          _______________________\nProject:            _______________________\nModule/Component:   _______________________\nDocument Version:   _______________________\n\nREVIEW DETAILS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReview Type:        â–¡ Formal Inspection  â–¡ Peer Review  â–¡ Pair Programming\nAuthor:             _______________________  Date: ____________\nReviewer(s):        _______________________\nModerator:          _______________________ (if applicable)\n\nFiles Reviewed:\nâ”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”\nâ”‚ File Path                           â”‚ Lines    â”‚ Revision   â”‚\nâ”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤\nâ”‚                                     â”‚          â”‚            â”‚\nâ”‚                                     â”‚          â”‚            â”‚\nâ””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜\n\nREVIEW METRICS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Lines Reviewed:      ________\nPreparation Time (min):    ________\nMeeting Time (min):        ________\nDefects Found:            Critical: ____ Major: ____ Minor: ____\n\nCHECKLIST USED\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ Part 11 Compliance    â–¡ IEC 62304 Safety    â–¡ Data Integrity\nâ–¡ Security (OWASP)      â–¡ Coding Standards    â–¡ Performance\nâ–¡ Other: _______________________\n\nFINDINGS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\n[Attached: Defect Log]\n\nOUTCOME\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ APPROVED - No changes required\nâ–¡ APPROVED WITH CONDITIONS - Minor changes, no re-review\nâ–¡ NOT APPROVED - Re-review required after rework\n\nComments:\n___________________________________________________________\n___________________________________________________________\n\nSIGNATURES\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nReviewer:      _____________________ Date: _______ Time: _______\nAuthor:        _____________________ Date: _______ Time: _______\nApprover:      _____________________ Date: _______ Time: _______\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nDocument Control: Rev 1.0 | Effective: YYYY-MM-DD | Page 1 of 1\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### Annexe B: Defect Classification Guide\n\n| CatÃ©gorie | SÃ©vÃ©ritÃ© | DÃ©finition | Exemples |\n|-----------|----------|------------|----------|\n| **Safety** | Critique | Impact potentiel sur la sÃ©curitÃ© patient | Calcul de dose incorrect, race condition sur donnÃ©es critiques |\n| **Data Integrity** | Critique | Corruption ou perte de donnÃ©es GxP | Audit trail absent, donnÃ©es modifiables aprÃ¨s signature |\n| **Regulatory** | Majeur | Non-conformitÃ© aux exigences FDA | ContrÃ´le d'accÃ¨s insuffisant, absence de validation d'entrÃ©e |\n| **Functional** | Majeur | Le code ne fait pas ce qui est spÃ©cifiÃ© | Logic error, mauvaise gestion des erreurs |\n| **Security** | Majeur | VulnÃ©rabilitÃ© de sÃ©curitÃ© | Injection SQL, credentials en dur |\n| **Performance** | Mineur | Impact sur les performances | Algorithm inefficace, memory leak |\n| **Maintainability** | Mineur | DifficultÃ© de maintenance future | Code dupliquÃ©, nommage obscur |\n| **Style** | CosmÃ©tique | Non-conformitÃ© aux standards de style | Formatting, commentaires manquants |\n\n### Annexe C: RÃ©fÃ©rences RÃ©glementaires ClÃ©s\n\n**FDA:**\n- 21 CFR Part 11 - Electronic Records; Electronic Signatures\n- 21 CFR Part 820 - Quality System Regulation\n- FDA Guidance: General Principles of Software Validation (2002)\n- FDA Guidance: Computer Software Assurance for Production and Quality System Software (2022)\n\n**International:**\n- IEC 62304:2006/Amd 1:2015 - Medical device software â€” Software life cycle processes\n- ISO 13485:2016 - Medical devices â€” Quality management systems\n- GAMP 5 Guide, 2nd Edition (ISPE, 2022)\n- EU GMP Annex 11 - Computerised Systems\n\n**Industry Standards:**\n- IEEE 1028 - Standard for Software Reviews and Audits\n- ISO/IEC 25010 - Software Quality Model\n- OWASP Top 10 - Web Application Security Risks\n\n### Annexe D: Ressources ComplÃ©mentaires\n\n**Formations RecommandÃ©es:**\n- ISPE GAMP 5 Training\n- FDA Regulatory Affairs Certification (RAC)\n- IEC 62304 Implementation Workshops\n\n**Outils:**\n- [SonarQube](https://www.sonarqube.org/) - Analyse statique open source\n- [Coverity](https://scan.coverity.com/) - DÃ©tection de dÃ©fauts\n- [GitHub Code Review](https://docs.github.com/en/pull-requests) - Revue collaborative\n\n**Publications:**\n- FDA Warning Letters Database (fda.gov)\n- ISPE Pharmaceutical Engineering Magazine\n- Medical Device & Diagnostic Industry (MD+DI)\n\n---\n\n## Sources de Recherche\n\nCette formation a Ã©tÃ© Ã©laborÃ©e Ã  partir des sources suivantes:\n\n- [FDA 21 CFR Part 11 Compliance Guide - Redzone](https://rzsoftware.com/what-is-fda-21-cfr-part-11-compliance-software-validation-guide/)\n- [IEC 62304 Software Lifecycle - Jama Software](https://www.jamasoftware.com/blog/an-in-depth-guide-to-iec-62304-software-lifecycle-processes-for-medical-devices/)\n- [GAMP 5 Guide 2nd Edition - ISPE](https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition)\n- [2023 FDA Warning Letters and Software Validation - Ketryx](https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation)\n- [Fagan Inspection - Wikipedia](https://en.wikipedia.org/wiki/Fagan_inspection)\n- [FDA Warning Letters Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n- [Code Review Workshops - Dr. Michaela Greiler](https://www.michaelagreiler.com/workshops/)\n- [Computer Software Assurance Guidance - FDA](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software)\n\n---\n\n*Document crÃ©Ã© le 2025-12-25*\n*Version 1.0*\n","structuredPatch":[],"originalFile":null},"tool_use_id":"toolu_0115eLfRM7MB6ubPguUway7Q"},"timestamp":1766707801556,"timestamp_pst":"2025-12-25 16:10:01 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"in_progress","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_0134kov12U6cZM2JvmZYKfay"},"timestamp":1766707971288,"timestamp_pst":"2025-12-25 16:12:51 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"in_progress","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"in_progress","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"pending","activeForm":"Designing practical exercises"}],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"in_progress","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_0134kov12U6cZM2JvmZYKfay"},"timestamp":1766707971544,"timestamp_pst":"2025-12-25 16:12:51 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"Write","tool_input":{"file_path":"/home/chris/FDA-Code-Review-Exercises.md","content":"# Exercices Pratiques - Formation RÃ©vision de Code FDA\n\n## Exercices DÃ©taillÃ©s par Module\n\n---\n\n## EXERCICE 1: Code d'Audit Trail Non-Conforme\n\n### Contexte\nVous devez rÃ©viser ce module de gestion des lots de production d'un systÃ¨me pharmaceutique.\n\n### Code Ã  Analyser\n\n```python\n# batch_manager.py - Pharmaceutical Batch Management System\n\nimport sqlite3\nfrom datetime import datetime\n\nclass BatchManager:\n    def __init__(self):\n        self.conn = sqlite3.connect('production.db')\n        self.admin_password = \"Pharma2024!\"  # For emergency access\n\n    def update_batch_status(self, batch_id, new_status, user=None):\n        \"\"\"Update the status of a production batch.\"\"\"\n        cursor = self.conn.cursor()\n\n        # Update the batch\n        cursor.execute(\n            \"UPDATE batches SET status = ? WHERE batch_id = ?\",\n            (new_status, batch_id)\n        )\n        self.conn.commit()\n        print(f\"Batch {batch_id} updated to {new_status}\")\n        return True\n\n    def delete_batch_record(self, batch_id):\n        \"\"\"Remove a batch from the system.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"DELETE FROM batches WHERE batch_id = ?\", (batch_id,))\n        self.conn.commit()\n        return True\n\n    def get_batch_history(self, batch_id):\n        \"\"\"Get batch history - returns last 10 changes only.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"SELECT * FROM batch_history WHERE batch_id = ? LIMIT 10\",\n            (batch_id,)\n        )\n        return cursor.fetchall()\n\n    def approve_batch(self, batch_id, approver):\n        \"\"\"Approve batch for release.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"UPDATE batches SET status = 'APPROVED', approved_by = ? WHERE batch_id = ?\",\n            (approver, batch_id)\n        )\n        self.conn.commit()\n\n    def calculate_expiry(self, manufacture_date, shelf_life_days):\n        \"\"\"Calculate expiration date.\"\"\"\n        # TODO: Fix this later\n        return manufacture_date + shelf_life_days\n\n    def export_batch_data(self, batch_id):\n        \"\"\"Export batch data for regulatory submission.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"SELECT * FROM batches WHERE batch_id = ?\", (batch_id,))\n        data = cursor.fetchone()\n\n        # Convert to readable format\n        output = str(data)\n        return output\n```\n\n### Questions d'Analyse\n\n**Partie A: Identification des DÃ©fauts (30 min)**\n\n1. Identifiez tous les dÃ©fauts de conformitÃ© 21 CFR Part 11\n2. Classifiez chaque dÃ©faut (Critique/Majeur/Mineur)\n3. Citez la rÃ©fÃ©rence rÃ©glementaire spÃ©cifique pour chaque dÃ©faut\n\n**Partie B: Proposition de Corrections (30 min)**\n\n4. RÃ©Ã©crivez la fonction `update_batch_status` avec un audit trail conforme\n5. Proposez une architecture pour rendre les suppressions conformes (soft delete)\n6. Comment sÃ©curiseriez-vous la gestion des credentials?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts identifiÃ©s:**\n\n| # | Ligne | DÃ©faut | SÃ©vÃ©ritÃ© | RÃ©fÃ©rence |\n|---|-------|--------|----------|-----------|\n| 1 | 8 | Mot de passe en dur dans le code | Critique | 21 CFR 11.10(d) |\n| 2 | 13-19 | Pas d'audit trail sur update_batch_status | Critique | 21 CFR 11.10(e) |\n| 3 | 13 | ParamÃ¨tre user non utilisÃ© | Majeur | 21 CFR 11.10(e) |\n| 4 | 21-25 | Suppression physique de donnÃ©es GxP | Critique | 21 CFR 11.10(c) |\n| 5 | 28 | Historique limitÃ© Ã  10 enregistrements | Majeur | 21 CFR 11.10(c) |\n| 6 | 35-40 | Approbation sans signature Ã©lectronique | Critique | 21 CFR 11.50 |\n| 7 | 42-44 | TODO non rÃ©solu avant release | Majeur | Best Practice |\n| 8 | 48-53 | Export non structurÃ© (str(data)) | Mineur | 21 CFR 11.10(b) |\n\n**Correction pour update_batch_status:**\n\n```python\ndef update_batch_status(self, batch_id, new_status, user_id, reason=None):\n    \"\"\"Update the status of a production batch with full audit trail.\"\"\"\n    if not user_id:\n        raise ValueError(\"User identification required for status update\")\n\n    cursor = self.conn.cursor()\n\n    # Get current state for audit\n    cursor.execute(\n        \"SELECT status FROM batches WHERE batch_id = ?\",\n        (batch_id,)\n    )\n    old_status = cursor.fetchone()[0]\n\n    # Update with transaction\n    try:\n        # Update batch\n        cursor.execute(\n            \"UPDATE batches SET status = ?, last_modified_by = ?, \"\n            \"last_modified_date = ? WHERE batch_id = ?\",\n            (new_status, user_id, datetime.utcnow().isoformat(), batch_id)\n        )\n\n        # Create audit record\n        cursor.execute(\n            \"\"\"INSERT INTO audit_trail\n               (table_name, record_id, field_name, old_value, new_value,\n                changed_by, changed_date, workstation, reason)\n               VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?)\"\"\",\n            ('batches', batch_id, 'status', old_status, new_status,\n             user_id, datetime.utcnow().isoformat(),\n             self._get_workstation_id(), reason)\n        )\n\n        self.conn.commit()\n        return True\n\n    except Exception as e:\n        self.conn.rollback()\n        raise\n```\n\n</details>\n\n---\n\n## EXERCICE 2: Revue IEC 62304 Classe C - Dispositif MÃ©dical Critique\n\n### Contexte\nModule de calcul de dose pour une pompe Ã  insuline (Classe C - risque vital).\n\n### Code Ã  Analyser\n\n```java\n// InsulinDoseCalculator.java - Version 2.3.1\n\npackage com.meddevice.insulin;\n\npublic class InsulinDoseCalculator {\n\n    private static final double MAX_BOLUS = 25.0; // Units\n    private double carbRatio;\n    private double sensitivity;\n    private double targetGlucose;\n\n    public InsulinDoseCalculator(double carbRatio, double sensitivity) {\n        this.carbRatio = carbRatio;\n        this.sensitivity = sensitivity;\n        this.targetGlucose = 100; // mg/dL default\n    }\n\n    /**\n     * Calculate insulin bolus for a meal\n     * @param currentGlucose Current blood glucose in mg/dL\n     * @param carbsGrams Carbohydrates to be consumed\n     * @return Recommended insulin dose in units\n     */\n    public double calculateMealBolus(double currentGlucose, double carbsGrams) {\n        // Correction dose\n        double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n\n        // Meal coverage\n        double mealDose = carbsGrams / carbRatio;\n\n        // Total bolus\n        double totalBolus = correctionDose + mealDose;\n\n        // Safety cap\n        if (totalBolus > MAX_BOLUS) {\n            totalBolus = MAX_BOLUS;\n        }\n\n        return Math.round(totalBolus * 10.0) / 10.0;\n    }\n\n    public double calculateCorrectionBolus(double currentGlucose) {\n        return (currentGlucose - targetGlucose) / sensitivity;\n    }\n\n    public void updateSettings(double newCarbRatio, double newSensitivity) {\n        this.carbRatio = newCarbRatio;\n        this.sensitivity = newSensitivity;\n    }\n\n    // Quick calculation mode for experienced users\n    public double quickCalc(double g, double c) {\n        return (g - 100) / sensitivity + c / carbRatio;\n    }\n}\n```\n\n### Checklist de Revue IEC 62304 Classe C\n\nÃ‰valuez chaque Ã©lÃ©ment:\n\n| # | CritÃ¨re | Conforme? | Commentaire |\n|---|---------|-----------|-------------|\n| 1 | Validation des entrÃ©es (limites physiologiques) | | |\n| 2 | Gestion de la division par zÃ©ro | | |\n| 3 | Gestion des valeurs nÃ©gatives | | |\n| 4 | Limite de sÃ©curitÃ© MAX testÃ©e | | |\n| 5 | Documentation du raisonnement algorithmique | | |\n| 6 | TraÃ§abilitÃ© vers les requirements | | |\n| 7 | Gestion des erreurs/exceptions | | |\n| 8 | Nommage clair et sans ambiguÃ¯tÃ© | | |\n| 9 | Thread safety (accÃ¨s concurrent) | | |\n| 10 | UnitÃ©s clairement documentÃ©es | | |\n\n### Questions d'Analyse\n\n1. **Risque Safety:** Identifiez 3 scÃ©narios oÃ¹ ce code pourrait causer un surdosage\n2. **Division par zÃ©ro:** OÃ¹ peut-elle se produire? Quelle est la consÃ©quence?\n3. **Valeurs limites:** Quelles validations manquent pour les entrÃ©es?\n4. **Fonction quickCalc:** Pourquoi est-elle problÃ©matique en contexte mÃ©dical?\n5. **Thread Safety:** Ce code est-il sÃ»r en environnement multi-thread?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts critiques identifiÃ©s:**\n\n1. **Division par zÃ©ro (Ligne 26, 39):**\n   - Si `sensitivity = 0`, exception non gÃ©rÃ©e\n   - ConsÃ©quence: Crash de l'appareil, potentielle perte de dose\n\n2. **Aucune validation des entrÃ©es:**\n   - `currentGlucose` pourrait Ãªtre nÃ©gatif ou irrÃ©aliste (ex: 5000 mg/dL)\n   - `carbsGrams` pourrait Ãªtre nÃ©gatif\n   - Pas de bornes physiologiques\n\n3. **RÃ©sultat nÃ©gatif non gÃ©rÃ©:**\n   - Si glucose < target, `correctionDose` devient nÃ©gatif\n   - Un bolus nÃ©gatif n'a pas de sens mÃ©dical\n\n4. **Fonction quickCalc:**\n   - Nommage cryptique (g, c)\n   - Pas de safety cap\n   - Pas de documentation\n   - Code dupliquÃ© avec calculateMealBolus\n\n5. **Thread Safety:**\n   - `carbRatio` et `sensitivity` modifiables via updateSettings()\n   - Pas de synchronisation\n   - Race condition possible pendant un calcul\n\n**Code corrigÃ©:**\n\n```java\npublic double calculateMealBolus(double currentGlucose, double carbsGrams)\n    throws InvalidInputException, CalculationException {\n\n    // Input validation with physiological limits\n    if (currentGlucose < 20 || currentGlucose > 600) {\n        throw new InvalidInputException(\n            \"Glucose value out of physiological range: \" + currentGlucose);\n    }\n    if (carbsGrams < 0 || carbsGrams > 500) {\n        throw new InvalidInputException(\n            \"Carbohydrate value out of valid range: \" + carbsGrams);\n    }\n    if (sensitivity <= 0) {\n        throw new CalculationException(\n            \"Invalid sensitivity factor: \" + sensitivity);\n    }\n    if (carbRatio <= 0) {\n        throw new CalculationException(\n            \"Invalid carb ratio: \" + carbRatio);\n    }\n\n    // Correction dose (negative means no correction needed)\n    double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n    correctionDose = Math.max(0, correctionDose); // No negative corrections\n\n    // Meal coverage\n    double mealDose = carbsGrams / carbRatio;\n\n    // Total with safety bounds\n    double totalBolus = correctionDose + mealDose;\n    totalBolus = Math.min(totalBolus, MAX_BOLUS);\n    totalBolus = Math.max(totalBolus, 0); // Ensure non-negative\n\n    // Round to 0.1 unit precision\n    return Math.round(totalBolus * 10.0) / 10.0;\n}\n```\n\n</details>\n\n---\n\n## EXERCICE 3: Simulation d'Inspection Fagan\n\n### Instructions\n\n**Formation des Ã©quipes (5 personnes):**\n- 1 Moderator\n- 1 Author\n- 1 Reader\n- 1 Recorder\n- 1 Inspector\n\n**Code Ã  inspecter:**\n\n```python\n# clinical_trial_randomization.py\n# Module de randomisation pour essais cliniques\n\nimport random\nimport hashlib\nfrom datetime import datetime\n\nclass TrialRandomizer:\n    \"\"\"Randomizes patients to treatment arms in a clinical trial.\"\"\"\n\n    def __init__(self, trial_id, arms, stratification_factors=None):\n        self.trial_id = trial_id\n        self.arms = arms  # e.g., ['Placebo', 'Treatment A', 'Treatment B']\n        self.stratification = stratification_factors\n        self.assignments = {}\n        self.seed = int(datetime.now().timestamp())\n        random.seed(self.seed)\n\n    def randomize_patient(self, patient_id, strata=None):\n        \"\"\"Assign a patient to a treatment arm.\"\"\"\n\n        if patient_id in self.assignments:\n            return self.assignments[patient_id]\n\n        # Simple randomization\n        arm = random.choice(self.arms)\n        self.assignments[patient_id] = arm\n\n        return arm\n\n    def get_arm_counts(self):\n        \"\"\"Get current enrollment counts per arm.\"\"\"\n        counts = {arm: 0 for arm in self.arms}\n        for patient, arm in self.assignments.items():\n            counts[arm] += 1\n        return counts\n\n    def unblind_patient(self, patient_id, reason):\n        \"\"\"Reveal treatment assignment for safety.\"\"\"\n        if patient_id not in self.assignments:\n            return None\n        return self.assignments[patient_id]\n\n    def export_randomization_list(self):\n        \"\"\"Export all assignments for regulatory submission.\"\"\"\n        output = []\n        for patient, arm in self.assignments.items():\n            output.append(f\"{patient},{arm}\")\n        return \"\\n\".join(output)\n\n    def re_randomize(self, patient_id):\n        \"\"\"Re-assign a patient to a different arm.\"\"\"\n        if patient_id in self.assignments:\n            del self.assignments[patient_id]\n        return self.randomize_patient(patient_id)\n```\n\n### Processus d'Inspection\n\n**Phase 1: PrÃ©paration (20 min)**\n- Chaque inspecteur examine le code individuellement\n- Note les dÃ©fauts potentiels sur le formulaire\n\n**Phase 2: RÃ©union d'Inspection (30 min)**\n- Le Reader lit le code ligne par ligne\n- Les inspecteurs signalent les dÃ©fauts\n- Le Recorder documente\n\n**Phase 3: Documentation (10 min)**\n- Compilation du rapport final\n- Classification des dÃ©fauts\n\n### Formulaire de DÃ©fauts\n\n| # | Ligne | Type | SÃ©vÃ©ritÃ© | Description | Action |\n|---|-------|------|----------|-------------|--------|\n| 1 | | | | | |\n| 2 | | | | | |\n| 3 | | | | | |\n| ... | | | | | |\n\n**Types de dÃ©fauts:**\n- REG = Regulatory\n- DATA = Data Integrity\n- SEC = Security\n- FUNC = Functional\n- PERF = Performance\n\n### MÃ©triques Ã  Calculer\n\n- Nombre de dÃ©fauts trouvÃ©s: ___\n- DÃ©fauts par ligne de code: ___\n- Temps de prÃ©paration: ___ min\n- Temps de rÃ©union: ___ min\n- DÃ©fauts critiques: ___\n\n---\n\n## EXERCICE 4: CrÃ©ation de Checklist PersonnalisÃ©e\n\n### Contexte\nVotre entreprise dÃ©veloppe un systÃ¨me LIMS (Laboratory Information Management System) pour un laboratoire de contrÃ´le qualitÃ© pharmaceutique.\n\n### Exigences du SystÃ¨me\n- Gestion des Ã©chantillons et tests\n- Calcul automatique des spÃ©cifications\n- GÃ©nÃ©ration de certificats d'analyse\n- Interface avec instruments de laboratoire\n- Signatures Ã©lectroniques pour approbation\n\n### TÃ¢che\nCrÃ©ez une checklist de code review spÃ©cifique pour ce systÃ¨me.\n\n### Template de Checklist\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n          CHECKLIST DE REVUE DE CODE - LIMS\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nProjet: ____________________  Date: ____________\nReviewer: __________________  Module: __________\n\nSECTION 1: CONFORMITÃ‰ 21 CFR PART 11\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 1.1 Audit trail implÃ©mentÃ© pour modifications de donnÃ©es\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.2 Horodatage avec timezone sur tous les enregistrements\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.3 [AJOUTEZ VOS CRITÃˆRES - minimum 8 items]\n      ...\n\nSECTION 2: INTÃ‰GRITÃ‰ DES DONNÃ‰ES (ALCOA+)\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 2.1 DonnÃ©es attribuables Ã  un utilisateur identifiÃ©\n      RÃ©fÃ©rence: FDA Data Integrity Guidance\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 2.2 [AJOUTEZ VOS CRITÃˆRES - minimum 6 items]\n      ...\n\nSECTION 3: CALCULS ET SPÃ‰CIFICATIONS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 3.1 Formules de calcul documentÃ©es et vÃ©rifiables\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 3.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 4: SÃ‰CURITÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 4.1 ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les\n      RÃ©fÃ©rence: 21 CFR 11.10(d)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 4.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 5: INTERFACE INSTRUMENTS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 5.1 Validation des donnÃ©es reÃ§ues des instruments\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 5.2 [AJOUTEZ VOS CRITÃˆRES - minimum 4 items]\n      ...\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nRÃ‰SUMÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Items: ___    Pass: ___    Fail: ___    N/A: ___\n\nRÃ©sultat Global:  â–¡ APPROUVÃ‰  â–¡ REJETÃ‰  â–¡ APPROUVÃ‰ AVEC RÃ‰SERVES\n\nSignature Reviewer: ___________________ Date: ___________\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### CritÃ¨res de RÃ©ussite\n- Minimum 28 items au total\n- Chaque section doit couvrir les risques spÃ©cifiques au LIMS\n- RÃ©fÃ©rences rÃ©glementaires pour items critiques\n- CritÃ¨res Pass/Fail clairs et objectifs\n\n---\n\n## EXERCICE 5: DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©\n\n### ScÃ©nario\nVous Ãªtes auditeur interne. Analysez ces artefacts de revue de code et identifiez les anomalies.\n\n### Document 1: Log de Revue\n\n```\nCode Review Log - Project MEDCALC-2024\n======================================\n\nReview #1042\n- Date: 2024-11-15 08:45:22 UTC\n- Reviewer: jennifer.smith@company.com\n- Author: jennifer.smith@company.com\n- Files: src/calculations/*.java (23 files, 4,521 lines)\n- Duration: 12 minutes\n- Defects: 0\n- Status: APPROVED\n- Comments: \"Code looks good\"\n\nReview #1043\n- Date: 2024-11-15 08:57:44 UTC\n- Reviewer: michael.jones@company.com\n- Author: david.wilson@company.com\n- Files: src/safety/AlarmHandler.java (1 file, 89 lines)\n- Duration: 45 minutes\n- Defects: 7 (3 Critical, 2 Major, 2 Minor)\n- Status: REWORK REQUIRED\n- Comments: [Detailed defect log attached]\n\nReview #1044\n- Date: 2024-11-15\n- Reviewer: admin\n- Author: dev_team\n- Files: hotfix-prod-emergency.patch\n- Duration: N/A\n- Defects: N/A\n- Status: EMERGENCY APPROVED\n- Comments: \"Production issue - approved by management\"\n```\n\n### Document 2: Git History\n\n```\ncommit a1b2c3d4\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 08:30:15 UTC\nMessage: \"Completed dose calculation module\"\n\ncommit e5f6g7h8\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 09:00:00 UTC\nMessage: \"Minor fixes after self-review\"\n\ncommit i9j0k1l2\nAuthor: system@company.com\nDate: 2024-11-15 22:00:00 UTC\nMessage: \"Applied hotfix-prod-emergency.patch\"\n```\n\n### Document 3: Metrics Dashboard\n\n```\nMonthly Code Review Metrics - November 2024\n==========================================\n\nReviewer Performance:\n- jennifer.smith: 47 reviews, 0 defects found, avg 8 min\n- michael.jones: 12 reviews, 156 defects found, avg 52 min\n- sarah.brown: 23 reviews, 67 defects found, avg 35 min\n- admin: 3 reviews, 0 defects found, avg 2 min\n\nDefect Density by Module:\n- UI Components: 2.3 defects/KLOC\n- Business Logic: 0.0 defects/KLOC (jennifer.smith reviews)\n- Safety Systems: 12.7 defects/KLOC (michael.jones reviews)\n- Database Layer: 4.1 defects/KLOC\n```\n\n### Questions d'Analyse\n\n1. **Review #1042:** Identifiez toutes les anomalies\n2. **Review #1044:** Quels problÃ¨mes de conformitÃ© voyez-vous?\n3. **MÃ©triques jennifer.smith:** Qu'est-ce qui est suspect?\n4. **Compte \"admin\":** Pourquoi est-ce problÃ©matique?\n5. **Actions correctives:** Que recommanderiez-vous?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**Review #1042 - Anomalies:**\n1. âŒ Self-review (auteur = reviewer) - Non conforme Part 820\n2. âŒ 4,521 lignes en 12 min = 377 lignes/min - Humainement impossible\n3. âŒ 0 dÃ©fauts sur 23 fichiers - Statistiquement improbable\n4. âŒ Commentaire vague \"Code looks good\" - Pas de preuve de revue\n\n**Review #1044 - ProblÃ¨mes:**\n1. âŒ Pas d'horodatage complet (heure manquante)\n2. âŒ Comptes gÃ©nÃ©riques (\"admin\", \"dev_team\")\n3. âŒ Pas de documentation de durÃ©e ou dÃ©fauts\n4. âŒ \"Emergency Approved\" sans procÃ©dure d'exception documentÃ©e\n5. âŒ Patch appliquÃ© sans revue formelle\n\n**MÃ©triques jennifer.smith:**\n1. 0 dÃ©fauts sur 47 revues = Outlier statistique majeur\n2. 8 min moyenne pour revues significatives = Trop rapide\n3. CorrÃ©lation: 0 dÃ©fauts dans Business Logic = probable self-review\n\n**Compte \"admin\":**\n1. Compte gÃ©nÃ©rique (non-nominatif) interdit par Part 11\n2. Pas de traÃ§abilitÃ© de l'utilisateur rÃ©el\n3. 3 revues sans dÃ©fauts = Pattern suspect\n\n**Actions correctives:**\n1. Annuler toutes les approbations de jennifer.smith et re-reviewer\n2. ImplÃ©menter contrÃ´le technique: bloquer self-review\n3. Ã‰liminer comptes gÃ©nÃ©riques\n4. DÃ©finir seuils minimum de durÃ©e de revue\n5. CAPA pour le processus d'exception \"emergency\"\n6. Formation obligatoire sur data integrity\n\n</details>\n\n---\n\n## EXERCICE 6: Examen Final Pratique\n\n### Instructions\n- DurÃ©e: 60 minutes\n- Code: 250 lignes\n- Vous devez trouver au moins 80% des dÃ©fauts critiques pour rÃ©ussir\n\n### Code Ã  RÃ©viser\n\n```csharp\n// MedicalRecordSystem.cs\n// Electronic Health Record Module for Clinical Practice\n\nusing System;\nusing System.Collections.Generic;\nusing System.IO;\nusing System.Security.Cryptography;\n\nnamespace HealthcareSoftware\n{\n    public class MedicalRecordSystem\n    {\n        private Dictionary<string, PatientRecord> records = new();\n        private const string ENCRYPTION_KEY = \"MySecretKey12345\"; // AES-128\n        private string connectionString = \"Server=prod-db;Database=EHR;User=sa;Password=admin123\";\n\n        public class PatientRecord\n        {\n            public string PatientId { get; set; }\n            public string Name { get; set; }\n            public DateTime DateOfBirth { get; set; }\n            public List<string> Diagnoses { get; set; }\n            public List<Medication> Medications { get; set; }\n            public string LastModifiedBy { get; set; }\n        }\n\n        public class Medication\n        {\n            public string DrugName { get; set; }\n            public double Dosage { get; set; }\n            public string Unit { get; set; }\n            public int FrequencyPerDay { get; set; }\n        }\n\n        // Create new patient record\n        public void CreateRecord(PatientRecord record)\n        {\n            records[record.PatientId] = record;\n            SaveToDatabase(record);\n        }\n\n        // Update existing record\n        public void UpdateRecord(string patientId, PatientRecord newData)\n        {\n            if (records.ContainsKey(patientId))\n            {\n                records[patientId] = newData;\n                SaveToDatabase(newData);\n            }\n        }\n\n        // Add medication to patient\n        public void AddMedication(string patientId, string drug, double dose, string unit, int freq)\n        {\n            var record = records[patientId];\n            record.Medications.Add(new Medication\n            {\n                DrugName = drug,\n                Dosage = dose,\n                Unit = unit,\n                FrequencyPerDay = freq\n            });\n            SaveToDatabase(record);\n        }\n\n        // Calculate total daily dose\n        public double CalculateDailyDose(string patientId, string drugName)\n        {\n            var record = records[patientId];\n            var med = record.Medications.Find(m => m.DrugName == drugName);\n            return med.Dosage * med.FrequencyPerDay;\n        }\n\n        // Check for drug interactions (simplified)\n        public bool CheckInteractions(string patientId)\n        {\n            var record = records[patientId];\n            // TODO: Implement drug interaction checking\n            return false;\n        }\n\n        // Export for regulatory audit\n        public void ExportRecords(string filePath)\n        {\n            using (var writer = new StreamWriter(filePath))\n            {\n                foreach (var record in records.Values)\n                {\n                    writer.WriteLine($\"{record.PatientId},{record.Name},{record.DateOfBirth}\");\n                }\n            }\n        }\n\n        // Delete patient record (GDPR compliance)\n        public void DeleteRecord(string patientId)\n        {\n            records.Remove(patientId);\n            // Delete from database\n            ExecuteQuery($\"DELETE FROM Patients WHERE PatientId = '{patientId}'\");\n        }\n\n        // Search patients\n        public List<PatientRecord> SearchPatients(string searchTerm)\n        {\n            var results = new List<PatientRecord>();\n            // Direct SQL for performance\n            var query = $\"SELECT * FROM Patients WHERE Name LIKE '%{searchTerm}%'\";\n            // Execute and parse results...\n            return results;\n        }\n\n        // Authentication\n        public bool AuthenticateUser(string username, string password)\n        {\n            var hashedPwd = ComputeHash(password);\n            var storedHash = GetStoredHash(username);\n            return hashedPwd == storedHash;\n        }\n\n        private string ComputeHash(string input)\n        {\n            using (var md5 = MD5.Create())\n            {\n                var bytes = System.Text.Encoding.UTF8.GetBytes(input);\n                var hash = md5.ComputeHash(bytes);\n                return Convert.ToBase64String(hash);\n            }\n        }\n\n        private void SaveToDatabase(PatientRecord record)\n        {\n            // Encrypt sensitive data\n            var encryptedName = Encrypt(record.Name);\n            // Save to DB...\n        }\n\n        private string Encrypt(string plainText)\n        {\n            // Simple XOR encryption for now\n            char[] chars = plainText.ToCharArray();\n            for (int i = 0; i < chars.Length; i++)\n            {\n                chars[i] = (char)(chars[i] ^ ENCRYPTION_KEY[i % ENCRYPTION_KEY.Length]);\n            }\n            return new string(chars);\n        }\n\n        private void ExecuteQuery(string sql)\n        {\n            // Execute the SQL query\n            Console.WriteLine($\"Executing: {sql}\");\n        }\n\n        private string GetStoredHash(string username)\n        {\n            // Retrieve from database\n            return \"\";\n        }\n\n        // Utility: Log access\n        public void LogAccess(string patientId, string action)\n        {\n            File.AppendAllText(\"access.log\",\n                $\"{DateTime.Now}: {action} on {patientId}\\n\");\n        }\n    }\n}\n```\n\n### Formulaire de RÃ©ponse\n\nComplÃ©tez ce formulaire avec tous les dÃ©fauts identifiÃ©s:\n\n| # | Ligne(s) | CatÃ©gorie | SÃ©vÃ©ritÃ© | Description | RÃ©fÃ©rence |\n|---|----------|-----------|----------|-------------|-----------|\n| 1 | | | | | |\n| 2 | | | | | |\n| ... | | | | | |\n\n**CatÃ©gories:** SEC (Security), REG (Regulatory), FUNC (Functional), DATA (Data Integrity)\n\n**Score minimum pour certification:**\n- Tous les dÃ©fauts Critiques identifiÃ©s\n- 80% des dÃ©fauts Majeurs identifiÃ©s\n- Documentation correcte des rÃ©fÃ©rences\n\n---\n\n## CorrigÃ© de l'Examen Final\n\n<details>\n<summary>Cliquer pour voir le corrigÃ© complet</summary>\n\n| # | Ligne(s) | Cat | SÃ©v | Description | RÃ©f |\n|---|----------|-----|-----|-------------|-----|\n| 1 | 13 | SEC | Critique | ClÃ© de chiffrement en dur | OWASP A02 |\n| 2 | 14 | SEC | Critique | Connection string avec credentials | OWASP A07 |\n| 3 | 14 | SEC | Critique | Mot de passe admin123 faible | CWE-521 |\n| 4 | 37-40 | DATA | Critique | Pas d'audit trail sur crÃ©ation | 21 CFR 11.10(e) |\n| 5 | 43-49 | DATA | Critique | Pas d'audit trail sur modification | 21 CFR 11.10(e) |\n| 6 | 43-49 | DATA | Majeur | Pas de vÃ©rification des modifications | Data Integrity |\n| 7 | 52-61 | DATA | Majeur | Ajout mÃ©dication sans vÃ©rification | Best Practice |\n| 8 | 64-69 | FUNC | Critique | NullReferenceException possible | Safety |\n| 9 | 64-69 | FUNC | Majeur | Pas de validation si mÃ©dicament existe | Functional |\n| 10 | 73-76 | FUNC | Critique | TODO non rÃ©solu - fonctionnalitÃ© critique absente | IEC 62304 |\n| 11 | 79-86 | DATA | Critique | Export incomplet (manque mÃ©dicaments, dates) | 21 CFR 11.10(b) |\n| 12 | 89-93 | DATA | Critique | Suppression physique de donnÃ©es mÃ©dicales | HIPAA, Retention |\n| 13 | 93 | SEC | Critique | SQL Injection | OWASP A03 |\n| 14 | 97-101 | SEC | Critique | SQL Injection via searchTerm | OWASP A03 |\n| 15 | 105-109 | SEC | Majeur | Timing attack possible sur authentification | CWE-208 |\n| 16 | 111-117 | SEC | Critique | MD5 pour hash de mot de passe (dÃ©prÃ©ciÃ©) | OWASP A02 |\n| 17 | 111-117 | SEC | Majeur | Pas de salt pour le hachage | CWE-916 |\n| 18 | 125-131 | SEC | Critique | XOR n'est pas du chiffrement sÃ©curisÃ© | OWASP A02 |\n| 19 | 140-143 | DATA | Majeur | Log sans utilisateur identifiÃ© | 21 CFR 11.10(e) |\n| 20 | 140-143 | SEC | Mineur | Fichier log en clair sans protection | Best Practice |\n| 21 | Global | DATA | Majeur | Pas de validation des entrÃ©es utilisateur | Best Practice |\n| 22 | Global | REG | Majeur | Pas de signatures Ã©lectroniques | 21 CFR 11.50 |\n\n**Total dÃ©fauts:** 22\n- Critiques: 12\n- Majeurs: 9\n- Mineurs: 1\n\n**Seuil de rÃ©ussite:**\n- 12/12 Critiques identifiÃ©s = 100% requis\n- 7/9 Majeurs identifiÃ©s = 80% minimum\n\n</details>\n\n---\n\n*Fin des exercices pratiques*\n"},"tool_use_id":"toolu_01FUU1Gt9mKBdsKEBd2XNaNf"},"timestamp":1766707971726,"timestamp_pst":"2025-12-25 16:12:51 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"Write","tool_input":{"file_path":"/home/chris/FDA-Code-Review-Exercises.md","content":"# Exercices Pratiques - Formation RÃ©vision de Code FDA\n\n## Exercices DÃ©taillÃ©s par Module\n\n---\n\n## EXERCICE 1: Code d'Audit Trail Non-Conforme\n\n### Contexte\nVous devez rÃ©viser ce module de gestion des lots de production d'un systÃ¨me pharmaceutique.\n\n### Code Ã  Analyser\n\n```python\n# batch_manager.py - Pharmaceutical Batch Management System\n\nimport sqlite3\nfrom datetime import datetime\n\nclass BatchManager:\n    def __init__(self):\n        self.conn = sqlite3.connect('production.db')\n        self.admin_password = \"Pharma2024!\"  # For emergency access\n\n    def update_batch_status(self, batch_id, new_status, user=None):\n        \"\"\"Update the status of a production batch.\"\"\"\n        cursor = self.conn.cursor()\n\n        # Update the batch\n        cursor.execute(\n            \"UPDATE batches SET status = ? WHERE batch_id = ?\",\n            (new_status, batch_id)\n        )\n        self.conn.commit()\n        print(f\"Batch {batch_id} updated to {new_status}\")\n        return True\n\n    def delete_batch_record(self, batch_id):\n        \"\"\"Remove a batch from the system.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"DELETE FROM batches WHERE batch_id = ?\", (batch_id,))\n        self.conn.commit()\n        return True\n\n    def get_batch_history(self, batch_id):\n        \"\"\"Get batch history - returns last 10 changes only.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"SELECT * FROM batch_history WHERE batch_id = ? LIMIT 10\",\n            (batch_id,)\n        )\n        return cursor.fetchall()\n\n    def approve_batch(self, batch_id, approver):\n        \"\"\"Approve batch for release.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"UPDATE batches SET status = 'APPROVED', approved_by = ? WHERE batch_id = ?\",\n            (approver, batch_id)\n        )\n        self.conn.commit()\n\n    def calculate_expiry(self, manufacture_date, shelf_life_days):\n        \"\"\"Calculate expiration date.\"\"\"\n        # TODO: Fix this later\n        return manufacture_date + shelf_life_days\n\n    def export_batch_data(self, batch_id):\n        \"\"\"Export batch data for regulatory submission.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"SELECT * FROM batches WHERE batch_id = ?\", (batch_id,))\n        data = cursor.fetchone()\n\n        # Convert to readable format\n        output = str(data)\n        return output\n```\n\n### Questions d'Analyse\n\n**Partie A: Identification des DÃ©fauts (30 min)**\n\n1. Identifiez tous les dÃ©fauts de conformitÃ© 21 CFR Part 11\n2. Classifiez chaque dÃ©faut (Critique/Majeur/Mineur)\n3. Citez la rÃ©fÃ©rence rÃ©glementaire spÃ©cifique pour chaque dÃ©faut\n\n**Partie B: Proposition de Corrections (30 min)**\n\n4. RÃ©Ã©crivez la fonction `update_batch_status` avec un audit trail conforme\n5. Proposez une architecture pour rendre les suppressions conformes (soft delete)\n6. Comment sÃ©curiseriez-vous la gestion des credentials?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts identifiÃ©s:**\n\n| # | Ligne | DÃ©faut | SÃ©vÃ©ritÃ© | RÃ©fÃ©rence |\n|---|-------|--------|----------|-----------|\n| 1 | 8 | Mot de passe en dur dans le code | Critique | 21 CFR 11.10(d) |\n| 2 | 13-19 | Pas d'audit trail sur update_batch_status | Critique | 21 CFR 11.10(e) |\n| 3 | 13 | ParamÃ¨tre user non utilisÃ© | Majeur | 21 CFR 11.10(e) |\n| 4 | 21-25 | Suppression physique de donnÃ©es GxP | Critique | 21 CFR 11.10(c) |\n| 5 | 28 | Historique limitÃ© Ã  10 enregistrements | Majeur | 21 CFR 11.10(c) |\n| 6 | 35-40 | Approbation sans signature Ã©lectronique | Critique | 21 CFR 11.50 |\n| 7 | 42-44 | TODO non rÃ©solu avant release | Majeur | Best Practice |\n| 8 | 48-53 | Export non structurÃ© (str(data)) | Mineur | 21 CFR 11.10(b) |\n\n**Correction pour update_batch_status:**\n\n```python\ndef update_batch_status(self, batch_id, new_status, user_id, reason=None):\n    \"\"\"Update the status of a production batch with full audit trail.\"\"\"\n    if not user_id:\n        raise ValueError(\"User identification required for status update\")\n\n    cursor = self.conn.cursor()\n\n    # Get current state for audit\n    cursor.execute(\n        \"SELECT status FROM batches WHERE batch_id = ?\",\n        (batch_id,)\n    )\n    old_status = cursor.fetchone()[0]\n\n    # Update with transaction\n    try:\n        # Update batch\n        cursor.execute(\n            \"UPDATE batches SET status = ?, last_modified_by = ?, \"\n            \"last_modified_date = ? WHERE batch_id = ?\",\n            (new_status, user_id, datetime.utcnow().isoformat(), batch_id)\n        )\n\n        # Create audit record\n        cursor.execute(\n            \"\"\"INSERT INTO audit_trail\n               (table_name, record_id, field_name, old_value, new_value,\n                changed_by, changed_date, workstation, reason)\n               VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?)\"\"\",\n            ('batches', batch_id, 'status', old_status, new_status,\n             user_id, datetime.utcnow().isoformat(),\n             self._get_workstation_id(), reason)\n        )\n\n        self.conn.commit()\n        return True\n\n    except Exception as e:\n        self.conn.rollback()\n        raise\n```\n\n</details>\n\n---\n\n## EXERCICE 2: Revue IEC 62304 Classe C - Dispositif MÃ©dical Critique\n\n### Contexte\nModule de calcul de dose pour une pompe Ã  insuline (Classe C - risque vital).\n\n### Code Ã  Analyser\n\n```java\n// InsulinDoseCalculator.java - Version 2.3.1\n\npackage com.meddevice.insulin;\n\npublic class InsulinDoseCalculator {\n\n    private static final double MAX_BOLUS = 25.0; // Units\n    private double carbRatio;\n    private double sensitivity;\n    private double targetGlucose;\n\n    public InsulinDoseCalculator(double carbRatio, double sensitivity) {\n        this.carbRatio = carbRatio;\n        this.sensitivity = sensitivity;\n        this.targetGlucose = 100; // mg/dL default\n    }\n\n    /**\n     * Calculate insulin bolus for a meal\n     * @param currentGlucose Current blood glucose in mg/dL\n     * @param carbsGrams Carbohydrates to be consumed\n     * @return Recommended insulin dose in units\n     */\n    public double calculateMealBolus(double currentGlucose, double carbsGrams) {\n        // Correction dose\n        double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n\n        // Meal coverage\n        double mealDose = carbsGrams / carbRatio;\n\n        // Total bolus\n        double totalBolus = correctionDose + mealDose;\n\n        // Safety cap\n        if (totalBolus > MAX_BOLUS) {\n            totalBolus = MAX_BOLUS;\n        }\n\n        return Math.round(totalBolus * 10.0) / 10.0;\n    }\n\n    public double calculateCorrectionBolus(double currentGlucose) {\n        return (currentGlucose - targetGlucose) / sensitivity;\n    }\n\n    public void updateSettings(double newCarbRatio, double newSensitivity) {\n        this.carbRatio = newCarbRatio;\n        this.sensitivity = newSensitivity;\n    }\n\n    // Quick calculation mode for experienced users\n    public double quickCalc(double g, double c) {\n        return (g - 100) / sensitivity + c / carbRatio;\n    }\n}\n```\n\n### Checklist de Revue IEC 62304 Classe C\n\nÃ‰valuez chaque Ã©lÃ©ment:\n\n| # | CritÃ¨re | Conforme? | Commentaire |\n|---|---------|-----------|-------------|\n| 1 | Validation des entrÃ©es (limites physiologiques) | | |\n| 2 | Gestion de la division par zÃ©ro | | |\n| 3 | Gestion des valeurs nÃ©gatives | | |\n| 4 | Limite de sÃ©curitÃ© MAX testÃ©e | | |\n| 5 | Documentation du raisonnement algorithmique | | |\n| 6 | TraÃ§abilitÃ© vers les requirements | | |\n| 7 | Gestion des erreurs/exceptions | | |\n| 8 | Nommage clair et sans ambiguÃ¯tÃ© | | |\n| 9 | Thread safety (accÃ¨s concurrent) | | |\n| 10 | UnitÃ©s clairement documentÃ©es | | |\n\n### Questions d'Analyse\n\n1. **Risque Safety:** Identifiez 3 scÃ©narios oÃ¹ ce code pourrait causer un surdosage\n2. **Division par zÃ©ro:** OÃ¹ peut-elle se produire? Quelle est la consÃ©quence?\n3. **Valeurs limites:** Quelles validations manquent pour les entrÃ©es?\n4. **Fonction quickCalc:** Pourquoi est-elle problÃ©matique en contexte mÃ©dical?\n5. **Thread Safety:** Ce code est-il sÃ»r en environnement multi-thread?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts critiques identifiÃ©s:**\n\n1. **Division par zÃ©ro (Ligne 26, 39):**\n   - Si `sensitivity = 0`, exception non gÃ©rÃ©e\n   - ConsÃ©quence: Crash de l'appareil, potentielle perte de dose\n\n2. **Aucune validation des entrÃ©es:**\n   - `currentGlucose` pourrait Ãªtre nÃ©gatif ou irrÃ©aliste (ex: 5000 mg/dL)\n   - `carbsGrams` pourrait Ãªtre nÃ©gatif\n   - Pas de bornes physiologiques\n\n3. **RÃ©sultat nÃ©gatif non gÃ©rÃ©:**\n   - Si glucose < target, `correctionDose` devient nÃ©gatif\n   - Un bolus nÃ©gatif n'a pas de sens mÃ©dical\n\n4. **Fonction quickCalc:**\n   - Nommage cryptique (g, c)\n   - Pas de safety cap\n   - Pas de documentation\n   - Code dupliquÃ© avec calculateMealBolus\n\n5. **Thread Safety:**\n   - `carbRatio` et `sensitivity` modifiables via updateSettings()\n   - Pas de synchronisation\n   - Race condition possible pendant un calcul\n\n**Code corrigÃ©:**\n\n```java\npublic double calculateMealBolus(double currentGlucose, double carbsGrams)\n    throws InvalidInputException, CalculationException {\n\n    // Input validation with physiological limits\n    if (currentGlucose < 20 || currentGlucose > 600) {\n        throw new InvalidInputException(\n            \"Glucose value out of physiological range: \" + currentGlucose);\n    }\n    if (carbsGrams < 0 || carbsGrams > 500) {\n        throw new InvalidInputException(\n            \"Carbohydrate value out of valid range: \" + carbsGrams);\n    }\n    if (sensitivity <= 0) {\n        throw new CalculationException(\n            \"Invalid sensitivity factor: \" + sensitivity);\n    }\n    if (carbRatio <= 0) {\n        throw new CalculationException(\n            \"Invalid carb ratio: \" + carbRatio);\n    }\n\n    // Correction dose (negative means no correction needed)\n    double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n    correctionDose = Math.max(0, correctionDose); // No negative corrections\n\n    // Meal coverage\n    double mealDose = carbsGrams / carbRatio;\n\n    // Total with safety bounds\n    double totalBolus = correctionDose + mealDose;\n    totalBolus = Math.min(totalBolus, MAX_BOLUS);\n    totalBolus = Math.max(totalBolus, 0); // Ensure non-negative\n\n    // Round to 0.1 unit precision\n    return Math.round(totalBolus * 10.0) / 10.0;\n}\n```\n\n</details>\n\n---\n\n## EXERCICE 3: Simulation d'Inspection Fagan\n\n### Instructions\n\n**Formation des Ã©quipes (5 personnes):**\n- 1 Moderator\n- 1 Author\n- 1 Reader\n- 1 Recorder\n- 1 Inspector\n\n**Code Ã  inspecter:**\n\n```python\n# clinical_trial_randomization.py\n# Module de randomisation pour essais cliniques\n\nimport random\nimport hashlib\nfrom datetime import datetime\n\nclass TrialRandomizer:\n    \"\"\"Randomizes patients to treatment arms in a clinical trial.\"\"\"\n\n    def __init__(self, trial_id, arms, stratification_factors=None):\n        self.trial_id = trial_id\n        self.arms = arms  # e.g., ['Placebo', 'Treatment A', 'Treatment B']\n        self.stratification = stratification_factors\n        self.assignments = {}\n        self.seed = int(datetime.now().timestamp())\n        random.seed(self.seed)\n\n    def randomize_patient(self, patient_id, strata=None):\n        \"\"\"Assign a patient to a treatment arm.\"\"\"\n\n        if patient_id in self.assignments:\n            return self.assignments[patient_id]\n\n        # Simple randomization\n        arm = random.choice(self.arms)\n        self.assignments[patient_id] = arm\n\n        return arm\n\n    def get_arm_counts(self):\n        \"\"\"Get current enrollment counts per arm.\"\"\"\n        counts = {arm: 0 for arm in self.arms}\n        for patient, arm in self.assignments.items():\n            counts[arm] += 1\n        return counts\n\n    def unblind_patient(self, patient_id, reason):\n        \"\"\"Reveal treatment assignment for safety.\"\"\"\n        if patient_id not in self.assignments:\n            return None\n        return self.assignments[patient_id]\n\n    def export_randomization_list(self):\n        \"\"\"Export all assignments for regulatory submission.\"\"\"\n        output = []\n        for patient, arm in self.assignments.items():\n            output.append(f\"{patient},{arm}\")\n        return \"\\n\".join(output)\n\n    def re_randomize(self, patient_id):\n        \"\"\"Re-assign a patient to a different arm.\"\"\"\n        if patient_id in self.assignments:\n            del self.assignments[patient_id]\n        return self.randomize_patient(patient_id)\n```\n\n### Processus d'Inspection\n\n**Phase 1: PrÃ©paration (20 min)**\n- Chaque inspecteur examine le code individuellement\n- Note les dÃ©fauts potentiels sur le formulaire\n\n**Phase 2: RÃ©union d'Inspection (30 min)**\n- Le Reader lit le code ligne par ligne\n- Les inspecteurs signalent les dÃ©fauts\n- Le Recorder documente\n\n**Phase 3: Documentation (10 min)**\n- Compilation du rapport final\n- Classification des dÃ©fauts\n\n### Formulaire de DÃ©fauts\n\n| # | Ligne | Type | SÃ©vÃ©ritÃ© | Description | Action |\n|---|-------|------|----------|-------------|--------|\n| 1 | | | | | |\n| 2 | | | | | |\n| 3 | | | | | |\n| ... | | | | | |\n\n**Types de dÃ©fauts:**\n- REG = Regulatory\n- DATA = Data Integrity\n- SEC = Security\n- FUNC = Functional\n- PERF = Performance\n\n### MÃ©triques Ã  Calculer\n\n- Nombre de dÃ©fauts trouvÃ©s: ___\n- DÃ©fauts par ligne de code: ___\n- Temps de prÃ©paration: ___ min\n- Temps de rÃ©union: ___ min\n- DÃ©fauts critiques: ___\n\n---\n\n## EXERCICE 4: CrÃ©ation de Checklist PersonnalisÃ©e\n\n### Contexte\nVotre entreprise dÃ©veloppe un systÃ¨me LIMS (Laboratory Information Management System) pour un laboratoire de contrÃ´le qualitÃ© pharmaceutique.\n\n### Exigences du SystÃ¨me\n- Gestion des Ã©chantillons et tests\n- Calcul automatique des spÃ©cifications\n- GÃ©nÃ©ration de certificats d'analyse\n- Interface avec instruments de laboratoire\n- Signatures Ã©lectroniques pour approbation\n\n### TÃ¢che\nCrÃ©ez une checklist de code review spÃ©cifique pour ce systÃ¨me.\n\n### Template de Checklist\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n          CHECKLIST DE REVUE DE CODE - LIMS\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nProjet: ____________________  Date: ____________\nReviewer: __________________  Module: __________\n\nSECTION 1: CONFORMITÃ‰ 21 CFR PART 11\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 1.1 Audit trail implÃ©mentÃ© pour modifications de donnÃ©es\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.2 Horodatage avec timezone sur tous les enregistrements\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.3 [AJOUTEZ VOS CRITÃˆRES - minimum 8 items]\n      ...\n\nSECTION 2: INTÃ‰GRITÃ‰ DES DONNÃ‰ES (ALCOA+)\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 2.1 DonnÃ©es attribuables Ã  un utilisateur identifiÃ©\n      RÃ©fÃ©rence: FDA Data Integrity Guidance\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 2.2 [AJOUTEZ VOS CRITÃˆRES - minimum 6 items]\n      ...\n\nSECTION 3: CALCULS ET SPÃ‰CIFICATIONS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 3.1 Formules de calcul documentÃ©es et vÃ©rifiables\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 3.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 4: SÃ‰CURITÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 4.1 ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les\n      RÃ©fÃ©rence: 21 CFR 11.10(d)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 4.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 5: INTERFACE INSTRUMENTS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 5.1 Validation des donnÃ©es reÃ§ues des instruments\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 5.2 [AJOUTEZ VOS CRITÃˆRES - minimum 4 items]\n      ...\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nRÃ‰SUMÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Items: ___    Pass: ___    Fail: ___    N/A: ___\n\nRÃ©sultat Global:  â–¡ APPROUVÃ‰  â–¡ REJETÃ‰  â–¡ APPROUVÃ‰ AVEC RÃ‰SERVES\n\nSignature Reviewer: ___________________ Date: ___________\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### CritÃ¨res de RÃ©ussite\n- Minimum 28 items au total\n- Chaque section doit couvrir les risques spÃ©cifiques au LIMS\n- RÃ©fÃ©rences rÃ©glementaires pour items critiques\n- CritÃ¨res Pass/Fail clairs et objectifs\n\n---\n\n## EXERCICE 5: DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©\n\n### ScÃ©nario\nVous Ãªtes auditeur interne. Analysez ces artefacts de revue de code et identifiez les anomalies.\n\n### Document 1: Log de Revue\n\n```\nCode Review Log - Project MEDCALC-2024\n======================================\n\nReview #1042\n- Date: 2024-11-15 08:45:22 UTC\n- Reviewer: jennifer.smith@company.com\n- Author: jennifer.smith@company.com\n- Files: src/calculations/*.java (23 files, 4,521 lines)\n- Duration: 12 minutes\n- Defects: 0\n- Status: APPROVED\n- Comments: \"Code looks good\"\n\nReview #1043\n- Date: 2024-11-15 08:57:44 UTC\n- Reviewer: michael.jones@company.com\n- Author: david.wilson@company.com\n- Files: src/safety/AlarmHandler.java (1 file, 89 lines)\n- Duration: 45 minutes\n- Defects: 7 (3 Critical, 2 Major, 2 Minor)\n- Status: REWORK REQUIRED\n- Comments: [Detailed defect log attached]\n\nReview #1044\n- Date: 2024-11-15\n- Reviewer: admin\n- Author: dev_team\n- Files: hotfix-prod-emergency.patch\n- Duration: N/A\n- Defects: N/A\n- Status: EMERGENCY APPROVED\n- Comments: \"Production issue - approved by management\"\n```\n\n### Document 2: Git History\n\n```\ncommit a1b2c3d4\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 08:30:15 UTC\nMessage: \"Completed dose calculation module\"\n\ncommit e5f6g7h8\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 09:00:00 UTC\nMessage: \"Minor fixes after self-review\"\n\ncommit i9j0k1l2\nAuthor: system@company.com\nDate: 2024-11-15 22:00:00 UTC\nMessage: \"Applied hotfix-prod-emergency.patch\"\n```\n\n### Document 3: Metrics Dashboard\n\n```\nMonthly Code Review Metrics - November 2024\n==========================================\n\nReviewer Performance:\n- jennifer.smith: 47 reviews, 0 defects found, avg 8 min\n- michael.jones: 12 reviews, 156 defects found, avg 52 min\n- sarah.brown: 23 reviews, 67 defects found, avg 35 min\n- admin: 3 reviews, 0 defects found, avg 2 min\n\nDefect Density by Module:\n- UI Components: 2.3 defects/KLOC\n- Business Logic: 0.0 defects/KLOC (jennifer.smith reviews)\n- Safety Systems: 12.7 defects/KLOC (michael.jones reviews)\n- Database Layer: 4.1 defects/KLOC\n```\n\n### Questions d'Analyse\n\n1. **Review #1042:** Identifiez toutes les anomalies\n2. **Review #1044:** Quels problÃ¨mes de conformitÃ© voyez-vous?\n3. **MÃ©triques jennifer.smith:** Qu'est-ce qui est suspect?\n4. **Compte \"admin\":** Pourquoi est-ce problÃ©matique?\n5. **Actions correctives:** Que recommanderiez-vous?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**Review #1042 - Anomalies:**\n1. âŒ Self-review (auteur = reviewer) - Non conforme Part 820\n2. âŒ 4,521 lignes en 12 min = 377 lignes/min - Humainement impossible\n3. âŒ 0 dÃ©fauts sur 23 fichiers - Statistiquement improbable\n4. âŒ Commentaire vague \"Code looks good\" - Pas de preuve de revue\n\n**Review #1044 - ProblÃ¨mes:**\n1. âŒ Pas d'horodatage complet (heure manquante)\n2. âŒ Comptes gÃ©nÃ©riques (\"admin\", \"dev_team\")\n3. âŒ Pas de documentation de durÃ©e ou dÃ©fauts\n4. âŒ \"Emergency Approved\" sans procÃ©dure d'exception documentÃ©e\n5. âŒ Patch appliquÃ© sans revue formelle\n\n**MÃ©triques jennifer.smith:**\n1. 0 dÃ©fauts sur 47 revues = Outlier statistique majeur\n2. 8 min moyenne pour revues significatives = Trop rapide\n3. CorrÃ©lation: 0 dÃ©fauts dans Business Logic = probable self-review\n\n**Compte \"admin\":**\n1. Compte gÃ©nÃ©rique (non-nominatif) interdit par Part 11\n2. Pas de traÃ§abilitÃ© de l'utilisateur rÃ©el\n3. 3 revues sans dÃ©fauts = Pattern suspect\n\n**Actions correctives:**\n1. Annuler toutes les approbations de jennifer.smith et re-reviewer\n2. ImplÃ©menter contrÃ´le technique: bloquer self-review\n3. Ã‰liminer comptes gÃ©nÃ©riques\n4. DÃ©finir seuils minimum de durÃ©e de revue\n5. CAPA pour le processus d'exception \"emergency\"\n6. Formation obligatoire sur data integrity\n\n</details>\n\n---\n\n## EXERCICE 6: Examen Final Pratique\n\n### Instructions\n- DurÃ©e: 60 minutes\n- Code: 250 lignes\n- Vous devez trouver au moins 80% des dÃ©fauts critiques pour rÃ©ussir\n\n### Code Ã  RÃ©viser\n\n```csharp\n// MedicalRecordSystem.cs\n// Electronic Health Record Module for Clinical Practice\n\nusing System;\nusing System.Collections.Generic;\nusing System.IO;\nusing System.Security.Cryptography;\n\nnamespace HealthcareSoftware\n{\n    public class MedicalRecordSystem\n    {\n        private Dictionary<string, PatientRecord> records = new();\n        private const string ENCRYPTION_KEY = \"MySecretKey12345\"; // AES-128\n        private string connectionString = \"Server=prod-db;Database=EHR;User=sa;Password=admin123\";\n\n        public class PatientRecord\n        {\n            public string PatientId { get; set; }\n            public string Name { get; set; }\n            public DateTime DateOfBirth { get; set; }\n            public List<string> Diagnoses { get; set; }\n            public List<Medication> Medications { get; set; }\n            public string LastModifiedBy { get; set; }\n        }\n\n        public class Medication\n        {\n            public string DrugName { get; set; }\n            public double Dosage { get; set; }\n            public string Unit { get; set; }\n            public int FrequencyPerDay { get; set; }\n        }\n\n        // Create new patient record\n        public void CreateRecord(PatientRecord record)\n        {\n            records[record.PatientId] = record;\n            SaveToDatabase(record);\n        }\n\n        // Update existing record\n        public void UpdateRecord(string patientId, PatientRecord newData)\n        {\n            if (records.ContainsKey(patientId))\n            {\n                records[patientId] = newData;\n                SaveToDatabase(newData);\n            }\n        }\n\n        // Add medication to patient\n        public void AddMedication(string patientId, string drug, double dose, string unit, int freq)\n        {\n            var record = records[patientId];\n            record.Medications.Add(new Medication\n            {\n                DrugName = drug,\n                Dosage = dose,\n                Unit = unit,\n                FrequencyPerDay = freq\n            });\n            SaveToDatabase(record);\n        }\n\n        // Calculate total daily dose\n        public double CalculateDailyDose(string patientId, string drugName)\n        {\n            var record = records[patientId];\n            var med = record.Medications.Find(m => m.DrugName == drugName);\n            return med.Dosage * med.FrequencyPerDay;\n        }\n\n        // Check for drug interactions (simplified)\n        public bool CheckInteractions(string patientId)\n        {\n            var record = records[patientId];\n            // TODO: Implement drug interaction checking\n            return false;\n        }\n\n        // Export for regulatory audit\n        public void ExportRecords(string filePath)\n        {\n            using (var writer = new StreamWriter(filePath))\n            {\n                foreach (var record in records.Values)\n                {\n                    writer.WriteLine($\"{record.PatientId},{record.Name},{record.DateOfBirth}\");\n                }\n            }\n        }\n\n        // Delete patient record (GDPR compliance)\n        public void DeleteRecord(string patientId)\n        {\n            records.Remove(patientId);\n            // Delete from database\n            ExecuteQuery($\"DELETE FROM Patients WHERE PatientId = '{patientId}'\");\n        }\n\n        // Search patients\n        public List<PatientRecord> SearchPatients(string searchTerm)\n        {\n            var results = new List<PatientRecord>();\n            // Direct SQL for performance\n            var query = $\"SELECT * FROM Patients WHERE Name LIKE '%{searchTerm}%'\";\n            // Execute and parse results...\n            return results;\n        }\n\n        // Authentication\n        public bool AuthenticateUser(string username, string password)\n        {\n            var hashedPwd = ComputeHash(password);\n            var storedHash = GetStoredHash(username);\n            return hashedPwd == storedHash;\n        }\n\n        private string ComputeHash(string input)\n        {\n            using (var md5 = MD5.Create())\n            {\n                var bytes = System.Text.Encoding.UTF8.GetBytes(input);\n                var hash = md5.ComputeHash(bytes);\n                return Convert.ToBase64String(hash);\n            }\n        }\n\n        private void SaveToDatabase(PatientRecord record)\n        {\n            // Encrypt sensitive data\n            var encryptedName = Encrypt(record.Name);\n            // Save to DB...\n        }\n\n        private string Encrypt(string plainText)\n        {\n            // Simple XOR encryption for now\n            char[] chars = plainText.ToCharArray();\n            for (int i = 0; i < chars.Length; i++)\n            {\n                chars[i] = (char)(chars[i] ^ ENCRYPTION_KEY[i % ENCRYPTION_KEY.Length]);\n            }\n            return new string(chars);\n        }\n\n        private void ExecuteQuery(string sql)\n        {\n            // Execute the SQL query\n            Console.WriteLine($\"Executing: {sql}\");\n        }\n\n        private string GetStoredHash(string username)\n        {\n            // Retrieve from database\n            return \"\";\n        }\n\n        // Utility: Log access\n        public void LogAccess(string patientId, string action)\n        {\n            File.AppendAllText(\"access.log\",\n                $\"{DateTime.Now}: {action} on {patientId}\\n\");\n        }\n    }\n}\n```\n\n### Formulaire de RÃ©ponse\n\nComplÃ©tez ce formulaire avec tous les dÃ©fauts identifiÃ©s:\n\n| # | Ligne(s) | CatÃ©gorie | SÃ©vÃ©ritÃ© | Description | RÃ©fÃ©rence |\n|---|----------|-----------|----------|-------------|-----------|\n| 1 | | | | | |\n| 2 | | | | | |\n| ... | | | | | |\n\n**CatÃ©gories:** SEC (Security), REG (Regulatory), FUNC (Functional), DATA (Data Integrity)\n\n**Score minimum pour certification:**\n- Tous les dÃ©fauts Critiques identifiÃ©s\n- 80% des dÃ©fauts Majeurs identifiÃ©s\n- Documentation correcte des rÃ©fÃ©rences\n\n---\n\n## CorrigÃ© de l'Examen Final\n\n<details>\n<summary>Cliquer pour voir le corrigÃ© complet</summary>\n\n| # | Ligne(s) | Cat | SÃ©v | Description | RÃ©f |\n|---|----------|-----|-----|-------------|-----|\n| 1 | 13 | SEC | Critique | ClÃ© de chiffrement en dur | OWASP A02 |\n| 2 | 14 | SEC | Critique | Connection string avec credentials | OWASP A07 |\n| 3 | 14 | SEC | Critique | Mot de passe admin123 faible | CWE-521 |\n| 4 | 37-40 | DATA | Critique | Pas d'audit trail sur crÃ©ation | 21 CFR 11.10(e) |\n| 5 | 43-49 | DATA | Critique | Pas d'audit trail sur modification | 21 CFR 11.10(e) |\n| 6 | 43-49 | DATA | Majeur | Pas de vÃ©rification des modifications | Data Integrity |\n| 7 | 52-61 | DATA | Majeur | Ajout mÃ©dication sans vÃ©rification | Best Practice |\n| 8 | 64-69 | FUNC | Critique | NullReferenceException possible | Safety |\n| 9 | 64-69 | FUNC | Majeur | Pas de validation si mÃ©dicament existe | Functional |\n| 10 | 73-76 | FUNC | Critique | TODO non rÃ©solu - fonctionnalitÃ© critique absente | IEC 62304 |\n| 11 | 79-86 | DATA | Critique | Export incomplet (manque mÃ©dicaments, dates) | 21 CFR 11.10(b) |\n| 12 | 89-93 | DATA | Critique | Suppression physique de donnÃ©es mÃ©dicales | HIPAA, Retention |\n| 13 | 93 | SEC | Critique | SQL Injection | OWASP A03 |\n| 14 | 97-101 | SEC | Critique | SQL Injection via searchTerm | OWASP A03 |\n| 15 | 105-109 | SEC | Majeur | Timing attack possible sur authentification | CWE-208 |\n| 16 | 111-117 | SEC | Critique | MD5 pour hash de mot de passe (dÃ©prÃ©ciÃ©) | OWASP A02 |\n| 17 | 111-117 | SEC | Majeur | Pas de salt pour le hachage | CWE-916 |\n| 18 | 125-131 | SEC | Critique | XOR n'est pas du chiffrement sÃ©curisÃ© | OWASP A02 |\n| 19 | 140-143 | DATA | Majeur | Log sans utilisateur identifiÃ© | 21 CFR 11.10(e) |\n| 20 | 140-143 | SEC | Mineur | Fichier log en clair sans protection | Best Practice |\n| 21 | Global | DATA | Majeur | Pas de validation des entrÃ©es utilisateur | Best Practice |\n| 22 | Global | REG | Majeur | Pas de signatures Ã©lectroniques | 21 CFR 11.50 |\n\n**Total dÃ©fauts:** 22\n- Critiques: 12\n- Majeurs: 9\n- Mineurs: 1\n\n**Seuil de rÃ©ussite:**\n- 12/12 Critiques identifiÃ©s = 100% requis\n- 7/9 Majeurs identifiÃ©s = 80% minimum\n\n</details>\n\n---\n\n*Fin des exercices pratiques*\n"},"tool_response":{"type":"create","filePath":"/home/chris/FDA-Code-Review-Exercises.md","content":"# Exercices Pratiques - Formation RÃ©vision de Code FDA\n\n## Exercices DÃ©taillÃ©s par Module\n\n---\n\n## EXERCICE 1: Code d'Audit Trail Non-Conforme\n\n### Contexte\nVous devez rÃ©viser ce module de gestion des lots de production d'un systÃ¨me pharmaceutique.\n\n### Code Ã  Analyser\n\n```python\n# batch_manager.py - Pharmaceutical Batch Management System\n\nimport sqlite3\nfrom datetime import datetime\n\nclass BatchManager:\n    def __init__(self):\n        self.conn = sqlite3.connect('production.db')\n        self.admin_password = \"Pharma2024!\"  # For emergency access\n\n    def update_batch_status(self, batch_id, new_status, user=None):\n        \"\"\"Update the status of a production batch.\"\"\"\n        cursor = self.conn.cursor()\n\n        # Update the batch\n        cursor.execute(\n            \"UPDATE batches SET status = ? WHERE batch_id = ?\",\n            (new_status, batch_id)\n        )\n        self.conn.commit()\n        print(f\"Batch {batch_id} updated to {new_status}\")\n        return True\n\n    def delete_batch_record(self, batch_id):\n        \"\"\"Remove a batch from the system.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"DELETE FROM batches WHERE batch_id = ?\", (batch_id,))\n        self.conn.commit()\n        return True\n\n    def get_batch_history(self, batch_id):\n        \"\"\"Get batch history - returns last 10 changes only.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"SELECT * FROM batch_history WHERE batch_id = ? LIMIT 10\",\n            (batch_id,)\n        )\n        return cursor.fetchall()\n\n    def approve_batch(self, batch_id, approver):\n        \"\"\"Approve batch for release.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\n            \"UPDATE batches SET status = 'APPROVED', approved_by = ? WHERE batch_id = ?\",\n            (approver, batch_id)\n        )\n        self.conn.commit()\n\n    def calculate_expiry(self, manufacture_date, shelf_life_days):\n        \"\"\"Calculate expiration date.\"\"\"\n        # TODO: Fix this later\n        return manufacture_date + shelf_life_days\n\n    def export_batch_data(self, batch_id):\n        \"\"\"Export batch data for regulatory submission.\"\"\"\n        cursor = self.conn.cursor()\n        cursor.execute(\"SELECT * FROM batches WHERE batch_id = ?\", (batch_id,))\n        data = cursor.fetchone()\n\n        # Convert to readable format\n        output = str(data)\n        return output\n```\n\n### Questions d'Analyse\n\n**Partie A: Identification des DÃ©fauts (30 min)**\n\n1. Identifiez tous les dÃ©fauts de conformitÃ© 21 CFR Part 11\n2. Classifiez chaque dÃ©faut (Critique/Majeur/Mineur)\n3. Citez la rÃ©fÃ©rence rÃ©glementaire spÃ©cifique pour chaque dÃ©faut\n\n**Partie B: Proposition de Corrections (30 min)**\n\n4. RÃ©Ã©crivez la fonction `update_batch_status` avec un audit trail conforme\n5. Proposez une architecture pour rendre les suppressions conformes (soft delete)\n6. Comment sÃ©curiseriez-vous la gestion des credentials?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts identifiÃ©s:**\n\n| # | Ligne | DÃ©faut | SÃ©vÃ©ritÃ© | RÃ©fÃ©rence |\n|---|-------|--------|----------|-----------|\n| 1 | 8 | Mot de passe en dur dans le code | Critique | 21 CFR 11.10(d) |\n| 2 | 13-19 | Pas d'audit trail sur update_batch_status | Critique | 21 CFR 11.10(e) |\n| 3 | 13 | ParamÃ¨tre user non utilisÃ© | Majeur | 21 CFR 11.10(e) |\n| 4 | 21-25 | Suppression physique de donnÃ©es GxP | Critique | 21 CFR 11.10(c) |\n| 5 | 28 | Historique limitÃ© Ã  10 enregistrements | Majeur | 21 CFR 11.10(c) |\n| 6 | 35-40 | Approbation sans signature Ã©lectronique | Critique | 21 CFR 11.50 |\n| 7 | 42-44 | TODO non rÃ©solu avant release | Majeur | Best Practice |\n| 8 | 48-53 | Export non structurÃ© (str(data)) | Mineur | 21 CFR 11.10(b) |\n\n**Correction pour update_batch_status:**\n\n```python\ndef update_batch_status(self, batch_id, new_status, user_id, reason=None):\n    \"\"\"Update the status of a production batch with full audit trail.\"\"\"\n    if not user_id:\n        raise ValueError(\"User identification required for status update\")\n\n    cursor = self.conn.cursor()\n\n    # Get current state for audit\n    cursor.execute(\n        \"SELECT status FROM batches WHERE batch_id = ?\",\n        (batch_id,)\n    )\n    old_status = cursor.fetchone()[0]\n\n    # Update with transaction\n    try:\n        # Update batch\n        cursor.execute(\n            \"UPDATE batches SET status = ?, last_modified_by = ?, \"\n            \"last_modified_date = ? WHERE batch_id = ?\",\n            (new_status, user_id, datetime.utcnow().isoformat(), batch_id)\n        )\n\n        # Create audit record\n        cursor.execute(\n            \"\"\"INSERT INTO audit_trail\n               (table_name, record_id, field_name, old_value, new_value,\n                changed_by, changed_date, workstation, reason)\n               VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?)\"\"\",\n            ('batches', batch_id, 'status', old_status, new_status,\n             user_id, datetime.utcnow().isoformat(),\n             self._get_workstation_id(), reason)\n        )\n\n        self.conn.commit()\n        return True\n\n    except Exception as e:\n        self.conn.rollback()\n        raise\n```\n\n</details>\n\n---\n\n## EXERCICE 2: Revue IEC 62304 Classe C - Dispositif MÃ©dical Critique\n\n### Contexte\nModule de calcul de dose pour une pompe Ã  insuline (Classe C - risque vital).\n\n### Code Ã  Analyser\n\n```java\n// InsulinDoseCalculator.java - Version 2.3.1\n\npackage com.meddevice.insulin;\n\npublic class InsulinDoseCalculator {\n\n    private static final double MAX_BOLUS = 25.0; // Units\n    private double carbRatio;\n    private double sensitivity;\n    private double targetGlucose;\n\n    public InsulinDoseCalculator(double carbRatio, double sensitivity) {\n        this.carbRatio = carbRatio;\n        this.sensitivity = sensitivity;\n        this.targetGlucose = 100; // mg/dL default\n    }\n\n    /**\n     * Calculate insulin bolus for a meal\n     * @param currentGlucose Current blood glucose in mg/dL\n     * @param carbsGrams Carbohydrates to be consumed\n     * @return Recommended insulin dose in units\n     */\n    public double calculateMealBolus(double currentGlucose, double carbsGrams) {\n        // Correction dose\n        double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n\n        // Meal coverage\n        double mealDose = carbsGrams / carbRatio;\n\n        // Total bolus\n        double totalBolus = correctionDose + mealDose;\n\n        // Safety cap\n        if (totalBolus > MAX_BOLUS) {\n            totalBolus = MAX_BOLUS;\n        }\n\n        return Math.round(totalBolus * 10.0) / 10.0;\n    }\n\n    public double calculateCorrectionBolus(double currentGlucose) {\n        return (currentGlucose - targetGlucose) / sensitivity;\n    }\n\n    public void updateSettings(double newCarbRatio, double newSensitivity) {\n        this.carbRatio = newCarbRatio;\n        this.sensitivity = newSensitivity;\n    }\n\n    // Quick calculation mode for experienced users\n    public double quickCalc(double g, double c) {\n        return (g - 100) / sensitivity + c / carbRatio;\n    }\n}\n```\n\n### Checklist de Revue IEC 62304 Classe C\n\nÃ‰valuez chaque Ã©lÃ©ment:\n\n| # | CritÃ¨re | Conforme? | Commentaire |\n|---|---------|-----------|-------------|\n| 1 | Validation des entrÃ©es (limites physiologiques) | | |\n| 2 | Gestion de la division par zÃ©ro | | |\n| 3 | Gestion des valeurs nÃ©gatives | | |\n| 4 | Limite de sÃ©curitÃ© MAX testÃ©e | | |\n| 5 | Documentation du raisonnement algorithmique | | |\n| 6 | TraÃ§abilitÃ© vers les requirements | | |\n| 7 | Gestion des erreurs/exceptions | | |\n| 8 | Nommage clair et sans ambiguÃ¯tÃ© | | |\n| 9 | Thread safety (accÃ¨s concurrent) | | |\n| 10 | UnitÃ©s clairement documentÃ©es | | |\n\n### Questions d'Analyse\n\n1. **Risque Safety:** Identifiez 3 scÃ©narios oÃ¹ ce code pourrait causer un surdosage\n2. **Division par zÃ©ro:** OÃ¹ peut-elle se produire? Quelle est la consÃ©quence?\n3. **Valeurs limites:** Quelles validations manquent pour les entrÃ©es?\n4. **Fonction quickCalc:** Pourquoi est-elle problÃ©matique en contexte mÃ©dical?\n5. **Thread Safety:** Ce code est-il sÃ»r en environnement multi-thread?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**DÃ©fauts critiques identifiÃ©s:**\n\n1. **Division par zÃ©ro (Ligne 26, 39):**\n   - Si `sensitivity = 0`, exception non gÃ©rÃ©e\n   - ConsÃ©quence: Crash de l'appareil, potentielle perte de dose\n\n2. **Aucune validation des entrÃ©es:**\n   - `currentGlucose` pourrait Ãªtre nÃ©gatif ou irrÃ©aliste (ex: 5000 mg/dL)\n   - `carbsGrams` pourrait Ãªtre nÃ©gatif\n   - Pas de bornes physiologiques\n\n3. **RÃ©sultat nÃ©gatif non gÃ©rÃ©:**\n   - Si glucose < target, `correctionDose` devient nÃ©gatif\n   - Un bolus nÃ©gatif n'a pas de sens mÃ©dical\n\n4. **Fonction quickCalc:**\n   - Nommage cryptique (g, c)\n   - Pas de safety cap\n   - Pas de documentation\n   - Code dupliquÃ© avec calculateMealBolus\n\n5. **Thread Safety:**\n   - `carbRatio` et `sensitivity` modifiables via updateSettings()\n   - Pas de synchronisation\n   - Race condition possible pendant un calcul\n\n**Code corrigÃ©:**\n\n```java\npublic double calculateMealBolus(double currentGlucose, double carbsGrams)\n    throws InvalidInputException, CalculationException {\n\n    // Input validation with physiological limits\n    if (currentGlucose < 20 || currentGlucose > 600) {\n        throw new InvalidInputException(\n            \"Glucose value out of physiological range: \" + currentGlucose);\n    }\n    if (carbsGrams < 0 || carbsGrams > 500) {\n        throw new InvalidInputException(\n            \"Carbohydrate value out of valid range: \" + carbsGrams);\n    }\n    if (sensitivity <= 0) {\n        throw new CalculationException(\n            \"Invalid sensitivity factor: \" + sensitivity);\n    }\n    if (carbRatio <= 0) {\n        throw new CalculationException(\n            \"Invalid carb ratio: \" + carbRatio);\n    }\n\n    // Correction dose (negative means no correction needed)\n    double correctionDose = (currentGlucose - targetGlucose) / sensitivity;\n    correctionDose = Math.max(0, correctionDose); // No negative corrections\n\n    // Meal coverage\n    double mealDose = carbsGrams / carbRatio;\n\n    // Total with safety bounds\n    double totalBolus = correctionDose + mealDose;\n    totalBolus = Math.min(totalBolus, MAX_BOLUS);\n    totalBolus = Math.max(totalBolus, 0); // Ensure non-negative\n\n    // Round to 0.1 unit precision\n    return Math.round(totalBolus * 10.0) / 10.0;\n}\n```\n\n</details>\n\n---\n\n## EXERCICE 3: Simulation d'Inspection Fagan\n\n### Instructions\n\n**Formation des Ã©quipes (5 personnes):**\n- 1 Moderator\n- 1 Author\n- 1 Reader\n- 1 Recorder\n- 1 Inspector\n\n**Code Ã  inspecter:**\n\n```python\n# clinical_trial_randomization.py\n# Module de randomisation pour essais cliniques\n\nimport random\nimport hashlib\nfrom datetime import datetime\n\nclass TrialRandomizer:\n    \"\"\"Randomizes patients to treatment arms in a clinical trial.\"\"\"\n\n    def __init__(self, trial_id, arms, stratification_factors=None):\n        self.trial_id = trial_id\n        self.arms = arms  # e.g., ['Placebo', 'Treatment A', 'Treatment B']\n        self.stratification = stratification_factors\n        self.assignments = {}\n        self.seed = int(datetime.now().timestamp())\n        random.seed(self.seed)\n\n    def randomize_patient(self, patient_id, strata=None):\n        \"\"\"Assign a patient to a treatment arm.\"\"\"\n\n        if patient_id in self.assignments:\n            return self.assignments[patient_id]\n\n        # Simple randomization\n        arm = random.choice(self.arms)\n        self.assignments[patient_id] = arm\n\n        return arm\n\n    def get_arm_counts(self):\n        \"\"\"Get current enrollment counts per arm.\"\"\"\n        counts = {arm: 0 for arm in self.arms}\n        for patient, arm in self.assignments.items():\n            counts[arm] += 1\n        return counts\n\n    def unblind_patient(self, patient_id, reason):\n        \"\"\"Reveal treatment assignment for safety.\"\"\"\n        if patient_id not in self.assignments:\n            return None\n        return self.assignments[patient_id]\n\n    def export_randomization_list(self):\n        \"\"\"Export all assignments for regulatory submission.\"\"\"\n        output = []\n        for patient, arm in self.assignments.items():\n            output.append(f\"{patient},{arm}\")\n        return \"\\n\".join(output)\n\n    def re_randomize(self, patient_id):\n        \"\"\"Re-assign a patient to a different arm.\"\"\"\n        if patient_id in self.assignments:\n            del self.assignments[patient_id]\n        return self.randomize_patient(patient_id)\n```\n\n### Processus d'Inspection\n\n**Phase 1: PrÃ©paration (20 min)**\n- Chaque inspecteur examine le code individuellement\n- Note les dÃ©fauts potentiels sur le formulaire\n\n**Phase 2: RÃ©union d'Inspection (30 min)**\n- Le Reader lit le code ligne par ligne\n- Les inspecteurs signalent les dÃ©fauts\n- Le Recorder documente\n\n**Phase 3: Documentation (10 min)**\n- Compilation du rapport final\n- Classification des dÃ©fauts\n\n### Formulaire de DÃ©fauts\n\n| # | Ligne | Type | SÃ©vÃ©ritÃ© | Description | Action |\n|---|-------|------|----------|-------------|--------|\n| 1 | | | | | |\n| 2 | | | | | |\n| 3 | | | | | |\n| ... | | | | | |\n\n**Types de dÃ©fauts:**\n- REG = Regulatory\n- DATA = Data Integrity\n- SEC = Security\n- FUNC = Functional\n- PERF = Performance\n\n### MÃ©triques Ã  Calculer\n\n- Nombre de dÃ©fauts trouvÃ©s: ___\n- DÃ©fauts par ligne de code: ___\n- Temps de prÃ©paration: ___ min\n- Temps de rÃ©union: ___ min\n- DÃ©fauts critiques: ___\n\n---\n\n## EXERCICE 4: CrÃ©ation de Checklist PersonnalisÃ©e\n\n### Contexte\nVotre entreprise dÃ©veloppe un systÃ¨me LIMS (Laboratory Information Management System) pour un laboratoire de contrÃ´le qualitÃ© pharmaceutique.\n\n### Exigences du SystÃ¨me\n- Gestion des Ã©chantillons et tests\n- Calcul automatique des spÃ©cifications\n- GÃ©nÃ©ration de certificats d'analyse\n- Interface avec instruments de laboratoire\n- Signatures Ã©lectroniques pour approbation\n\n### TÃ¢che\nCrÃ©ez une checklist de code review spÃ©cifique pour ce systÃ¨me.\n\n### Template de Checklist\n\n```\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n          CHECKLIST DE REVUE DE CODE - LIMS\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n\nProjet: ____________________  Date: ____________\nReviewer: __________________  Module: __________\n\nSECTION 1: CONFORMITÃ‰ 21 CFR PART 11\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 1.1 Audit trail implÃ©mentÃ© pour modifications de donnÃ©es\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.2 Horodatage avec timezone sur tous les enregistrements\n      RÃ©fÃ©rence: 21 CFR 11.10(e)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 1.3 [AJOUTEZ VOS CRITÃˆRES - minimum 8 items]\n      ...\n\nSECTION 2: INTÃ‰GRITÃ‰ DES DONNÃ‰ES (ALCOA+)\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 2.1 DonnÃ©es attribuables Ã  un utilisateur identifiÃ©\n      RÃ©fÃ©rence: FDA Data Integrity Guidance\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 2.2 [AJOUTEZ VOS CRITÃˆRES - minimum 6 items]\n      ...\n\nSECTION 3: CALCULS ET SPÃ‰CIFICATIONS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 3.1 Formules de calcul documentÃ©es et vÃ©rifiables\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 3.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 4: SÃ‰CURITÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 4.1 ContrÃ´le d'accÃ¨s basÃ© sur les rÃ´les\n      RÃ©fÃ©rence: 21 CFR 11.10(d)\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 4.2 [AJOUTEZ VOS CRITÃˆRES - minimum 5 items]\n      ...\n\nSECTION 5: INTERFACE INSTRUMENTS\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nâ–¡ 5.1 Validation des donnÃ©es reÃ§ues des instruments\n      â–¡ Pass  â–¡ Fail  â–¡ N/A\n      Notes: _____________________________________________\n\nâ–¡ 5.2 [AJOUTEZ VOS CRITÃˆRES - minimum 4 items]\n      ...\n\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\nRÃ‰SUMÃ‰\nâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\nTotal Items: ___    Pass: ___    Fail: ___    N/A: ___\n\nRÃ©sultat Global:  â–¡ APPROUVÃ‰  â–¡ REJETÃ‰  â–¡ APPROUVÃ‰ AVEC RÃ‰SERVES\n\nSignature Reviewer: ___________________ Date: ___________\nâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•\n```\n\n### CritÃ¨res de RÃ©ussite\n- Minimum 28 items au total\n- Chaque section doit couvrir les risques spÃ©cifiques au LIMS\n- RÃ©fÃ©rences rÃ©glementaires pour items critiques\n- CritÃ¨res Pass/Fail clairs et objectifs\n\n---\n\n## EXERCICE 5: DÃ©tection de ProblÃ¨mes d'IntÃ©gritÃ©\n\n### ScÃ©nario\nVous Ãªtes auditeur interne. Analysez ces artefacts de revue de code et identifiez les anomalies.\n\n### Document 1: Log de Revue\n\n```\nCode Review Log - Project MEDCALC-2024\n======================================\n\nReview #1042\n- Date: 2024-11-15 08:45:22 UTC\n- Reviewer: jennifer.smith@company.com\n- Author: jennifer.smith@company.com\n- Files: src/calculations/*.java (23 files, 4,521 lines)\n- Duration: 12 minutes\n- Defects: 0\n- Status: APPROVED\n- Comments: \"Code looks good\"\n\nReview #1043\n- Date: 2024-11-15 08:57:44 UTC\n- Reviewer: michael.jones@company.com\n- Author: david.wilson@company.com\n- Files: src/safety/AlarmHandler.java (1 file, 89 lines)\n- Duration: 45 minutes\n- Defects: 7 (3 Critical, 2 Major, 2 Minor)\n- Status: REWORK REQUIRED\n- Comments: [Detailed defect log attached]\n\nReview #1044\n- Date: 2024-11-15\n- Reviewer: admin\n- Author: dev_team\n- Files: hotfix-prod-emergency.patch\n- Duration: N/A\n- Defects: N/A\n- Status: EMERGENCY APPROVED\n- Comments: \"Production issue - approved by management\"\n```\n\n### Document 2: Git History\n\n```\ncommit a1b2c3d4\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 08:30:15 UTC\nMessage: \"Completed dose calculation module\"\n\ncommit e5f6g7h8\nAuthor: jennifer.smith@company.com\nDate: 2024-11-15 09:00:00 UTC\nMessage: \"Minor fixes after self-review\"\n\ncommit i9j0k1l2\nAuthor: system@company.com\nDate: 2024-11-15 22:00:00 UTC\nMessage: \"Applied hotfix-prod-emergency.patch\"\n```\n\n### Document 3: Metrics Dashboard\n\n```\nMonthly Code Review Metrics - November 2024\n==========================================\n\nReviewer Performance:\n- jennifer.smith: 47 reviews, 0 defects found, avg 8 min\n- michael.jones: 12 reviews, 156 defects found, avg 52 min\n- sarah.brown: 23 reviews, 67 defects found, avg 35 min\n- admin: 3 reviews, 0 defects found, avg 2 min\n\nDefect Density by Module:\n- UI Components: 2.3 defects/KLOC\n- Business Logic: 0.0 defects/KLOC (jennifer.smith reviews)\n- Safety Systems: 12.7 defects/KLOC (michael.jones reviews)\n- Database Layer: 4.1 defects/KLOC\n```\n\n### Questions d'Analyse\n\n1. **Review #1042:** Identifiez toutes les anomalies\n2. **Review #1044:** Quels problÃ¨mes de conformitÃ© voyez-vous?\n3. **MÃ©triques jennifer.smith:** Qu'est-ce qui est suspect?\n4. **Compte \"admin\":** Pourquoi est-ce problÃ©matique?\n5. **Actions correctives:** Que recommanderiez-vous?\n\n### RÃ©ponses Attendues\n\n<details>\n<summary>Cliquer pour voir les rÃ©ponses</summary>\n\n**Review #1042 - Anomalies:**\n1. âŒ Self-review (auteur = reviewer) - Non conforme Part 820\n2. âŒ 4,521 lignes en 12 min = 377 lignes/min - Humainement impossible\n3. âŒ 0 dÃ©fauts sur 23 fichiers - Statistiquement improbable\n4. âŒ Commentaire vague \"Code looks good\" - Pas de preuve de revue\n\n**Review #1044 - ProblÃ¨mes:**\n1. âŒ Pas d'horodatage complet (heure manquante)\n2. âŒ Comptes gÃ©nÃ©riques (\"admin\", \"dev_team\")\n3. âŒ Pas de documentation de durÃ©e ou dÃ©fauts\n4. âŒ \"Emergency Approved\" sans procÃ©dure d'exception documentÃ©e\n5. âŒ Patch appliquÃ© sans revue formelle\n\n**MÃ©triques jennifer.smith:**\n1. 0 dÃ©fauts sur 47 revues = Outlier statistique majeur\n2. 8 min moyenne pour revues significatives = Trop rapide\n3. CorrÃ©lation: 0 dÃ©fauts dans Business Logic = probable self-review\n\n**Compte \"admin\":**\n1. Compte gÃ©nÃ©rique (non-nominatif) interdit par Part 11\n2. Pas de traÃ§abilitÃ© de l'utilisateur rÃ©el\n3. 3 revues sans dÃ©fauts = Pattern suspect\n\n**Actions correctives:**\n1. Annuler toutes les approbations de jennifer.smith et re-reviewer\n2. ImplÃ©menter contrÃ´le technique: bloquer self-review\n3. Ã‰liminer comptes gÃ©nÃ©riques\n4. DÃ©finir seuils minimum de durÃ©e de revue\n5. CAPA pour le processus d'exception \"emergency\"\n6. Formation obligatoire sur data integrity\n\n</details>\n\n---\n\n## EXERCICE 6: Examen Final Pratique\n\n### Instructions\n- DurÃ©e: 60 minutes\n- Code: 250 lignes\n- Vous devez trouver au moins 80% des dÃ©fauts critiques pour rÃ©ussir\n\n### Code Ã  RÃ©viser\n\n```csharp\n// MedicalRecordSystem.cs\n// Electronic Health Record Module for Clinical Practice\n\nusing System;\nusing System.Collections.Generic;\nusing System.IO;\nusing System.Security.Cryptography;\n\nnamespace HealthcareSoftware\n{\n    public class MedicalRecordSystem\n    {\n        private Dictionary<string, PatientRecord> records = new();\n        private const string ENCRYPTION_KEY = \"MySecretKey12345\"; // AES-128\n        private string connectionString = \"Server=prod-db;Database=EHR;User=sa;Password=admin123\";\n\n        public class PatientRecord\n        {\n            public string PatientId { get; set; }\n            public string Name { get; set; }\n            public DateTime DateOfBirth { get; set; }\n            public List<string> Diagnoses { get; set; }\n            public List<Medication> Medications { get; set; }\n            public string LastModifiedBy { get; set; }\n        }\n\n        public class Medication\n        {\n            public string DrugName { get; set; }\n            public double Dosage { get; set; }\n            public string Unit { get; set; }\n            public int FrequencyPerDay { get; set; }\n        }\n\n        // Create new patient record\n        public void CreateRecord(PatientRecord record)\n        {\n            records[record.PatientId] = record;\n            SaveToDatabase(record);\n        }\n\n        // Update existing record\n        public void UpdateRecord(string patientId, PatientRecord newData)\n        {\n            if (records.ContainsKey(patientId))\n            {\n                records[patientId] = newData;\n                SaveToDatabase(newData);\n            }\n        }\n\n        // Add medication to patient\n        public void AddMedication(string patientId, string drug, double dose, string unit, int freq)\n        {\n            var record = records[patientId];\n            record.Medications.Add(new Medication\n            {\n                DrugName = drug,\n                Dosage = dose,\n                Unit = unit,\n                FrequencyPerDay = freq\n            });\n            SaveToDatabase(record);\n        }\n\n        // Calculate total daily dose\n        public double CalculateDailyDose(string patientId, string drugName)\n        {\n            var record = records[patientId];\n            var med = record.Medications.Find(m => m.DrugName == drugName);\n            return med.Dosage * med.FrequencyPerDay;\n        }\n\n        // Check for drug interactions (simplified)\n        public bool CheckInteractions(string patientId)\n        {\n            var record = records[patientId];\n            // TODO: Implement drug interaction checking\n            return false;\n        }\n\n        // Export for regulatory audit\n        public void ExportRecords(string filePath)\n        {\n            using (var writer = new StreamWriter(filePath))\n            {\n                foreach (var record in records.Values)\n                {\n                    writer.WriteLine($\"{record.PatientId},{record.Name},{record.DateOfBirth}\");\n                }\n            }\n        }\n\n        // Delete patient record (GDPR compliance)\n        public void DeleteRecord(string patientId)\n        {\n            records.Remove(patientId);\n            // Delete from database\n            ExecuteQuery($\"DELETE FROM Patients WHERE PatientId = '{patientId}'\");\n        }\n\n        // Search patients\n        public List<PatientRecord> SearchPatients(string searchTerm)\n        {\n            var results = new List<PatientRecord>();\n            // Direct SQL for performance\n            var query = $\"SELECT * FROM Patients WHERE Name LIKE '%{searchTerm}%'\";\n            // Execute and parse results...\n            return results;\n        }\n\n        // Authentication\n        public bool AuthenticateUser(string username, string password)\n        {\n            var hashedPwd = ComputeHash(password);\n            var storedHash = GetStoredHash(username);\n            return hashedPwd == storedHash;\n        }\n\n        private string ComputeHash(string input)\n        {\n            using (var md5 = MD5.Create())\n            {\n                var bytes = System.Text.Encoding.UTF8.GetBytes(input);\n                var hash = md5.ComputeHash(bytes);\n                return Convert.ToBase64String(hash);\n            }\n        }\n\n        private void SaveToDatabase(PatientRecord record)\n        {\n            // Encrypt sensitive data\n            var encryptedName = Encrypt(record.Name);\n            // Save to DB...\n        }\n\n        private string Encrypt(string plainText)\n        {\n            // Simple XOR encryption for now\n            char[] chars = plainText.ToCharArray();\n            for (int i = 0; i < chars.Length; i++)\n            {\n                chars[i] = (char)(chars[i] ^ ENCRYPTION_KEY[i % ENCRYPTION_KEY.Length]);\n            }\n            return new string(chars);\n        }\n\n        private void ExecuteQuery(string sql)\n        {\n            // Execute the SQL query\n            Console.WriteLine($\"Executing: {sql}\");\n        }\n\n        private string GetStoredHash(string username)\n        {\n            // Retrieve from database\n            return \"\";\n        }\n\n        // Utility: Log access\n        public void LogAccess(string patientId, string action)\n        {\n            File.AppendAllText(\"access.log\",\n                $\"{DateTime.Now}: {action} on {patientId}\\n\");\n        }\n    }\n}\n```\n\n### Formulaire de RÃ©ponse\n\nComplÃ©tez ce formulaire avec tous les dÃ©fauts identifiÃ©s:\n\n| # | Ligne(s) | CatÃ©gorie | SÃ©vÃ©ritÃ© | Description | RÃ©fÃ©rence |\n|---|----------|-----------|----------|-------------|-----------|\n| 1 | | | | | |\n| 2 | | | | | |\n| ... | | | | | |\n\n**CatÃ©gories:** SEC (Security), REG (Regulatory), FUNC (Functional), DATA (Data Integrity)\n\n**Score minimum pour certification:**\n- Tous les dÃ©fauts Critiques identifiÃ©s\n- 80% des dÃ©fauts Majeurs identifiÃ©s\n- Documentation correcte des rÃ©fÃ©rences\n\n---\n\n## CorrigÃ© de l'Examen Final\n\n<details>\n<summary>Cliquer pour voir le corrigÃ© complet</summary>\n\n| # | Ligne(s) | Cat | SÃ©v | Description | RÃ©f |\n|---|----------|-----|-----|-------------|-----|\n| 1 | 13 | SEC | Critique | ClÃ© de chiffrement en dur | OWASP A02 |\n| 2 | 14 | SEC | Critique | Connection string avec credentials | OWASP A07 |\n| 3 | 14 | SEC | Critique | Mot de passe admin123 faible | CWE-521 |\n| 4 | 37-40 | DATA | Critique | Pas d'audit trail sur crÃ©ation | 21 CFR 11.10(e) |\n| 5 | 43-49 | DATA | Critique | Pas d'audit trail sur modification | 21 CFR 11.10(e) |\n| 6 | 43-49 | DATA | Majeur | Pas de vÃ©rification des modifications | Data Integrity |\n| 7 | 52-61 | DATA | Majeur | Ajout mÃ©dication sans vÃ©rification | Best Practice |\n| 8 | 64-69 | FUNC | Critique | NullReferenceException possible | Safety |\n| 9 | 64-69 | FUNC | Majeur | Pas de validation si mÃ©dicament existe | Functional |\n| 10 | 73-76 | FUNC | Critique | TODO non rÃ©solu - fonctionnalitÃ© critique absente | IEC 62304 |\n| 11 | 79-86 | DATA | Critique | Export incomplet (manque mÃ©dicaments, dates) | 21 CFR 11.10(b) |\n| 12 | 89-93 | DATA | Critique | Suppression physique de donnÃ©es mÃ©dicales | HIPAA, Retention |\n| 13 | 93 | SEC | Critique | SQL Injection | OWASP A03 |\n| 14 | 97-101 | SEC | Critique | SQL Injection via searchTerm | OWASP A03 |\n| 15 | 105-109 | SEC | Majeur | Timing attack possible sur authentification | CWE-208 |\n| 16 | 111-117 | SEC | Critique | MD5 pour hash de mot de passe (dÃ©prÃ©ciÃ©) | OWASP A02 |\n| 17 | 111-117 | SEC | Majeur | Pas de salt pour le hachage | CWE-916 |\n| 18 | 125-131 | SEC | Critique | XOR n'est pas du chiffrement sÃ©curisÃ© | OWASP A02 |\n| 19 | 140-143 | DATA | Majeur | Log sans utilisateur identifiÃ© | 21 CFR 11.10(e) |\n| 20 | 140-143 | SEC | Mineur | Fichier log en clair sans protection | Best Practice |\n| 21 | Global | DATA | Majeur | Pas de validation des entrÃ©es utilisateur | Best Practice |\n| 22 | Global | REG | Majeur | Pas de signatures Ã©lectroniques | 21 CFR 11.50 |\n\n**Total dÃ©fauts:** 22\n- Critiques: 12\n- Majeurs: 9\n- Mineurs: 1\n\n**Seuil de rÃ©ussite:**\n- 12/12 Critiques identifiÃ©s = 100% requis\n- 7/9 Majeurs identifiÃ©s = 80% minimum\n\n</details>\n\n---\n\n*Fin des exercices pratiques*\n","structuredPatch":[],"originalFile":null},"tool_use_id":"toolu_01FUU1Gt9mKBdsKEBd2XNaNf"},"timestamp":1766707971981,"timestamp_pst":"2025-12-25 16:12:51 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PreToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PreToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"completed","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01AfVW5pVLUrU1qyfqjMPAez"},"timestamp":1766707981768,"timestamp_pst":"2025-12-25 16:13:01 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"PostToolUse","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"PostToolUse","tool_name":"TodoWrite","tool_input":{"todos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"completed","activeForm":"Designing practical exercises"}]},"tool_response":{"oldTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"in_progress","activeForm":"Designing practical exercises"}],"newTodos":[{"content":"Research FDA software validation requirements (21 CFR Part 11, GAMP 5)","status":"completed","activeForm":"Researching FDA software validation requirements"},{"content":"Research code review best practices in regulated environments","status":"completed","activeForm":"Researching code review best practices"},{"content":"Research common FDA compliance issues and audit findings","status":"completed","activeForm":"Researching FDA compliance issues"},{"content":"Research training methodologies for technical compliance","status":"completed","activeForm":"Researching training methodologies"},{"content":"Create detailed training plan structure","status":"completed","activeForm":"Creating training plan structure"},{"content":"Design practical exercises for each module","status":"completed","activeForm":"Designing practical exercises"}]},"tool_use_id":"toolu_01AfVW5pVLUrU1qyfqjMPAez"},"timestamp":1766707982147,"timestamp_pst":"2025-12-25 16:13:02 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"Stop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"Stop","stop_hook_active":false},"timestamp":1766708004296,"timestamp_pst":"2025-12-25 16:13:24 PST"}
{"source_app":"pai","session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","hook_event_type":"SubagentStop","payload":{"session_id":"9eb2be27-98c6-4f30-9ce6-34978a757643","transcript_path":"/home/chris/.claude/projects/-home-chris/9eb2be27-98c6-4f30-9ce6-34978a757643.jsonl","cwd":"/home/chris","permission_mode":"bypassPermissions","hook_event_name":"SubagentStop","stop_hook_active":false,"agent_id":"a91006e","agent_transcript_path":"/home/chris/.claude/projects/-home-chris/agent-a91006e.jsonl"},"timestamp":1766708015835,"timestamp_pst":"2025-12-25 16:13:35 PST"}
